Two	O
modes	O
of	O
microsatellite	O
instability	O
in	O
human	O
cancer	B
:	O
differential	O
connection	O
of	O
defective	O
DNA	O
mismatch	O
repair	O
to	O
dinucleotide	O
repeat	O
instability	O
Abstract	O
Microsatellite	O
instability	O
(	O
MSI	O
)	O
is	O
associated	O
with	O
defective	O
DNA	O
mismatch	O
repair	O
in	O
various	O
human	O
malignancies	B
.	O

Using	O
a	O
unique	O
fluorescent	O
technique	O
,	O
we	O
have	O
observed	O
two	O
distinct	O
modes	O
of	O
dinucleotide	O
microsatellite	O
alterations	O
in	O
human	O
colorectal	B
cancer	I
.	O

Type	O
A	O
alterations	O
are	O
defined	O
as	O
length	O
changes	O
of	O
≤6	O
bp	O
.	O

Type	O
B	O
changes	O
are	O
more	O
drastic	O
and	O
involve	O
modifications	O
of	O
≥8	O
bp	O
.	O

We	O
show	O
here	O
that	O
defective	O
mismatch	O
repair	O
is	O
necessary	O
and	O
sufficient	O
for	O
Type	O
A	O
changes	O
.	O

These	O
changes	O
were	O
observed	O
in	O
cell	O
lines	O
and	O
in	O
tumours	B
from	O
mismatch	O
repair	O
gene	O
-	O
knockout	O
mice	O
.	O

No	O
Type	O
B	O
instability	O
was	O
seen	O
in	O
these	O
cells	O
or	O
tumours	B
.	O

In	O
a	O
panel	O
of	O
human	O
colorectal	O
tumours	B
,	O
both	O
Type	O
A	O
MSI	O
and	O
Type	O
B	O
instability	O
were	O
observed	O
.	O

Both	O
types	O
of	O
MSI	O
were	O
associated	O
with	O
hMSH2	O
or	O
hMLH1	O
mismatch	O
repair	O
gene	O
alterations	O
.	O

Intriguingly	O
,	O
p53	O
mutations	O
,	O
which	O
are	O
generally	O
regarded	O
as	O
uncommon	O
in	O
human	O
tumours	B
of	O
the	O
MSI+	B
phenotype	O
,	O
were	O
frequently	O
associated	O
with	O
Type	B
A	I
instability	I
,	O
whereas	O
none	O
was	O
found	O
in	O
tumours	B
with	O
Type	B
B	I
instability	I
,	O
reflecting	O
the	O
prevailing	O
viewpoint	O
.	O

Inspection	O
of	O
published	O
data	O
reveals	O
that	O
the	O
microsatellite	O
instability	O
that	O
has	O
been	O
observed	O
in	O
various	O
malignancies	O
,	O
including	O
those	O
associated	O
with	O
Hereditary	B
Non	I
-	I
Polyposis	I
Colorectal	I
Cancer	I
(	O
HNPCC	B
)	O
,	O
is	O
predominantly	O
Type	O
B.	O
Our	O
findings	O
indicate	O
that	O
Type	O
B	O
instability	O
is	O
not	O
a	O
simple	O
reflection	O
of	O
a	O
repair	O
defect	O
.	O

We	O
suggest	O
that	O
there	O
are	O
at	O
least	O
two	O
qualitatively	O
distinct	O
modes	O
of	O
dinucleotide	B
MSI	I
in	O
human	O
colorectal	B
cancer	I
,	O
and	O
that	O
different	O
molecular	O
mechanisms	O
may	O
underlie	O
these	O
modes	O
of	O
MSI	O
.	O

The	O
relationship	O
between	O
MSI	O
and	O
defective	O
mismatch	O
repair	O
may	O
be	O
more	O
complex	O
than	O
hitherto	O
suspected	O
.	O

Analysis	O
of	O
microsatellites	O
in	O
MEFs	O
and	O
tumours	B
from	O
MMR	O
-	O
defective	O
animals	O
therefore	O
indicates	O
that	O
Type	O
A	O
MSI	O
is	O
a	O
direct	O
consequence	O
of	O
defective	O
MMR	O
.	O

The	O
absence	O
of	O
more	O
extensive	O
microsatellite	O
length	O
changes	O
may	O
indicate	O
further	O
that	O
an	O
Msh2	O
or	O
Mlh1	O
defect	O
is	O
insufficient	O
for	O
the	O
development	O
of	O
Type	O
B	O
instability	O
.	O

Mismatch	O
repair	O
gene	O
inactivation	O
is	O
associated	O
with	O
both	O
Type	O
A	O
and	O
Type	O
B	O
MSI	O
in	O
human	O
colorectal	B
cancer	I
HNPCC	B
patients	O
inherit	O
mutations	O
in	O
MMR	O
genes	O
(	O
6,7	O
)	O
.	O

More	O
than	O
90	O
%	O
of	O
HNPCC	B
tumours	B
are	O
MSI+	B
(	O
20	O
)	O
.	O

The	O
MSI+	O
phenotype	O
is	O
also	O
frequent	O
among	O
sporadic	O
colorectal	O
carcinomas	B
(	O
2–4,6,21	O
)	O
.	O

Inspection	O
of	O
published	O
data	O
derived	O
from	O
the	O
conventional	O
microsatellite	O
analysis	O
reveals	O
that	O
microsatellite	O
changes	O
thus	O
far	O
reported	O
in	O
various	O
tumours	B
,	O
including	O
those	O
in	O
HNPCC	B
individuals	O
,	O
are	O
largely	O
Type	O
B	O
(	O
2–4,20–22	O
)	O
.	O

We	O
considered	O
the	O
possibility	O
that	O
the	O
more	O
subtle	O
Type	O
A	O
MSI	O
might	O
have	O
remained	O
undetected	O
in	O
some	O
cases	O
.	O

Using	O
our	O
fluorescent	O
assay	O
with	O
a	O
panel	O
of	O
five	O
dinucleotide	O
repeat	O
microsatellites	O
,	O
we	O
found	O
that	O
the	O
frequencies	O
of	O
Type	O
A	O
and	O
Type	B
B	I
MSI	I
among	O
79	O
colorectal	O
carcinomas	B
were	O
30	O
%	O
and	O
17	O
%	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
that	O
Type	O
B	O
instability	O
is	O
common	O
in	O
HNPCC	B
colon	B
tumours	I
,	O
the	O
IC690	O
tumour	B
and	O
the	O
colorectal	O
carcinoma	B
cell	O
line	O
,	O
NoTa	O
(	O
Table	O
1	O
)	O
,	O
both	O
of	O
which	O
were	O
derived	O
from	O
patients	O
who	O
fulfilled	O
the	O
Amsterdam	O
Criteria	O
II	O
for	O
HNPCC	B
(	O
23	O
)	O
,	O
exhibited	O
Type	O
B	O
instability	O
(	O
Figure	O
1	O
G	O
and	O
H	O
)	O
.	O

Our	O
finding	O
that	O
17	O
%	O
of	O
colorectal	O
tumours	B
display	O
Type	B
B	I
MSI	I
is	O
consistent	O
with	O
the	O
generally	O
reported	O
figure	O
of	O
around	O
20	O
%	O
for	O
MSI	B
among	O
colorectal	O
carcinomas	B
(	O
20,24,25	O
)	O
.	O

The	O
observation	O
that	O
a	O
further	O
30	O
%	O
of	O
tumours	B
displayed	O
Type	B
A	I
MSI	I
suggests	O
that	O
the	O
frequency	O
of	O
MSI	O
,	O
at	O
least	O
in	O
colorectal	O
carcinomas	B
,	O
has	O
previously	O
been	O
underestimated	O
.	O

The	O
relationship	O
between	O
MSI	O
and	O
defective	O
MMR	O
in	O
our	O
set	O
of	O
colorectal	O
tumours	B
was	O
investigated	O
further	O
.	O

hMSH2	O
and	O
hMLH1	O
MMR	O
genes	O
of	O
12	O
tumours	B
with	O
Type	O
A	O
and	O
9	O
with	O
Type	B
B	I
MSI	I
were	O
sequenced	O
.	O

The	O
same	O
genes	O
in	O
the	O
NoTa	O
cell	O
line	O
were	O
also	O
sequenced	O
(	O
Figure	O
3A	O
and	O
Table	O
1	O
)	O
.	O

Sequence	O
alterations	O
causing	O
amino	O
acid	O
substitutions	O
were	O
identified	O
in	O
5	O
of	O
the	O
21	O
tumours	B
.	O

Four	O
of	O
these	O
(	O
80	O
%	O
)	O
were	O
associated	O
with	O
Type	B
A	I
MSI	I
.	O

In	O
addition	O
,	O
one	O
patient	O
with	O
Type	B
A	I
MSI	I
(	O
IC793	O
)	O
in	O
whom	O
no	O
mutation	O
was	O
identified	O
was	O
negative	O
for	O
immunohistochemical	O
staining	O
of	O
hMLH1	O
(	O
Figure	O
3B	O
,	O
panel	O
b	O
)	O
.	O

This	O
is	O
consistent	O
with	O
a	O
possible	O
epigenetic	O
hMLH1	O
gene	O
silencing	O
(	O
26–28	O
)	O
.	O

In	O
one	O
other	O
Type	O
A	O
case	O
(	O
IC669	O
)	O
and	O
one	O
Type	O
B	O
case	O
(	O
IC690	O
)	O
,	O
there	O
was	O
an	O
abnormal	O
intracellular	O
distribution	O
of	O
hMLH1	O
which	O
remained	O
predominantly	O
cytoplasmic	O
(	O
Figure	O
3B	O
,	O
panels	O
c	O
and	O
d	O
)	O
.	O

Among	O
the	O
10	O
tumours	B
displaying	O
Type	B
B	I
MSI	I
,	O
there	O
was	O
an	O
example	O
of	O
base	O
substitutions	O
causing	O
amino	O
acid	O
change	O
in	O
hMLH1	O
.	O

In	O
this	O
case	O
,	O
IC690	O
,	O
the	O
failure	O
of	O
hMLH1	O
to	O
localize	O
to	O
the	O
nucleus	O
was	O
associated	O
with	O
the	O
codon	O
226	O
mutation	O
in	O
exon	O
8	O
(	O
Figure	O
3A	O
,	O
panel	O
c	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
Type	O
A	O
instability	O
,	O
as	O
well	O
as	O
Type	O
B	O
,	O
is	O
indeed	O
associated	O
with	O
MMR	O
defects	O
.	O

DISCUSSION	O
The	O
fluorescent	O
technique	O
we	O
used	O
here	O
allows	O
the	O
unequivocal	O
designation	O
of	O
Type	O
A	O
and	O
Type	O
B	O
MSI	O
,	O
and	O
has	O
revealed	O
a	O
previously	O
unrecognized	O
complexity	O
in	O
the	O
relationship	O
between	O
dinucleotide	O
MSI	O
and	O
defective	O
DNA	O
MMR	O
in	O
human	O
cancer	B
.	O

Type	O
A	O
MSI	O
(	O
changes	O
≤	O
6	O
bp	O
)	O
is	O
clearly	O
linked	O
with	O
MMR	O
inactivation	O
in	O
both	O
mice	O
and	O
humans	O
,	O
which	O
implies	O
that	O
Type	O
A	O
MSI	O
is	O
a	O
direct	O
consequence	O
of	O
defective	O
MMR	O
.	O

Since	O
we	O
found	O
no	O
evidence	O
of	O
Type	O
B	O
instability	O
(	O
changes	O
≥	O
8	O
bp	O
)	O
in	O
MMR	O
-	O
defective	O
animals	O
,	O
it	O
is	O
possible	O
that	O
changes	O
in	O
addition	O
to	O
repair	O
deficiency	O
contribute	O
to	O
,	O
or	O
are	O
responsible	O
for	O
,	O
Type	O
B	O
MSI	O
.	O

One	O
important	O
finding	O
of	O
this	O
study	O
is	O
that	O
Type	O
A	O
instability	O
is	O
frequent	O
among	O
human	O
tumours	B
.	O

Type	O
A	O
MSI	O
predominated	O
in	O
our	O
large	O
panel	O
of	O
colorectal	O
carcinomas	B
.	O

We	O
suggest	O
that	O
,	O
because	O
the	O
changes	O
associated	O
with	O
Type	O
A	O
instability	O
are	O
more	O
subtle	O
,	O
the	O
frequency	O
of	O
MSI	O
among	O
colorectal	O
tumours	B
may	O
have	O
been	O
considerably	O
underestimated	O
.	O

Our	O
findings	O
also	O
reveal	O
a	O
hitherto	O
unrecognized	O
association	O
between	O
defective	O
MMR	O
and	O
p53	O
mutation	O
.	O

Significantly	O
,	O
Type	B
A	I
MSI	I
was	O
strongly	O
associated	O
with	O
p53	O
mutation	O
in	O
human	O
colorectal	O
tumours	B
.	O

Since	O
Type	O
A	O
instability	O
is	O
unequivocally	O
associated	O
with	O
MMR	O
deficiency	O
,	O
this	O
novel	O
finding	O
implies	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
p53	O
mutations	O
are	O
common	O
in	O
MMR	O
-	O
defective	O
tumours	B
,	O
at	O
least	O
in	O
human	O
colorectal	B
cancer	I
.	O

Established	O
guidelines	O
for	O
classification	O
of	O
MSI	O
utilize	O
the	O
frequency	O
of	O
changes	O
in	O
a	O
defined	O
set	O
of	O
microsatellite	O
markers	O
,	O
i.e.	O
MSI	O
-	O
H	O
and	O
-L	O
(	O
10	O
)	O
.	O

However	O
,	O
qualitative	O
differences	O
in	O
microsatellite	O
changes	O
are	O
not	O
widely	O
discussed	O
.	O

In	O
one	O
of	O
the	O
earliest	O
report	O
of	O
the	O
MSI	O
phenomenon	O
,	O
however	O
,	O
Thibodeau	O
et	O
al.	O
divided	O
microsatellite	O
changes	O
into	O
two	O
categories	O
;	O
Type	O
I	O
and	O
II	O
mutations	O
(	O
3	O
)	O
.	O

The	O
former	O
was	O
defined	O
a	O
'	O
significant	O
increase	O
(	O
expansion	O
)	O
or	O
decrease	O
(	O
deletion	O
)	O
in	O
the	O
apparent	O
fragment	O
size	O
'	O
and	O
the	O
latter	O
as	O
a	O
'	O
single	O
2	O
bp	O
change	O
'	O
.	O

This	O
distinction	O
has	O
received	O
little	O
attention	O
since	O
then	O
.	O

Our	O
data	O
indicate	O
that	O
Type	O
A	O
MSI	O
,	O
which	O
appears	O
similar	O
to	O
their	O
Type	O
II	O
mutation	O
,	O
is	O
more	O
frequent	O
than	O
hitherto	O
suspected	O
,	O
and	O
suggest	O
that	O
it	O
represents	O
the	O
bona	O
fide	O
MMR	O
-	O
deficient	O
phenotype	O
.	O

On	O
the	O
other	O
hand	O
,	O
Type	O
I	O
mutations	O
may	O
correspond	O
to	O
our	O
Type	O
B	O
instability	O
.	O

The	O
problem	O
is	O
that	O
mutations	O
in	O
MMR	O
genes	O
have	O
been	O
reported	O
in	O
tumours	B
displaying	O
this	O
type	O
of	O
instability	O
.	O

More	O
than	O
90	O
%	O
of	O
HNPCC	B
tumours	B
are	O
MSI+	B
(	O
20	O
)	O
,	O
and	O
this	O
type	O
of	O
MSI	O
can	O
be	O
categorized	O
as	O
Type	O
B	O
/	O
Type	B
I	I
(	O
2–4,20–22	O
)	O
.	O

However	O
,	O
the	O
frequencies	O
of	O
mutation	O
in	O
the	O
two	O
major	O
MMR	O
genes	O
,	O
hMSH2	O
and	O
hMLH1	O
,	O
in	O
HNPCC	B
kindred	O
are	O
not	O
high	O
in	O
some	O
reports	O
(	O
35–40	O
)	O
.	O

Among	O
the	O
panel	O
of	O
tumours	B
displaying	O
Type	B
B	I
MSI	I
,	O
we	O
found	O
a	O
base	O
substitution	O
mutation	O
in	O
hMLH1	O
and	O
one	O
case	O
with	O
a	O
possible	O
hMLH1	O
silencing	O
.	O

This	O
incidence	O
of	O
MMR	O
gene	O
inactivation	O
in	O
the	O
Type	O
B	O
group	O
is	O
not	O
unduly	O
low	O
,	O
compared	O
with	O
the	O
reported	O
frequencies	O
in	O
the	O
literature	O
(	O
25,36,41–43	O
)	O
.	O

The	O
relationship	O
between	O
Type	O
B	O
MSI	O
and	O
defective	O
MMR	O
is	O
probably	O
more	O
complex	O
than	O
hitherto	O
suspected	O
.	O

Background	O
Cancer	B
is	O
thought	O
to	O
arise	O
through	O
a	O
multistep	O
process	O
involving	O
sequential	O
cycles	O
of	O
mutation	O
and	O
selection	O
[	O
1	O
]	O
.	O

The	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
,	O
but	O
perhaps	O
six	O
general	O
cellular	O
functions	O
are	O
typically	O
altered	O
[	O
2	O
]	O
.	O

Numbers	O
of	O
oncogenic	O
mutations	O
may	O
also	O
be	O
inferred	O
from	O
the	O
age	O
-	O
related	O
increases	O
in	O
frequencies	O
observed	O
with	O
many	O
cancer	B
types	O
.	O

For	O
example	O
,	O
logarithms	O
of	O
cancer	B
frequencies	O
versus	O
age	O
typically	O
yield	O
straight	O
lines	O
,	O
with	O
slopes	O
proportional	O
to	O
numbers	O
of	O
cancer	B
mutations	O
[	O
3	O
]	O
.	O

Colorectal	B
cancer	I
epidemiology	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
before	O
transformation	O
[	O
3	O
-	O
6	O
]	O
.	O

The	O
variability	O
in	O
estimated	O
numbers	O
of	O
mutations	O
may	O
reflect	O
a	O
number	O
of	O
differences	O
.	O

For	O
example	O
,	O
estimates	O
vary	O
between	O
populations	O
,	O
with	O
five	O
to	O
six	O
mutations	O
in	O
England	O
and	O
six	O
to	O
seven	O
mutations	O
in	O
Finland	O
[	O
4	O
]	O
.	O

Recent	O
advances	O
in	O
cancer	B
genetics	O
also	O
reveal	O
biologic	O
colorectal	B
cancer	I
heterogeneity	O
.	O

Approximately	O
5	O
%	O
of	O
all	O
colorectal	B
cancers	I
have	O
strong	O
familial	O
predispositions	O
and	O
arise	O
in	O
individuals	O
with	O
germline	O
mutations	O
in	O
critical	O
susceptibility	O
loci	O
[	O
7	O
]	O
.	O

Such	O
hereditary	O
cancers	B
(	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
and	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
)	O
typically	O
present	O
at	O
younger	O
ages	O
and	O
should	O
require	O
fewer	O
somatic	O
mutations	O
than	O
their	O
sporadic	O
counterparts	O
because	O
one	O
mutation	O
is	O
inherited	O
.	O

Genetic	O
instability	O
also	O
divides	O
colorectal	B
cancers	I
into	O
two	O
groups	O
[	O
8	O
]	O
.	O

Approximately	O
10	O
to	O
15	O
%	O
of	O
sporadic	O
cancers	B
exhibit	O
microsatellite	B
instability	I
(	O
MSI	O
)	O
secondary	O
to	O
somatic	O
loss	O
of	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
.	O

Most	O
other	O
cancers	B
exhibit	O
chromosomal	B
instability	I
(	O
CIN	B
)	O
characterized	O
by	O
aneuploidy	B
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
[	O
7,8	O
]	O
.	O

CIN	B
and	O
MSI+	B
colorectal	B
cancers	I
have	O
different	O
characteristics	O
with	O
respect	O
to	O
mutated	O
loci	O
,	O
tumor	B
location	O
,	O
morphology	O
,	O
and	O
clinical	O
outcomes	O
[	O
7,8	O
]	O
.	O

Numbers	O
of	O
oncogenic	O
mutations	O
may	O
differ	O
between	O
cancer	B
subtypes	O
.	O

Therefore	O
,	O
colorectal	B
cancers	I
arising	O
in	O
a	O
population	O
-	O
based	O
setting	O
were	O
molecularly	O
classified	O
as	O
either	O
sporadic	O
or	O
hereditary	O
,	O
and	O
MSI+	B
or	O
MSI-	B
.	O

Cancers	B
were	O
also	O
classified	O
with	O
respect	O
to	O
clinical	O
stage	O
because	O
additional	O
mutations	O
may	O
be	O
required	O
for	O
invasion	O
or	O
metastasis	O
.	O

Ages	O
at	O
cancer	B
for	O
each	O
subgroup	O
were	O
used	O
to	O
infer	O
numbers	O
of	O
mutations	O
required	O
for	O
each	O
type	O
of	O
colorectal	B
cancer	I
.	O

Conclusion	O

The	O
biology	O
of	O
cancer	B
must	O
underlie	O
the	O
epidemiology	O
of	O
cancer	B
.	O

Here	O
we	O
illustrate	O
that	O
multistage	O
models	O
provide	O
conceptually	O
plausible	O
solutions	O
even	O
when	O
colorectal	B
cancers	I
are	O
divided	O
into	O
biologically	O
relevant	O
and	O
quite	O
different	O
subtypes	O
.	O

Ages	O
at	O
cancer	B
are	O
consistent	O
with	O
five	O
or	O
six	O
somatic	O
oncogenic	O
mutations	O
for	O
hereditary	O
(	O
HNPCC	B
)	O
MSI+	B
cancers	B
and	O
seven	O
or	O
eight	O
mutations	O
for	O
its	O
sporadic	O
counterpart	O
.	O

The	O
apparent	O
requirement	O
for	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
in	O
sporadic	O
MSI+	B
cancers	B
may	O
reflect	O
that	O
MMR	O
inactivation	O
is	O
commonly	O
epigenetic	O
,	O
which	O
may	O
involve	O
multiple	O
steps	O
.	O

Ages	O
at	O
MSI-	B
cancers	B
were	O
consistent	O
with	O
six	O
or	O
seven	O
oncogenic	O
mutations	O
,	O
with	O
similar	O
estimates	O
for	O
all	O
clinical	O
stages	O
,	O
suggesting	O
that	O
mutations	O
acquired	O
very	O
early	O
in	O
life	O
dictate	O
the	O
cancer	B
phenotype	O
at	O
the	O
time	O
of	O
transformation	O
.	O

Better	O
integration	O
of	O
cancer	B
epidemiology	O
with	O
its	O
biology	O
remains	O
a	O
further	O
challenge	O
.	O

Background	O
Carcinogenesis	O
is	O
a	O
multi	O
-	O
step	O
process	O
that	O
involves	O
the	O
accumulation	O
of	O
numerous	O
genetic	O
and	O
epigenetic	O
changes	O
in	O
cells	O
[	O
1	O
]	O
.	O

These	O
genetic	O
aberrations	O
affect	O
a	O
limited	O
number	O
of	O
identified	O
pathways	O
that	O
are	O
involved	O
in	O
(	O
colorectal	O
)	O
carcinogenesis	B
[	O
2	O
]	O
.	O

A	O
genetic	O
model	O
for	O
sporadic	O
colorectal	B
cancer	I
has	O
been	O
proposed	O
,	O
which	O
describes	O
the	O
sequential	O
accumulation	O
of	O
specific	O
genetic	O
alterations	O
in	O
various	O
pathways	O
,	O
involving	O
tumour	B
suppressor	O
genes	O
(	O
e.g.	O
APC	O
,	O
SMAD4	O
,	O
TP53	O
)	O
and	O
oncogenes	O
(	O
e.g.	O
CTNNB1	O
,	O
K	O
-	O
ras	O
)	O
[	O
3,4	O
]	O
.	O

Important	O
molecular	O
pathways	O
that	O
upon	O
activation	O
affect	O
the	O
early	O
and	O
intermediate	O
stages	O
of	O
colorectal	O
carcinogenesis	B
are	O
the	O
Wnt	O
and	O
Ras	O
signalling	O
pathways	O
,	O
whereas	O
TP53	O
inactivation	O
is	O
considered	O
a	O
late	O
event	O
.	O

Activation	O
of	O
the	O
Wnt	O
pathway	O
plays	O
a	O
central	O
role	O
in	O
the	O
aetiology	O
of	O
most	O
colorectal	B
cancers	I
and	O
is	O
often	O
the	O
result	O
of	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
APC	O
gene	O
,	O
that	O
lead	O
to	O
partial	O
or	O
complete	O
loss	O
of	O
this	O
region	O
and	O
thereby	O
to	O
loss	O
of	O
the	O
β	O
-	O
catenin	O
regulating	O
function	O
[	O
5,6	O
]	O
.	O

Conversely	O
,	O
in	O
tumours	B
lacking	O
these	O
APC	O
mutations	O
[	O
7	O
]	O
,	O
activating	O
missense	O
mutations	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
at	O
codons	O
31	O
,	O
33	O
,	O
37	O
and	O
45	O
of	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
(	O
encoding	O
the	O
β	O
-	O
catenin	O
protein	O
)	O
can	O
render	O
it	O
stable	O
as	O
it	O
can	O
no	O
longer	O
be	O
tagged	O
for	O
cellular	O
degradation	O
.	O

Activation	O
of	O
the	O
Ras	O
pathway	O
in	O
cancer	B
is	O
marked	O
by	O
the	O
loss	O
of	O
the	O
intrinsic	O
GTPase	O
activity	O
of	O
the	O
Ras	O
protein	O
,	O
which	O
can	O
be	O
ascribed	O
to	O
missense	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
exon	O
1	O
,	O
which	O
are	O
responsible	O
for	O
90	O
%	O
activating	O
mutations	O
in	O
the	O
of	O
the	O
K	O
-	O
ras	O
gene	O
[	O
8	O
]	O
.	O

According	O
to	O
the	O
paradigm	O
for	O
colorectal	B
cancer	I
development	O
,	O
mutations	O
in	O
the	O
APC	O
and	O
K	O
-	O
ras	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
early	O
developmental	O
stages	O
of	O
colorectal	B
cancer	I
[	O
3	O
]	O
.	O

However	O
,	O
a	O
recent	O
study	O
based	O
on	O
the	O
analysis	O
of	O
APC	O
,	O
K	O
-	O
ras	O
and	O
TP53	O
genes	O
concluded	O
that	O
simultaneous	O
occurrence	O
of	O
all	O
three	O
genetic	O
alterations	O
is	O
rare	O
and	O
that	O
multiple	O
genetic	O
pathways	O
may	O
be	O
relevant	O
to	O
colorectal	B
cancer	I
[	O
9	O
]	O
.	O

Genetic	O
instability	O
is	O
seen	O
in	O
most	O
types	O
of	O
cancer	B
[	O
10	O
]	O
.	O

Two	O
distinct	O
types	O
of	O
genetic	O
instability	O
appear	O
to	O
occur	O
in	O
colorectal	B
cancer	I
[	O
11	O
]	O
:	O
chromosomal	O
and	O
microsatellite	O
instability	O
.	O

Chromosomal	B
instability	I
results	O
in	O
gains	O
or	O
losses	O
of	O
entire	O
chromosomes	O
or	O
parts	O
of	O
them	O
,	O
and	O
gives	O
rise	O
to	O
aneuploid	O
tumours	B
and	O
occurs	O
in	O
the	O
majority	O
of	O
cancers	B
.	O

A	O
smaller	O
proportion	O
of	O
colorectal	B
cancers	I
displays	O
microsatellite	B
instability	I
,	O
represented	O
by	O
diploid	O
cells	O
acquiring	O
high	O
mutation	O
rates	O
,	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
defective	B
mismatch	I
repair	I
[	O
12	O
]	O
.	O

These	O
tumours	B
are	O
less	O
likely	O
to	O
harbour	O
mutations	O
in	O
genes	O
associated	O
with	O
chromosomally	B
instable	I
and	O
generally	O
aneuploid	O
tumours	B
,	O
such	O
as	O
APC	O
,	O
K	O
-	O
ras	O
and	O
TP53	O
[	O
13	O
-	O
21	O
]	O
,	O
suggesting	O
that	O
these	O
tumours	B
form	O
a	O
distinct	O
group	O
.	O

Moreover	O
,	O
microsatellite	B
instable	I
tumours	B
are	O
found	O
predominantly	O
in	O
the	O
proximal	O
colon	O
[	O
22,23	O
]	O
,	O
are	O
more	O
likely	O
to	O
occur	O
in	O
patients	O
with	O
a	O
positive	B
family	I
history	I
of	O
colorectal	B
cancer	I
[	O
22,23	O
]	O
,	O
are	O
often	O
less	O
differentiated	O
than	O
microsatellite	B
stable	I
tumours	B
[	O
22	O
]	O
,	O
and	O
occur	O
more	O
frequently	O
in	O
women	O
[	O
24	O
]	O
and	O
at	O
older	O
age	O
[	O
25	O
]	O
.	O

Moreover	O
,	O
in	O
tumours	B
displaying	O
microsatellite	B
instability	I
,	O
mutations	O
the	O
CTNNB1	O
gene	O
were	O
more	O
frequent	O
[	O
26	O
]	O
.	O

Methods	O
Study	O
population	O
The	O
prospective	O
Netherlands	O
Cohort	O
Study	O
on	O
diet	O
and	O
cancer	B
was	O
initiated	O
in	O
September	O
1986	O
.	O

The	O
study	O
design	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
29	O
]	O
.	O

The	O
study	O
population	O
originated	O
from	O
204	O
municipal	O
population	O
registries	O
throughout	O
the	O
Netherlands	O
,	O
and	O
included	O
a	O
total	O
of	O
58,279	O
men	O
and	O
62,573	O
women	O
between	O
the	O
ages	O
of	O
55	O
and	O
69	O
years	O
at	O
baseline	O
.	O

Incident	O
cancer	B
cases	O
are	O
identified	O
by	O
monitoring	O
of	O
the	O
entire	O
cohort	O
for	O
cancer	B
occurrence	O
through	O
annual	O
record	O
linkage	O
to	O
the	O
Netherlands	O
Cancer	O
Registry	O
,	O
i.e.	O
nine	O
regional	O
cancer	B
registries	O
throughout	O
the	O
Netherlands	O
,	O
and	O
to	O
PALGA	O
,	O
a	O
nationwide	O
network	O
and	O
registry	O
of	O
histo-	O
and	O
cytopathology	O
[	O
30	O
]	O
.	O

Together	O
,	O
the	O
NCR	O
and	O
PALGA	O
provide	O
a	O
near	O
100	O
%	O
coverage	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

The	O
first	O
2.3	O
years	O
of	O
follow	O
up	O
were	O
excluded	O
because	O
of	O
possible	O
pre	O
-	O
clinical	O
disease	O
affecting	O
exposure	O
status	O
and	O
because	O
of	O
incomplete	O
nationwide	O
coverage	O
of	O
PALGA	O
in	O
some	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
in	O
that	O
period	O
.	O

From	O
1989	O
until	O
1994	O
,	O
929	O
incident	O
cases	O
with	O
histologically	O
confirmed	O
colorectal	B
cancer	I
were	O
identified	O
within	O
the	O
cohort	O
,	O
of	O
whom	O
819	O
could	O
also	O
be	O
linked	O
to	O
a	O
PALGA	O
report	O
of	O
the	O
lesion	O
.	O

The	O
PALGA	O
reports	O
were	O
used	O
to	O
identify	O
and	O
locate	O
tumour	B
tissue	O
from	O
eligible	O
colorectal	B
cancer	I
patients	O
in	O
Dutch	O
pathology	O
laboratories	O
.	O

Colon	O
and	O
rectal	B
cancer	I
were	O
classified	O
according	O
to	O
site	O
as	O
follows	O
,	O
colon	O
:	O
cecum	O
through	O
sigmoid	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.0	O
,	O
153.1	O
,	O
153.2	O
,	O
153.3	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
,	O
153.7	O
)	O
,	O
rectosigmoid	O
(	O
ICD	O
-	O
O	O
code	O
154.0	O
)	O
,	O
and	O
rectum	O
(	O
ICD	O
-	O
O	O
code	O
154.1	O
)	O
.	O

Tissue	O
samples	O
Tumour	B
material	O
of	O
colorectal	B
cancer	I
patients	O
was	O
collected	O
after	O
approval	O
by	O
the	O
Ethical	O
Review	O
Board	O
of	O
Maastricht	O
University	O
,	O
PALGA	O
and	O
the	O
NCR	O
.	O

Tissue	O
samples	O
from	O
819	O
colorectal	B
cancer	I
patients	O
were	O
localized	O
in	O
54	O
pathology	O
laboratories	O
throughout	O
the	O
Netherlands	O
.	O

Forty	O
-	O
four	O
(	O
5	O
%	O
)	O
tumour	B
tissue	O
samples	O
could	O
not	O
be	O
retrieved	O
from	O
the	O
pathology	O
archives	O
.	O

Of	O
775	O
available	O
tissue	O
samples	O
,	O
737	O
(	O
95	O
%	O
)	O
contained	O
sufficient	O
tumour	B
material	O
for	O
molecular	O
analyses	O
.	O

Tissue	O
sections	O
were	O
cut	O
from	O
each	O
sample	O
,	O
which	O
were	O
used	O
for	O
DNA	O
isolation	O
and	O
immunohistochemical	O
analysis	O
.	O

DNA	O
isolation	O
DNA	O
isolation	O
was	O
described	O
in	O
detail	O
elsewhere	O
[	O
27	O
]	O
.	O

Briefly	O
,	O
a	O
4	O
μm	O
section	O
,	O
cut	O
from	O
each	O
paraffin	O
-	O
embedded	O
tumour	B
tissue	O
block	O
,	O
was	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
for	O
histopathological	O
examination	O
by	O
a	O
pathologist	O
.	O

Five	O
20	O
μm	O
sections	O
of	O
tumour	B
tissue	O
were	O
cut	O
from	O
each	O
sample	O
for	O
DNA	O
isolation	O
.	O

Tumour	B
tissue	O
was	O
separated	O
from	O
normal	O
colon	O
epithelium	O
using	O
the	O
HE	O
section	O
as	O
a	O
reference	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
macrodissected	O
tumour	B
tissue	O
using	O
proteinase	O
K	O
(	O
Qiagen	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
and	O
the	O
Puregene	O
DNA	O
isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O

DNA	O
concentration	O
and	O
purity	O
was	O
measured	O
at	O
260	O
and	O
280	O
nm	O
.	O

Conclusion	O
In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
mutations	O
in	O
the	O
CTNNB1	O
gene	O
are	O
presumably	O
of	O
minor	O
importance	O
in	O
sporadic	O
colorectal	B
cancer	I
.	O

Although	O
APC	O
and	O
K	O
-	O
ras	O
mutations	O
are	O
often	O
observed	O
seperately	O
in	O
a	O
tumour	B
,	O
these	O
mutations	O
seem	O
to	O
also	O
occur	O
in	O
a	O
co	O
-	O
dependent	O
manner	O
.	O

Tumours	B
that	O
display	O
mismatch	O
repair	O
deficiency	O
,	O
may	O
form	O
a	O
distinct	O
sub	O
-	O
group	O
as	O
they	O
differ	O
from	O
tumours	B
with	O
APC	O
and/or	O
K	O
-	O
ras	O
mutations	O
with	O
regard	O
to	O
age	O
,	O
sex	O
,	O
tumour	B
sub	O
-	O
localisation	O
and	O
differentiation	O
.	O

Background	O
BRAF	O
is	O
a	O
member	O
of	O
the	O
RAF	O
family	O
of	O
kinases	O
that	O
acts	O
upstream	O
of	O
the	O
MEK1	O
/	O
2	O
kinases	O
in	O
response	O
to	O
RAS	O
signals	O
.	O

Activating	O
mutations	O
in	O
BRAF	O
have	O
been	O
reported	O
in	O
5–15	O
%	O
of	O
colorectal	O
carcinomas	B
(	O
CRC	B
)	O
,	O
with	O
by	O
far	O
the	O
most	O
common	O
mutation	O
being	O
a	O
1796	O
T	O
to	O
A	O
transversion	O
leading	O
to	O
a	O
V600E	O
substitution	O
[	O
1	O
-	O
3	O
]	O
.	O

The	O
BRAF	O
V600E	O
hotspot	O
mutation	O
is	O
strongly	O
associated	O
with	O
the	O
microsatellite	O
instability	O
(	O
MSI+	O
)	O
phenotype	O
but	O
is	O
mutually	O
exclusive	O
with	O
KRAS	O
mutations	O
[	O
4	O
-	O
7	O
]	O
.	O

Interestingly	O
,	O
BRAF	O
mutations	O
are	O
found	O
only	O
in	O
MSI+	B
sporadic	O
tumors	B
that	O
result	O
from	O
aberrant	O
MLH1	O
promoter	O
methylation	O
and	O
do	O
not	O
occur	O
in	O
MSI+	B
tumors	B
from	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
patients	O
[	O
5,8	O
-	O
10	O
]	O
,	O
thus	O
providing	O
a	O
convenient	O
discriminator	O
between	O
sporadic	O
and	O
familial	O
cases	O
.	O

The	O
majority	O
of	O
MSI+	B
sporadic	O
tumors	B
belong	O
to	O
a	O
larger	O
CRC	B
group	O
referred	O
to	O
as	O
the	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP+	O
)	O
that	O
is	O
characterised	O
by	O
widespread	O
hypermethylation	O
of	O
CpG	O
islands	O
located	O
with	O
gene	O
promoter	O
regions	O
[	O
11	O
]	O
.	O

Both	O
MSI+	B
and	O
CIMP+	O
tumors	B
are	O
thought	O
to	O
arise	O
from	O
large	B
hyperplastic	I
polyps	B
and	O
serrated	O
adenomas	B
[	O
12,13	O
]	O
and	O
recent	O
work	O
has	O
demonstrated	O
a	O
high	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
these	O
lesions	B
[	O
7,14,15	O
]	O
.	O

Although	O
the	O
positive	O
association	O
with	O
MSI+	O
and	O
inverse	O
association	O
with	O
KRAS	O
mutation	O
have	O
been	O
well	O
documented	O
,	O
little	O
is	O
known	O
about	O
the	O
other	O
properties	O
of	O
tumors	B
with	O
BRAF	O
mutation	O
.	O

In	O
the	O
present	O
study	O
we	O
analysed	O
for	O
BRAF	O
V600E	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
275	O
CRCs	B
that	O
were	O
well	O
characterised	O
for	O
the	O
major	O
pathological	O
and	O
molecular	O
features	O
of	O
this	O
disease	O
.	O

Our	O
results	O
demonstrate	O
that	O
oncogenic	O
BRAF	O
mutation	O
occurs	O
preferentially	O
within	O
a	O
subgroup	O
of	O
CRCs	B
that	O
have	O
distinctive	O
features	O
.	O

It	O
could	O
therefore	O
be	O
used	O
as	O
a	O
convenient	O
marker	O
for	O
the	O
further	O
characterisation	O
of	O
these	O
tumors	B
,	O
particularly	O
in	O
relation	O
to	O
their	O
prognosis	O
and	O
response	O
to	O
adjuvant	O
chemotherapy	O
.	O

Results	O
Figure	O
1A	O
shows	O
representative	O
Fluorescent	O
-	O
SSCP	O
results	O
for	O
the	O
screening	O
of	O
BRAF	O
mutations	O
in	O
this	O
CRC	B
series	O
,	O
while	O
Figure	O
1B	O
shows	O
DNA	O
sequencing	O
confirmation	O
of	O
the	O
1799	O
T	O
to	O
A	O
transversion	O
resulting	O
in	O
the	O
V600E	O
mutation	O
.	O

The	O
overall	O
frequency	O
of	O
BRAF	O
mutation	O
was	O
8.4	O
%	O
(	O
23	O
/	O
275	O
)	O
,	O
comparing	O
favourably	O
with	O
frequencies	O
of	O
9–11	O
%	O
reported	O
for	O
other	O
large	O
studies	O
of	O
this	O
tumor	B
type	O
[	O
6,16,17	O
]	O
.	O

The	O
mean	O
age	O
of	O
patients	O
with	O
and	O
without	O
BRAF	O
mutation	O
was	O
identical	O
(	O
Table	O
1	O
)	O
.	O

Strong	O
associations	O
were	O
observed	O
between	O
BRAF	O
mutation	O
and	O
tumor	B
origin	O
in	O
the	O
proximal	O
side	O
of	O
the	O
large	O
bowel	O
,	O
poor	O
histological	O
grade	O
,	O
mucinous	O
appearance	O
and	O
the	O
presence	O
of	O
infiltrating	O
lymphocytes	O
.	O

Higher	O
frequencies	O
of	O
BRAF	O
mutation	O
were	O
also	O
observed	O
in	O
females	O
and	O
in	O
node	O
negative	O
tumors	B
but	O
these	O
did	O
not	O
reach	O
significance	O
.	O

(	O
A	O
)	O
Representative	O
F	O
-	O
SSCP	O
gel	O
used	O
to	O
detect	O
BRAF	O
mutationsin	O
colorectal	B
cancer	I
.	O

WT	O
,	O
wild	O
-	O
type	O
;	O
M	O
,	O
mutation	O
.	O

(	O
B	O
)	O
DNA	O
sequencing	O
gel	O
resultconfirms	O
the	O
presence	O
of	O
a	O
1799	O
T	O
to	O
A	O
mutation	O
giving	O
rise	O
to	O
the	O
V600E	O
mutation	O
.	O

Associations	O
between	O
BRAF	O
mutation	O
and	O
clinicopathological	O
features	O
of	O
colorectal	B
cancer	I
.	O

a	O
Data	O
was	O
unavailable	O
for	O
gender	O
in	O
43	O
cases	O
,	O
infiltrating	O
lymphocytes	O
in	O
55	O
cases	O
,	O
nodal	O
involvement	O
in	O
77	O
cases	O
,	O
tumor	B
site	O
in	O
56	O
cases	O
,	O
grade	O
in	O
106	O
cases	O
and	O
mucinous	O
appearance	O
in	O
89	O
cases	O
.	O

BRAF	O
mutations	O
showed	O
no	O
association	O
with	O
TP53	O
mutations	O
and	O
were	O
mutually	O
exclusive	O
with	O
the	O
presence	O
of	O
KRAS	O
mutations	O
(	O
Table	O
2	O
)	O
.	O

In	O
contrast	O
,	O
BRAF	O
mutations	O
were	O
approximately	O
10-fold	O
more	O
frequent	O
in	O
MSI+	B
and	O
CIMP+	O
tumors	B
compared	O
to	O
tumors	B
without	O
these	O
phenotypes	O
.	O

A	O
strong	O
association	O
was	O
also	O
seen	O
with	O
methylation	O
of	O
the	O
MLH1	O
gene	O
promoter	O
and	O
in	O
particular	O
with	O
methylation	O
of	O
its	O
proximal	O
region	O
.	O

We	O
have	O
previously	O
examined	O
the	O
methylation	O
status	O
of	O
7	O
different	O
CpG	O
islands	O
in	O
this	O
CRC	B
series	O
[	O
18	O
]	O
.	O

The	O
mean	O
number	O
of	O
these	O
methylated	O
sites	O
was	O
3-fold	O
higher	O
in	O
tumors	B
with	O
BRAF	O
mutation	O
compared	O
to	O
those	O
without	O
(	O
2.6	O
±	O
1.7	O
vs	O
0.8	O
±	O
1.0	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
MSI+	O
was	O
the	O
only	O
significant	O
independent	O
predictor	O
of	O
BRAF	O
mutation	O
(	O
RR	O
=	O
6.3	O
,	O
95%CI	O
[	O
1.2–32.3	O
]	O
;	O
P	O
=	O
0.028	O
)	O
in	O
a	O
model	O
that	O
included	O
CIMP+	O
,	O
tumor	B
site	O
,	O
histological	O
grade	O
,	O
presence	O
of	O
infiltrating	O
lymphocytes	O
and	O
mucinous	O
appearance	O
.	O

Associations	O
between	O
BRAF	O
mutation	O
and	O
molecular	O
features	O
of	O
colorectal	B
cancer	I
.	O

a	O
Data	O
was	O
unavailable	O
for	O
MSI	O
status	O
in	O
40	O
cases	O
,	O
methylation	O
status	O
in	O
83	O
cases	O
,	O
KRAS	O
mutation	O
in	O
26	O
cases	O
and	O
TP53	O
mutation	O
in	O
26	O
cases	O
We	O
next	O
examined	O
whether	O
the	O
characteristic	O
features	O
of	O
tumors	B
with	O
BRAF	O
mutation	O
were	O
still	O
apparent	O
following	O
stratification	O
into	O
MSI	O
and	O
CIMP	O
phenotypes	O
.	O

Although	O
the	O
statistical	O
power	O
of	O
this	O
subgroup	O
analysis	O
was	O
limited	O
,	O
the	O
morphological	O
features	O
of	O
infiltrating	O
lymphocytes	O
,	O
poor	O
histological	O
grade	O
and	O
mucinous	O
appearance	O
were	O
clearly	O
associated	O
with	O
BRAF	O
mutation	O
regardless	O
of	O
tumor	B
MSI	O
status	O
(	O
Table	O
3	O
)	O
.	O

Similarly	O
,	O
these	O
features	O
were	O
each	O
more	O
common	O
in	O
tumors	B
with	O
BRAF	O
mutation	O
in	O
both	O
the	O
CIMP-	O
and	O
CIMP+	O
subgroups	O
(	O
Table	O
4	O
)	O
.	O

Similar	O
to	O
previous	O
observations	O
in	O
a	O
separate	O
CRC	B
cohort	O
[	O
20	O
]	O
,	O
the	O
frequency	O
of	O
KRAS	O
mutation	O
was	O
lower	O
in	O
MSI+	B
compared	O
to	O
MSI-	B
tumors	B
(	O
P	O
=	O
0.034	O
;	O
Table	O
3	O
)	O
,	O
while	O
the	O
frequency	O
of	O
TP53	O
mutation	O
was	O
also	O
considerably	O
lower	O
in	O
MSI+	B
tumors	B
with	O
wildtype	O
BRAF	O
than	O
in	O
MSI-	B
tumors	B
with	O
wildtype	O
BRAF	O
(	O
P	O
=	O
0.014	O
)	O
.	O

Mismatch	O
repair	O
and	O
treatment	O
resistance	O
in	O
ovarian	B
cancer	I
Abstract	O
Background	O
The	O
treatment	O
of	O
ovarian	B
cancer	I
is	O
hindered	O
by	O
intrinsic	O
or	O
acquired	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
frequency	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
inactivation	O
in	O
ovarian	B
cancer	I
and	O
its	O
association	O
with	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
.	O

Methods	O
We	O
determined	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
as	O
a	O
marker	O
for	O
MMR	O
inactivation	O
(	O
analysis	O
of	O
BAT25	O
and	O
BAT26	O
)	O
,	O
MLH1	O
promoter	O
methylation	O
status	O
(	O
methylation	O
specific	O
PCR	O
on	O
bisulfite	O
treated	O
DNA	O
)	O
and	O
mRNA	O
expression	O
of	O
MLH1	O
,	O
MSH2	O
,	O
MSH3	O
,	O
MSH6	O
and	O
PMS2	O
(	O
quantitative	O
RT	O
-	O
PCR	O
)	O
in	O
75	O
ovarian	O
carcinomas	B
and	O
eight	O
ovarian	B
cancer	I
cell	O
lines	O
Results	O
MSI	B
was	O
detected	O
in	O
three	O
of	O
the	O
eight	O
cell	O
lines	O
i.e.	O
A2780	O
(	O
no	O
MLH1	O
mRNA	O
expression	O
due	O
to	O
promoter	O
methylation	O
)	O
,	O
SKOV3	O
(	O
no	O
MLH1	O
mRNA	O
expression	O
)	O
and	O
2774	O
(	O
no	O
altered	O
expression	O
of	O
MMR	O
genes	O
)	O
.	O

Overall	O
,	O
there	O
was	O
no	O
association	O
between	O
cisplatin	O
response	O
and	O
MMR	O
status	O
in	O
these	O
eight	O
cell	O
lines	O
.	O

Seven	O
of	O
the	O
75	O
ovarian	O
carcinomas	B
showed	O
MLH1	O
promoter	O
methylation	O
,	O
however	O
,	O
none	O
of	O
these	O
showed	O
MSI	O
.	O

Forty	O
-	O
six	O
of	O
these	O
patients	O
received	O
platinum	O
-	O
based	O
chemotherapy	O
(	O
11	O
non	O
-	O
responders	O
,	O
34	O
responders	O
,	O
one	O
unknown	O
response	O
)	O
.	O

The	O
resistance	O
seen	O
in	O
the	O
eleven	O
non	O
-	O
responders	O
was	O
not	B
related	I
to	I
MSI	I
and	O
therefore	O
also	O
not	O
to	O
MMR	O
inactivation	O
.	O

Conclusion	O

No	O
MMR	O
inactivation	O
was	O
detected	O
in	O
75	O
ovarian	O
carcinoma	B
specimens	O
and	O
no	O
association	O
was	O
seen	O
between	O
MMR	B
inactivation	I
and	O
resistance	O
in	O
the	O
ovarian	B
cancer	I
cell	O
lines	O
as	O
well	O
as	O
the	O
ovarian	O
carcinomas	B
.	O

In	O
the	O
discussion	O
,	O
the	O
results	O
were	O
compared	O
to	O
that	O
of	O
twenty	O
similar	O
studies	O
in	O
the	O
literature	O
including	O
in	O
total	O
1315	O
ovarian	B
cancer	I
patients	O
.	O

Although	O
no	O
association	O
between	O
response	O
and	O
MMR	O
status	O
was	O
seen	O
in	O
the	O
primary	O
tumor	B
the	O
possible	O
role	O
of	O
MMR	O
inactivation	O
in	O
acquired	O
resistance	O
deserves	O
further	O
investigation	O
.	O

Interestingly	O
,	O
a	O
number	O
of	O
in	O
vitro	O
studies	O
have	O
suggested	O
a	O
relationship	O
between	O
MMR	O
deficiency	O
and	O
platinum	O
-	O
drug	O
resistance	O
.	O

Several	O
resistant	O
sublines	O
of	O
ovarian	O
and	O
melanoma	B
cell	O
lines	O
generated	O
by	O
cisplatin	O
selection	O
,	O
appeared	O
to	O
be	O
MMR	O
deficient	O
[	O
11	O
-	O
15	O
]	O
.	O

In	O
addition	O
,	O
a	O
colon	O
(	O
HCT116	O
)	O
and	O
an	O
endometrioid	O
cell	O
line	O
(	O
HEC59	O
)	O
,	O
deficient	B
for	I
MLH1	I
and	I
MSH2	I
respectively	O
,	O
were	O
2.1	O
and	O
1.8	O
fold	O
resistant	O
to	O
cisplatin	O
compared	O
to	O
cell	O
lines	O
complemented	O
with	O
chromosome	O
3	O
,	O
containing	O
MLH1	O
,	O
or	O
chromosome	O
2	O
,	O
containing	O
MSH2	O
[	O
15	O
-	O
17	O
]	O
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
inactivation	O
of	O
proteins	O
involved	O
in	O
the	O
initiation	O
of	O
MMR	O
might	O
cause	O
cisplatin	O
resistance	O
.	O

It	O
is	O
thought	O
that	O
the	O
DNA	O
damage	O
caused	O
by	O
platin	O
-	O
drugs	O
is	O
recognized	O
by	O
MMR	O
.	O

The	O
cell	O
will	O
then	O
undergo	O
several	O
unsuccessful	O
repair	O
cycles	O
,	O
finally	O
resulting	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O

When	O
MMR	O
is	O
inactive	O
the	O
DNA	O
damage	O
caused	O
by	O
platin	O
-	O
drugs	O
will	O
not	O
be	O
picked	O
up	O
and	O
will	O
therefore	O
not	O
result	O
in	O
apoptosis	O
rendering	O
the	O
cells	O
resistant	O
to	O
platin	O
-	O
drugs	O
.	O

Several	O
studies	O
have	O
determined	O
the	O
frequency	O
of	O
MMR	O
inactivation	O
in	O
ovarian	B
cancer	I
using	O
MSI	O
as	O
a	O
marker	O
[	O
18	O
-	O
37	O
]	O
.	O

However	O
,	O
there	O
was	O
a	O
wide	O
range	O
observed	O
(	O
0%–39	O
%	O
)	O
and	O
so	O
far	O
only	O
a	O
few	O
studies	O
have	O
linked	O
MMR	O
inactivation	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
.	O

Thus	O
,	O
there	O
is	O
still	O
no	O
general	O
agreement	O
about	O
the	O
frequency	O
of	O
MMR	O
inactivation	O
and	O
its	O
possible	O
involvement	O
in	O
the	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
seen	O
in	O
ovarian	B
cancer	I
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
frequency	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
inactivation	O
in	O
ovarian	B
cancer	I
and	O
whether	O
it	O
is	O
associated	O
with	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
.	O

To	O
this	O
purpose	O
we	O
analyzed	O
seventy	O
-	O
five	O
ovarian	O
carcinomas	B
and	O
eight	O
ovarian	B
cancer	I
cell	O
lines	O
.	O

In	O
the	O
discussion	O
,	O
the	O
results	O
were	O
compared	O
to	O
that	O
of	O
twenty	O
similar	O
studies	O
in	O
the	O
literature	O
including	O
in	O
total	O
1315	O
ovarian	B
cancer	I
patients	O
.	O

Another	O
difference	O
between	O
the	O
studies	O
is	O
the	O
distribution	O
of	O
the	O
various	O
histological	O
types	O
of	O
the	O
ovarian	O
carcinoma	B
tissues	O
analyzed	O
(	O
Table	O
2	O
)	O
.	O

This	O
difference	O
in	O
the	O
distribution	O
could	O
be	O
a	O
cause	O
for	O
the	O
wide	O
range	O
in	O
the	O
MSI	O
frequency	O
especially	O
since	O
it	O
has	O
been	O
suggested	O
that	O
certain	O
histological	O
types	O
have	O
a	O
higher	O
frequency	O
of	O
MSI	O
.	O

To	O
determine	O
whether	O
there	O
is	O
a	O
relation	O
between	O
histology	O
and	O
MSI	O
within	O
these	O
studies	O
,	O
we	O
looked	O
at	O
the	O
frequency	O
of	O
MSI	O
per	O
histological	O
type	O
for	O
the	O
628	O
patients	O
with	O
known	O
histology	O
(	O
Table	O
2	O
)	O
.	O

The	O
summary	O
of	O
these	O
studies	O
suggests	O
that	O
the	O
frequency	O
of	O
MSI	O
is	O
higher	O
in	O
the	O
mucinous	B
and	O
endometrioid	O
adenocarcinoma	B
compared	O
to	O
clear	O
cell	O
and	O
serous	O
adenocarcinoma	B
(	O
the	O
overall	O
frequencies	O
of	O
MSI	B
were	O
22	O
%	O
,	O
16	O
%	O
,	O
9	O
%	O
and	O
8	O
%	O
,	O
respectively	O
)	O
(	O
Table	O
2	O
)	O
.	O

We	O
hypothesize	O
that	O
mucinous	O
and	O
endometrioid	O
histology	O
might	O
be	O
prone	O
to	O
a	O
higher	O
MSI	O
frequency	O
since	O
sporadic	O
endometrial	O
carcinoma	B
,	O
which	O
is	O
closely	O
related	O
to	O
endometrioid	O
ovarian	B
cancer	I
,	O
has	O
a	O
MSI	O
frequency	O
of	O
20–30	O
%	O
[	O
49	O
-	O
51	O
]	O
and	O
MSI	B
is	O
almost	O
universal	O
present	O
in	O
the	O
colorectal	O
tumors	B
of	O
the	O
hereditary	B
nonpolyposis	I
colon	I
cancer	I
(	O
HNPCC	B
)	O
syndrome	O
which	O
all	O
have	O
a	O
mucinous	B
histological	O
type	O
.	O

Therefore	O
,	O
the	O
different	O
histology	O
's	O
of	O
the	O
ovarian	O
carcinomas	B
included	O
in	O
the	O
several	O
studies	O
seems	O
to	O
be	O
a	O
plausible	O
cause	O
for	O
the	O
wide	O
range	O
in	O
MSI	O
frequency	O
reported	O
in	O
these	O
studies	O
.	O

Next	O
we	O
addressed	O
the	O
second	O
part	O
of	O
the	O
aim	O
of	O
this	O
study	O
,	O
is	O
MMR	O
inactivation	O
associated	O
with	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
in	O
ovarian	B
cancer	I
.	O

Forty	O
-	O
six	O
of	O
the	O
75	O
ovarian	O
carcinomas	B
we	O
analyzed	O
had	O
been	O
treated	O
with	O
platinum	O
-	O
based	O
chemotherapy	O
,	O
eleven	O
did	O
not	O
respond	O
and	O
34	O
did	O
.	O

For	O
one	O
patient	O
the	O
response	O
was	O
not	O
known	O
.	O

Methylation	O
of	O
the	O
MLH1	O
promoter	O
was	O
detected	O
in	O
two	O
of	O
the	O
eleven	O
non	O
-	O
responders	O
(	O
18	O
%	O
)	O
and	O
four	O
of	O
the	O
34	O
responders	O
(	O
12	O
%	O
)	O
and	O
this	O
was	O
not	O
significantly	O
different	O
(	O
p	O
=	O
0.664	O
)	O
.	O

Since	O
we	O
did	O
not	O
detect	O
any	O
MSI	O
,	O
the	O
resistance	O
seen	O
in	O
the	O
eleven	O
patients	O
could	O
not	O
be	O
associated	O
with	O
MSI	O
and	O
MMR	B
inactivation	I
.	O

The	O
relation	O
between	O
MMR	O
deficiency	O
and	O
platinum	O
-	O
drug	O
resistance	O
has	O
been	O
investigated	O
in	O
only	O
a	O
few	O
in	O
vivo	O
studies	O
.	O

Similarly	O
to	O
our	O
result	O
,	O
no	B
MSI	I
was	O
detected	O
by	O
Mesquita	O
et	O
al.	O
[	O
18	O
]	O
who	O
studied	O
34	O
ovarian	O
carcinomas	B
of	O
which	O
seven	O
did	O
not	O
respond	O
to	O
cisplatin	O
/	O
paclitaxel	O
therapy	O
.	O

So	O
the	O
resistance	O
seen	O
in	O
these	O
seven	O
nonresponding	O
patients	O
was	O
also	O
not	O
associated	O
with	O
MMR	B
inactivation	I
.	O

In	O
contrast	O
,	O
Samimi	O
et	O
al.	O
[	O
52	O
]	O
found	O
an	O
inverse	O
relation	O
between	O
MLH1	O
protein	O
expression	O
and	O
the	O
response	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
in	O
54	O
ovarian	O
carcinomas	B
.	O

Again	O
,	O
the	O
number	O
of	O
ovarian	O
carcinomas	B
included	O
in	O
these	O
studies	O
is	O
small	O
and	O
no	O
further	O
conclusion	O
can	O
be	O
drawn	O
from	O
these	O
results	O
.	O

Since	O
platinum	O
-	O
drug	O
resistance	O
is	O
thought	O
to	O
be	O
multifactorial	O
the	O
involvement	O
of	O
other	O
resistance	O
mechanisms	O
could	O
have	O
overruled	O
the	O
possible	O
contribution	O
of	O
MMR	O
status	O
.	O

However	O
,	O
platinum	O
treatment	O
does	O
seem	O
to	O
select	O
for	O
MMR	O
deficient	O
cells	O
since	O
in	O
vitro	O
enrichment	O
for	O
MLH1	B
deficient	I
colon	B
cancer	I
HCT116	O
cells	O
in	O
a	O
mixed	O
cell	O
population	O
was	O
seen	O
after	O
cisplatin	O
treatment	O
[	O
53	O
]	O
.	O

In	O
addition	O
,	O
several	O
in	O
vivo	O
studies	O
found	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
MSI	O
and	O
MLH1	O
methylation	O
after	O
platinum	O
-	O
based	O
chemotherapy	O
as	O
well	O
as	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
cells	O
positive	O
for	O
MLH1	O
and	O
MSH2	O
[	O
14,19,25,52	O
]	O
.	O

Moreover	O
,	O
an	O
increase	O
in	O
MLH1	O
methylation	O
after	O
platinum	O
-	O
based	O
chemotherapy	O
was	O
associated	O
with	O
poor	O
survival	O
in	O
ovarian	B
cancer	I
patients	O
[	O
19	O
]	O
.	O

These	O
results	O
as	O
well	O
as	O
the	O
in	O
vitro	O
studies	O
mentioned	O
in	O
the	O
introduction	O
,	O
suggest	O
that	O
MMR	O
inactivation	O
causes	O
a	O
low	O
level	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
which	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
intrinsic	O
resistance	O
.	O

However	O
,	O
due	O
to	O
selection	O
during	O
chemotherapy	O
MMR	O
inactivation	O
might	O
play	O
a	O
greater	O
role	O
in	O
the	O
acquired	O
resistance	O
.	O

We	O
therefore	O
propose	O
that	O
the	O
role	O
of	O
MMR	O
inactivation	O
in	O
acquired	O
resistance	O
in	O
ovarian	B
cancer	I
should	O
be	O
further	O
investigated	O
.	O

Whole	O
-	O
chromosome	O
plots	O
of	O
running	O
average	O
of	O
fractions	O
of	O
samples	O
showing	O
up-	O
/	O
down	O
-	O
regulation	O
in	O
tumor	B
versus	O
normal	B
samples	O
(	O
Chromosome	O
17,18,19,20,21,22,X	O
,	O
Y	O
)	O
.	O

For	O
each	O
chromosome	O
you	O
see	O
a	O
separate	O
figure	O
.	O

Gray	O
dots	O
denote	O
the	O
number	O
of	O
patients	O
with	O
up-	O
or	O
down	O
-	O
regulation	O
for	O
a	O
single	O
gene	O
.	O

Orange	O
/	O
green	O
lines	O
represent	O
a	O
running	O
average	O
of	O
these	O
values	O
.	O

The	O
plots	O
are	O
made	O
to	O
be	O
easily	O
comparable	O
with	O
whole	O
-	O
genome	O
CGH	O
plots	O
(	O
like	O
e.g.	O
those	O
in	O
Knösel	O
et	O
al.	O
[	O
21	O
]	O
)	O

Further	O
details	O
of	O
plot	O
construction	O
are	O
described	O
in	O
the	O
methods	O
section	O
.	O

Individual	O
chromosomal	O
islands	O
of	O
up-	O
or	O
down	O
-	O
regulation	O
.	O

These	O
are	O
condensed	O
results	O
of	O
the	O
ChARM	O
analyses	O
:	O
overlapping	O
regions	O
with	O
evidence	O
for	O
up-	O
or	O
down	O
-	O
regulation	O
from	O
various	O
analyses	O
of	O
different	O
cross	O
-	O
correlation	O
window	O
sizes	O
have	O
been	O
fused	O
into	O
single	O
regions	O
.	O

The	O
original	O
ChARM	O
output	O
including	O
p	O
values	O
for	O
each	O
region	O
and	O
additional	O
annotation	O
can	O
be	O
found	O
in	O
Additional	O
file	O
1	O
.	O

Hereditary	O
colorectal	B
cancer	I
syndromes	O
are	O
indicated	O
along	O
with	O
their	O
OMIM	O
ID	O
.	O

Gene	O
symbols	O
are	O
official	O
or	O
provisional	O
HUGO	O
symbols	O
if	O
available	O
,	O
otherwise	O
names	O
of	O
Unigene	O
clusters	O
.	O

Information	O
about	O
known	O
tumor	B
genes	O
in	O
misregulated	O
regions	O
were	O
extracted	O
from	O
the	O
literature	O
.	O

Tumor	B
-	O
associated	O
genes	O
are	O
located	O
within	O
expression	O
islands	O
or	O
in	O
near	O
vicinity	O
.	O

Statistics	O
on	O
expression	O
imbalances	O
across	O
human	O
chromosomes	O
.	O

Here	O
,	O
estimates	O
of	O
portions	O
of	O
chromosomes	O
that	O
are	O
affected	O
by	O
regional	O
regulation	O
of	O
expression	O
are	O
given	O
.	O

The	O
second	O
column	O
gives	O
the	O
number	O
of	O
genes	O
on	O
a	O
particular	O
chromosome	O
that	O
were	O
included	O
in	O
our	O
analysis	O
.	O

The	O
following	O
columns	O
contain	O
the	O
numbers	O
of	O
genes	O
that	O
are	O
located	O
in	O
deregulated	O
expression	O
islands	O
(	O
up	O
/	O
down	O
)	O
.	O

Individual	O
chromosomal	O
islands	O
with	O
gain	O
of	O
expression	O
8q11.23-q21.13	O
Gain	O
of	O
expression	O
in	O
region	O
8q11.23-q21.13	O
is	O
strongest	O
in	O
a	O
small	O
interval	O
(	O
8q12.1	O
)	O
that	O
spans	O
genes	O
from	O
TCEA1	O
to	O
PLAG1	O
(	O
see	O
Figures	O
6	O
,	O
7	O
,	O
8)	O
.	O

There	O
have	O
been	O
numerous	O
reports	O
of	O
copy	O
number	O
gains	O
of	O
chromosome	O
8q	O
in	O
CRC	B
[	O
18,21,23,25	O
]	O
which	O
suggests	O
a	O
possible	O
mechanism	O
leading	O
to	O
over	O
-	O
expression	O
in	O
our	O
patients	O
.	O

The	O
known	O
blood	O
cell	O
oncogene	O
LYN	O
is	O
located	O
in	O
this	O
interval	O
and	O
it	O
is	O
up	O
-	O
regulated	O
in	O
several	O
of	O
our	O
tumor	B
samples	O
.	O

It	O
has	O
been	O
reported	O
before	O
that	O
LYN	O
is	O
expressed	O
in	O
colorectal	O
tumors	B
[	O
26	O
]	O
.	O

The	O
concerted	O
up	O
-	O
regulation	O
of	O
LYN	O
along	O
with	O
other	O
genes	O
in	O
this	O
region	O
suggests	O
a	O
role	O
for	O
LYN	O
in	O
CRC	B
.	O

Another	O
interesting	O
gene	O
in	O
this	O
interval	O
is	O
PLAG1	O
(	O
pleomorphic	O
adenoma	B
gene	O
1	O
)	O
for	O
which	O
chromosomal	O
aberrations	O
have	O
been	O
described	O
that	O
lead	O
to	O
over	O
-	O
expression	O
in	O
salivary	O
gland	O
tumors	B
[	O
27,28	O
]	O
.	O

No	O
informative	O
expression	O
measures	O
were	O
obtained	O
for	O
the	O
MOS	O
protein	O
kinase	O
gene	O
which	O
is	O
located	O
between	O
RPS20	O
and	O
PLAG1	O
,	O
although	O
this	O
may	O
be	O
due	O
to	O
technical	O
limitations	O
.	O

Genes	O
encoding	O
components	O
of	O
the	O
translation	O
machinery	O
,	O
the	O
mitochondrial	O
ribosomal	O
protein	O
MRPL15	O
and	O
cytosolic	O
ribosomal	O
proteins	O
RPL7	O
and	O
RPS20	O
,	O
are	O
located	O
in	O
this	O
region	O
,	O
highlighting	O
the	O
need	O
for	O
enhanced	O
translation	O
in	O
cancer	B
cells	O
.	O

The	O
concomitant	O
down	O
-	O
regulation	O
of	O
the	O
TOX	O
and	O
ANKTM1	O
genes	O
in	O
many	O
patients	O
in	O
an	O
environment	O
of	O
transcriptional	O
activation	O
is	O
remarkable	O
,	O
but	O
the	O
functional	O
significance	O
remains	O
unclear	O
.	O

Buffart	O
et	O
al.	O
have	O
reported	O
amplifications	B
of	I
8q11-q24	I
in	O
metastasizing	O
CRC	B
[	O
29	O
]	O
,	O
highlighting	O
a	O
possible	O
mechanism	O
for	O
gain	O
of	O
expression	O
in	O
this	O
region	O
.	O

In	O
summary	O
,	O
our	O
analysis	O
suggests	O
that	O
chromosomal	O
region	O
8q12.1	O
is	O
a	O
candidate	O
target	O
region	O
for	O
genetic	O
alterations	O
that	O
lead	O
to	O
over	O
-	O
expression	O
in	O
CRC	B
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
T	O
/	O
N	O
relative	O
expression	O
heat	O
map	O
)	O
.	O

Heat	O
map	O
of	O
fold	O
change	O
of	O
tumor	B
-	O
versus	O
-	O
normal	O
expression	O
.	O

Genes	O
are	O
given	O
in	O
chromosomal	O
order	O
on	O
the	O
horizontal	O
axis	O
.	O

Patient	O
codes	O
are	O
given	O
on	O
the	O
vertical	O
axis	O
.	O

The	O
legend	O
depicts	O
which	O
colors	O
code	O
for	O
which	O
expression	O
changes	O
on	O
a	O
loge	O
scale	O
(	O
green	O
:	O
down	O
in	O
tumor	O
;	O
red	O
:	O
up	O
in	O
tumor	O
)	O
.	O

View	O
in	O
conjunction	O
with	O
Figures	O
7	O
and	O
8	O
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
patient	O
counts	O
with	O
coordinate	O
up	O
-	O
regulation	O
)	O
.	O

Grayscale	O
plot	O
of	O
cross	O
-	O
comparison	O
of	O
up	O
-	O
regulation	O
patterns	O
across	O
patients	O
for	O
gene	O
pairs	O
in	O
a	O
particular	O
region	O
.	O

Both	O
,	O
horizontal	O
and	O
vertical	O
axes	O
comprise	O
the	O
same	O
genes	O
in	O
chromosomal	O
order	O
.	O

In	O
each	O
square	O
total	O
counts	O
of	O
patients	O
with	O
consistent	O
up	O
-	O
regulation	O
in	O
two	O
genes	O
are	O
coded	O
by	O
different	O
shades	O
of	O
gray	O
.	O

Dark	O
squared	O
regions	O
along	O
the	O
diagonal	O
indicate	O
coordinated	O
regulation	O
in	O
patient	O
subgroups	O
.	O

Note	O
,	O
that	O
many	O
more	O
patients	O
show	O
up	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
this	O
figure	O
than	O
down	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
Figure	O
8	O
.	O

The	O
left	O
region	O
of	O
exceptionally	O
strong	O
up	O
-	O
regulation	O
spans	O
TCEA1	O
,	O
LYPLA1	O
,	O
MRPL15	O
,	O
the	O
known	O
tumor	O
gene	O
LYN	O
,	O
and	O
PLAG1	O
.	O

Note	O
that	O
TOX	O
and	O
ANKTM1	O
are	O
down	O
-	O
regulated	O
in	O
approximately	O
half	O
of	O
the	O
tumor	B
samples	O
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
patient	O
counts	O
with	O
coordinate	O
down	O
-	O
regulation	O
)	O
.	O

Grayscale	O
plot	O
of	O
cross	O
-	O
comparison	O
of	O
down	O
-	O
regulation	O
patterns	O
across	O
patients	O
for	O
gene	O
pairs	O
in	O
a	O
particular	O
region	O
.	O

Both	O
,	O
horizontal	O
and	O
vertical	O
axes	O
comprise	O
the	O
same	O
genes	O
in	O
chromosomal	O
order	O
.	O

In	O
each	O
square	O
total	O
counts	O
of	O
patients	O
with	O
consistent	O
down	O
-	O
regulation	O
in	O
two	O
genes	O
are	O
coded	O
by	O
different	O
shades	O
of	O
gray	O
.	O

Dark	O
squared	O
regions	O
along	O
the	O
diagonal	O
indicate	O
coordinated	O
regulation	O
in	O
patient	O
subgroups	O
.	O

View	O
in	O
conjunction	O
with	O
Figures	O
6	O
and	O
7	O
.	O

20q11.22-q11.23	O
The	O
region	O
20q11.22-q11.23	O
was	O
among	O
the	O
most	O
frequently	O
up	O
-	O
regulated	O
regions	O
(	O
see	O
Figures	O
12	O
,	O
13	O
,	O
14	O
)	O
.	O

Amplifications	O
of	O
regions	O
on	O
chromosome	O
20q	O
have	O
been	O
identified	O
independently	O
by	O
several	O
groups	O
in	O
CRCs	B
[	O
19,21,23,24	O
]	O
.	O

The	O
interval	O
comprises	O
the	O
known	O
tumor	B
gene	O
SRC	O
(	O
located	O
between	O
MANBAL	O
and	O
BLCAP	O
in	O
Figures	O
12	O
,	O
13	O
,	O
14	O
)	O
for	O
which	O
no	O
informative	O
expression	O
measures	O
were	O
obtained	O
.	O

We	O
note	O
that	O
it	O
is	O
possible	O
that	O
the	O
SRC	O
gene	O
is	O
the	O
primary	O
target	O
of	O
up	O
-	O
regulation	O
in	O
our	O
CRC	B
patients	O
,	O
the	O
up	O
-	O
regulation	O
of	O
other	O
genes	O
being	O
just	O
piggy	O
-	O
back	O
effects	O
.	O

However	O
,	O
also	O
the	O
up	O
-	O
regulation	O
of	O
the	O
CTNN1L1	O
transcript	O
could	O
be	O
of	O
potential	O
functional	O
significance	O
for	O
CRC	B
development	O
.	O

CTNN1L1	O
shows	O
partial	O
homology	O
to	O
the	O
known	O
colorectal	B
cancer	I
gene	O
beta	O
-	O
catenin	O
in	O
the	O
armadillo	O
repeat	O
region	O
and	O
has	O
a	O
nuclear	O
localization	O
signal	O
,	O
suggesting	O
that	O
it	O
could	O
play	O
an	O
important	O
role	O
in	O
signal	O
transduction	O
to	O
the	O
nucleus	O
in	O
CRC	B
.	O

Also	O
up	O
-	O
regulation	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
Itchy	O
(	O
ITCH	O
)	O
could	O
be	O
of	O
potential	O
importance	O
as	O
selective	O
ubiquitin	O
-	O
tagging	O
of	O
signaling	O
proteins	O
for	O
destruction	O
is	O
an	O
emerging	O
mechanism	O
in	O
cancer	B
biology	O
.	O

The	O
need	O
for	O
accelerated	O
protein	O
synthesis	O
in	O
cancer	B
cells	O
is	O
reflected	O
by	O
the	O
up	O
-	O
regulation	O
of	O
the	O
translation	O
initiation	O
factor	O
EIF2S2	O
.	O

Remarkably	O
,	O
we	O
found	O
dramatic	O
down	O
-	O
regulation	O
against	O
the	O
regional	O
trend	O
of	O
C20orf110	O
alias	O
p53-inducible	O
protein	O
2	O
(	O
TP53INP2	O
)	O
whose	O
expression	O
is	O
usually	O
positively	O
controlled	O
by	O
the	O
p53	O
protein	O
.	O

For	O
unknown	O
reasons	O
p53	O
seems	O
to	O
be	O
unable	O
to	O
induce	O
TP53INP2	O
expression	O
in	O
the	O
majority	O
of	O
CRCs	B
studied	O
here	O
.	O

Down	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
14q24.1	O
-	O
14q24.3	O
–	O
the	O
FOS	O
region	O
(	O
patient	O
counts	O
with	O
coordinate	O
up	O
-	O
regulation	O
)	O
.	O

Grayscale	O
cross	O
-	O
comparison	O
plot	O
of	O
up	O
-	O
regulation	O
patterns	O
across	O
patients	O
(	O
analogous	O
to	O
Figures	O
7	O
,	O
10	O
,	O
13	O
)	O
.	O

View	O
this	O
plot	O
in	O
conjunction	O
with	O
Figures	O
30	O
and	O
32	O
.	O

Down	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
14q24.1	O
-	O
14q24.3	O
–	O
the	O
FOS	O
region	O
(	O
patient	O
counts	O
with	O
coordinate	O
down	O
-	O
regulation	O
)	O
.	O

Grayscale	O
cross	O
-	O
comparison	O
plot	O
of	O
down	O
-	O
regulation	O
patterns	O
across	O
patients	O
(	O
analogous	O
to	O
Figures	O
8	O
,	O
11	O
,	O
14	O
)	O
.	O

View	O
this	O
plot	O
in	O
conjunction	O
with	O
Figures	O
30	O
and	O
31	O
.	O

Note	O
,	O
that	O
many	O
more	O
patients	O
show	O
down	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
this	O
plot	O
than	O
up	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
Figure	O
31	O
.	O

This	O
region	O
has	O
been	O
reported	O
in	O
other	O
studies	O
to	O
be	O
frequently	O
deleted	O
in	O
colon	B
cancer	I
metastases	O
(	O
see	O
Table	O
1	O
)	O
.	O

The	O
FOS	O
oncogene	O
is	O
the	O
5th	O
gene	O
from	O
the	O
right	O
and	O
is	O
one	O
of	O
the	O
most	O
strongly	O
down	O
-	O
regulated	O
genes	O
in	O
this	O
region	O
.	O

Note	O
the	O
expression	O
of	O
MLH3	O
,	O
KIAA0317	O
,	O
KIAA0440	O
/	O
SIPA1L1	O
,	O
NUMB	O
,	O
SYNJ2BP	O
and	O
PSEN1	O
.	O

Discussion	O
Global	O
analysis	O
of	O
chromosomal	O
regions	O
with	O
expression	O
gain	O
or	O
loss	O
We	O
found	O
that	O
25	O
%	O
of	O
the	O
genes	O
lie	O
in	O
regions	O
that	O
are	O
affected	O
by	O
expression	O
imbalance	O
in	O
colon	B
cancer	I
.	O

This	O
does	O
not	O
mean	O
that	O
25	O
%	O
of	O
the	O
genes	O
are	O
misregulated	O
as	O
many	O
genes	O
that	O
fall	O
into	O
these	O
regions	O
are	O
not	O
expressed	O
at	O
all	O
in	O
tumors	B
and	O
in	O
normal	B
epithelium	O
of	O
the	O
colon	O
.	O

Additionally	O
,	O
we	O
note	O
that	O
these	O
numbers	O
are	O
probably	O
an	O
upper	O
limit	O
because	O
the	O
sliding	O
window	O
approach	O
probably	O
included	O
several	O
genes	O
in	O
close	O
proximity	O
to	O
the	O
boundaries	O
of	O
misexpressed	O
regions	O
.	O

Nevertheless	O
,	O
the	O
number	O
of	O
regions	O
of	O
imbalanced	O
expression	O
is	O
remarkable	O
and	O
suggest	O
that	O
there	O
is	O
extensive	O
regulation	O
in	O
CRC	B
at	O
the	O
genomic	O
level	O
.	O

Recently	O
,	O
Nakao	O
et	O
al.	O
estimated	O
from	O
genome	O
-	O
wide	O
array	O
CGH	O
data	O
that	O
~17	O
%	O
of	O
the	O
human	O
genome	O
is	O
affected	O
by	O
DNA	O
copy	O
number	O
changes	O
in	O
CRC	B
[	O
23	O
]	O
.	O

Prior	O
to	O
a	O
more	O
detailed	O
analysis	O
of	O
individual	O
regions	O
in	O
this	O
study	O
,	O
this	O
suggested	O
that	O
not	O
all	O
regional	O
expression	O
changes	O
in	O
CRC	B
will	O
be	O
explainable	O
by	O
DNA	O
copy	O
number	O
aberrations	O
.	O

There	O
are	O
only	O
slightly	O
more	O
genes	O
with	O
expression	O
loss	O
than	O
regions	O
with	O
expression	O
gain	O
.	O

One	O
can	O
argue	O
that	O
a	O
tumor	O
ought	O
to	O
show	O
a	O
higher	O
frequency	O
of	O
expression	O
loss	O
than	O
expression	O
gain	O
.	O

Reasons	O
are	O
that	O
there	O
should	O
be	O
a	O
tendency	O
to	O
lose	O
tumor	O
suppressor	O
genes	O
selectively	O
and	O
to	O
lose	O
non	O
-	O
essential	O
genes	O
(	O
genomic	O
ballast	O
)	O
as	O
a	O
side	O
effect	O
.	O

If	O
transcription	O
would	O
be	O
a	O
process	O
that	O
is	O
predominantly	O
driven	O
by	O
positive	O
regulation	O
of	O
transcriptional	O
activators	O
,	O
one	O
would	O
assume	O
that	O
any	O
partial	O
genome	O
loss	O
results	O
in	O
a	O
slow	O
down	O
of	O
transcription	O
.	O

In	O
the	O
light	O
of	O
these	O
considerations	O
,	O
an	O
equally	O
high	O
number	O
of	O
regions	O
with	O
expression	O
gain	O
can	O
be	O
interpreted	O
in	O
two	O
ways	O
.	O

Either	O
positive	O
selection	O
drives	O
expression	O
gain	O
of	O
some	O
regions	O
in	O
cancer	O
cells	O
,	O
or	O
a	O
default	O
phenotype	O
of	O
transcription	O
suppression	O
dominates	O
in	O
normal	O
cells	O
which	O
is	O
relaxed	O
during	O
tumor	O
cell	O
development	O
.	O

Gene	O
expression	O
in	O
chromosomal	O
regions	O
with	O
frequent	O
DNA	O
copy	O
number	O
changes	O
in	O
CRC	B
Most	O
studies	O
reported	O
frequent	O
gains	O
of	O
chromosome	O
7	O
,	O
8q	O
,	O
13q	O
,	O
20q	O
and	O
losses	O
of	O
4	O
and	O
18q	O
in	O
CRC	B
[	O
18,19,21	O
-	O
25	O
]	O
.	O

These	O
broadly	O
-	O
defined	O
alterations	O
are	O
in	O
perfect	O
agreement	O
with	O
chromosome	O
-	O
specific	O
trends	O
in	O
our	O
expression	O
data	O
,	O
especially	O
the	O
exclusive	O
presence	O
of	O
domains	O
of	O
expression	O
gain	O
on	O
8	O
,	O
13	O
and	O
20	O
and	O
the	O
exclusive	O
presence	O
of	O
domains	O
of	O
expression	O
loss	O
on	O
chromosome	O
4	O
and	O
18	O
(	O
see	O
Table	O
2	O
and	O
Figures	O
21	O
,	O
22	O
,	O
23	O
,	O
24	O
,	O
25	O
,	O
26	O
)	O
.	O

There	O
is	O
a	O
single	O
discrepancy	O
for	O
chromosome	O
7	O
:	O
region	O
7q11	O
-	O
7q12	O
has	O
been	O
reported	O
as	O
amplified	O
in	O
CRC	B
,	O
but	O
its	O
expression	O
is	O
significantly	O
down	O
-	O
regulated	O
in	O
our	O
tumor	O
samples	O
.	O

Conclusion	O
Roughly	O
a	O
quarter	O
of	O
all	O
human	O
genes	O
is	O
located	O
in	O
islands	O
of	O
misregulated	O
gene	O
expression	O
in	O
colorectal	B
cancer	I
.	O

There	O
are	O
only	O
slightly	O
more	O
down	O
-	O
regulated	O
than	O
up	O
-	O
regulated	O
genes	O
.	O

Chromosomal	O
regions	O
that	O
are	O
linked	O
to	O
hereditary	O
colorectal	B
cancer	I
often	O
exhibit	O
deregulated	O
expression	O
,	O
suggesting	O
that	O
they	O
are	O
implicated	O
in	O
spontaneous	O
CRC	B
not	O
only	O
through	O
collection	O
of	O
mutations	O
.	O

Thus	O
,	O
genes	O
in	O
these	O
chromosomal	O
hotspots	O
may	O
be	O
systematically	O
tested	O
in	O
patients	O
with	O
sporadic	O
CRC	B
for	O
molecular	O
lesions	B
and	O
for	O
transcriptional	O
silencing	O
.	O

Chromosomal	O
regions	O
that	O
are	O
frequently	O
deleted	O
in	O
CRC	B
very	O
often	O
comprise	O
islands	O
in	O
which	O
we	O
found	O
reduced	O
expression	O
.	O

Although	O
many	O
regions	O
that	O
are	O
known	O
to	O
be	O
amplified	O
in	O
colorectal	O
tumors	B
show	O
a	O
gain	O
of	O
expression	O
,	O
there	O
are	O
also	O
a	O
considerable	O
number	O
of	O
amplified	O
islands	O
that	O
show	O
no	O
alterations	O
or	O
even	O
down	O
-	O
regulation	O
.	O

Comparison	O
of	O
published	O
CGH	O
studies	O
with	O
our	O
expression	O
data	O
suggests	O
that	O
amplified	O
or	O
deleted	O
chromosomal	O
regions	O
are	O
responsible	O
for	O
many	O
islands	O
with	O
aberrant	O
expression	O
.	O

However	O
,	O
we	O
suggest	O
that	O
it	O
is	O
necessary	O
to	O
invoke	O
other	O
mechanism	O
like	O
epigenetic	O
regulation	O
of	O
chromatin	O
or	O
disruption	O
of	O
enhancer	O
actions	O
to	O
explain	O
the	O
remaining	O
expression	O
imbalances	O
.	O

Non	B
-	I
dysplastic	I
serrated	O
polyps	B
:	O
HP	B
and	O
SSA	B
Non	B
-	I
dysplastic	I
serrated	O
polyps	B
comprise	O
conventional	O
HPs	B
and	O
the	O
variant	O
lesion	B
which	O
has	O
been	O
described	O
as	O
SSA	B
.	O

In	O
this	O
study	O
,	O
SSAs	B
accounted	O
for	O
approximately	O
3	O
%	O
of	O
the	O
overall	O
series	O
of	O
polyps	B
and	O
were	O
more	O
age	O
-	O
related	O
than	O
HPs	B
.	O

Importantly	O
,	O
SSAs	B
have	O
been	O
linked	O
with	O
the	O
subset	O
of	O
colorectal	B
cancer	I
with	O
BRAF	O
mutation	O
,	O
DNA	O
methylation	O
,	O
MSI	B
and	O
serrated	B
architecture.14,18,37	I
In	O
this	O
study	O
there	O
was	O
a	O
high	O
frequency	O
of	O
BRAF	O
mutation	O
in	O
conventional	O
HPs	B
(	O
67	O
%	O
)	O
as	O
well	O
as	O
in	O
SSAs	B
(	O
81	O
%	O
)	O
.	O

Previous	O
reports	O
have	O
shown	O
very	O
similar	O
results	O
for	O
BRAF	O
mutation	O
in	O
SSA,16	B
but	O
higher	O
frequencies	O
of	O
KRAS	O
mutation	O
and	O
lower	O
frequencies	O
of	O
BRAF	O
mutation	O
in	O
HPs.12,16,38	B
As	O
mentioned	O
in	O
Materials	O
and	O
methods	O
,	O
there	O
had	O
been	O
selection	O
of	O
larger	O
HPs	B
in	O
an	O
earlier	O
cell	O
kinetic	O
study	O
involving	O
the	O
same	O
material	O
.	O

Large	O
HPs	B
are	O
more	O
likely	O
to	O
include	O
the	O
subset	O
described	O
as	O
'	O
microvesicular	O
'	O
,	O
in	O
which	O
the	O
columnar	O
cells	O
contain	O
apical	O
mucin	O
droplets	O
within	O
small	O
vesicles	O
while	O
goblet	O
cells	O
are	O
rendered	O
inconspicuous.25BRAF	O
mutation	O
occurs	O
more	O
frequently	O
in	O
the	O
microvesicular	O
variant	O
of	O
HP.16	B
By	O
contrast	O
,	O
KRAS	O
mutation	O
occurs	O
much	O
more	O
commonly	O
in	O
the	O
goblet	O
cell	O
variant	O
of	O
HP	B
,	O
which	O
is	O
usually	O
small	O
,	O
located	O
in	O
the	O
left	O
colon	O
or	O
rectum	O
and	O
deviates	O
minimally	O
from	O
normal	B
colorectal	O
mucosa	O
in	O
terms	O
of	O
differentiation	O
and	O
architecture.16,25	O
The	O
latter	O
were	O
under	O
-	O
represented	O
in	O
this	O
series	O
(	O
details	O
not	O
shown	O
)	O
.	O

dysplastic	B
serrated	O
polyps	B
:	O
MP	B
and	O
SA	B
Serrated	O
polyps	B
with	O
dysplasia	B
,	O
i.e.	O
MPs	B
and	O
SAs	B
,	O
together	O
comprised	O
only	O
2	O
%	O
of	O
the	O
overall	O
consecutive	O
series	O
of	O
1250	O
polyps	B
.	O

While	O
mutation	O
of	O
KRAS	O
and	O
BRAF	O
was	O
associated	O
with	O
conventional	O
adenoma	B
and	O
SSA	B
,	O
respectively	O
(	O
see	O
above	O
)	O
,	O
BRAF	O
and	O
KRAS	O
mutation	O
occurred	O
with	O
similar	O
frequency	O
in	O
both	O
MPs	B
(	O
40	O
%	O
and	O
50	O
%	O
,	O
respectively	O
)	O
and	O
SAs	B
(	O
33	O
%	O
and	O
27	O
%	O
,	O
respectively	O
)	O
.	O

In	O
the	O
literature	O
,	O
the	O
frequency	O
of	O
BRAF	O
and	O
KRAS	O
mutation	O
in	O
MP	B
or	O
SA	B
has	O
ranged	O
from	O
36	O
to	O
100	O
%	O
and	O
from	O
0	O
%	O
to	O
60	O
%	O
,	O
respectively.12,16,39–42	O
These	O
findings	O
indicate	O
that	O
this	O
subset	O
of	O
colorectal	O
polyps	B
is	O
likely	O
to	O
be	O
heterogeneous	O
in	O
terms	O
of	O
its	O
molecular	O
origins	O
.	O

These	O
polyps	B
were	O
therefore	O
reclassified	O
according	O
to	O
their	O
resemblance	O
to	O
HP	B
or	O
SSA	B
(	O
Group	O
A	O
)	O
(	O
Figure	O
1A	O
,	O
B	O
,	O
E	O
,	O
F	O
)	O
or	O
to	O
conventional	O
adenoma	B
(	O
Group	O
B	O
)	O
(	O
Figure	O
1C	O
,	O
D	O
)	O
.	O

Particular	O
histological	O
features	O
among	O
the	O
Group	O
A	O
polyps	B
were	O
:	O
marked	O
serration	O
,	O
a	O
papillary	B
or	I
villous	I
architecture	I
,	O
a	O
relatively	O
abundant	O
eosinophilic	O
cytoplasm	O
,	O
columnar	O
cells	O
with	O
apical	O
mucin	O
droplets	O
,	O
nuclei	O
that	O
were	O
enlarged	O
,	O
ovoid	O
,	O
vesicular	O
and	O
contained	O
a	O
prominent	O
nucleolus	O
,	O
and	O
adjacent	O
non	B
-	I
dysplastic	I
serrated	O
polyp	B
.	O

Particular	O
histological	O
features	O
among	O
the	O
Group	O
B	O
polyps	B
were	O
:	O
some	O
glandular	O
serration	O
,	O
frequent	O
villous	O
change	O
and	O
epithelial	B
dysplasia	I
that	I
appeared	I
adenomatous	I
(	O
cytoplasmic	O
basophilia	O
and	O
nuclei	O
that	O
were	O
elongated	O
,	O
pseudostratified	O
and	O
hyperchromatic	O
without	O
a	O
prominent	O
nucleolus	O
)	O
.	O

Importantly	O
,	O
BRAF	O
mutation	O
occurred	O
more	O
frequently	O
among	O
Group	O
A	O
polyps	B
(	O
P	O
<	O
0.03	O
)	O
,	O
whereas	O
there	O
was	O
a	O
trend	O
for	O
KRAS	O
to	O
be	O
more	O
frequent	O
among	O
Group	O
B	O
polyps	B
(	O
P	O
=	O
0.06	O
)	O
.	O

In	O
summary	O
,	O
MPs	B
and	O
SAs	B
account	O
for	O
only	O
about	O
2	O
%	O
of	O
colorectal	O
polyps	B
.	O

Nevertheless	O
,	O
those	O
serrated	O
polyps	B
with	O
dysplasia	B
show	O
frequent	O
mutation	O
of	O
either	O
KRAS	O
or	O
BRAF	O
and	O
frequent	O
loss	O
of	O
expression	O
of	O
MGMT	O
(	O
particularly	O
MP	B
)	O
.	O

Additionally	O
,	O
four	O
of	O
25	O
(	O
16	O
%	O
)	O
showed	O
high	B
-	I
grade	I
dysplasia	I
and	O
in	O
three	O
of	O
these	O
there	O
was	O
concordant	O
aberrant	O
nuclear	O
expression	O
of	O
p53	O
.	O

Along	O
with	O
SSAs	B
,	O
these	O
rare	O
polyps	B
may	O
serve	O
as	O
the	O
precursors	O
of	O
sporadic	O
CRCs	B
with	O
BRAF	O
mutation	O
and	O
DNA	O
methylation	O
(	O
with	B
and	I
without	I
DNA	I
MSI	I
)	O
and	O
a	O
subset	O
of	O
CRCs	B
with	O
KRAS	O
mutation	O
.	O

Their	O
malignant	O
potential	O
is	O
explained	O
by	O
the	O
accumulation	O
of	O
genetic	O
alterations	O
that	O
may	O
in	O
turn	O
depend	O
upon	O
the	O
inactivation	O
of	O
the	O
DNA	O
repair	O
gene	O
MGMT.28	O
The	O
importance	O
of	O
these	O
'	O
fusion	O
'	O
polyps	B
as	O
cancer	B
precursors	O
may	O
be	O
under	O
-	O
appreciated	O
because	O
critical	O
rate	O
-	O
limiting	O
changes	O
governing	O
malignant	O
transition	O
,	O
particularly	O
in	O
association	O
with	O
loss	O
of	O
function	O
of	O
MLH1	O
of	O
p53	O
,	O
occur	O
rapidly	O
and	O
can	O
rarely	O
be	O
'	O
caught	O
in	O
the	O
act	O
'	O
.	O

Methods	O
Patients	O
A	O
large	O
colorectal	B
cancer	I
family	O
(	O
Figure	O
1	O
)	O
with	O
a	O
recently	O
identified	O
mutation	O
in	O
the	O
MLH1	O
gene	O
(	O
c.1046dupT	O
,	O
p.	O

Pro350fs	O
)	O
was	O
studied	O
.	O

Nine	O
family	O
members	O
are	O
affected	O
with	O
colorectal	B
cancer	I
.	O

Another	O
two	O
family	O
members	O
are	O
affected	B
with	O
polyps	B
and	O
three	O
cases	O
with	O
skin	O
cancer	B
(	O
non	O
-	O
specified	O
)	O
and	O
one	O
case	O
with	O
endometrium	O
cancer	B
(	O
non	O
-	O
specified	O
)	O
are	O
seen	O
as	O
well	O
.	O

Peripheral	O
blood	O
lymphocytes	O
were	O
collected	O
from	O
the	O
family	O
members	O
.	O

DNA	O
was	O
extracted	O
using	O
standard	O
procedures	O
.	O

A	O
total	O
of	O
thirteen	O
family	O
members	O
were	O
genotyped	O
on	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
10	O
K	O
2.0	O
SNP	O
arrays	O
.	O

The	O
arrays	O
were	O
processed	O
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
.	O

The	O
mean	O
SNP	O
call	O
rate	O
was	O
96.3	O
%	O
(	O
89.0%-98.5	O
%	O
)	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Medical	O
Ethical	O
Committee	O
of	O
the	O
LUMC	O
(	O
protocol	O
P01	O
-	O
019	O
)	O
.	O

Workflow	O
We	O
processed	O
the	O
data	O
according	O
to	O
the	O
following	O
workflow	O
:	O
1	O
)	O
First	O
,	O
the	O
genotype	O
data	O
were	O
generated	O
by	O
GeneChip	O
DNA	O
Analysis	O
Software	O
(	O
GDAS	O
)	O
from	O
Affymetrix	O
.	O

2	O
)	O
These	O
genotype	O
data	O
were	O
combined	O
with	O
the	O
pedigree	O
and	O
the	O
marker	O
information	O
in	O
Alohomora	O
.	O

3	O
)	O
In	O
this	O
program	O
the	O
uninformative	O
SNPs	O
were	O
removed	O
as	O
well	O
.	O

4	O
)	O
To	O
be	O
able	O
to	O
perform	O
linkage	O
analysis	O
in	O
the	O
desired	O
program	O
,	O
the	O
output	O
files	O
(	O
in	O
Merlin	O
-	O
format	O
)	O
of	O
Alohomora	O
were	O
by	O
Mega2	O
converted	O
to	O
the	O
proper	O
format	O
.	O

5	O
)	O
Mega2	O
also	O
removed	O
the	O
Mendelian	O
inconsistent	O
errors	O
.	O

6	O
)	O
The	O
files	O
were	O
then	O
ready	O
to	O
perform	O
parametric	O
linkage	O
analysis	O
using	O
2	O
flanking	O
markers	O
in	O
MENDEL	O
;	O
affected	O
-	O
only	O
analysis	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
using	O
liability	O
classes	O
was	O
performed	O
.	O

7	O
)	O
Based	O
on	O
the	O
second	O
analysis	O
,	O
regions	O
of	O
interest	O
were	O
defined	O
that	O
were	O
further	O
tested	O
for	O
Mendelian	O
consistent	O
errors	O
and	O
8)	O
possible	O
linkage	O
disequilibrium	O
was	O
removed	O
in	O
SNPLINK	O
.	O

9	O
)	O
Multipoint	O
parametric	O
linkage	O
analysis	O
using	O
the	O
liability	O
classes	O
was	O
then	O
performed	O
in	O
Simwalk2	O
for	O
the	O
ROIs	O
and	O
10	O
)	O
finally	O
,	O
the	O
haplotypes	O
were	O
inferred	O
in	O
Simwalk2	O
.	O

Data	O
formatting	O
and	O
quality	O
control	O
Genotype	O
data	O
of	O
the	O
individual	O
family	O
members	O
were	O
generated	O
using	O
GeneChip	O
DNA	O
Analysis	O
Software	O
(	O
GDAS	O
)	O
from	O
Affymetrix	O
.	O

In	O
the	O
Alohomora	O
program	O
[	O
32	O
]	O
the	O
pedigree	O
information	O
,	O
allele	O
frequencies	O
and	O
map	O
position	O
of	O
the	O
SNPs	O
were	O
combined	O
with	O
the	O
genotype	O
data	O
generated	O
by	O
GDAS	O
.	O

The	O
uninformative	O
SNPs	O
in	O
this	O
pedigree	O
,	O
that	O
show	O
either	O
only	O
A	O
alleles	O
and	O
No	O
Calls	O
or	O
only	O
B	O
alleles	O
and	O
No	O
Calls	O
,	O
were	O
removed	O
from	O
further	O
analysis	O
by	O
Alohomora	O
.	O

The	O
data	O
files	O
were	O
exported	O
in	O
Merlin	O
format	O
.	O

Subsequently	O
,	O
in	O
Mega2	O
[	O
33	O
]	O
these	O
Alohomora	O
files	O
were	O
converted	O
into	O
the	O
appropriate	O
format	O
for	O
the	O
programs	O
used	O
for	O
linkage	O
analysis	O
,	O
i.e.	O
either	O
the	O
Mendel	O
5	O
format	O
or	O
the	O
SimWalk2	O
format	O
.	O

Mendelian	O
inconsistent	O
errors	O
were	O
removed	O
from	O
analysis	O
with	O
Mega2	O
by	O
setting	O
all	O
genotypes	O
of	O
these	O
SNPs	O
to	O
unknown	O
.	O

Results	O
HLA	O
class	O
I	O
,	O
β2	O
m	O
and	O
APM	O
component	O
expression	O
In	O
order	O
to	O
compare	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
sporadic	O
MSI	B
-	I
H	I
and	O
MSS	B
right	O
sided	O
tumors	B
(	O
RST	B
)	O
and	O
HNPCC	B
MSI	B
-	I
H	I
cases	O
,	O
we	O
used	O
an	O
antibody	O
panel	O
recognizing	O
monomorphic	O
determinants	O
expressed	O
on	O
HLA	O
class	O
I	O
heavy	O
chains	O
,	O
β2	O
m	O
and	O
APM	O
components	O
(	O
Figure	O
1	O
)	O
.	O

In	O
total	O
,	O
we	O
identified	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
about	O
34.6	O
%	O
of	O
the	O
RST	B
and	O
42.7	O
%	O
of	O
the	O
HNPCC	B
cases	O
.	O

The	O
frequency	O
of	O
alterations	O
differed	O
significantly	O
between	O
the	O
sporadic	O
MSS	B
and	O
MSI	B
-	I
H	I
RST	B
.	O

The	O
lack	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
more	O
frequent	O
in	O
MSI	B
-	I
H	I
sporadic	O
cases	O
than	O
in	O
MSS	B
cases	O
(	O
p	O
<	O
0.0001	O
)	O
,	O
as	O
it	O
was	O
16.7	O
%	O
in	O
the	O
latter	O
group	O
,	O
but	O
60.6	O
%	O
in	O
the	O
former	O
(	O
Table	O
2	O
)	O
.	O

Subsequently	O
,	O
we	O
have	O
investigated	O
the	O
frequency	O
of	O
a	O
concomitant	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
with	O
that	O
of	O
either	O
the	O
β2	O
m	O
molecule	O
or	O
of	O
any	O
APM	O
component	O
.	O

In	O
the	O
sporadic	O
subset	O
,	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
more	O
often	O
associated	O
with	O
that	O
of	O
one	O
of	O
the	O
APM	O
components	O
,	O
occurring	O
in	O
about	O
37	O
%	O
of	O
HLA	B
-	I
negative	I
tumors	B
regardless	O
of	O
their	O
mismatch	O
repair	O
status	O
(	O
Table	O
2	O
)	O
.	O

β2	O
m	O
loss	O
was	O
only	O
found	O
in	O
one	O
HLA	B
class	I
I	I
negative	I
MSI	B
-	I
H	I
sporadic	O
tumor	B
(	O
case	O
65	O
)	O
that	O
interestingly	O
also	O
presented	O
loss	O
of	O
the	O
APM	O
molecules	O
TAP2	O
,	O
Calreticulin	O
and	O
Tapasin	O
(	O
Figure	O
2	O
)	O
.	O

In	O
contrast	O
,	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
HNPCC	B
cases	O
was	O
more	O
frequently	O
associated	O
with	O
that	O
of	O
β2	O
m	O
(	O
Table	O
2	O
)	O
,	O
as	O
it	O
was	O
found	O
in	O
46.9	O
%	O
of	O
the	O
HLA	B
class	I
I	I
-	I
negative	I
tumors	B
.	O

In	O
contrast	O
loss	O
of	O
any	O
APM	O
component	O
was	O
observed	O
in	O
only	O
6	O
%	O
of	O
these	O
cases	O
(	O
h38	O
,	O
h49	O
)	O
which	O
also	O
showed	O
loss	O
of	O
β2	O
m	O
expression	O
.	O

In	O
sporadic	O
RST	B
,	O
the	O
simultaneous	O
loss	O
of	O
more	O
than	O
one	O
APM	O
molecule	O
per	O
case	O
was	O
frequent	O
(	O
Figure	O
2	O
)	O
.	O

Only	O
3	O
out	O
of	O
10	O
cases	O
lost	O
a	O
single	O
APM	O
component	O
.	O

The	O
TAP2	O
molecule	O
was	O
most	O
frequently	O
lost	O
(	O
6	O
cases	O
)	O
,	O
followed	O
by	O
TAP1	O
,	O
Tapasin	O
and	O
LMP2	O
(	O
5	O
cases	O
)	O
,	O
Calreticulin	O
(	O
4	O
cases	O
)	O
,	O
LMP7	O
(	O
2	O
cases	O
)	O
,	O
and	O
Calnexin	O
and	O
ERp57	O
(	O
1	O
case	O
)	O
.	O

Loss	O
of	O
the	O
LPM10	O
protein	O
was	O
detected	O
in	O
neither	O
sporadic	O
RST	B
nor	O
HNPCC	B
tumors	B
.	O

The	O
HNPCC	B
cases	O
h38	O
and	O
h49	O
lost	O
the	O
expression	O
of	O
TAP2	O
and	O
LMP7	O
respectively	O
.	O

LOH	O
and	O
frameshift	O
analysis	O
Polymorphic	O
markers	O
around	O
the	O
classical	O
HLA	O
genes	O
(	O
A	O
,	O
B	O
and	O
C	O
)	O
,	O
TAP	O
1	O
and	O
TAP2	O
genes	O
were	O
used	O
to	O
study	O
LOH	O
and	O
reveal	O
possible	O
chromosomal	O
aberrations	O
that	O
could	O
relate	O
to	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
HNPCC	B
cases	O
,	O
LOH	O
analysis	O
was	O
only	O
performed	O
around	O
the	O
HLA	O
genes	O
since	O
loss	O
of	O
the	O
TAP1	O
and	O
TAP2	O
proteins	O
was	O
rarely	O
associated	O
with	O
HLA	O
class	O
I	O
loss	O
.	O

LOH	O
was	O
more	O
frequent	O
in	O
the	O
MSS	B
tumors	B
(	O
50	O
%	O
)	O
than	O
in	O
the	O
MSI	B
-	I
H	I
sporadic	O
(	O
20	O
%	O
)	O
and	O
HNPCC	B
(	O
6	O
%	O
)	O
tumors	B
with	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
(	O
P	O
<	O
0.05	O
)	O
(	O
Figure	O
3	O
,	O
4	O
)	O
.	O

Furthermore	O
,	O
the	O
patterns	O
of	O
LOH	O
in	O
the	O
MSS	B
cases	O
might	O
indicate	O
loss	O
of	O
the	O
entire	O
6p21.3	O
region	O
,	O
in	O
contrast	O
to	O
the	O
MSI	B
-	I
H	I
cases	O
(	O
hereditary	O
and	O
sporadic	O
forms	O
)	O
where	O
LOH	O
seems	O
to	O
be	O
limited	O
.	O

Discussion	O
Abnormalities	B
in	I
HLA	I
class	I
I	I
cell	I
surface	I
expression	I
are	O
commonly	O
observed	O
in	O
tumors	B
and	O
are	O
interpreted	O
as	O
a	O
mechanism	O
by	O
which	O
tumor	B
cells	O
evade	O
the	O
host	O
immune	O
system	O
[	O
1	O
]	O
.	O

In	O
colorectal	B
cancer	I
,	O
especially	O
in	O
MSI	B
-	I
H	I
tumors	B
,	O
the	O
high	O
degree	O
of	O
lymphocytic	O
infiltrate	O
in	O
some	O
cases	O
may	O
suggest	O
an	O
active	O
immune	O
response	O
during	O
tumor	B
development	O
[	O
41,42	O
]	O
.	O

Moreover	O
,	O
MSI	B
-	I
H	I
tumors	B
might	O
cause	O
increased	O
immune	O
reactivity	O
as	O
a	O
consequence	O
of	O
the	O
high	O
amounts	O
of	O
aberrant	O
frameshift	O
peptides	O
they	O
generate	O
[	O
8,18	O
]	O
.	O

A	O
selective	O
pressure	O
by	O
CTLs	O
upon	O
these	O
tumors	B
would	O
favor	O
the	O
outgrowth	O
of	O
tumor	B
cells	O
that	O
lost	O
HLA	O
class	O
I	O
expression	O
at	O
the	O
cell	O
surface	O
allowing	O
them	O
to	O
surpass	O
the	O
action	O
of	O
the	O
immune	O
system	O
.	O

Applying	O
immunohistochemistry	O
on	O
tissue	O
arrays	O
,	O
we	O
compared	O
HLA	O
class	O
I	O
expression	O
in	O
both	O
sporadic	O
RST	B
(	O
MSI	B
-	I
H	I
and	O
MSS	B
sub	O
-	O
groups	O
)	O
and	O
HNPCC	B
tumors	B
.	O

RST	B
were	O
chosen	O
because	O
of	O
the	O
high	O
percentage	O
of	O
MSI	B
-	I
H	I
cases	O
in	O
this	O
specific	O
tumor	B
type	O
[	O
43	O
]	O
.	O

Indeed	O
,	O
immunohistochemical	O
staining	O
with	O
mAb	O
showed	O
that	O
HLA	O
class	O
I	O
loss	O
was	O
frequent	O
in	O
the	O
MSI	B
-	I
H	I
cases	O
analyzed	O
when	O
compared	O
to	O
their	O
MSS	B
counterpart	O
.	O

This	O
finding	O
supports	O
the	O
hypothesis	O
that	O
MSI	B
-	I
H	I
tumors	B
face	O
greater	O
selective	O
pressure	O
to	O
lose	O
HLA	O
class	O
I	O
expression	O
,	O
as	O
described	O
by	O
Kloor	O
et	O
al	O
[	O
8	O
]	O
.	O

However	O
,	O
we	O
have	O
shown	O
for	O
the	O
first	O
time	O
that	O
distinct	O
molecular	O
mechanisms	O
underlie	O
HLA	O
class	O
I	O
loss	O
in	O
sporadic	O
MSI	B
-	I
H	I
and	O
HNPCC	B
colon	B
cancers	I
.	O

In	O
the	O
latter	O
,	O
HLA	O
class	O
I	O
loss	O
was	O
preferentially	O
associated	O
with	O
that	O
of	O
β2	O
m	O
,	O
while	O
in	O
the	O
former	O
HLA	O
class	O
I	O
loss	O
was	O
associated	O
with	O
that	O
of	O
one	O
or	O
more	O
APM	O
components	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

We	O
investigated	O
the	O
genetic	O
abnormalities	O
underlying	O
the	O
HLA	O
class	O
I	O
loss	O
of	O
expression	O
.	O

They	O
included	O
LOH	O
on	O
chromosome	O
region	O
6p21.3	O
(	O
encompassing	O
HLA	O
class	O
I	O
and	O
TAP	O
genes	O
)	O
,	O
mutations	O
in	O
APM	O
components	O
and	O
mutations	O
in	O
β2	O
m	O
.	O

Loss	O
of	O
heterozygosity	O
at	O
6p21.3	O
was	O
most	O
prevalent	O
in	O
MSS	B
tumors	B
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
these	O
tumors	B
frequently	O
possess	O
gross	O
chromosomal	O
aberrations	O
and	O
are	O
often	O
aneuploid	O
[	O
13	O
]	O
.	O

Moreover	O
,	O
since	O
LOH	O
events	O
in	O
MSS	B
tumors	B
normally	O
comprise	O
large	O
areas	O
of	O
a	O
chromosome	O
,	O
LOH	O
on	O
6p21	O
might	O
not	O
be	O
a	O
direct	O
consequence	O
of	O
selective	O
pressure	O
directed	O
to	O
the	O
loss	O
of	O
HLA	O
expression	O
but	O
instead	O
to	O
other	O
genes	O
within	O
the	O
same	O
chromosomal	O
region	O
.	O

The	O
general	O
absence	O
of	O
LOH	O
in	O
MSI	B
-	I
H	I
tumors	B
suggests	O
that	O
this	O
is	O
not	O
the	O
major	O
mechanism	O
by	O
which	O
the	O
cells	O
abrogate	O
HLA	O
class	O
I	O
expression	O
.	O

The	O
genome	O
's	O
coding	O
regions	O
contain	O
multiple	O
microsatellite	O
repeats	O
,	O
which	O
are	O
considered	O
hotspots	O
for	O
mutations	O
in	O
mismatch	B
repair	I
-	I
deficient	I
tumors	B
[	O
43	O
]	O
.	O

Such	O
repeats	O
are	O
also	O
present	O
within	O
the	O
exons	O
of	O
the	O
APM	O
components	O
,	O
β2	O
m	O
,	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
genes	O
.	O

In	O
about	O
half	O
of	O
the	O
MSI	B
-	I
H	I
cases	O
,	O
loss	O
of	O
expression	O
of	O
HLA	O
class	O
I	O
was	O
concordant	O
with	O
the	O
detection	O
of	O
one	O
or	O
more	O
mutations	O
in	O
these	O
genes	O
.	O

We	O
have	O
discovered	O
novel	O
mutations	O
in	O
the	O
antigen	O
presenting	O
machinery	O
genes	O
;	O
Tapasin	O
,	O
Erp57	O
,	O
Calreticulin	O
and	O
Calnexin	O
in	O
colorectal	B
cancer	I
.	O

Previous	O
reports	O
associated	O
the	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
MSI	B
-	I
H	I
tumors	B
with	O
defects	O
on	O
β2	O
m	O
molecule	O
[	O
7,9	O
]	O
.	O

However	O
,	O
the	O
authors	O
did	O
not	O
distinguish	O
the	O
sporadic	O
/	O
hereditary	O
nature	O
of	O
the	O
tumors	B
that	O
were	O
studied	O
.	O

We	O
can	O
not	O
exclude	O
that	O
the	O
MSI	B
-	I
H	I
cases	O
included	O
in	O
these	O
studies	O
were	O
mainly	O
HNPCC	B
tumors	B
.	O

Dietary	O
fat	O
and	O
risk	O
of	O
colon	O
and	O
rectal	O
cancer	B
with	O
aberrant	O
MLH1	O
expression	O
,	O
or	O
genes	O
Abstract	O
Objective	O
To	O
investigate	O
baseline	O
fat	O
intake	O
and	O
the	O
risk	O
of	O
colon	O
and	O
rectal	O
tumors	B
lacking	O
MLH1	O
(	O
mutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	O
type	O
2	O
)	O
repair	O
gene	O
expression	O
and	O
harboring	O
mutations	O
in	O
the	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
)	O
tumor	B
suppressor	O
gene	O
and	O
in	O
the	O
KRAS	O
(	O
v	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
)	O
oncogene	O
.	O

Methods	O
After	O
7.3	O
years	O
of	O
follow	O
-	O
up	O
of	O
the	O
Netherlands	O
Cohort	O
Study	O
(	O
n	O
=	O
120,852	O
)	O
,	O
adjusted	O
incidence	O
rate	O
ratios	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
computed	O
,	O
based	O
on	O
401	O
colon	O
and	O
130	O
rectal	O
cancer	B
patients	O
.	O

Results	O
Total	O
,	O
saturated	O
and	O
monounsaturated	O
fat	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
colon	O
or	O
rectal	O
cancer	B
,	O
or	O
different	O
molecular	O
subgroups	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
polyunsaturated	O
fat	O
and	O
the	O
risk	O
of	O
overall	O
or	O
subgroups	O
of	O
rectal	O
cancer	B
.	O

Linoleic	O
acid	O
,	O
the	O
most	O
abundant	O
polyunsaturated	O
fatty	O
acid	O
in	O
the	O
diet	O
,	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
colon	O
tumors	B
with	O
only	O
a	O
KRAS	O
mutation	O
and	O
no	O
additional	O
truncating	O
APC	O
mutation	O
or	O
lack	O
of	O
MLH1	O
expression	O
(	O
RR	O
=	O
1.41	O
,	O
95	O
%	O
CI	O
1.18–1.69	O
for	O
one	O
standard	O
deviation	O
(	O
i.e.	O
,	O
7.5	O
g	O
/	O
day	O
)	O
increase	O
in	O
intake	O
,	O
p	O
-	O
trend	O
over	O
the	O
quartiles	O
of	O
intake	O
<	O
0.001	O
)	O
.	O

Linoleic	O
acid	O
intake	O
was	O
not	O
associated	O
with	O
risk	O
of	O
colon	O
tumors	B
without	O
any	O
of	O
the	O
gene	O
defects	O
,	O
or	O
with	O
tumors	B
harboring	O
aberrations	O
in	O
either	O
MLH1	O
or	O
APC	O
.	O

Conclusion	O
Linoleic	O
acid	O
intake	O
is	O
associated	O
with	O
colon	O
tumors	B
with	O
an	O
aberrant	O
KRAS	O
gene	O
,	O
but	O
an	O
intact	O
APC	O
gene	O
and	O
MLH1	O
expression	O
,	O
suggesting	O
a	O
unique	O
etiology	O
of	O
tumors	B
with	O
specific	O
genetic	O
aberrations	O
.	O

These	O
observations	O
and	O
hypotheses	O
prompted	O
us	O
to	O
investigate	O
the	O
associations	O
between	O
the	O
intake	O
of	O
total	O
fat	O
and	O
different	O
types	O
of	O
fat	O
and	O
the	O
risk	O
of	O
colon	O
and	O
rectal	O
tumors	B
lacking	O
MLH1	O
expression	O
and	O
with	O
and	O
without	O
APC	O
gene	O
mutations	O
,	O
two	O
early	O
events	O
in	O
colorectal	O
tumorigenesis	B
,	O
independent	O
of	O
tumors	B
harboring	O
KRAS	O
gene	O
mutations	O
.	O

Materials	O
and	O
methods	O
Study	O
population	O
The	O
prospective	O
NLCS	O
was	O
initiated	O
in	O
The	O
Netherlands	O
in	O
September	O
1986	O
.	O

The	O
study	O
design	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
23	O
]	O
.	O

Briefly	O
,	O
at	O
baseline	O
a	O
total	O
of	O
58,279	O
men	O
and	O
62,573	O
women	O
,	O
between	O
the	O
ages	O
of	O
55	O
and	O
69	O
years	O
,	O
completed	O
a	O
self	O
-	O
administered	O
food	O
frequency	O
and	O
lifestyle	O
questionnaire	O
.	O

Incident	O
cancer	B
cases	O
are	O
identified	O
by	O
monitoring	O
of	O
the	O
entire	O
cohort	O
for	O
cancer	B
occurrence	O
through	O
annual	O
record	O
linkage	O
to	O
the	O
National	O
Cancer	O
Registry	O
(	O
NCR	O
)	O
,	O
consisting	O
of	O
nine	O
regional	O
cancer	B
registries	O
throughout	O
The	O
Netherlands	O
,	O
and	O
to	O
PALGA	O
,	O
a	O
nationwide	O
network	O
and	O
registry	O
of	O
histo-	O
and	O
cytopathology	O
[	O
24	O
]	O
.	O

The	O
NCR	O
and	O
PALGA	O
together	O
provide	O
a	O
near	O
100	O
%	O
coverage	O
of	O
the	O
204	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

Accumulation	O
of	O
person	O
-	O
time	O
in	O
the	O
cohort	O
was	O
estimated	O
through	O
biennial	O
vital	O
status	O
follow	O
-	O
up	O
of	O
a	O
subcohort	O
of	O
3,500	O
men	O
and	O
women	O
who	O
were	O
randomly	O
selected	O
after	O
baseline	O
exposure	O
measurement	O
[	O
24	O
]	O
.	O

Cases	O
with	O
prevalent	O
cancer	B
other	O
than	O
non	B
-	I
melanoma	I
skin	O
cancer	B
were	O
excluded	O
from	O
the	O
subcohort	O
,	O
which	O
left	O
3,346	O
men	O
and	O
women	O
for	O
analysis	O
next	O
to	O
all	O
colorectal	B
cancer	I
cases	O
from	O
the	O
entire	O
cohort	O
.	O

No	O
subcohort	O
members	O
were	O
lost	O
to	O
follow	O
-	O
up	O
.	O

A	O
flow	O
diagram	O
of	O
subcohort	O
members	O
and	O
patients	O
on	O
whom	O
the	O
analyses	O
are	O
based	O
is	O
given	O
in	O
Fig.	O
1	O
.	O

Fig.	O
1Flow	O
diagram	O
of	O
the	O
number	O
of	O
subjects	O
on	O
whom	O
the	O
final	O
statistical	O
analyses	O
were	O
based	O
.	O

aNetherlands	O
Cancer	O
Registry	O
.	O

bPathologisch	O
Anatomisch	O
Landelijk	O
Geautomatiseerd	O
Archief	O
.	O

cPatients	O
with	O
rectosigmoid	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analyses	O
.	O

dmutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	B
type	I
2	I
.	O

eAdenomatous	O
polyposis	O
coli	O
.	O

fMutation	O
cluster	O
region	O
.	O

gv	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
.	O

hPatients	O
with	O
rectal	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analysis	O
according	O
to	O
MLH1	O
expression	O
Flow	O
diagram	O
of	O
the	O
number	O
of	O
subjects	O
on	O
whom	O
the	O
final	O
statistical	O
analyses	O
were	O
based	O
.	O

aNetherlands	O
Cancer	O
Registry	O
.	O

bPathologisch	O
Anatomisch	O
Landelijk	O
Geautomatiseerd	O
Archief	O
.	O

cPatients	O
with	O
rectosigmoid	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analyses	O
.	O

dmutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	B
type	I
2	I
.	O

eAdenomatous	O
polyposis	O
coli	O
.	O

fMutation	O
cluster	O
region	O
.	O

gv	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
.	O

hPatients	O
with	O
rectal	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analysis	O
according	O
to	O
MLH1	O
expression	O
The	O
first	O
2.3	O
years	O
of	O
follow	O
up	O
were	O
excluded	O
because	O
of	O
possible	O
preclinical	O
disease	B
affecting	O
exposure	O
status	O
and	O
because	O
of	O
incomplete	O
nationwide	O
coverage	O
of	O
PALGA	O
alone	O
(	O
i.e.	O
,	O
not	O
in	O
combination	O
with	O
the	O
NCR	O
)	O
in	O
some	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

Within	O
this	O
period	O
,	O
83	O
subcohort	O
members	O
deceased	O
or	O
were	O
diagnosed	O
with	O
cancer	B
other	O
than	O
non	B
-	I
melanoma	I
skin	O
cancer	B
,	O
leaving	O
3,263	O
subcohort	O
members	O
for	O
analysis	O
.	O

From	O
1989	O
to	O
1994	O
,	O
929	O
incident	O
cases	O
with	O
histologically	O
confirmed	O
colorectal	B
cancer	I
were	O
identified	O
within	O
the	O
entire	O
cohort	O
,	O
of	O
whom	O
819	O
could	O
also	O
be	O
linked	O
to	O
a	O
PALGA	O
report	O
of	O
the	O
lesion	B
.	O

The	O
PALGA	O
reports	O
were	O
used	O
to	O
identify	O
and	O
locate	O
tumor	B
tissues	O
from	O
eligible	O
colorectal	B
cancer	I
patients	O
in	O
54	O
pathology	O
laboratories	O
throughout	O
the	O
Netherlands	O
.	O

Cancers	B
were	O
classified	O
according	O
to	O
site	O
as	O
follows	O
,	O
colon	O
:	O
cecum	O
through	O
sigmoid	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153:0	O
,	O
153.1	O
,	O
153.2	O
,	O
153.3	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
,	O
153.7	O
)	O
,	O
proximal	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.0	O
,	O
153.1	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
)	O
,	O
distal	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.2	O
,	O
153,3	O
,	O
`	O
53.7	O
)	O
,	O
rectosigmoid	O
(	O
ICD	O
-	O
O	O
code	O
154.0	O
)	O
,	O
and	O
rectum	O
(	O
ICD	O
-	O
O	O
code	O
154.1	O
)	O
.	O

This	O
still	O
does	O
not	O
satisfy	O
our	O
third	O
query	O
,	O
i.e.	O
,	O
why	O
are	O
the	O
associations	O
specifically	O
confined	O
to	O
this	O
subgroup	O
of	O
colon	B
cancer	I
patients	O
whose	O
tumors	B
are	O
characterized	O
by	O
activating	O
KRAS	O
mutations	O
,	O
and	O
not	O
truncating	O
APC	O
mutations	O
or	O
lack	O
of	O
MLH1	O
expression	O
?	O

It	O
is	O
speculative	O
,	O
but	O
plausible	O
,	O
that	O
when	O
KRAS	O
is	O
the	O
only	O
one	O
of	O
the	O
three	O
genes	O
affected	B
,	O
the	O
mutation	O
may	O
more	O
likely	O
be	O
the	O
result	O
of	O
exogenous	O
exposure	O
,	O
for	O
example	O
a	O
relatively	O
high	O
linoleic	O
acid	O
intake	O
.	O

In	O
contrast	O
,	O
when	O
a	O
KRAS	O
mutation	O
co	O
-	O
occurs	O
with	O
a	O
mutation	O
in	O
APC	O
or	O
,	O
although	O
more	O
rarely	O
,	O
in	O
addition	O
to	O
a	O
defective	O
MLH1	O
,	O
these	O
other	O
early	O
gene	O
defects	O
also	O
had	O
a	O
role	O
in	O
tumor	B
formation	O
and	O
may	O
have	O
resulted	O
in	O
a	O
mutator	O
phenotype	O
leading	O
to	O
mutations	O
in	O
other	O
genes	O
(	O
such	O
as	O
the	O
KRAS	O
gene	O
)	O
irrespective	O
of	O
exogenous	O
factors	O
.	O

Since	O
there	O
is	O
no	O
information	O
on	O
the	O
timing	O
of	O
genetic	O
aberrations	O
in	O
this	O
type	O
of	O
human	O
studies	O
,	O
we	O
can	O
not	O
verify	O
this	O
with	O
our	O
data	O
.	O

Aberrations	O
in	O
other	O
genes	O
,	O
not	O
available	O
for	O
this	O
study	O
,	O
but	O
possibly	O
involved	O
in	O
early	O
tumorigenesis	O
of	O
colorectal	B
cancer	I
,	O
could	O
not	O
be	O
accounted	O
for	O
in	O
analyses	O
and	O
may	O
have	O
influenced	O
results	O
.	O

However	O
,	O
a	O
recent	O
systematic	O
sequence	O
analysis	O
of	O
13,023	O
exons	O
in	O
individual	O
colorectal	B
cancers	I
showed	O
that	O
the	O
prevalence	O
of	O
mutations	O
other	O
than	O
in	O
APC	O
,	O
KRAS	O
and	O
TP53	O
is	O
rather	O
low	O
[	O
44	O
]	O
,	O
and	O
mutations	O
in	O
TP53	O
is	O
not	O
an	O
early	O
event	O
in	O
colorectal	O
carcinogenesis	O
.	O

Finally	O
,	O
results	O
are	O
based	O
on	O
relatively	O
small	O
numbers	O
of	O
patients	O
,	O
especially	O
in	O
the	O
reference	O
group	O
of	O
polyunsaturated	O
fat	O
or	O
linoleic	O
acid	O
intake	O
(	O
four	O
patients	O
,	O
see	O
Table	O
4	O
)	O
,	O
and	O
point	O
estimates	O
of	O
RRs	O
for	O
quartiles	O
of	O
intake	O
of	O
polyunstaturated	O
fat	O
or	O
linoleic	O
acid	O
should	O
therefore	O
,	O
be	O
interpreted	O
cautiously	O
.	O

Nevertheless	O
,	O
as	O
discussed	O
previously	O
,	O
the	O
association	O
appears	O
to	O
be	O
robust	O
when	O
regarding	O
the	O
results	O
for	O
one	O
standard	O
deviation	O
increase	O
in	O
linoleic	O
acid	O
intake	O
(	O
based	O
on	O
a	O
total	O
of	O
65	O
patients	O
)	O
.	O

Therefore	O
,	O
Breivik	O
and	O
Glaudernack	O
's	O
hypothesis	O
for	O
distinct	O
carcinogens	O
to	O
exert	O
their	O
effect	O
on	O
two	O
proposed	O
types	O
of	O
genetic	O
instability	O
,	O
i.e.	O
,	O
microsatellite	O
instability	O
and	O
chromosomal	O
instability	O
[	O
16	O
]	O
,	O
may	O
be	O
extended	O
to	O
the	O
potential	O
effect	O
of	O
carcinogens	O
on	O
more	O
specific	O
genetic	O
pathways	O
to	O
colorectal	O
tumorigenesis	O
,	O
as	O
for	O
example	O
the	O
KRAS	O
mutated	O
pathway	O
.	O

The	O
data	O
from	O
this	O
large	O
prospective	O
cohort	O
study	O
suggest	O
that	O
linoleic	O
acid	O
intake	O
is	O
strongly	O
associated	O
with	O
colon	O
tumors	B
with	O
an	O
aberrant	O
KRAS	O
gene	O
,	O
but	O
an	O
intact	O
APC	O
gene	O
and	O
MLH1	O
expression	O
.	O

Verification	O
in	O
other	O
studies	O
is	O
warranted	O
.	O

Possibly	O
,	O
tumors	B
revealing	O
the	O
involvement	O
of	O
distinct	O
genetic	O
pathways	O
on	O
the	O
basis	O
of	O
specific	O
genetic	O
aberrations	O
,	O
may	O
have	O
a	O
unique	O
etiology	O
.	O

Discussion	O
We	O
report	O
the	O
analysis	O
of	O
the	O
combined	O
miRNA	O
/	O
mRNA	O
expression	O
for	O
the	O
discrimination	O
of	O
MSI	B
-	I
H	I
versus	O
MSS	B
human	O
colon	B
cancer	I
.	O

Because	O
colorectal	O
tumors	B
characterized	O
by	O
MSI	B
are	O
distinct	O
from	O
MSS	B
tumors	B
in	O
many	O
molecular	O
aspects	O
,	O
such	O
the	O
association	O
with	O
the	O
methylator	O
phenotype	O
,	O
which	O
is	O
responsible	O
for	O
MLH1	O
methylation	O
,	O
the	O
higher	O
frequency	O
of	O
BRAF	O
mutations	O
and	O
the	O
lower	O
frequencies	O
of	O
KRAS	O
,	O
APC	O
and	O
TP53	O
mutations	O
,	O
MSI	B
and	O
MSS	B
colon	B
cancers	I
represent	O
tumors	B
with	O
a	O
different	O
molecular	O
background	O
.	O

Thus	O
,	O
it	O
is	O
reasonable	O
that	O
their	O
overall	O
gene	O
expression	O
pattern	O
(	O
including	O
both	O
mRNAs	O
and	O
microRNAs	O
)	O
might	O
be	O
affected	O
by	O
any	O
of	O
the	O
above	O
mentioned	O
mechanisms	O
.	O

Indeed	O
,	O
our	O
analyses	O
identified	O
14	O
miRNAs	O
and	O
451	O
mRNAs	O
differentially	O
expressed	O
between	O
the	O
two	O
genetically	O
distinct	O
colon	B
cancer	I
classes	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
mRNA	O
/	O
miRNA	O
gene	O
expression	O
profile	O
able	O
to	O
distinguish	O
MSS	B
versus	O
MSI	B
colon	B
cancers	I
,	O
but	O
also	O
indicate	O
that	O
the	O
combination	O
of	O
miRNA	O
/	O
mRNA	O
gene	O
expression	O
data	O
can	O
distinguish	O
microsatellite	O
instability	O
status	O
of	O
human	O
colorectal	B
cancers	I
better	O
than	O
each	O
RNA	O
class	O
independently	O
,	O
suggesting	O
that	O
the	O
combination	O
of	O
mRNA	O
and	O
miRNA	O
expression	O
may	O
potentially	O
represent	O
a	O
general	O
approach	O
for	O
improving	O
characterization	O
and	O
classification	O
of	O
bio	O
-	O
molecular	O
and	O
possibly	O
clinical	O
traits	O
associated	O
with	O
human	O
cancer	B
.	O

We	O
also	O
examined	O
the	O
prediction	O
power	O
of	O
published	O
lists	O
of	O
genes	O
differentially	O
expressed	O
between	O
MSI	B
-	I
H	I
and	O
MSS	B
colorectal	B
cancers	I
[	O
34	O
-	O
36	O
]	O
against	O
our	O
data	O
set	O
.	O

Two	O
published	O
lists	O
describe	O
differentially	O
expressed	O
genes	O
(	O
100	O
genes	O
in	O
the	O
report	O
from	O
Di	O
Pietro	O
et	O
al.	O
2005	O
[	O
36	O
]	O
and	O
542	O
genes	O
from	O
Banerjea	O
et	O
al.	O
2004	O
[	O
35	O
]	O
)	O
and	O
one	O
is	O
a	O
short	O
list	O
of	O
predictors	O
(	O
9	O
genes	O
in	O
Kruhoffer	O
et	O
al.	O
2005	O
[	O
34	O
]	O
)	O
.	O

Although	O
these	O
studies	O
were	O
all	O
performed	O
on	O
Affymetrix	O
platforms	O
,	O
they	O
generated	O
only	O
partially	O
overlapping	O
results	O
.	O

The	O
list	O
of	O
genes	O
from	O
Di	O
Pietro	O
et	O
al.	O
[	O
36	O
]	O
was	O
the	O
one	O
that	O
better	O
correlated	O
with	O
our	O
results	O
.	O

Twenty	O
two	O
of	O
their	O
100	O
genes	O
were	O
present	O
in	O
our	O
list	O
of	O
differentially	O
expressed	O
genes	O
and	O
,	O
for	O
all	O
the	O
remaining	O
genes	O
,	O
expression	O
tendency	O
completely	O
matched	O
our	O
data	O
.	O

A	O
cluster	O
analysis	O
of	O
our	O
data	O
set	O
using	O
the	O
100	O
genes	O
from	O
the	O
Di	O
Pietro	O
's	O
paper	O
could	O
generate	O
a	O
good	O
,	O
although	O
not	O
perfect	O
,	O
separation	O
between	O
MSS	B
versus	O
MSI	B
-	I
H	I
tumors	B
and	O
performed	O
well	O
in	O
the	O
prediction	O
of	O
our	O
samples	O
(	O
36	O
of	O
39	O
samples	O
were	O
correctly	O
classified	O
using	O
the	O
SVM	O
prediction	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
that	O
a	O
similar	O
set	O
of	O
genes	O
emerged	O
as	O
differentially	O
expressed	O
between	O
MSS	B
and	O
MSI	B
-	I
H	I
colon	B
cancers	I
in	O
the	O
Di	O
Pietro	O
's	O
and	O
our	O
studies	O
,	O
with	O
discrepancies	O
possibly	O
due	O
to	O
small	O
statistical	O
differences	O
.	O

Discrepancies	O
between	O
results	O
obtained	O
with	O
different	O
microarray	O
platforms	O
are	O
not	O
uncommon	O
and	O
are	O
mainly	O
determined	O
by	O
differences	O
in	O
microarray	O
probe	O
sequences	O
used	O
to	O
detect	O
mRNA	O
transcripts	O
[	O
37	O
]	O
and	O
in	O
algorithms	O
used	O
for	O
predictor	O
genes	O
identification	O
.	O

Hence	O
,	O
the	O
parallel	O
between	O
Di	O
Pietro	O
's	O
and	O
our	O
results	O
is	O
significant	O
given	O
that	O
data	O
were	O
generated	O
using	O
a	O
different	O
set	O
of	O
samples	O
and	O
a	O
different	O
microarray	O
platform	O
,	O
and	O
suggests	O
that	O
the	O
commonly	O
identified	O
set	O
of	O
genes	O
may	O
represent	O
the	O
most	O
significant	O
differences	O
between	O
MSI	B
-	I
H	I
and	O
MSS	B
colon	B
cancers	I
(	O
Additional	O
file	O
6	O
)	O
.	O

Unfortunately	O
,	O
data	O
sets	O
from	O
published	O
reports	O
were	O
not	O
available	O
for	O
cross	O
confirmation	O
of	O
our	O
list	O
of	O
predictive	O
genes	O
on	O
published	O
microarray	O
data	O
.	O

Conclusion	O
This	O
report	O
provides	O
the	O
first	O
study	O
on	O
microRNA	O
expression	O
in	O
MSI	B
versus	O
MSS	B
colon	B
cancer	I
.	O

We	O
identified	O
microRNAs	O
that	O
are	O
differentially	O
expressed	O
between	O
these	O
two	O
classes	O
of	O
tumors	B
;	O
moreover	O
,	O
the	O
addition	O
of	O
microRNAs	O
in	O
the	O
molecular	O
classifier	O
improves	O
the	O
separation	O
between	O
MSI	B
and	O
MSS	B
cancer	B
samples	O
,	O
suggesting	O
that	O
the	O
mRNA	O
/	O
miRNA	O
combination	O
could	O
provide	O
an	O
improved	O
stratification	O
of	O
tumor	O
-	O
associated	O
characters	O
.	O

Interestingly	O
,	O
the	O
most	O
prominent	O
class	O
of	O
differentially	O
expressed	O
miRNAs	O
includes	O
various	O
members	O
of	O
the	O
oncogenic	O
miR-17	O
-	O
92	O
family	O
,	O
suggesting	O
that	O
these	O
microRNAs	O
have	O
a	O
role	O
in	O
bio	O
-	O
pathologic	O
characteristics	O
that	O
distinguish	O
MSS	B
versus	O
MSI	B
colon	B
cancers	I
.	O

Introduction	O
Over	O
the	O
past	O
ten	O
years	O
,	O
aberrant	O
DNA	O
methylation	O
has	O
been	O
recognized	O
as	O
one	O
of	O
the	O
most	O
common	O
molecular	O
abnormalities	O
in	O
breast	B
cancer	I
[	O
1,2	O
]	O
.	O

A	O
large	O
body	O
of	O
evidence	O
implicates	O
potential	O
hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
loss	O
of	O
expression	O
of	O
a	O
variety	O
of	O
crucial	O
genes	O
.	O

Tumor	O
-	O
suppressor	O
genes	O
with	O
aberrant	O
methylation	O
in	O
breast	B
cancers	I
include	O
ARHI	O
[	O
3,4	O
]	O
,	O
RASSF1A	O
[	O
5	O
]	O
,	O
HIN-1	O
[	O
6	O
]	O
,	O
the	O
retinoic	O
acid	O
receptor	O
II	O
gene	O
(	O
RARβ2	O
)	O
[	O
7	O
]	O
,	O
hMLH1	O
[	O
8	O
]	O
,	O
14	O
-	O
3	O
-	O
3	O
σ	O
[	O
9	O
]	O
,	O
RIZ1	O
[	O
10	O
]	O
,	O
p16	O
[	O
11	O
]	O
,	O
the	O
E	O
-	O
cadherin	O
gene	O
[	O
12	O
]	O
,	O
PTEN	O
[	O
13	O
]	O
,	O
and	O
BRCA1	O
[	O
14	O
]	O
.	O

Methylation	O
in	O
breast	B
cancer	I
has	O
been	O
related	O
to	O
clinical	O
and	O
pathologic	O
characteristics	O
evident	O
at	O
presentation	O
and	O
clinical	O
outcomes	O
.	O

A	O
higher	O
prevalence	O
of	O
HIN-1	O
and	O
RAR	O
β2	O
methylation	O
was	O
found	O
in	O
the	O
lymph	O
nodes	O
,	O
bone	O
,	O
brain	O
,	O
and	O
lung	O
metastases	B
than	O
the	O
primary	O
tumor	B
[	O
15	O
]	O
.	O

Widschwendter	O
and	O
colleagues	O
[	O
16	O
]	O
reported	O
that	O
the	O
methylation	O
of	O
certain	O
genes	O
was	O
associated	O
with	O
hormone	O
receptor	O
(	O
HR	O
)	O
status	O
,	O
in	O
addition	O
to	O
the	O
response	O
to	O
treatment	O
with	O
tamoxifen	O
.	O

A	O
high	O
prevalence	O
of	O
PGR	O
,	O
HSD17B4	O
,	O
and	O
CDH13	O
methylation	O
has	O
been	O
associated	O
with	O
HER-2	B
/	I
neu	I
-	I
positive	I
breast	B
cancer	I
[	O
17	O
]	O
.	O

Methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
is	O
a	O
sensitive	O
assay	O
used	O
to	O
detect	O
methylation	O
and	O
analyze	O
the	O
methylation	O
status	O
of	O
genes	O
of	O
interest	O
.	O

However	O
,	O
problems	O
inherent	O
to	O
this	O
assay	O
(	O
such	O
as	O
those	O
caused	O
by	O
the	O
use	O
of	O
different	O
primers	O
for	O
the	O
methylated	O
or	O
unmethylated	O
alleles	O
,	O
the	O
gel	O
-	O
based	O
data	O
analysis	O
system	O
used	O
,	O
and	O
difficulties	O
in	O
quantitation	O
)	O
have	O
caused	O
frequent	O
false	O
-	O
positive	O
results	O
in	O
tissue	O
-	O
sample	O
analyses	O
.	O

A	O
new	O
technique	O
,	O
pyrosequencing	O
,	O
has	O
been	O
adapted	O
for	O
use	O
in	O
highly	O
sensitive	O
and	O
quantitative	O
methylation	O
analyses	O
[	O
18,19	O
]	O
.	O

Pyrosequencing	O
methylation	O
analysis	O
is	O
a	O
modification	O
of	O
the	O
combined	O
bisulfite	O
restriction	O
analysis	O
(	O
COBRA	O
)	O
that	O
compares	O
favorably	O
with	O
COBRA	O
in	O
sensitivity	O
,	O
specificity	O
,	O
and	O
robustness	O
[	O
18	O
]	O
.	O

Tost	O
and	O
colleagues	O
also	O
confirmed	O
that	O
the	O
pyrosequencing	O
technique	O
is	O
quantitative	O
,	O
amenable	O
to	O
the	O
analysis	O
of	O
bisulfite	O
-	O
treated	O
DNA	O
derived	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
samples	O
,	O
highly	O
reproducible	O
,	O
and	O
accurate	O
[	O
19	O
]	O
.	O

Bisulfite	O
pyrosequencing	O
has	O
been	O
used	O
in	O
clinical	O
trials	O
of	O
hypomethylating	O
drug	O
treatment	O
and	O
provides	O
accurate	O
and	O
reliable	O
results	O
[	O
20	O
]	O
.	O

To	O
investigate	O
methylation	O
profiles	O
in	O
breast	B
cancer	I
cells	O
,	O
we	O
used	O
bisulfite	O
pyrosequencing	O
to	O
screen	O
12	O
known	O
tumor	O
-	O
suppressor	O
genes	O
in	O
90	O
pairs	O
of	O
breast	B
cancers	I
and	O
normal	B
tissues	O
.	O

Although	O
all	O
12	O
genes	O
had	O
been	O
reported	O
to	O
exhibit	O
hypermethylation	O
in	O
a	O
fraction	O
of	O
breast	B
cancer	I
cases	O
,	O
our	O
assays	O
provided	O
a	O
comprehensive	O
survey	O
of	O
their	O
methylation	O
status	O
and	O
confirmed	O
that	O
five	O
genes	O
could	O
be	O
useful	O
in	O
defining	O
a	O
methylation	O
profile	O
in	O
breast	B
cancer	I
cells	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
two	O
panels	O
of	O
methylation	O
profiles	O
correlated	O
,	O
either	O
positively	O
or	O
negatively	O
,	O
to	O
HR	O
status	O
.	O

Statistical	O
methods	O
and	O
analysis	O
In	O
the	O
studied	O
cohort	O
,	O
adjacent	O
normal	B
breast	O
tissue	O
was	O
taken	O
from	O
each	O
of	O
90	O
patients	O
during	O
surgery	O
.	O

Taking	O
advantage	O
of	O
paired	O
normal	B
/	O
tumor	B
samples	O
in	O
this	O
study	O
,	O
we	O
chose	O
the	O
value	O
of	O
normal	B
samples	O
as	O
the	O
reference	O
.	O

If	O
using	O
the	O
sample	O
mean	O
plus	O
two	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
pooled	O
normal	B
samples	O
(	O
and	O
a	O
minimum	O
of	O
10	O
%	O
methylation	O
)	O
as	O
a	O
cut	O
-	O
off	O
point	O
,	O
there	O
is	O
>	O
97	O
%	O
probability	O
that	O
the	O
methylation	O
level	O
for	O
a	O
normal	B
tissue	O
will	O
be	O
lower	O
than	O
the	O
cut	O
-	O
off	O
point	O
.	O

It	O
is	O
reasonable	O
to	O
assume	O
that	O
a	O
value	O
larger	O
than	O
the	O
cut	O
-	O
off	O
point	O
is	O
likely	O
to	O
be	O
abnormal	O
(	O
or	O
positive	O
)	O
.	O

Panels	O
of	O
genes	O
,	O
that	O
is	O
to	O
say	O
,	O
HIN-1	O
/	O
RASSF1A	O
and	O
RIL	O
/	O
CDH13	O
were	O
considered	O
positive	O
if	O
both	O
markers	O
in	O
each	O
panel	O
were	O
positive	O
.	O

Descriptive	O
analyses	O
were	O
performed	O
first	O
for	O
exploratory	O
purposes	O
.	O

Pair	O
-	O
wise	O
scatter	O
plots	O
are	O
presented	O
to	O
show	O
the	O
correlations	O
among	O
the	O
genes	O
methylated	O
.	O

Heat	O
maps	O
were	O
plotted	O
to	O
show	O
levels	O
of	O
gene	O
expression	O
or	O
methylation	O
using	O
hierarchical	O
clustering	O
to	O
visually	O
represent	O
the	O
association	O
of	O
different	O
genes	O
or	O
samples	O
by	O
histopathologic	O
tumor	B
characteristics	O
(	O
ERs	O
,	O
PRs	O
,	O
and	O
HER-2	O
/	O
neu	O
)	O
.	O

Chi	O
-	O
square	O
or	O
Fisher	O
's	O
exact	O
test	O
were	O
used	O
to	O
assess	O
the	O
dependence	O
between	O
two	O
categorical	O
variables	O
.	O

Pearson	O
's	O
correlation	O
coefficient	O
was	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
two	O
continuous	O
variables	O
.	O

The	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
was	O
used	O
to	O
compare	O
either	O
continuous	O
or	O
categorical	O
variables	O
between	O
two	O
groups	O
.	O

Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
applied	O
to	O
compare	O
the	O
values	O
of	O
gene	O
methylation	O
with	O
tumor	B
characteristics	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
assess	O
the	O
ability	O
of	O
various	O
levels	O
of	O
gene	O
methylation	O
to	O
predict	O
the	O
ER	O
,	O
PR	O
,	O
HR	O
,	O
or	O
HER-2	O
/	O
neu	O
status	O
.	O

All	O
reported	O
p	O
values	O
are	O
two	O
-	O
sided	O
and	O
considered	O
statistically	O
significant	O
if	O
p	O
<	O
0.05	O
.	O

Analyses	O
were	O
performed	O
using	O
S	O
-	O
PLUS	O
2000	O
software	O
(	O
Insightful	O
Corp.	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
.	O

Discussion	O
Although	O
a	O
large	O
body	O
of	O
evidence	O
has	O
demonstrated	O
that	O
aberrant	O
DNA	O
methylation	O
has	O
an	O
important	O
role	O
in	O
breast	O
carcinogenesis	B
,	O
variation	O
in	O
the	O
data	O
is	O
still	O
a	O
problem	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
bisulfite	O
pyrosequencing	O
to	O
quantitate	O
the	O
methylation	O
of	O
12	O
known	O
tumor	O
-	O
suppressor	O
genes	O
in	O
breast	B
cancers	I
.	O

To	O
avoid	O
contamination	O
with	O
normal	B
tissues	O
,	O
we	O
isolated	O
breast	B
cancer	I
cells	O
by	O
microdissection	O
and	O
compared	O
levels	O
of	O
methylation	O
with	O
those	O
in	O
normal	B
breast	O
epithelial	O
cells	O
from	O
the	O
same	O
patients	O
.	O

Bisulfite	O
pyrosequencing	O
provided	O
sensitive	O
and	O
reproducible	O
measurements	O
.	O

The	O
variation	O
between	O
the	O
different	O
assays	O
was	O
<	O
6	O
%	O
.	O

Our	O
data	O
confirmed	O
that	O
RIL	O
,	O
HIN-1	O
,	O
RASSF1A	O
,	O
CDH13	O
,	O
and	O
RARβ2	O
were	O
frequently	O
methylated	O
in	O
breast	B
cancers	I
but	O
not	O
in	O
normal	B
breast	O
tissues	O
.	O

The	O
other	O
six	O
genes	O
were	O
not	O
highly	O
methylated	O
in	O
breast	B
cancers	I
or	O
methylated	O
in	O
either	O
malignant	B
and	O
normal	B
breast	O
tissues	O
;	O
ARHI	O
,	O
as	O
an	O
imprinted	O
gene	O
,	O
has	O
a	O
different	O
methylation	O
status	O
.	O

All	O
the	O
inconsistencies	O
indicate	O
that	O
these	O
seven	O
genes	O
are	O
unsuitable	O
for	O
methylation	O
profile	O
studies	O
.	O

In	O
the	O
past	O
,	O
methylation	O
data	O
have	O
been	O
correlated	O
to	O
clinical	O
pathologic	O
parameters	O
,	O
to	O
clarify	O
the	O
role	O
of	O
methylation	O
in	O
breast	O
carcinogenesis	B
.	O

Our	O
most	O
interesting	O
finding	O
was	O
a	O
correlation	O
between	O
gene	O
methylation	O
and	O
the	O
HR	O
status	O
.	O

Methylation	O
in	O
breast	B
cancer	I
has	O
already	O
been	O
connected	O
to	O
hormone	O
regulation	O
,	O
but	O
the	O
correlation	O
is	O
not	O
clear	O
yet	O
.	O

Campan	O
and	O
colleagues	O
[	O
26	O
]	O
reviewed	O
the	O
DNA	O
methylation	O
profiles	O
of	O
breast	O
,	O
endometrial	O
,	O
ovarian	O
,	O
and	O
proximal	O
colon	O
cancers	B
but	O
did	O
not	O
find	O
evidence	O
for	O
global	O
hormone	O
-	O
specific	O
DNA	O
methylation	O
alterations	O
.	O

Widschwendter	O
and	O
colleagues	O
[	O
16	O
]	O
reported	O
significant	O
differences	O
in	O
the	O
HR	O
status	O
between	O
clusters	O
of	O
DNA	O
methylation	O
profiles	O
.	O

Their	O
results	O
suggested	O
the	O
existence	O
of	O
an	O
interaction	O
between	O
DNA	O
methylation	O
and	O
HR	O
biology	O
in	O
breast	B
cancer	I
cells	O
.	O

In	O
our	O
own	O
study	O
,	O
we	O
found	O
that	O
the	O
ER	O
status	O
was	O
positively	O
associated	O
with	O
the	O
methylation	O
of	O
HIN-1	O
and	O
RASSF1A	O
but	O
negatively	O
correlated	O
to	O
the	O
methylation	O
of	O
RIL	O
.	O

In	O
addition	O
,	O
the	O
PR	O
status	O
was	O
positively	O
associated	O
with	O
the	O
methylation	O
of	O
HIN-1	O
and	O
negatively	O
associated	O
with	O
the	O
methylation	O
of	O
CDH13	O
.	O

Moreover	O
,	O
if	O
data	O
from	O
the	O
methylation	O
of	O
individual	O
genes	O
were	O
combined	O
into	O
two	O
panels	O
,	O
methylation	O
of	O
the	O
HIN-1	O
/	O
RASSF1A	O
panel	O
strongly	O
predicted	O
the	O
expression	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
and	O
methylation	O
of	O
the	O
RIL	O
/	O
CDH13	O
panel	O
strongly	O
predicted	O
the	O
negative	O
expression	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
.	O

The	O
status	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
has	O
been	O
recognized	O
as	O
an	O
important	O
prognostic	O
factor	O
in	O
patients	O
with	O
breast	B
cancer	I
,	O
in	O
addition	O
to	O
a	O
predictive	O
marker	O
for	O
the	O
response	O
to	O
treatment	O
with	O
endocrine	O
therapy	O
.	O

The	O
presence	O
of	O
ERs	O
and/or	O
PRs	O
is	O
predictive	O
of	O
the	O
response	O
to	O
treatment	O
with	O
the	O
antiestrogen	O
tamoxifen	O
[	O
27	O
]	O
.	O

ER	O
and	O
PR	O
expression	O
patterns	O
are	O
heavily	O
influenced	O
by	O
changes	O
in	O
the	O
chromatin	O
structure	O
during	O
transcription	O
.	O

Indeed	O
,	O
both	O
the	O
predominant	O
mammalian	O
DNA	O
methyltransferase	O
and	O
histone	O
deacetylases	O
have	O
crucial	O
roles	O
in	O
maintaining	O
transcriptionally	O
repressive	O
chromatin	O
by	O
forming	O
suppressive	O
complexes	O
at	O
replication	O
foci	O
[	O
28	O
]	O
.	O

Our	O
current	O
studies	O
provide	O
evidence	O
that	O
epigenetic	O
changes	O
are	O
tightly	O
connected	O
with	O
HR	O
regulation	O
in	O
breast	B
cancer	I
.	O

Tumors	B
negatively	O
stained	O
for	O
HCA2	O
and/or	O
HC10	O
were	O
stained	O
for	O
mismatch	O
repair	O
proteins	O
MLH1	O
and	O
PMS2	O
.	O

MLH1	B
and	I
PMS2	I
are	I
deficient	I
in	O
sporadic	O
MSI	B
tumors	B
.	O

Therefore	O
,	O
the	O
expression	O
of	O
these	O
proteins	O
was	O
used	O
to	O
differentiate	O
MSI	B
and	O
MSS	B
rectal	B
cancers	I
.	O

Tissue	O
stromal	O
cells	O
,	O
normal	B
epithelium	O
or	O
lymph	O
follicles	O
served	O
as	O
positive	O
internal	O
controls	O
when	O
analyzing	O
MLH1	O
,	O
PMS2	O
expression	O
.	O

The	O
expression	O
of	O
MLH1	O
and	O
PMS2	O
was	O
scored	O
positive	O
if	O
tumor	B
cells	O
showed	O
expression	O
,	O
and	O
negative	O
if	O
tumor	B
cells	O
showed	O
no	O
expression	O
of	O
either	O
MLH1	O
or	O
PMS2	O
,	O
provided	O
that	O
and	O
tissue	O
stromal	O
cells	O
did	O
show	O
expression	O
,	O
indicating	O
microsatellite	B
stable	I
(	O
MSS	B
)	O
and	O
microsatellite	B
instable	I
(	O
MSI	B
)	O
tumors	B
,	O
respectively	O
[	O
7	O
]	O
.	O

Statistical	O
analyses	O
All	O
analyses	O
were	O
performed	O
with	O
SPSS	O
statistical	O
software	O
(	O
version	O
12.0	O
for	O
Windows	O
,	O
SPSS	O
Inc	O
,	O
Chicago	O
,	O
USA	O
)	O
.	O

Mann	O
–	O
Whitney	O
U	O
,	O
t	O
test	O
and	O
χ2-tests	O
were	O
used	O
to	O
compare	O
variables	O
.	O

Kaplan	O
–	O
Meier	O
analyses	O
were	O
performed	O
to	O
analyze	O
patient	O
survival	O
.	O

The	O
entry	O
date	O
for	O
the	O
survival	O
analyses	O
was	O
the	O
time	O
of	O
surgery	O
of	O
the	O
primary	O
tumor	B
.	O

Events	O
for	O
time	O
to	O
local	O
recurrence	O
,	O
distant	O
recurrence	O
,	O
cancer	B
-	O
specific	O
survival	O
,	O
disease	B
-	O
free	O
and	O
overall	O
survival	O
were	O
defined	O
as	O
follows	O
:	O
from	O
time	O
of	O
surgery	O
to	O
time	O
of	O
local	O
disease	B
relapse	O
(	O
for	O
local	O
recurrence	O
)	O
,	O
time	O
of	O
distant	O
disease	B
relapse	O
(	O
for	O
distant	O
recurrence	O
)	O
,	O
time	O
of	O
disease	B
relapse	O
or	O
death	O
by	O
disease	B
(	O
for	O
cancer	B
specific	O
survival	O
)	O
,	O
time	O
of	O
disease	B
relapse	O
or	O
death	O
(	O
for	O
disease	B
free	O
survival	O
)	O
and	O
time	O
of	O
death	O
,	O
respectively	O
(	O
for	O
overall	O
survival	O
)	O
.	O

Non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
were	O
first	O
separately	O
analyzed	O
in	O
univariate	O
analysis	O
and	O
second	O
,	O
variables	O
with	O
a	O
P	O
value	O
of	O
<	O
0.10	O
in	O
the	O
univariate	O
analyses	O
were	O
subjected	O
to	O
a	O
multivariate	O
analysis	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
on	O
the	O
whole	O
group	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
the	O
following	O
variables	O
:	O
HLA	O
class	O
I	O
,	O
randomization	O
for	O
radiotherapy	O
,	O
TNM	O
and	O
circumferential	O
margin	O
.	O

Cox	O
'	O
regression	O
analyses	O
were	O
used	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

Most	O
rectal	O
tumors	B
have	O
high	O
numbers	O
of	O
tumor	B
cells	O
positive	O
for	O
HCA2	O
or	O
HC10	O
Numbers	O
(	O
N	O
)	O
of	O
patients	O
are	O
indicated	O
with	O
percentages	O
shown	O
in	O
parentheses	O
,	O
showing	O
:	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
,	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
and	O
total	O
absence	O
(	O
absence	O
)	O
Examples	O
of	O
HCA2	O
and	O
HC10	O
immunohistochemical	O
staining	O
of	O
rectal	O
tumors	B
;	O
a	O
–	O
c	O
HCA2	O
,	O
d	O
–	O
f	O
HC10	O
expression	O
.	O

a	O
,	O
d	O
Expression	O
of	O
HLA	O
class	O
I	O
in	O
>	O
50	O
%	O
tumor	B
cells	O
;	O
b	O
,	O
e	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
<	O
50	O
%	O
tumor	B
cells	O
;	O
c	O
,	O
f	O
epithelial	O
cells	O
show	O
total	O
absence	O
for	O
HCA2	O
or	O
HC10	O
and	O
only	O
stromal	O
and	O
infiltrative	O
cells	O
show	O
positive	O
staining	O
for	O
HCA2	O
or	O
HC10	O
;	O
Original	O
magnification	O
×20	O
Analysis	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
tumors	B
Together	O
,	O
the	O
results	O
obtained	O
with	O
HCA2	O
and	O
HC10	O
are	O
expected	O
to	O
reflect	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
cancer	B
.	O

In	O
a	O
group	O
of	O
64	O
tumors	B
it	O
was	O
studied	O
whether	O
an	O
additional	O
staining	O
for	O
β2	O
m	O
would	O
better	O
define	O
HLA	O
class	O
I	O
expression	O
.	O

The	O
results	O
of	O
the	O
addition	O
of	O
β2	O
m	O
to	O
HCA2	O
and	O
HC10	O
were	O
comparable	O
to	O
those	O
obtained	O
with	O
HCA2	O
and	O
HC10	O
,	O
i.e.	O
only	O
1	O
of	O
64	O
tumors	B
was	O
differently	O
classified	O
.	O

Therefore	O
,	O
β2	O
m	O
was	O
not	O
scored	O
in	O
the	O
whole	O
cohort	O
and	O
HLA	O
class	O
I	O
expression	O
was	O
assessed	O
by	O
combining	O
HCA2	O
and	O
HC10	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	O
cells	O
(	O
further	O
referred	O
to	O
as	O
'	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
'	O
)	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
87	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

Only	O
3	O
(	O
0.6	O
%	O
)	O
irradiated	O
tumors	B
and	O
8	O
(	O
1.5	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
total	O
loss	O
of	O
HLA	O
class	O
I	O
(	O
negative	O
for	O
both	O
HCA2	O
and	O
HC10	O
)	O
.	O

Survival	O
results	O
of	O
patients	O
with	O
total	O
absence	O
of	O
HLA	O
class	O
I	O
on	O
tumor	B
cells	O
did	O
not	O
show	O
significant	O
difference	O
from	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

Therefore	O
,	O
these	O
groups	O
were	O
combined	O
and	O
will	O
be	O
further	O
referred	O
to	O
as	O
'	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
'	O
.	O

The	O
complete	O
results	O
are	O
shown	O
in	O
Table	O
2	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
-	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
,	O
indicating	O
that	O
irradiation	O
had	O
no	O
effect	O
on	O
HLA	O
class	O
I	O
expression	O
in	O
these	O
patients	O
.	O

Table	O
2Expression	O
of	O
HLA	O
class	O
I	O
in	O
rectal	O
cancer	B
using	O
HCA2	O
and	O
HC10	O
antibodiesHCA2HC10HLA	O
class	O
IHigh	O
(	O
N	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
N	O
(	O
%	O
)	O
IrradiatedHigh	O
(	O
N	O
)	O
27037406	O
(	O
85%	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
997070	O
(	O
15%	O
)	O
Non	O
-	O
irradiatedHigh	O
(	O
N	O
)	O
27732445	O
(	O
84%	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
1368787	O
(	O
16%	O
)	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
χ2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
χ2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	O
class	O
I	O
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	B
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O

Examples	O
of	O
Kaplan	O
–	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	B
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
–	O
d	O
)	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	B
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
have	O
a	O
better	O
overall	O
,	O
and	O
disease	B
free	O
survival	O
Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	B
free	O
survival	O
,	O
cancer	B
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Multivariate	O
analysis	O
Multivariate	O
analysis	O
was	O
performed	O
to	O
identify	O
factors	O
with	O
independent	O
prognostic	O
significance	O
and	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
.	O

Analyses	O
included	O
TNM	O
,	O
circumferential	O
margin	O
,	O
randomization	O
for	O
preoperative	O
radiotherapy	O
and	O
HLA	O
class	O
I	O
expression	O
(	O
low	B
vs.	I
high	I
HLA	I
class	I
I	I
positive	I
tumor	I
cells	I
)	O
(	O
Table	O
5	O
)	O
.	O

Advanced	O
pathological	O
(	O
TNM	O
)	O
stage	O
and	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margins	O
retained	O
their	O
strength	O
as	O
independent	O
prognostic	O
factors	O
in	O
these	O
survival	O
analyses	O
.	O

HLA	O
class	O
I	O
expression	O
showed	O
independent	O
prognostic	O
value	O
for	O
overall	O
survival	O
and	O
disease	B
-	O
free	O
survival	O
(	O
HR	O
:	O
1.3	O
,	O
P	O
=	O
0.042	O
and	O
HR	O
:	O
1.4	O
,	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
,	O
but	O
not	O
for	O
cancer	B
-	O
specific	O
survival	O
.	O

Table	O
5Multivariate	O
analysis	O
confirms	O
independent	O
better	O
overall	O
,	O
and	O
disease	B
free	O
survival	O
for	O
rectal	O
cancer	B
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
IOverall	O
survivalDisease	O
free	O
survivalCancer	O
specific	O
survivalHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHLA	O
High10.04210.00610.653	O
Low1.3	O
(	O
1.0–1.6	O
)	O
1.4	O
(	O
1.1–1.8	O
)	O
1.1	O
(	O
0.8–1.5	O
)	O
Randomization	O
TME10.63210.21410.282	O
TME	O
+	O
RT1	O
(	O
0.8–1.2	O
)	O
0.9	O
(	O
0.7–1.1	O
)	O
1.1	O
(	O
0.9–1.5	O
)	O
TNM	O
I111	O
II2.2	O
(	O
1.7–3.0	O
)	O
<0.0012.1	O
(	O
1.6–2.8	O
)	O
<0.0013.5	O
(	O
2.0–6.1	O
)	O
<0.001	O
III3.1	O
(	O
2.4–4.1	O
)	O
<0.0013.1	O
(	O
2.3–4.0	O
)	O
<0.0019.0	O
(	O
5.4–14.9	O
)	O
<0.001	O
IV11.8	O
(	O
8.1–17.1	O
)	O
<0.001––50.3	O
(	O
28.5–89.1	O
)	O
<0.001CRM	O
Negative1<0.0011<0.0011<0.001	O
Positive1.3	O
(	O
1.1–1.5	O
)	O
1.8	O
(	O
1.4–2.2	O
)	O
1.3	O
(	O
1.1–1.5	O
)	O
Multivariate	O
analysis	O
for	O
cancer	B
specific	O
,	O
overall	O
and	O
disease	B
free	O
survival	O
was	O
performed	O
to	O
identify	O
factors	O
with	O
independent	O
prognostic	O
significance	O
and	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
shown	O
in	O
parentheses	O
.	O

HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
,	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
,	O
Radiotherapy	O
(	O
RT	O
)	O
;	O
circumferential	O
margin	O
(	O
CRM	O
)	O
;	O
P	O
value	O
is	O
based	O
on	O
Cox	O
'	O
regression	O
analyses	O
*	O
Statistical	O
significant	O
P	O
values	O
and	O
HR	O
are	O
in	O
bold	O

Case	O
presentation	O
In	O
November	O
2006	O
,	O
a	O
56-year	O
old	O
woman	O
(	O
III-1	O
in	O
pedigree	O
,	O
Figure	O
1	O
)	O
visited	O
our	O
clinic	O
for	O
genetic	O
counseling	O
because	O
she	O
was	O
worried	O
about	O
the	O
many	O
cases	O
of	O
cancer	B
that	O
had	O
occurred	O
in	O
her	O
family	O
.	O

The	O
direct	O
reason	O
for	O
her	O
visit	O
was	O
the	O
recent	O
death	O
of	O
her	O
39-year	O
old	O
son	O
(	O
IV-1	O
)	O
with	O
a	O
symptomatic	O
,	O
and	O
already	O
metastasized	B
,	O
rectal	O
adenocarcinoma	B
.	O

The	O
counselee	O
had	O
been	O
diagnosed	O
with	O
an	O
endometrial	O
and	O
a	O
sigmoid	O
carcinoma	B
at	O
age	O
53-	O
and	O
54-years	O
old	O
,	O
respectively	O
.	O

She	O
reported	O
her	O
overwhelming	O
family	O
history	O
,	O
which	O
easily	O
fulfilled	O
the	O
criteria	O
that	O
enable	O
selection	O
of	O
families	O
that	O
are	O
at	O
risk	O
for	O
Lynch	B
syndrome	I
(	O
Table	O
1	O
)	O
.	O

Subsequent	O
IHC	O
-	O
analysis	O
on	O
archival	O
tumor	B
material	O
of	O
her	O
sigmoid	O
carcinoma	B
demonstrated	O
abrogation	O
of	O
the	O
MSH2	O
and	O
MSH6	O
proteins	O
,	O
which	O
is	O
typically	O
associated	O
with	O
a	O
germline	O
MSH2	O
mutation	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
,	O
in	O
DNA	O
extracted	O
from	O
peripheral	O
lymphocytes	O
,	O
identified	O
an	O
entire	O
MSH2	O
gene	O
deletion	O
(	O
exons	O
1–16	O
)	O
and	O
confirmed	O
the	O
diagnosis	O
of	O
Lynch	B
syndrome	I
.	O

Pedigree	O
of	O
a	O
Lynch	B
syndrome	I
family	O
,	O
showing	O
organ	O
systems	O
and	O
age	O
of	O
diagnosis	O
,	O
see	O
legend	O
.	O

Year	O
,	O
year	O
of	O
diagnosis	O
/	O
diagnoses	O
;	O
asterisk	O
,	O
anamnestically	O
obtained	O
information	O
;	O
urinary	O
tract	O
,	O
urothelial	O
carcinoma	B
of	O
renal	O
pelvis	O
or	O
ureter	O
;	O
skin	O
,	O
keratoacanthoma	B
;	O
asc	O
.	O
,	O
ascending	O
colon	O
;	O
transv	O
.	O
,	O
transverse	O
colon	O
;	O
desc	O
.	O
,	O
descending	O
colon	O
.	O

In	O
retrospect	O
,	O
some	O
doctors	O
had	O
indeed	O
signaled	O
noteworthy	O
features	O
in	O
this	O
family	O
.	O

First	O
,	O
in	O
1979	O
,	O
a	O
gynecologist	O
who	O
was	O
treating	O
patient	O
II-6	O
consulted	O
a	O
colleague	O
about	O
the	O
very	O
early	O
onset	O
of	O
endometrial	O
carcinoma	B
.	O

His	O
colleague	O
reassured	O
him	O
at	O
that	O
time	O
that	O
the	O
age	O
at	O
presentation	O
,	O
41	O
years	O
old	O
,	O
was	O
not	O
in	O
fact	O
very	O
rare	O
.	O

Second	O
,	O
in	O
2005	O
,	O
a	O
gastroenterologist	O
spoke	O
of	O
possible	O
HNPCC	B
in	O
patient	O
III-2	O
,	O
who	O
was	O
diagnosed	O
with	O
carcinoma	B
of	O
the	O
papilla	O
of	O
Vater	O
after	O
she	O
had	O
developed	O
three	O
separate	O
colon	O
carcinomas	B
,	O
but	O
no	O
further	O
action	O
was	O
taken	O
.	O

Third	O
,	O
in	O
2006	O
,	O
an	O
oncologist	O
treating	O
patient	O
IV-1	O
suggested	O
MSI	O
testing	O
on	O
tumor	B
material	O
after	O
his	O
mother	O
(	O
III-1	O
)	O
had	O
expressed	O
her	O
concern	O
about	O
the	O
family	O
history	O
,	O
but	O
did	O
not	O
proceed	O
.	O

Discussion	O
This	O
family	O
is	O
a	O
fine	O
example	O
of	O
the	O
plethora	O
of	O
tumors	B
that	O
may	O
occur	O
in	O
Lynch	B
syndrome	I
and	O
demonstrates	O
why	O
the	O
term	O
Lynch	B
syndrome	I
is	O
preferred	O
nowadays	O
over	O
HNPCC	B
(	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
)	O
,	O
which	O
only	O
refers	O
to	O
CRC	B
.	O

The	O
organ	O
involvement	O
in	O
this	O
family	O
included	O
seven	O
organ	O
systems	O
:	O
colon	O
,	O
uterus	O
,	O
skin	O
,	O
stomach	O
,	O
urinary	O
tract	O
,	O
pancreas	O
and	O
hepatobiliary	O
system	O
.	O

The	O
manifestation	O
of	O
keratoacanthoma	B
in	O
this	O
family	O
enabled	O
a	O
sub	O
-	O
classification	O
to	O
Muir	B
Torre	I
syndrome	I
(	O
MTS	B
)	O
.	O

MTS	B
is	O
a	O
variant	O
of	O
Lynch	B
syndrome	I
and	O
germline	O
mutations	O
in	O
the	O
three	O
main	O
Lynch	B
syndrome	I
genes	O
(	O
MLH1	O
,	O
MSH2	O
and	O
MSH6	O
)	O
have	O
been	O
identified	O
in	O
MTS	B
families	O
[	O
7,8	O
]	O
.	O

Keratoacanthoma	B
should	O
be	O
regarded	O
as	O
one	O
of	O
the	O
tumors	B
that	O
lie	O
in	O
the	O
constellation	O
of	O
Lynch	B
syndrome	I
but	O
their	O
manifestation	O
could	O
depend	O
on	O
modifier	O
genes	O
and/or	O
environmental	O
factors	O
.	O

This	O
case	O
report	O
shows	O
a	O
considerable	O
delay	O
in	O
diagnosing	O
Lynch	B
syndrome	I
which	O
negatively	O
influenced	O
the	O
management	O
of	O
many	O
family	O
members	O
.	O

None	O
of	O
the	O
family	O
members	O
underwent	O
presymptomatic	O
screening	O
on	O
the	O
basis	O
of	O
the	O
family	O
history	O
,	O
while	O
clinical	O
surveillance	O
has	O
been	O
shown	O
to	O
decrease	O
mortality	O
in	O
Lynch	B
syndrome	I
families	O
[	O
9	O
]	O
.	O

Remarkably	O
,	O
in	O
none	O
of	O
the	O
medical	O
reports	O
we	O
obtained	O
was	O
a	O
family	O
history	O
reported	O
extending	O
further	O
than	O
first	O
-	O
degree	O
relatives	O
.	O

Conclusion	O
This	O
family	O
clearly	O
illustrates	O
a	O
lack	O
of	O
awareness	O
about	O
a	O
hereditary	O
tumor	B
syndrome	I
among	O
doctors	O
as	O
well	O
as	O
patients	O
.	O

In	O
general	O
,	O
it	O
is	O
prudent	O
to	O
be	O
aware	O
of	O
classic	O
hereditary	O
features	O
,	O
like	O
young	O
age	O
at	O
diagnosis	O
,	O
multiple	O
tumors	B
in	O
multiple	O
organs	O
and	O
a	O
positive	O
family	O
history	O
,	O
and	O
to	O
refer	O
suspected	O
cases	O
for	O
genetic	O
counseling	O
.	O

More	O
specifically	O
,	O
these	O
features	O
can	O
be	O
found	O
in	O
the	O
Amsterdam	O
and	O
Bethesda	O
criteria	O
(	O
Table	O
1	O
)	O
.	O

Subsequently	O
,	O
the	O
identification	O
of	O
at	O
-	O
risk	O
persons	O
will	O
optimize	O
the	O
timing	O
and	O
efficiency	O
that	O
surveillance	O
and	O
treatment	O
are	O
carried	O
out	O
.	O

The	O
DNA	O
sequence	O
of	O
each	O
microsatellite	O
in	O
the	O
tumor	B
was	O
compared	O
with	O
that	O
of	O
the	O
matched	O
normal	B
mucosa	O
.	O

It	O
was	O
considered	O
as	O
unstable	O
if	O
there	O
was	O
an	O
absence	O
,	O
shortening	O
or	O
prolongation	O
of	O
the	O
DNA	O
sequence	O
.	O

MSI	O
-	O
L	O
was	O
defined	O
as	O
1	O
unstable	O
microsatellite	O
out	O
of	O
5	O
,	O
while	O
MSI	O
-	O
H	O
was	O
defined	O
as	O
more	O
than	O
1	O
unstable	O
microsatellite	O
out	O
of	O
5	O
.	O

If	O
the	O
tumor	B
microsatellites	O
were	O
identical	O
to	O
those	O
of	O
the	O
normal	O
tissue	O
,	O
the	O
microsatellite	O
was	O
considered	O
as	O
stable	O
(	O
MSS	O
)	O
.	O

For	O
the	O
MSI	B
-	I
L	I
CRCs	B
,	O
BAT-40	O
and	O
MYCL	O
were	O
detected	O
.	O

If	O
either	O
of	O
these	O
two	O
markers	O
was	O
unstable	O
,	O
this	O
colorectal	O
sample	O
was	O
considered	O
as	O
MSI	O
-	O
H.	O
Immunohistochemical	O
staining	O
for	O
MSH2	O
,	O
MSH6	O
and	O
MLH1	O
on	O
TMAs	O
The	O
CRC	B
microarray	O
was	O
constructed	O
as	O
previously	O
described	O
[	O
8,9	O
]	O
.	O

Briefly	O
,	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
blocks	O
of	O
CRC	B
resections	O
were	O
cut	O
from	O
the	O
donor	O
block	O
and	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
(	O
HE	O
)	O
.	O

These	O
slides	O
were	O
used	O
to	O
guide	O
the	O
sampling	O
from	O
morphologically	O
representative	O
regions	O
of	O
the	O
tissues	O
.	O

A	O
tissue	O
array	O
instrument	O
(	O
Beecher	O
Instruments	O
,	O
Silver	O
Spring	O
,	O
MD	O
)	O
was	O
used	O
to	O
create	O
holes	O
in	O
a	O
recipient	O
paraffin	O
block	O
and	O
to	O
acquire	O
tissue	O
cores	O
from	O
the	O
donor	O
block	O
by	O
a	O
thin	O
-	O
walled	O
needle	O
with	O
an	O
inner	O
diameter	O
of	O
1.0	O
mm	O
,	O
held	O
in	O
an	O
X	O
-	O
Y	O
precision	O
guide	O
.	O

The	O
cylindrical	O
samples	O
were	O
retrieved	O
from	O
the	O
selected	O
regions	O
in	O
the	O
donors	O
and	O
extruded	O
directly	O
into	O
the	O
recipient	O
blocks	O
with	O
defined	O
array	O
coordinates	O
.	O

Three	O
cores	O
were	O
obtained	O
from	O
each	O
sample	O
.	O

After	O
the	O
construction	O
of	O
the	O
array	O
block	O
,	O
multiple	O
4-mm	O
thick	O
sections	O
were	O
cut	O
with	O
a	O
microtome	O
using	O
an	O
adhesive	O
-	O
coated	O
tape	O
sectioning	O
system	O
(	O
Instrumedics	O
,	O
Hackensack	O
,	O
NJ	O
)	O
.	O

In	O
our	O
analysis	O
the	O
rates	O
of	O
lost	O
cases	O
attributable	O
to	O
tissue	O
damage	O
were	O
less	O
than	O
5	O
%	O
for	O
the	O
different	O
markers	O
.	O

TMA	O
slides	O
were	O
stained	O
with	O
MLH1	O
antibodies	O
(	O
1:50	O
dilution	O
,	O
No.	O
sc-494	O
,	O
Santa	O
Cruz	O
,	O
Biotrade	O
Ltd	O
,	O
Shanghai	O
,	O
China	O
)	O
and	O
MSH2	O
(	O
1:100	O
dilution	O
,	O
No.	O
sc-581	O
,	O
Santa	O
Cruz	O
,	O
Biotrade	O
Ltd	O
,	O
Shanghai	O
,	O
China	O
)	O
.	O

IHC	O
staining	O
for	O
samples	O
on	O
the	O
tissue	O
microarray	O
was	O
carried	O
out	O
using	O
Envision	O
ready	O
-	O
to	O
-	O
use	O
methods	O
(	O
Dako	O
Diagnostics	O
,	O
Zug	O
,	O
Switzerland	O
)	O
.	O

Slides	O
were	O
deparaffinized	O
in	O
xylene	O
and	O
rehydrated	O
through	O
graded	O
concentrations	O
of	O
ethanol	O
to	O
distilled	O
water	O
,	O
and	O
endogenous	O
peroxidase	O
activity	O
was	O
blocked	O
by	O
incubation	O
with	O
30	O
mL	O
/	O
L	O
H2O2	O
in	O
methanol	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
sections	O
were	O
submitted	O
to	O
antigen	O
retrieval	O
in	O
a	O
pressure	O
cooker	O
containing	O
0.01	O
mmol	O
/	O
L	O
natrium	O
citricium	O
buffer	O
for	O
10	O
min	O
.	O

Slides	O
were	O
subsequently	O
incubated	O
in	O
100	O
mL	O
/	O
L	O
normal	O
goat	O
serum	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

Sections	O
were	O
permeabilized	O
in	O
PBS	O
-	O
Triton	O
and	O
incubated	O
overnight	O
with	O
primary	O
antibody	O
at	O
4	O
°	O
C	O
.	O

The	O
pathologist	O
and	O
technician	O
who	O
reviewed	O
the	O
immunostaining	O
of	O
the	O
tissue	O
samples	O
were	O
blinded	O
to	O
the	O
patient	O
's	O
information	O
.	O

Stained	O
slides	O
and	O
individual	O
cores	O
were	O
scored	O
as	O
either	O
positive	O
(	O
showing	O
nuclear	O
staining	O
in	O
at	O
least	O
some	O
tumor	B
cells	O
)	O
or	O
negative	O
.	O

Regarding	O
the	O
location	O
of	O
gene	O
mutations	O
,	O
we	O
found	O
that	O
3	O
patients	O
bore	O
mutations	O
in	O
exon	O
7	O
of	O
MSH2	O
,	O
2	O
had	O
mutations	O
in	O
exon	O
12	O
of	O
MSH2	O
,	O
1	O
had	O
a	O
mutation	O
in	O
exon	O
2	O
of	O
MSH6	O
,	O
and	O
2	O
had	O
mutations	O
in	O
exon	O
5	O
of	O
MSH6	O
.	O

No	O
MLH1	O
mutations	O
were	O
found	O
in	O
our	O
cohort	O
.	O

All	O
8	O
mutations	O
were	O
considered	O
pathogenic	O
mutations	O
.	O

The	O
mutation	O
of	O
C1886	O
A	O
>	O
G	O
,	O
C1668	O
C	O
>	O
T	O
was	O
reported	O
as	O
a	O
pathogenic	O
mutation	O
previously	O
[	O
22	O
-	O
25	O
]	O
.	O

However	O
,	O
the	O
other	O
six	O
mutations	O
have	O
not	O
been	O
reported	O
in	O
other	O
publications	O
and	O
are	O
likely	O
to	O
be	O
novel	O
mutations	O
.	O

We	O
also	O
attempted	O
to	O
screen	O
for	O
the	O
presence	O
of	O
all	O
these	O
mutations	O
in	O
50	O
randomly	O
selected	O
patients	O
in	O
the	O
MSS	B
group	O
and	O
in	O
50	O
normal	B
people	O
.	O

The	O
result	O
of	O
this	O
screen	O
was	O
negative	O
,	O
and	O
all	O
these	O
CRCs	B
with	O
mutations	O
stained	O
negatively	O
for	O
MSH2	O
or	O
/	O
and	O
MSH6	O
,	O
indicating	O
that	O
these	O
6	O
mutations	O
may	O
be	O
pathogenic	O
mutations	O
but	O
not	O
polymorphisms	O
.	O

In	O
terms	O
of	O
the	O
clinical	O
features	O
of	O
the	O
8	O
cases	O
with	O
mutations	O
,	O
only	O
1	O
conformed	O
to	O
the	O
Amsterdam	O
criteria	O
II	O
;	O
all	O
the	O
others	O
did	O
not	O
have	O
any	O
family	O
history	O
of	O
malignancy	O
.	O

Moreover	O
,	O
the	O
median	O
age	O
was	O
59	O
with	O
4	O
patients	O
that	O
were	O
older	O
than	O
60	O
years	O
old	O
.	O

One	O
limitation	O
of	O
this	O
study	O
is	O
that	O
it	O
is	O
a	O
single	O
-	O
center	O
study	O
with	O
a	O
relatively	O
small	O
sample	O
size	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
need	O
to	O
be	O
confirmed	O
by	O
a	O
well	O
designed	O
multi	O
-	O
center	O
study	O
,	O
which	O
is	O
one	O
of	O
our	O
ongoing	O
studies	O
in	O
China	O
.	O

Background	O
The	O
colon	O
is	O
composed	O
of	O
a	O
dynamic	O
and	O
self	O
-	O
renewing	O
epithelium	O
that	O
turns	O
over	O
every	O
three	O
to	O
five	O
days	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
at	O
the	O
base	O
of	O
the	O
crypt	O
,	O
variable	O
numbers	O
(	O
between	O
1	O
and	O
16	O
)	O
of	O
slowly	O
dividing	O
,	O
stationary	O
,	O
pluripotent	O
stem	O
cells	O
give	O
rise	O
to	O
more	O
rapidly	O
proliferating	O
,	O
transient	O
amplifying	O
cells	O
.	O

These	O
cells	O
differentiate	O
chiefly	O
into	O
post	O
-	O
mitotic	O
columnar	O
colonocytes	O
,	O
mucin	O
-	O
secreting	O
goblet	O
cells	O
,	O
and	O
enteroendocrine	O
cells	O
as	O
they	O
migrate	O
from	O
the	O
crypt	O
base	O
to	O
the	O
surface	O
where	O
they	O
are	O
sloughed	O
into	O
the	O
lumen	O
[	O
1	O
]	O
.	O

Several	O
signaling	O
pathways	O
,	O
notably	O
Wnt	O
,	O
Tgfβ	O
,	O
Bmp	O
,	O
Hedgehog	O
and	O
Notch	O
,	O
play	O
pivotal	O
roles	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
of	O
the	O
developing	O
and	O
adult	O
colon	O
[	O
2	O
]	O
.	O

Their	O
perturbation	O
,	O
via	O
mutation	O
or	O
epigenetic	O
modification	O
,	O
occurs	O
in	O
human	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
and	O
the	O
instillation	O
of	O
these	O
changes	O
via	O
genetic	O
engineering	O
in	O
mice	O
confers	O
a	O
correspondingly	O
high	O
risk	O
for	O
neoplasia	B
in	O
the	O
mouse	O
models	O
.	O

Moreover	O
,	O
tumor	B
cell	O
de	O
-	O
differentiation	O
correlates	O
with	O
key	O
tumor	B
features	O
,	O
such	O
as	O
tumor	B
progression	O
rates	O
,	O
invasiveness	O
,	O
drug	O
resistance	O
and	O
metastatic	O
potential	O
[	O
3	O
-	O
5	O
]	O
.	O

A	O
variety	O
of	O
scientific	O
and	O
organizational	O
obstacles	O
make	O
it	O
a	O
challenging	O
proposition	O
to	O
undertake	O
large	O
-	O
scale	O
comparisons	O
of	O
human	O
cancer	B
to	O
the	O
wide	O
range	O
of	O
genetically	O
engineered	O
mouse	O
models	O
.	O

To	O
evaluate	O
the	O
potential	O
of	O
this	O
approach	O
to	O
provide	O
integrated	O
views	O
of	O
the	O
molecular	O
basis	O
of	O
cancer	B
risk	O
,	O
tumor	B
development	O
and	O
malignant	B
progression	O
,	O
we	O
have	O
undertaken	O
a	O
comparative	O
analysis	O
of	O
a	O
variety	O
of	O
individually	O
developed	O
mouse	O
colon	O
tumor	B
models	O
(	O
reviewed	O
in	O
[	O
6,7	O
]	O
)	O
to	O
human	O
CRC	B
.	O

The	O
ApcMin	O
/	O
+	O
(	O
multiple	O
intestinal	O
neoplasia	O
)	O
mouse	O
model	O
harbors	O
a	O
germline	O
mutation	O
in	O
the	O
Apc	O
tumor	B
suppressor	O
gene	O
and	O
exhibits	O
multiple	O
tumors	B
in	O
the	O
small	O
intestine	O
and	O
colon	O
[	O
8	O
]	O
.	O

A	O
major	O
function	O
of	O
APC	O
is	O
to	O
regulate	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
as	O
part	O
of	O
a	O
β	O
-	O
catenin	O
degradation	O
complex	O
.	O

Loss	O
of	O
APC	O
results	O
in	O
a	O
failure	O
to	O
degrade	O
β	O
-	O
catenin	O
,	O
which	O
instead	O
enters	O
the	O
nucleus	O
to	O
act	O
as	O
a	O
transcriptional	O
co	O
-	O
activator	O
with	O
the	O
lymphoid	O
enhancer	O
factor	O
/	O
T	O
-	O
cell	O
factor	O
(	O
LEF	O
/	O
TCF	O
)	O
family	O
of	O
transcription	O
factors	O
[	O
9	O
]	O
.	O

The	O
localization	O
of	O
β	O
-	O
catenin	O
within	O
the	O
nucleus	O
indicates	O
activated	O
canonical	O
WNT	O
signaling	O
.	O

In	O
addition	O
to	O
germline	O
APC	O
mutations	O
that	O
occur	O
in	O
persons	O
with	O
familial	B
adenomatous	I
polyposis	I
coli	O
(	O
FAP	B
)	O
and	O
ApcMin	O
/	O
+	O
mice	O
,	O
loss	O
of	O
functional	O
APC	O
and	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
occurs	O
in	O
more	O
than	O
80	O
%	O
of	O
human	O
sporadic	O
CRCs	B
[	O
10	O
]	O
.	O

Similar	O
to	O
the	O
ApcMin	O
/	O
+	O
model	O
,	O
tumors	B
in	O
the	O
azoxymethane	O
(	O
AOM	O
)	O
carcinogen	O
model	O
,	O
which	O
occur	O
predominantly	O
in	O
the	O
colon	O
[	O
11	O
]	O
,	O
have	O
signaling	O
alterations	O
marked	O
by	O
activated	O
canonical	O
WNT	O
signaling	O
.	O

Results	O
Strategy	O
for	O
cross	O
-	O
species	O
analysis	O
Our	O
strategy	O
for	O
the	O
characterization	O
of	O
mouse	O
models	O
of	O
human	O
CRC	B
(	O
Figure	O
1	O
)	O
relies	O
on	O
gene	O
expression	O
differences	O
and	O
relative	O
patterning	O
across	O
a	O
range	O
of	O
mouse	O
CRC	B
models	O
,	O
normal	B
mouse	O
colon	O
developmental	O
stages	O
,	O
and	O
human	O
CRCs	B
.	O

Achieving	O
this	O
comparison	O
was	O
facilitated	O
by	O
the	O
use	O
of	O
reference	O
RNAs	O
from	O
whole	O
-	O
mouse	O
and	O
normal	B
adult	O
colon	O
reference	O
RNAs	O
for	O
both	O
mouse	O
and	O
human	O
measurements	O
.	O

Mouse	O
tumor	B
samples	O
were	O
profiled	O
on	O
cDNA	O
microarrays	O
using	O
the	O
embryonic	O
day	O
(	O
E	O
)	O
17.5	O
whole	O
mouse	O
reference	O
RNA	O
identical	O
to	O
that	O
used	O
previously	O
[	O
15	O
]	O
to	O
examine	O
embryonic	O
mouse	O
colon	O
gene	O
expression	O
dynamics	O
from	O
E13.5	O
to	O
E18.5	O
,	O
during	O
which	O
time	O
the	O
primitive	O
,	O
undifferentiated	O
,	O
pseudo	O
-	O
stratified	O
colonic	O
endoderm	O
becomes	O
a	O
differentiated	O
,	O
single	O
-	O
layered	O
epithelium	O
.	O

This	O
strategy	O
allowed	O
us	O
to	O
construct	O
a	O
gene	O
expression	O
database	O
of	O
mouse	O
colon	O
tumors	B
in	O
which	O
gene	O
expression	O
levels	O
of	O
the	O
tumors	B
could	O
be	O
referenced	O
,	O
ranked	O
,	O
and	O
statistically	O
compared	O
to	O
an	O
average	O
value	O
among	O
the	O
tumors	B
or	O
to	O
embryonic	O
or	O
adult	O
colon	O
gene	O
expression	O
levels	O
on	O
a	O
per	O
-	O
gene	O
basis	O
.	O

First	O
,	O
we	O
compared	O
the	O
four	O
models	O
with	O
each	O
other	O
,	O
then	O
to	O
mouse	O
colon	O
development	O
,	O
and	O
finally	O
to	O
human	O
CRCs	B
using	O
gene	O
ortholog	O
mapping	O
(	O
Figure	O
1	O
)	O
.	O

Stratification	O
of	O
murine	O
colon	O
tumor	B
models	O
by	O
localization	O
of	O
β	O
-	O
catenin	O
and	O
plan	O
for	O
analysis	O
.	O

Colon	O
tumors	B
from	O
four	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
CRC	B
were	O
subjected	O
to	O
microarray	O
gene	O
expression	O
profiling	O
.	O

The	O
gene	O
expression	O
profiles	O
from	O
the	O
different	O
mouse	O
model	O
tumors	B
were	O
compared	O
and	O
contrasted	O
to	O
each	O
other	O
,	O
as	O
well	O
as	O
to	O
those	O
from	O
embryonic	O
mouse	O
colon	O
development	O
and	O
100	O
human	O
CRCs	B
.	O

Mouse	O
colon	O
tumors	B
partition	O
into	O
classes	O
reflecting	O
differential	O
canonical	O
WNT	O
signaling	O
activity	O
To	O
discover	O
gene	O
expression	O
programs	O
underlying	O
differences	O
between	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
CRC	B
,	O
gene	O
expression	O
level	O
values	O
for	O
each	O
transcript	O
in	O
each	O
tumor	B
sample	O
was	O
set	O
to	O
its	O
ratio	O
relative	O
to	O
its	O
median	O
across	O
the	O
series	O
of	O
tumor	B
models	O
.	O

Using	O
non	O
-	O
parametric	O
statistical	O
analyses	O
,	O
1,798	O
cDNA	O
transcripts	O
were	O
identified	O
as	O
differentially	O
expressed	O
among	O
the	O
four	O
mouse	O
models	O
of	O
CRC	B
.	O

Five	O
major	O
gene	O
patterns	O
were	O
identified	O
using	O
K	O
-	O
means	O
clustering	O
(	O
clusters	O
C1-C5	O
;	O
Figure	O
2a	O
,	O
top	O
)	O
.	O

Genes	O
belonging	O
to	O
these	O
clusters	O
were	O
strongly	O
associated	O
with	O
annotated	O
gene	O
function	O
categories	O
(	O
see	O
Table	O
1	O
for	O
detailed	O
biological	O
descriptions	O
and	O
associations	O
)	O
.	O

For	O
example	O
,	O
cluster	O
C1	O
,	O
composed	O
of	O
transcripts	O
that	O
exhibited	O
lower	O
expression	O
in	O
Smad3-	O
/	O
-	O
tumors	B
and	O
higher	O
expression	O
in	O
AOM	O
,	O
ApcMin	O
/	O
+	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
,	O
contains	O
391	O
transcripts	O
,	O
including	O
Cdk4	O
,	O
Ctnnb1	O
,	O
Myc	O
,	O
Ezh2	O
,	O
Mcm2	O
and	O
Tcf3	O
.	O

Gene	O
list	O
over	O
-	O
representation	O
analysis	O
using	O
Ingenuity	O
Pathway	O
Analysis	O
applications	O
demonstrated	O
highly	O
significant	O
associations	O
to	O
cell	O
cycle	O
progression	O
,	O
replication	O
,	O
post	O
-	O
transcriptional	O
control	O
and	O
cancer	B
.	O

Similarly	O
,	O
cluster	O
C2	O
,	O
composed	O
of	O
663	O
transcripts	O
that	O
exhibited	O
high	O
expression	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
,	O
but	O
low	B
in	I
Smad3-	I
/	I
-	I
and	I
Tgfb1-	I
/	I
-	I
;	I
Rag2-	I
/	I
-	I
tumors	B
,	O
included	O
transcripts	O
for	O
contact	O
growth	O
inhibition	O
(	O
Metap1	O
,	O
Pcyox1	O
)	O
,	O
mitosis	O
(	O
Mif	O
,	O
Pik1	O
)	O
,	O
cell	O
cycle	O
progression	O
and	O
checkpoint	O
control	O
(	O
Id2	O
,	O
Ptp4A2	O
,	O
Tp53	O
)	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C11-C17	O
PS	O
,	O
ProbeSets	O
.	O

Human	O
CRCs	B
exhibit	O
gene	O
expression	O
profile	O
complexity	O
consistent	O
with	O
significant	O
tumor	B
subclasses	O
.	O

Genes	O
potentially	O
able	O
to	O
distinguish	O
cancer	B
subtypes	O
were	O
identified	O
from	O
Affymetrix	O
HG	O
-	O
U133	O
plus2	O
Genechip	O
expression	O
profiles	O
by	O
filtering	O
for	O
3,285	O
probe	O
sets	O
that	O
were	O
top	O
-	O
ranked	O
by	O
raw	O
expression	O
and	O
their	O
differential	O
regulation	O
in	O
at	O
least	O
10	O
out	O
of	O
100	O
human	O
colorectal	B
cancer	I
tumors	B
.	O

Coordinately	O
regulated	O
transcripts	O
and	O
similarly	O
behaving	O
samples	O
were	O
identified	O
via	O
hierarchical	O
tree	O
clustering	O
.	O

Seven	O
different	O
gene	O
clusters	O
(	O
C11	O
-	O
17	O
)	O
were	O
identified	O
that	O
distinguished	O
ten	O
or	O
more	O
tumors	B
from	O
the	O
other	O
tumors	B
.	O

Gene	O
clusters	O
were	O
found	O
to	O
be	O
highly	O
enriched	O
for	O
gene	O
functions	O
listed	O
in	O
Table	O
3	O
.	O

Data	O
were	O
processed	O
using	O
Robust	O
Microarray	O
Analysis	O
(	O
RMA	O
)	O
with	O
expression	O
value	O
ratios	O
depicted	O
as	O
the	O
relative	O
expression	O
per	O
probe	O
set	O
in	O
each	O
sample	O
relative	O
to	O
the	O
median	O
of	O
its	O
expression	O
across	O
the	O
100	O
CRCs	B
.	O

A	O
striking	O
heterogeneity	O
of	O
gene	O
expression	O
was	O
observed	O
,	O
including	O
metallothionein	O
genes	O
in	O
cluster	O
C15	O
previously	O
shown	O
to	O
be	O
predictive	O
of	O
microsatellite	O
instability	O
(	O
indicated	O
by	O
asterisk	O
)	O
,	O
and	O
C17	O
represented	O
by	O
734	O
probesets	O
rich	O
in	O
genes	O
associated	O
with	O
extracellular	O
matrix	O
and	O
connective	O
tissue	O
,	O
tumor	B
invasion	O
and	O
malignancy	B
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	B
,	O
human	O
CRC	B
.	O

Staging	O
:	O
nAC	O
,	O
normal	B
colon	O
;	O
Dukes	O
A	O
-	O
D	O
,	O
human	O
tumors	B
obtained	O
from	O
individuals	O
.	O

Clusters	O
C11-C17	O
labeled	O
to	O
the	O
right	O
of	O
the	O
heatmap	O
correspond	O
to	O
the	O
K	O
-	O
means	O
functional	O
clusters	O
listed	O
in	O
Table	O
3	O
.	O

To	O
evaluate	O
if	O
similar	O
sets	O
of	O
genes	O
are	O
systematically	O
activated	O
or	O
repressed	O
in	O
human	O
CRC	B
,	O
as	O
in	O
the	O
mouse	O
colon	O
tumors	B
,	O
we	O
undertook	O
two	O
procedures	O
to	O
align	O
the	O
data	O
.	O

First	O
,	O
gene	O
expression	O
values	O
for	O
the	O
mouse	O
and	O
human	O
tumors	B
were	O
separately	O
normalized	O
and	O
referenced	O
relative	O
to	O
their	O
respective	O
normal	B
adult	O
colon	O
controls	O
;	O
second	O
,	O
mouse	O
and	O
human	O
gene	O
identifiers	O
were	O
reduced	O
to	O
a	O
single	O
ortholog	O
gene	O
identifier	O
.	O

The	O
latter	O
is	O
a	O
somewhat	O
complex	O
procedure	O
that	O
requires	O
identifying	O
microarray	O
probes	O
from	O
each	O
platform	O
that	O
can	O
be	O
mapped	O
to	O
a	O
single	O
gene	O
ortholog	O
and	O
undertaking	O
a	O
procedure	O
to	O
aggregate	O
redundant	O
probes	O
within	O
a	O
platform	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
.	O

This	O
approach	O
allowed	O
the	O
identification	O
of	O
8,621	O
gene	O
transcripts	O
on	O
the	O
HG	O
-	O
U133	O
plus2	O
and	O
Vanderbilt	O
NIA	O
20	O
K	O
cDNA	O
arrays	O
for	O
which	O
relative	O
expression	O
values	O
could	O
be	O
mapped	O
for	O
nearly	O
all	O
mouse	O
and	O
human	O
samples	O
.	O

A	O
clustering	O
-	O
based	O
assessment	O
of	O
expression	O
across	O
the	O
whole	O
mouse	O
-	O
human	O
ortholog	O
gene	O
set	O
identified	O
a	O
large	O
number	O
of	O
transcripts	O
behaving	O
similarly	O
across	O
colon	O
tumors	B
,	O
many	O
irrespective	O
,	O
but	O
some	O
respective	O
of	O
species	O
.	O

Notably	O
,	O
the	O
great	O
majority	O
of	O
genes	O
over	O
-	O
expressed	O
in	O
all	O
tumors	O
were	O
also	O
over	O
-	O
expressed	O
during	O
colon	O
development	O
(	O
Figure	O
6a	O
)	O
.	O

To	O
evaluate	O
the	O
statistical	O
significance	O
of	O
this	O
pattern	O
,	O
we	O
used	O
a	O
Venn	O
overlap	O
filtering	O
strategy	O
and	O
Fisher	O
's	O
exact	O
test	O
analysis	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
2,212	O
ortholog	O
genes	O
over	O
-	O
expressed	O
in	O
at	O
least	O
10	O
%	O
of	O
the	O
human	O
cancers	B
relative	O
to	O
adult	O
colon	O
were	O
also	O
over	O
-	O
expressed	O
in	O
developing	O
colon	O
.	O

If	O
there	O
was	O
not	O
a	O
selection	O
for	O
developmental	O
genes	O
among	O
those	O
over	O
-	O
expressed	O
in	O
tumors	B
,	O
the	O
expected	O
overlap	O
would	O
be	O
(	O
2,718	O
/	O
8,621	O
)	O
×	O
2,212	O
=	O
697	O
transcripts	O
.	O

Using	O
Fisher	O
's	O
exact	O
test	O
for	O
the	O
significance	O
of	O
the	O
increased	O
overlap	O
of	O
1,080	O
versus	O
697	O
transcripts	O
is	O
p	O
<	O
1e-300	O
.	O

Similarly	O
,	O
genes	O
under	O
-	O
expressed	O
in	O
mouse	O
colon	O
development	O
and	O
human	O
CRCs	B
also	O
strongly	O
overlapped	O
(	O
Figure	O
6b	O
;	O
431	O
of	O
737	O
,	O
p	O
<	O
1e-76	O
)	O
.	O

This	O
result	O
is	O
significantly	O
greater	O
than	O
the	O
8	O
-	O
19	O
%	O
of	O
genes	O
that	O
were	O
estimated	O
to	O
be	O
over	O
-	O
expressed	O
in	O
human	O
colon	O
tumors	B
and	O
fetal	O
gut	O
morphogenesis	O
based	O
upon	O
a	O
computational	O
extrapolation	O
of	O
SAGE	O
data	O
[	O
27	O
]	O
.	O

Thus	O
,	O
our	O
findings	O
not	O
only	O
confirm	O
but	O
also	O
significantly	O
expand	O
and	O
experimentally	O
validate	O
the	O
previously	O
suggested	O
recapitulation	O
of	O
embryonic	O
signatures	O
by	O
human	O
CRCs	B
.	O

All	O
overlaps	O
between	O
tumor	B
expression	O
and	O
development	O
were	O
pooled	O
to	O
form	O
a	O
set	O
of	O
2,116	O
ortholog	O
gene	O
transcripts	O
.	O

This	O
was	O
subjected	O
to	O
hierarchical	O
tree	O
and	O
K	O
-	O
means	O
clustering	O
to	O
define	O
six	O
expression	O
clusters	O
,	O
C18-C23	O
(	O
Figure	O
6c	O
;	O
Table	O
4	O
)	O
.	O

These	O
clusters	O
provide	O
an	O
impressive	O
partitioning	O
of	O
groups	O
of	O
genes	O
associated	O
with	O
different	O
biological	O
functions	O
critical	O
for	O
colon	O
development	O
,	O
maturation	O
and	O
oncogenesis	B
.	O

Cluster	B
C22	I
(	I
860	I
transcripts	I
of	I
genes	I
strongly	I
expressed	I
both	I
developmentally	I
and	I
across	I
all	I
tumors	I
)	I
is	O
highly	O
enriched	O
with	O
genes	O
associated	O
with	O
cell	O
cycle	O
progression	O
,	O
replication	O
,	O
cancer	B
,	O
tumor	B
morphology	O
and	O
cellular	O
movement	O
.	O

Cluster	B
C18	I
(	I
258	I
transcripts	I
down	I
-	I
regulated	I
in	I
mouse	I
and	I
human	I
tumors	I
,	I
as	I
well	I
as	I
in	I
development	I
)	I
is	O
highly	O
enriched	O
in	O
genes	O
associated	O
with	O
digestive	O
tract	O
function	O
,	O
biochemical	O
and	O
lipid	O
metabolism	O
.	O

This	O
cluster	O
is	O
clearly	O
composed	O
of	O
genes	O
associated	O
with	O
the	O
mature	O
GI	O
tract	O
.	O

Thus	O
,	O
as	O
opposed	O
to	O
recapitulating	O
developmental	O
gene	O
activation	O
,	O
the	O
cluster	O
C18	O
pattern	O
indicates	O
a	O
corresponding	O
arrest	O
of	O
differentiation	O
in	O
both	O
mouse	O
and	O
human	O
tumors	B
.	O

Cluster	B
C23	I
(	I
142	I
transcripts	I
over	I
-	I
expressed	I
in	I
all	I
mouse	I
models	I
and	I
human	I
CRC	I
,	I
but	I
with	I
low	I
expression	I
in	I
development	I
)	I
maps	O
to	O
genes	O
highly	O
associated	O
with	O
the	O
disruption	O
of	O
basement	O
membranes	O
,	O
invasion	O
and	O
cell	O
cycle	O
progression	O
,	O
as	O
well	O
as	O
altered	O
transcriptional	O
control	O
.	O

Cluster	O
C21	O
(	O
313	O
transcripts	O
in	O
which	O
human	O
tumors	B
somewhat	O
variably	O
express	O
a	O
set	O
of	O
genes	O
that	O
are	O
rarely	O
expressed	O
by	O
the	O
mouse	O
tumors	B
)	O
is	O
remarkable	O
for	O
its	O
composition	O
of	O
genes	O
associated	O
with	O
cell	O
cycle	O
proliferation	O
,	O
tissue	O
disruption	O
and	O
angiogenesis	O
.	O

Thus	O
,	O
while	O
categorically	O
quite	O
similar	O
to	O
cluster	O
C23	O
,	O
the	O
genes	O
in	O
cluster	O
C21	O
represent	O
a	O
separately	O
regulated	O
module	O
that	O
is	O
enriched	O
for	O
genes	O
associated	O
with	O
invasion	O
.	O

Clusters	B
C21	I
and	I
C23	I
reveal	I
sets	I
of	I
genes	I
likely	I
involved	I
in	I
tumor	I
progression	I
.	O

Cluster	B
C22	I
(	I
with	I
genes	I
over	I
-	I
expressed	I
in	I
all	I
mouse	I
and	I
human	I
tumors	I
and	I
strongly	I
expressed	I
in	I
embryonic	I
colon	I
)	I
represents	O
a	O
group	O
of	O
genes	O
highly	O
correlated	O
with	O
transformation	O
.	O

The	O
top	O
-	O
ranked	O
transcription	O
factor	O
present	O
in	O
this	O
cluster	O
,	O
with	O
regulation	O
independent	O
of	O
β	O
-	O
catenin	O
localization	O
,	O
is	O
Myc	O
/	O
MYC	O
(	O
Figure	O
7b	O
)	O
.	O

Although	O
Myc	O
was	O
lower	O
in	O
expression	O
in	O
the	O
Smad3-	O
/	O
-	O
tumors	B
compared	O
to	O
tumors	B
from	O
the	O
other	O
three	O
models	O
,	O
it	O
was	O
elevated	O
in	O
all	O
four	O
models	O
relative	O
to	O
normal	B
adult	O
colon	O
.	O

Myc	O
/	O
MYC	O
was	O
over	O
-	O
expressed	O
in	O
all	O
mouse	O
and	O
human	O
tumors	B
as	O
well	O
as	O
in	O
development	O
.	O

This	O
contrasts	O
with	O
Sox4	O
,	O
which	O
is	O
unaltered	O
in	O
expression	O
in	O
the	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
but	O
is	O
up	O
-	O
regulated	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
relative	O
to	O
normal	B
adult	O
colon	O
(	O
Figure	O
7b	O
)	O
.	O

Myc	O
/	O
MYC	O
over	O
-	O
expression	O
may	O
be	O
independent	O
of	O
nuclear	O
β	O
-	O
catenin	O
status	O
.	O

Increased	O
Myc	O
/	O
MYC	O
expression	O
may	O
reflect	O
both	O
activation	O
of	O
canonical	O
Wnt	O
signaling	O
,	O
as	O
it	O
is	O
a	O
target	O
of	O
nuclear	O
β	O
-	O
catenin	O
/	O
TCF	O
[	O
28	O
]	O
,	O
and	O
deregulation	O
of	O
TGFβ	O
signaling	O
,	O
as	O
TGFβ1	O
is	O
known	O
to	O
repress	O
Myc	O
/	O
MYC	O
[	O
29	O
-	O
31	O
]	O
.	O

These	O
observations	O
suggest	O
a	O
fundamental	O
role	O
for	O
Myc	O
/	O
MYC	O
in	O
colonic	O
neoplasia	B
.	O

As	O
shown	O
in	O
Figure	O
2a	O
,	O
the	O
microarray	O
patterns	O
of	O
gene	O
expression	O
for	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
are	O
mirror	O
images	O
of	O
those	O
for	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
.	O

It	O
is	O
perhaps	O
not	O
surprising	O
that	O
combining	O
these	O
two	O
transcriptional	O
programs	O
results	O
in	O
increased	O
number	O
and	O
invasiveness	O
of	O
colonic	O
tumors	B
as	O
recently	O
reported	O
for	O
ApcMin	O
/	O
+	O
mice	O
crossed	O
to	O
Smad3-	O
/	O
-	O
mice	O
[	O
45	O
]	O
.	O

Moreover	O
,	O
combined	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
and	O
inhibition	O
of	O
TGFβ	O
signaling	O
also	O
results	O
in	O
more	O
advanced	O
intestinal	O
tumors	B
in	O
Apcdelta716	O
/	O
+	O
;	O
Smad4+	O
/	O
-	O
mice	O
[	O
46	O
]	O
,	O
and	O
intestine	O
-	O
specific	O
deletion	O
of	O
the	O
type	O
II	O
TGFβ	O
receptor	O
in	O
Apc1638N	O
/	O
wt	O
mice	O
[	O
47	O
]	O
.	O

The	O
findings	O
that	O
shared	O
over	O
-	O
expressed	O
signatures	O
are	O
identifiable	O
in	O
all	O
four	O
mouse	O
models	O
of	O
CRC	B
,	O
which	O
are	O
also	O
representative	O
of	O
the	O
majority	O
of	O
embryonic	O
colonic	O
over	O
-	O
expressed	O
signatures	O
,	O
and	O
that	O
these	O
signatures	O
are	O
also	O
present	O
in	O
all	O
human	O
CRCs	B
,	O
suggest	O
that	O
colon	O
tumors	B
may	O
arise	O
independently	O
of	O
canonical	O
WNT	O
signaling	O
status	O
.	O

A	O
likely	O
candidate	O
to	O
impart	O
this	O
oncogenic	O
signaling	O
is	O
Myc	O
,	O
which	O
is	O
an	O
embryonic	O
up	O
-	O
regulated	O
transcript	O
that	O
is	O
also	O
upregulated	O
in	O
all	O
human	O
CRCs	B
and	O
mouse	O
tumor	B
models	O
independently	O
of	O
nuclear	O
β	O
-	O
catenin	O
status	O
.	O

Embryology	O
provides	O
insight	O
into	O
the	O
biology	O
of	O
mouse	O
and	O
human	O
colon	O
tumors	B
It	O
has	O
long	O
been	O
suggested	O
that	O
cancer	B
represents	O
a	O
reversion	O
to	O
an	O
embryonic	O
state	O
,	O
partly	O
based	O
upon	O
the	O
observation	O
that	O
several	O
oncofetal	O
antigens	O
are	O
diagnostic	O
for	O
some	O
tumors	B
[	O
48,49	O
]	O
.	O

To	O
assess	O
the	O
embryology	O
-	O
related	O
aspects	O
of	O
tumorigenesis	B
and	O
tumor	B
progression	O
in	O
CRC	B
,	O
we	O
analyzed	O
and	O
compared	O
the	O
transcriptomes	O
of	O
normal	B
mouse	O
colon	O
development	O
and	O
models	O
of	O
CRC	B
.	O

Our	O
data	O
show	O
that	O
developmentally	O
regulated	O
genes	O
represent	O
approximately	O
56	O
%	O
of	O
mouse	O
tumor	B
signatures	O
,	O
and	O
that	O
the	O
tumor	B
signatures	O
from	O
the	O
four	O
mouse	O
models	O
recapitulate	O
approximately	O
85	O
%	O
of	O
developmentally	O
regulated	O
genes	O
.	O

There	O
are	O
at	O
least	O
two	O
regulatory	O
programs	O
that	O
determine	O
the	O
expression	O
of	O
developmental	O
genes	O
by	O
mouse	O
tumors	B
(	O
Figures	O
2	O
,	O
4	O
,	O
and	O
8)	O
.	O

The	O
simpler	O
program	O
is	O
evident	O
by	O
the	O
over	O
-	O
expression	O
of	O
the	O
earliest	O
genes	O
of	O
colon	O
development	O
by	O
the	O
nuclear	O
β	O
-	O
catenin	O
-	O
positive	O
models	O
.	O

The	O
more	O
subtle	O
program	O
could	O
be	O
detected	O
only	O
in	O
reference	O
to	O
adult	O
colon	O
and	O
is	O
highly	O
shared	O
by	O
nuclear	O
β	O
-	O
catenin	O
-	O
negative	O
models	O
.	O

This	O
program	O
,	O
though	O
modified	O
by	O
nuclear	O
β	O
-	O
catenin	O
status	O
,	O
is	O
represented	O
by	O
a	O
large	O
scale	O
over	O
-	O
expression	O
of	O
developmentally	O
expressed	O
genes	O
in	O
tumors	B
that	O
are	O
both	O
positive	O
and	O
negative	O
for	O
canonical	O
WNT	O
signaling	O
.	O

Genes	O
found	O
within	O
this	O
signature	O
have	O
a	O
large	O
overlap	O
with	O
those	O
present	O
in	O
the	O
colon	O
at	O
later	O
developmental	O
stages	O
(	O
E16.5-E18.5	O
)	O
.	O

An	O
integrated	O
view	O
of	O
colon	B
cancer	I
transcriptional	O
programs	O
provides	O
novel	O
insight	O
into	O
neoplasia	B
.	O

Murine	O
colon	O
tumor	B
adenomas	B
and	O
human	O
CRCs	B
both	O
show	O
adoption	O
and	O
dysregulation	O
of	O
signatures	O
tightly	O
controlled	O
during	O
embryonic	O
mouse	O
colon	O
development	O
.	O

The	O
use	O
of	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
colon	B
cancer	I
allows	O
for	O
the	O
identification	O
of	O
models	O
that	O
resemble	O
different	O
stages	O
of	O
embryonic	O
mouse	O
colon	O
development	O
and	O
that	O
are	O
recapitulated	O
by	O
specific	O
tumor	B
types	O
.	O

(	O
a	O
)	O
All	O
tumors	B
exhibit	O
large	O
-	O
scale	O
activation	O
of	O
developmental	O
patterns	O
.	O

Nuclear	B
β	I
-	I
catenin	I
-	I
positive	I
(	O
ApcMin	O
/	O
+	O
and	O
AOM	O
)	O
tumors	B
map	O
more	O
strongly	O
to	O
early	O
development	O
stages	O
during	O
(	O
more	O
proliferative	O
,	O
less	O
differentiated	O
)	O
,	O
whereas	O
nuclear	B
β	I
-	I
catenin	I
-	I
negative	I
(	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
and	O
Smad3-	O
/	O
-	O
)	O
tumors	B
map	O
more	O
strongly	O
to	O
later	O
stages	O
consistent	O
with	O
increased	O
epithelial	O
differentiation	O
.	O

(	O
b	O
)	O
Overall	O
representation	O
of	O
the	O
relationship	O
of	O
mouse	O
colon	O
tumor	B
models	O
and	O
human	O
CRC	B
to	O
development	O
and	O
non	O
-	O
developmental	O
expression	O
patterns	O
.	O

Gene	O
expression	O
clusters	O
mapped	O
to	O
the	O
progression	O
of	O
adenomatous	O
and	O
carcinomatous	O
transformation	O
identified	O
in	O
Figures	O
5	O
and	O
6	O
are	O
shown	O
as	O
the	O
clusters	O
of	O
genes	O
whose	O
expression	O
is	O
either	O
gained	O
or	O
lost	O
associated	O
with	O
the	O
stage	O
of	O
progression	O
.	O

For	O
example	O
normal	B
development	O
could	O
be	O
considered	O
as	O
'	O
subverted	O
'	O
if	O
there	O
is	O
an	O
absence	O
of	O
expression	O
of	O
genes	O
normally	O
expressed	O
at	O
high	O
level	O
in	O
the	O
developing	O
colon	O
that	O
fail	O
to	O
be	O
expressed	O
in	O
tumors	B
(	O
for	O
example	O
,	O
C18	O
,	O
C19	O
)	O
,	O
or	O
that	O
are	O
activated	O
in	O
tumor	B
but	O
not	O
normally	O
expressed	O
in	O
development	O
(	O
C20	O
)	O
.	O

Upregulated	O
clusters	O
are	O
enriched	O
for	O
genes	O
with	O
known	O
oncogenic	O
functions	O
and	O
down	O
-	O
regulated	O
clusters	O
for	O
genes	O
associated	O
with	O
tumor	B
suppression	O
.	O

Both	O
mouse	O
colon	O
tumor	B
models	O
and	O
human	O
CRC	B
share	O
in	O
the	O
activation	O
of	O
embryonic	O
colon	O
expression	O
(	O
C22	O
)	O
,	O
or	O
partially	O
overlap	O
(	O
C23	O
,	O
dotted	O
lines	O
)	O
the	O
loss	O
or	O
repression	O
of	O
adult	O
differentiation	O
-	O
associated	O
genes	O
(	O
C19	O
)	O
,	O
and	O
the	O
loss	O
of	O
tumor	B
suppressor	O
genes	O
(	O
C18	O
)	O
.	O

Many	O
human	O
CRCs	B
also	O
lack	O
the	O
expression	O
of	O
additional	O
tumor	B
suppressor	O
programs	O
and	O
gain	O
the	O
expression	O
of	O
oncogenes	O
that	O
are	O
not	O
over	O
-	O
expressed	O
during	O
normal	B
developmental	O
morphogenesis	O
(	O
C21	O
)	O
.	O

How	O
do	O
genes	O
tightly	O
regulated	O
during	O
mouse	O
colon	O
development	O
become	O
activated	O
in	O
colon	O
tumors	B
?	O

While	O
activated	O
canonical	O
WNT	O
signaling	O
imparts	O
a	O
strong	O
influence	O
,	O
its	O
absence	O
in	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
and	O
Smad3-	O
/	O
-	O
tumors	B
,	O
as	O
determined	O
by	O
the	O
absence	O
of	O
nuclear	O
β	O
-	O
catenin	O
,	O
did	O
not	O
prevent	O
the	O
large	O
scale	O
activation	O
of	O
developmental	O
/	O
embryonic	O
gene	O
expression	O
.	O

One	O
mechanism	O
may	O
be	O
through	O
epigenetic	O
alterations	O
.	O

In	O
human	O
CRCs	B
,	O
these	O
types	O
of	O
alterations	O
in	O
gene	O
expression	O
programs	O
[	O
50	O
]	O
suggest	O
a	O
link	O
between	O
cellular	O
homeostasis	O
and	O
tumorigenesis	B
.	O

The	O
recruitment	O
of	O
histone	O
acetyltransferases	O
and	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
are	O
key	O
steps	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
during	O
normal	B
development	O
and	O
carcinogenesis	B
[	O
51	O
]	O
.	O

Induction	O
of	O
Hdac2	O
expression	O
occurs	O
in	O
82	O
%	O
of	O
human	O
CRCs	B
as	O
well	O
as	O
in	O
tumors	B
from	O
ApcMin	O
/	O
+	O
mice	O
[	O
19	O
]	O
.	O

Alternatively	O
,	O
common	O
regulatory	O
controls	O
may	O
operate	O
in	O
parallel	O
growth	O
and	O
differentiation	O
/	O
anti	O
-	O
diifferentiation	O
pathways	O
such	O
that	O
a	O
single	O
or	O
small	O
subset	O
of	O
regulators	O
,	O
such	O
as	O
MYC	O
or	O
one	O
or	O
more	O
micro	O
RNAs	O
,	O
may	O
be	O
responsible	O
for	O
the	O
control	O
of	O
multiple	O
pathways	O
.	O

Indeed	O
,	O
consistent	O
with	O
our	O
observation	O
of	O
nuclear	O
β	O
-	O
catenin	O
-	O
independent	O
activation	O
of	O
Myc	O
in	O
all	O
mouse	O
models	O
and	O
across	O
the	O
board	O
for	O
human	O
CRC	B
,	O
deletion	O
of	O
Myc	O
has	O
recently	O
been	O
demonstrated	O
to	O
completely	O
abrogate	O
nuclear	O
β	O
-	O
catenin	O
-	O
driven	O
small	O
bowel	O
oncogenesis	B
in	O
mouse	O
models	O
[	O
52	O
]	O
.	O

Comparative	O
analysis	O
reveals	O
underlying	O
development	O
-	O
related	O
signatures	O
in	O
human	O
CRCs	B
As	O
shown	O
in	O
Figure	O
5	O
,	O
considerable	O
and	O
intriguing	O
heterogeneity	O
of	O
human	O
CRC	B
is	O
observed	O
among	O
genes	O
highly	O
relevant	O
for	O
differential	O
malignant	B
behavior	O
.	O

However	O
,	O
employing	O
between	O
-	O
tumors	B
normalization	O
and	O
referencing	O
strategies	O
prevents	O
the	O
detection	O
of	O
gene	O
expression	O
patterns	O
that	O
are	O
shared	O
between	O
tumors	B
.	O

Using	O
the	O
adult	O
normal	B
colon	O
as	O
a	O
reference	O
,	O
as	O
shown	O
in	O
Figure	O
6	O
,	O
a	O
large	O
fraction	O
of	O
differential	O
gene	O
expression	O
relative	O
to	O
adult	O
colon	O
could	O
be	O
demonstrated	O
that	O
recapitulated	O
developmental	O
gene	O
expression	O
by	O
virtue	O
of	O
both	O
activating	O
embryonic	O
colon	O
gene	O
expression	O
and	O
failing	O
to	O
express	O
genes	O
associated	O
with	O
normal	B
colon	O
maturation	O
.	O

Within	O
these	O
developmentally	O
regulated	O
gene	O
sets	O
,	O
our	O
analyses	O
revealed	O
little	O
evidence	O
of	O
CRC	B
subsets	O
,	O
including	O
those	O
suggestive	O
of	O
nuclear	B
β	I
-	I
catenin	I
negative	I
tumors	B
that	O
might	O
approximate	O
the	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
signature	O
.	O

Our	O
inability	O
to	O
identify	O
distinct	O
subclasses	O
with	O
respect	O
to	O
developmental	O
genes	O
in	O
the	O
human	O
CRCs	B
is	O
perhaps	O
not	O
surprising	O
in	O
that	O
over	O
80	O
%	O
of	O
microsatellite	B
-	I
unstable	I
(	O
MSI+	B
)	O
CRCs	B
from	O
HNPCC	B
families	O
exhibit	O
nuclear	O
β	O
-	O
catenin	O
[	O
53	O
]	O
.	O

In	O
addition	O
,	O
within	O
the	O
developmental	O
genes	O
,	O
little	O
evidence	O
was	O
apparent	O
for	O
signatures	O
related	O
to	O
MSI+	B
tumors	B
,	O
often	O
associated	O
with	O
HNPCC	B
,	O
although	O
some	O
of	O
this	O
type	O
of	O
signature	O
was	O
perhaps	O
apparent	O
in	O
the	O
median	O
normalized	O
depiction	O
of	O
the	O
tumors	B
as	O
highlighted	O
in	O
Figure	O
5	O
.	O

Inter	O
-	O
organism	O
gene	O
ortholog	O
and	O
inter	O
-	O
platform	O
comparison	O
strategy	O
Pairs	O
of	O
human	O
and	O
mouse	O
ortholog	O
genes	O
(	O
12,693	O
)	O
were	O
curated	O
using	O
the	O
Mouse	O
Genome	O
Informatics	O
(	O
MGI	O
;	O
The	O
Jackson	O
Laboratory	O
)	O
[	O
61	O
]	O
and	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
Homologene	O
[	O
62	O
]	O
databases	O
.	O

Individual	O
microarray	O
elements	O
or	O
features	O
were	O
mapped	O
to	O
these	O
.	O

The	O
concatenated	O
human	O
and	O
mouse	O
RefSeq	O
IDs	O
was	O
used	O
as	O
the	O
composite	O
ID	O
for	O
the	O
orthologous	O
gene	O
pair	O
in	O
the	O
ortholog	O
genome	O
definition	O
.	O

NIA	O
/	O
Research	O
Genetics	O
mouse	O
cDNAs	O
were	O
mapped	O
to	O
human	O
orthologs	O
using	O
a	O
variety	O
of	O
resources	O
,	O
usually	O
via	O
the	O
Stanford	O
Online	O
Universal	O
Reference	O
resource	O
[	O
63	O
]	O
.	O

Gene	O
transcript	O
assignments	O
were	O
made	O
unique	O
by	O
choosing	O
the	O
longest	O
corresponding	O
transcript	O
.	O

To	O
map	O
the	O
Affymetrix	O
human	O
and	O
mouse	O
array	O
data	O
into	O
the	O
ortholog	O
genome	O
,	O
we	O
used	O
a	O
sequence	O
matching	O
approach	O
.	O

First	O
,	O
we	O
obtained	O
human	O
and	O
mouse	O
transcript	O
sequences	O
from	O
RefSeq	O
[	O
64	O
]	O
and	O
probe	O
sequences	O
from	O
the	O
manufacturer	O
's	O
website	O
[	O
65	O
]	O
.	O

Next	O
,	O
we	O
computed	O
all	O
perfect	O
probe	O
-	O
transcript	O
pairs	O
.	O

We	O
excluded	O
probes	O
that	O
matched	O
multiple	O
gene	O
symbols	O
but	O
accepted	O
probes	O
that	O
matched	O
multiple	O
transcripts	O
.	O

Probe	O
sets	O
were	O
assigned	O
to	O
represent	O
a	O
given	O
transcript	O
if	O
at	O
least	O
50	O
%	O
of	O
the	O
perfect	O
match	O
probes	O
of	O
the	O
probe	O
set	O
matched	O
to	O
that	O
transcript	O
.	O

The	O
newly	O
assigned	O
transcript	O
identifiers	O
were	O
then	O
used	O
to	O
map	O
probe	O
sets	O
to	O
ortholog	O
genes	O
.	O

Since	O
some	O
transcripts	O
have	O
multiple	O
probe	O
-	O
set	O
representations	O
on	O
both	O
the	O
Affymetrix	O
and	O
cDNA	O
microarrays	O
to	O
one	O
ortholog	O
identifier	O
,	O
we	O
employed	O
an	O
ad	O
hoc	O
strategy	O
to	O
use	O
the	O
average	O
of	O
those	O
probe	O
sets	O
or	O
cDNAs	O
that	O
exhibited	O
consistent	O
regulation	O
across	O
a	O
sample	O
series	O
.	O

In	O
such	O
cases	O
,	O
the	O
signals	O
of	O
the	O
regulated	O
probe	O
sets	O
that	O
were	O
interpreted	O
as	O
being	O
in	O
agreement	O
were	O
averaged	O
and	O
assigned	O
to	O
the	O
corresponding	O
ortholog	O
.	O

We	O
excluded	O
probe	O
sets	O
or	O
cDNAs	O
that	O
we	O
were	O
aware	O
corresponded	O
to	O
non	O
-	O
transcript	O
genomic	O
sequence	O
as	O
tested	O
using	O
BLAT	O
at	O
the	O
UCSC	O
Goldenpath	O
website	O
[	O
66	O
]	O
.	O

Mouse	O
-	O
human	O
RefSeq	O
gene	O
ortholog	O
assignments	O
can	O
be	O
found	O
at	O
GenomeTrafac	O
[	O
67,68	O
]	O
.	O

All	O
ortholog	O
assignments	O
and	O
cross	O
-	O
species	O
mapping	O
annotations	O
were	O
incorporated	O
into	O
annotations	O
associated	O
with	O
the	O
Affymetrix	O
HG	O
-	O
U133	O
plus2.0	O
genome	O
.	O

Gene	O
expression	O
ratios	O
obtained	O
for	O
the	O
mouse	O
samples	O
were	O
then	O
represented	O
as	O
expression	O
values	O
within	O
the	O
human	O
platform	O
for	O
all	O
of	O
the	O
probe	O
sets	O
that	O
mapped	O
to	O
the	O
corresponding	O
mouse	O
gene	O
ortholog	O
.	O

Data	O
for	O
the	O
primary	O
human	O
sample	O
series	O
,	O
as	O
well	O
as	O
the	O
combined	O
mouse	O
-	O
human	O
data	O
sets	O
,	O
are	O
available	O
in	O
the	O
Cincinnati	O
Children	O
's	O
Hospital	O
Medical	O
Center	O
microarray	O
data	O
server	O
[	O
69	O
]	O
in	O
the	O
HG	O
-	O
U133	O
genome	O
under	O
the	O
KaiserEtAl_2006	O
folders	O
(	O
'	O
guest	O
'	O
login	O
;	O
all	O
cross	O
-	O
platform	O
ortholog	O
gene	O
identifiers	O
are	O
contained	O
as	O
annotation	O
fields	O
within	O
the	O
HG	O
-	O
U133	O
genome	O
table	O
)	O
.	O

Statistical	O
and	O
data	O
visualization	O
approaches	O
Most	O
normalization	O
,	O
expression	O
-	O
level	O
referencing	O
,	O
statistical	O
comparisons	O
,	O
and	O
data	O
visualization	O
were	O
performed	O
using	O
GeneSpring	O
v7.0	O
(	O
Silicon	O
Genetics	O
-	O
Agilent	O
(	O
part	O
of	O
Agilent	O
Technologies	O
)	O
.	O

Fisher	O
's	O
exact	O
test	O
was	O
performed	O
online	O
at	O
the	O
MATFORSK	O
Fisher	O
's	O
Exact	O
Test	O
server	O
[	O
70	O
]	O
.	O

To	O
identify	O
differentially	O
expressed	O
features	O
between	O
two	O
or	O
more	O
classes	O
,	O
we	O
applied	O
GeneSpring	O
's	O
Wilcoxon	O
-	O
Mann	O
-	O
Whitney	O
or	O
the	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
respectively	O
.	O

For	O
three	O
or	O
more	O
classes	O
,	O
the	O
initial	O
non	O
-	O
parametric	O
test	O
was	O
followed	O
by	O
the	O
Student	O
-	O
Newman	O
-	O
Keuls	O
post	O
-	O
hoc	O
test	O
.	O

Results	O
from	O
the	O
primary	O
analyses	O
were	O
corrected	O
for	O
multiple	O
testing	O
effects	O
by	O
applying	O
Benjamini	O
and	O
Hochberg	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
correction	O
[	O
71	O
]	O
.	O

In	O
general	O
,	O
due	O
to	O
the	O
referencing	O
strategies	O
,	O
good	O
platform	O
technical	O
performances	O
,	O
and	O
moderately	O
low	O
within	O
-	O
group	O
biological	O
variation	O
of	O
gene	O
expression	O
,	O
stringent	O
cutoffs	O
could	O
be	O
used	O
,	O
that	O
is	O
,	O
the	O
FDR	O
level	O
of	O
significance	O
was	O
set	O
between	O
FDR	O
<	O
5.10	O
-	O
5	O
and	O
FDR	O
<	O
5.10	O
-	O
4	O
.	O

K	O
-	O
means	O
clustering	O
was	O
performed	O
using	O
the	O
GeneSpring	O
K	O
-	O
means	O
tool	O
and	O
the	O
Pearson	O
correlation	O
similarity	O
measure	O
.	O

Ontology	O
-	O
based	O
analysis	O
of	O
gene	O
cluster	O
-	O
associated	O
functional	O
correlates	O
Gene	O
expression	O
clusters	O
were	O
analyzed	O
for	O
the	O
occurrence	O
of	O
multiple	O
genes	O
involved	O
in	O
related	O
gene	O
function	O
categories	O
by	O
comparing	O
each	O
list	O
of	O
coordinately	O
regulated	O
clustered	O
genes	O
to	O
categories	O
within	O
Gene	O
Ontology	O
,	O
pathways	O
,	O
or	O
literature	O
-	O
based	O
gene	O
associations	O
using	O
GATACA	O
[	O
72	O
]	O
,	O
Ontoexpress	O
[	O
73	O
]	O
,	O
and	O
Ingenuity	O
Pathway	O
Analysis	O
,	O
version	O
3	O
(	O
IPA	O
,	O
Ingenuity	O
Systems	O
,	O
Redwood	O
City	O
,	O
CA	O
,	O
USA	O
)	O
[	O
74	O
]	O
.	O

To	O
do	O
this	O
,	O
each	O
cluster	O
indicated	O
in	O
Figures	O
2	O
,	O
4	O
,	O
5	O
,	O
6	O
and	O
8	O
was	O
converted	O
to	O
a	O
list	O
of	O
gene	O
identifiers	O
,	O
uploaded	O
to	O
the	O
application	O
,	O
and	O
examined	O
for	O
over	O
-	O
representation	O
of	O
multiple	O
genes	O
from	O
one	O
or	O
more	O
molecular	O
networks	O
,	O
or	O
functional	O
or	O
disease	B
associations	O
as	O
developed	O
from	O
literature	O
mining	O
.	O

Networks	O
of	O
these	O
focus	O
genes	O
were	O
algorithmically	O
generated	O
based	O
on	O
the	O
relationships	O
of	O
individual	O
genes	O
as	O
derived	O
from	O
literature	O
review	O
and	O
used	O
to	O
identify	O
the	O
biological	O
functions	O
and/or	O
associated	O
pathological	O
processes	O
most	O
significant	O
for	O
each	O
gene	O
cluster	O
.	O

Fisher	O
's	O
exact	O
test	O
was	O
used	O
to	O
calculate	O
a	O
p	O
value	O
estimating	O
the	O
probability	O
that	O
a	O
particular	O
functional	O
classification	O
or	O
category	O
of	O
genes	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
or	O
cluster	O
of	O
gene	O
expression	O
more	O
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O

For	O
each	O
cluster	O
,	O
only	O
the	O
top	O
significant	O
functional	O
classes	O
and	O
canonical	O
pathways	O
are	O
shown	O
.	O

Figure	O
7a	O
shows	O
a	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
and	O
an	O
associated	O
-	O
gene	O
network	O
that	O
was	O
a	O
top	O
-	O
ranked	O
association	O
of	O
the	O
clusters	O
that	O
exhibited	O
significant	O
over	O
-	O
expression	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
versus	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
mouse	O
models	O
.	O

Genes	O
or	O
gene	O
products	O
are	O
represented	O
as	O
nodes	O
,	O
and	O
biological	O
relationships	O
between	O
nodes	O
are	O
represented	O
as	O
edges	O
(	O
lines	O
)	O
.	O

All	O
edges	O
are	O
supported	O
by	O
at	O
least	O
one	O
literature	O
reference	O
from	O
a	O
manuscript	O
,	O
or	O
from	O
canonical	O
information	O
stored	O
in	O
the	O
Ingenuity	O
Pathways	O
Knowledge	O
Base	O
.	O

promoter	O
methylation	O
in	O
peripheral	O
blood	O
DNA	O
of	O
mutation	O
negative	O
familial	O
breast	B
cancer	I
patients	O
with	O
a	O
tumour	B
phenotype	O
Abstract	O
Introduction	O
Individuals	O
with	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
have	O
an	O
elevated	O
risk	O
of	O
developing	O
breast	B
cancer	I
,	O
and	O
often	O
display	O
characteristic	O
clinicopathological	O
features	O
.	O

We	O
hypothesised	O
that	O
inactivation	O
of	O
BRCA1	O
by	O
promoter	O
methylation	O
could	O
occur	O
as	O
a	O
germline	O
or	O
an	O
early	O
somatic	O
event	O
that	O
predisposes	O
to	O
breast	B
cancer	I
with	O
the	O
phenotype	O
normally	O
associated	O
with	O
BRCA1	O
germline	O
mutation	O
.	O

Methods	O
We	O
examined	O
seven	O
cases	O
from	O
breast	O
-	O
ovarian	B
cancer	I
families	O
with	O
tumours	B
that	O
showed	O
BRCA1-like	O
pathology	O
but	O
did	O
not	O
have	O
detectable	O
BRCA1	O
or	O
BRCA2	O
germline	O
mutations	O
present	O
.	O

Methylation	O
levels	O
were	O
tested	O
by	O
several	O
quantitative	O
techniques	O
including	O
MethyLight	O
,	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
and	O
a	O
newly	O
developed	O
digital	O
MS	O
-	O
HRM	O
assay	O
.	O

Results	O
In	O
one	O
patient	O
,	O
methylation	O
of	O
10	O
%	O
of	O
the	O
BRCA1	O
alleles	O
was	O
detected	O
in	O
the	O
peripheral	O
blood	O
DNA	O
,	O
consistent	O
with	O
20	O
%	O
of	O
cells	O
having	O
one	O
methylated	O
allele	O
.	O

Buccal	O
mucosa	O
DNA	O
from	O
this	O
individual	O
displayed	O
approximately	O
5	O
%	O
BRCA1	O
methylation	O
.	O

In	O
two	O
other	O
patients	O
,	O
methylation	O
of	O
BRCA1	O
was	O
detected	O
in	O
the	O
peripheral	O
blood	O
at	O
significantly	O
lower	O
but	O
still	O
readily	O
detectable	O
levels	O
(	O
approximately	O
1	O
%	O
)	O
.	O

Tumour	B
DNAs	O
from	O
these	O
three	O
patients	O
were	O
heavily	O
methylated	O
at	O
BRCA1	O
.	O

The	O
other	O
patients	O
had	O
no	O
detectable	O
BRCA1	O
methylation	O
in	O
their	O
peripheral	O
blood	O
.	O

One	O
of	O
seven	O
age	O
-	O
matched	O
controls	O
showed	O
extremely	O
low	O
levels	O
of	O
methylation	O
in	O
their	O
peripheral	O
blood	O
(	O
approximately	O
0.1	O
%	O
)	O
.	O

Conclusion	O
These	O
results	O
demonstrate	O
that	O
in	O
some	O
cases	O
of	O
breast	B
cancer	I
,	O
low	O
-	O
level	O
promoter	O
methylation	O
of	O
BRCA1	O
occurs	O
in	O
normal	B
tissues	O
of	O
the	O
body	O
and	O
is	O
associated	O
with	O
the	O
development	O
of	O
BRCA1-like	O
breast	B
cancer	I
.	O

Introduction	O
In	O
1994	O
,	O
BRCA1	O
was	O
identified	O
as	O
the	O
first	O
major	O
gene	O
associated	O
with	O
familial	O
breast	B
cancer	I
predisposition	O
[	O
1	O
]	O
.	O

Since	O
then	O
many	O
inactivating	O
mutations	O
in	O
BRCA1	O
have	O
been	O
identified	O
as	O
breast	B
cancer	I
predisposition	O
alleles	O
.	O

Breast	B
cancers	I
associated	O
with	O
BRCA1	O
mutations	O
often	O
show	O
characteristic	O
histological	O
features	O
including	O
high	O
grade	O
,	O
high	O
mitotic	O
count	O
,	O
solid	O
architecture	O
and	O
prominent	O
lymphocytic	O
infiltrates	O
,	O
all	O
features	O
resembling	O
so	O
-	O
called	O
medullary	O
cancer	B
[	O
2	O
-	O
4	O
]	O
.	O

BRCA1-associated	O
tumours	B
are	O
usually	O
negative	O
by	O
immunohistochemistry	O
for	O
the	O
oestrogen	O
receptor	O
(	O
ER	O
)	O
,	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
and	O
HER2	O
[	O
5	O
-	O
7	O
]	O
.	O

However	O
,	O
the	O
majority	O
of	O
breast	B
cancers	I
that	O
exhibit	O
a	O
BRCA1-like	O
phenotype	O
do	O
not	O
harbour	O
detectable	O
germline	O
mutations	O
in	O
BRCA1	O
.	O

Some	O
of	O
this	O
discordance	O
may	O
be	O
due	O
to	O
epigenetic	O
defects	O
in	O
breast	B
cancer	I
susceptibility	O
genes	O
such	O
as	O
BRCA1	O
contributing	O
to	O
breast	B
cancer	I
predisposition	O
.	O

Recent	O
reports	O
of	O
somatic	O
methylation	O
(	O
or	O
epimutations	O
)	O
affecting	O
an	O
allele	O
of	O
the	O
MLH1	O
gene	O
in	O
patients	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
indicate	O
inactivation	O
of	O
tumour	B
suppressor	O
genes	O
by	O
promoter	O
methylation	O
can	O
occur	O
early	O
in	O
development	O
or	O
possibly	O
in	O
the	O
germline	O
[	O
8	O
-	O
10	O
]	O
.	O

Allelic	O
methylation	O
is	O
functionally	O
equivalent	O
to	O
a	O
mutation	O
in	O
that	O
loss	O
of	O
activity	O
of	O
the	O
second	O
allele	O
arising	O
from	O
a	O
mutation	O
,	O
loss	O
of	O
heterozygosity	O
or	O
a	O
second	O
methylation	O
event	O
will	O
inactivate	O
the	O
gene	O
.	O

Methylation	O
of	O
the	O
BRCA1	O
promoter	O
has	O
been	O
shown	O
to	O
occur	O
in	O
approximately	O
20	O
%	O
of	O
breast	B
cancer	I
patients	O
[	O
11	O
-	O
14	O
]	O
.	O

Sporadic	O
tumours	B
with	O
BRCA1	O
promoter	O
methylation	O
have	O
been	O
reported	O
to	O
be	O
ER	B
and	I
PR	I
negative	I
[	O
13,14	O
]	O
,	O
or	O
to	O
display	O
similar	O
pathological	O
features	O
to	O
those	O
of	O
BRCA1-mutated	O
hereditary	O
breast	B
cancers	I
[	O
15	O
]	O
.	O

Furthermore	O
,	O
tumours	B
with	O
BRCA1	O
methylation	O
appear	O
to	O
have	O
similar	O
global	O
gene	O
expression	O
profiles	O
to	O
BRCA1	O
mutated	O
tumours	B
[	O
16	O
]	O
and	O
similar	O
genomic	O
copy	O
number	O
profiles	O
[	O
17	O
]	O
.	O

Other	O
authors	O
have	O
claimed	O
that	O
BRCA1	O
methylated	O
tumours	B
have	O
distinct	O
pathologies	O
to	O
those	O
seen	O
in	O
BRCA1	O
mutated	O
tumours	B
[	O
18	O
]	O
.	O

The	O
discrepancy	O
may	O
at	O
least	O
in	O
part	O
be	O
resolved	O
by	O
the	O
hypothesis	O
that	O
the	O
timing	O
of	O
BRCA1	O
methylation	O
will	O
influence	O
tumour	B
phenotype	O
;	O
the	O
earlier	O
in	O
tumorigenesis	O
methylation	O
occurs	O
,	O
the	O
greater	O
the	O
similarity	O
to	O
tumours	B
arising	O
from	O
germline	O
BRCA1	O
mutations	O
.	O

It	O
must	O
also	O
be	O
taken	O
into	O
consideration	O
that	O
while	O
most	O
tumours	B
arising	O
in	O
BRCA1	O
mutation	O
carriers	O
have	O
typical	O
pathology	O
,	O
a	O
sizeable	O
minority	O
do	O
not	O
.	O

We	O
hypothesised	O
that	O
some	O
individuals	O
are	O
predisposed	O
to	O
develop	O
breast	B
cancer	I
with	O
the	O
features	O
associated	O
with	O
BRCA1	O
mutations	O
because	O
they	O
carry	O
a	O
methylated	O
BRCA1	O
allele	O
in	O
their	O
somatic	O
tissues	O
.	O

In	O
digital	O
MS	O
-	O
HRM	O
,	O
bisulfite	O
modified	O
DNA	O
is	O
diluted	O
to	O
the	O
point	O
where	O
the	O
individual	O
PCR	O
reactions	O
contained	O
0	O
,	O
1	O
or	O
occasionally	O
2	O
amplifiable	O
templates	O
.	O

This	O
eliminates	O
the	O
problem	O
of	O
PCR	O
bias	O
where	O
unmethylated	O
or	O
methylated	O
templates	O
have	O
different	O
amplification	O
efficiencies	O
,	O
hence	O
skewing	O
the	O
actual	O
methylated	O
to	O
unmethylated	O
ratios	O
.	O

Multiple	O
replicates	O
of	O
the	O
diluted	O
sample	O
are	O
amplified	O
by	O
PCR	O
where	O
it	O
is	O
expected	O
that	O
many	O
reactions	O
will	O
not	O
amplify	O
because	O
of	O
the	O
absence	O
of	O
template	O
.	O

The	O
melting	O
profile	O
of	O
each	O
reaction	O
or	O
'	O
clone	O
'	O
is	O
then	O
used	O
to	O
determine	O
its	O
methylation	O
status	O
.	O

The	O
proportion	O
of	O
methylation	O
in	O
a	O
sample	O
can	O
be	O
readily	O
estimated	O
by	O
comparing	O
the	O
number	O
of	O
reactions	O
with	O
a	O
peak	O
with	O
elevated	O
melting	O
temperature	O
characteristic	O
of	O
methylation	O
,	O
over	O
those	O
with	O
an	O
lower	O
melting	O
temperature	O
unmethylated	O
peak	O
.	O

Digital	O
MS	O
-	O
HRM	O
was	O
performed	O
on	O
peripheral	O
blood	O
and	O
buccal	O
mucosal	O
DNA	O
from	O
KCF3	O
.	O

For	O
the	O
peripheral	O
blood	O
DNA	O
,	O
13	O
of	O
the	O
107	O
clones	O
had	O
a	O
methylated	O
peak	O
on	O
melting	O
analysis	O
(	O
Figure	O
3	O
)	O
,	O
equating	O
to	O
12	O
%	O
BRCA1	O
methylation	O
in	O
the	O
peripheral	O
blood	O
.	O

In	O
the	O
buccal	O
mucosa	O
,	O
4	O
of	O
the	O
69	O
clones	O
were	O
methylated	O
,	O
equating	O
to	O
6	O
%	O
methylation	O
.	O

These	O
results	O
confirmed	O
the	O
level	O
of	O
BRCA1	O
methylation	O
estimated	O
by	O
both	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
.	O

When	O
considered	O
at	O
a	O
cellular	O
rather	O
than	O
an	O
allelic	O
level	O
,	O
we	O
estimate	O
that	O
the	O
peripheral	O
blood	O
contains	O
approximately	O
25	O
%	O
of	O
cells	O
with	O
one	O
methylated	O
BRCA1	O
allele	O
and	O
that	O
the	O
buccal	O
mucosa	O
contains	O
approximately	O
10	O
%	O
methylated	O
cells	O
.	O

Digital	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
and	O
sequencing	O
for	O
KCF3	O
peripheral	O
blood	O
DNA	O
.	O

The	O
blue	O
curve	O
indicates	O
the	O
unmethylated	O
control	O
.	O

The	O
black	O
curve	O
indicates	O
the	O
methylated	O
control	O
.	O

The	O
green	O
curves	O
indicate	O
unmethylated	O
amplicons	O
.	O

The	O
red	O
curves	O
indicate	O
methylated	O
amplicons	O
.	O

Sequencing	O
for	O
the	O
unmethylated	O
and	O
methylated	O
controls	O
are	O
shown	O
above	O
the	O
digital	O
MS	O
-	O
HRM	O
results	O
.	O

Sequences	O
of	O
the	O
indicated	O
red	O
amplicons	O
(	O
lettered	O
)	O
are	O
shown	O
to	O
right	O
of	O
the	O
figure	O
where	O
the	O
letter	O
to	O
the	O
right	O
of	O
the	O
chromatograph	O
corresponds	O
to	O
the	O
curve	O
shown	O
.	O

Representative	O
methylated	O
and	O
unmethylated	O
clones	O
from	O
the	O
digital	O
MS	O
-	O
HRM	O
experiments	O
were	O
sequenced	O
to	O
confirm	O
the	O
methylation	O
status	O
(	O
Figure	O
3	O
)	O
.	O

A	O
stretch	O
of	O
22	O
bases	O
containing	O
four	O
CpG	O
sites	O
was	O
analysed	O
.	O

For	O
the	O
peripheral	O
blood	O
DNA	O
of	O
KCF3	O
(	O
Figure	O
3	O
)	O
,	O
four	O
of	O
the	O
six	O
methylated	O
clones	O
had	O
a	O
cytosine	O
present	O
at	O
all	O
four	O
CpGs	O
,	O
confirming	O
the	O
methylation	O
seen	O
by	O
other	O
methodologies	O
.	O

One	O
clone	O
had	O
cytosines	O
present	O
at	O
all	O
CpGs	O
sites	O
but	O
also	O
had	O
an	O
additional	O
cytosine	O
present	O
at	O
a	O
conversion	O
site	O
where	O
a	O
thymine	O
would	O
be	O
expected	O
,	O
preceding	O
a	O
CpG	O
site	O
.	O

The	O
other	O
non	O
-	O
CpG	O
cytosines	O
were	O
converted	O
indicating	O
that	O
this	O
corresponded	O
to	O
a	O
methylated	O
allele	O
.	O

For	O
one	O
other	O
clone	O
only	O
two	O
of	O
the	O
CpGs	O
were	O
methylated	O
but	O
this	O
may	O
have	O
been	O
due	O
to	O
incomplete	O
conversion	O
.	O

The	O
assay	O
conditions	O
used	O
in	O
this	O
study	O
could	O
not	O
distinguish	O
between	O
samples	O
with	O
pathogenic	O
BRCA1	O
mutations	O
and	O
those	O
with	O
pathogenic	O
BRCA2	O
mutations	O
.	O

Ionising	O
radiation	O
has	O
previously	O
been	O
show	O
to	O
separate	O
fibroblast	O
cells	O
which	O
carry	O
BRCA1	O
or	O
BRCA2	O
mutations	O
from	O
sporadic	O
cases	O
with	O
100	O
%	O
accuracy	O
[	O
31	O
]	O
,	O
but	O
our	O
experiment	O
differs	O
in	O
several	O
respects	O
.	O

We	O
compared	O
BRCA1	O
and	O
BRCA2	O
cases	O
to	O
familial	O
BRCAX	O
cases	O
as	O
an	O
appropriate	O
reference	O
group	O
for	O
familial	O
breast	O
cases	O
likely	O
to	O
be	O
identified	O
as	O
carriers	O
of	O
BRCA1	O
/	O
2	O
mutations	O
or	O
unclassified	O
variants	O
,	O
we	O
used	O
LCLs	O
instead	O
of	O
fibroblasts	O
,	O
we	O
selected	O
a	O
lower	O
IR	O
exposure	O
(	O
10Gy	O
vs	O
15Gy	O
)	O
,	O
and	O
we	O
chose	O
a	O
relatively	O
early	O
time	O
point	O
of	O
30	O
mins	O
after	O
exposure	O
to	O
IR	O
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
functional	O
differences	O
in	O
response	O
to	O
IR	O
between	O
the	O
BRCA1	O
,	O
BRCA2	O
and	O
BRCAX	O
cell	O
lines	O
.	O

Some	O
or	O
all	O
of	O
these	O
factors	O
may	O
explain	O
the	O
difference	O
in	O
the	O
ability	O
of	O
this	O
study	O
to	O
distinguish	O
BRCA1	O
from	O
BRCA2	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
DNA	O
damage	O
repair	O
.	O

However	O
,	O
differences	O
in	O
post	O
-	O
irradiation	O
response	O
between	O
BRCAX	O
individuals	O
and	O
BRCA1	O
/	O
2	O
mutation	O
carriers	O
are	O
supported	O
by	O
alternative	O
analysis	O
we	O
have	O
conducted	O
of	O
the	O
subset	O
of	O
genes	O
reported	O
to	O
be	O
involved	O
in	O
post	O
-	O
irradiation	O
response	O
,	O
comparing	O
mutation	O
-	O
negative	O
normal	B
female	O
controls	O
to	O
BRCAX	O
individuals	O
without	O
an	O
LCS	O
variant	O
,	O
or	O
to	O
BRCA1	O
or	O
BRCA2	O
truncating	O
mutation	O
carriers	O
.	O

Our	O
results	O
indicate	O
substantial	O
differences	O
in	O
radiation	O
response	O
between	O
normal	B
controls	O
and	O
the	O
patient	O
groups	O
,	O
and	O
also	O
considerable	O
differences	O
between	O
the	O
BRCAX	O
group	O
and	O
BRCA1	O
and	O
BRCA2	O
carriers	O
[	O
37	O
]	O
.	O

Alternative	O
IR	O
exposures	O
and/or	O
post	O
-	O
IR	O
timepoints	O
,	O
and	O
possibly	O
different	O
DNA	O
damaging	O
agents	O
,	O
should	O
be	O
considered	O
for	O
future	O
experiments	O
.	O

The	O
ultimate	O
aim	O
of	O
this	O
experiment	O
was	O
to	O
identify	O
array	O
profiles	O
that	O
would	O
be	O
useful	O
for	O
the	O
classification	O
of	O
unclassified	O
sequence	O
variants	O
of	O
BRCA1	O
or	O
BRCA2	O
.	O

In	O
the	O
clinical	O
setting	O
,	O
individuals	O
generally	O
present	O
with	O
full	O
sequencing	O
of	O
both	O
genes	O
,	O
and	O
presence	O
of	O
a	O
variant	O
in	O
one	O
gene	O
or	O
the	O
other	O
.	O

We	O
thus	O
assessed	O
the	O
ability	O
to	O
distinguish	O
BRCA1	O
or	O
BRCA2	O
,	O
separately	O
,	O
from	O
BRCAX	O
individuals	O
.	O

Importantly	O
,	O
since	O
most	O
unclassified	O
variants	O
are	O
predicted	O
to	O
cause	O
amino	O
acid	O
substitutions	O
,	O
we	O
also	O
assessed	O
the	O
relevance	O
of	O
mutation	O
effect	O
for	O
expression	O
profiles	O
.	O

We	O
found	O
that	O
the	O
genes	O
which	O
significantly	O
differed	O
between	O
BRCA1	O
or	O
BRCA2	O
and	O
BRCAX	O
LCLs	O
were	O
dependent	O
on	O
mutation	O
effect	O
.	O

Accordingly	O
,	O
the	O
SVM	O
prediction	O
for	O
each	O
mutation	O
effect	O
was	O
best	O
if	O
the	O
appropriate	O
gene	O
list	O
was	O
used	O
,	O
in	O
terms	O
of	O
both	O
accuracy	O
of	O
prediction	O
(	O
BRCA1	O
or	O
BRCA2	O
vs	O
BRCAX	O
)	O
and	O
confidence	O
in	O
the	O
classification	O
as	O
determined	O
by	O
the	O
distance	O
of	O
the	O
prediction	O
from	O
the	O
SVM	O
plane	O
.	O

Thus	O
we	O
strongly	O
urge	O
that	O
mutation	O
effect	O
is	O
taken	O
into	O
account	O
if	O
this	O
type	O
of	O
assay	O
is	O
to	O
be	O
developed	O
for	O
use	O
in	O
predicting	O
the	O
clinical	O
significance	O
of	O
BRCA1	O
/	O
2	O
variants	O
.	O

The	O
current	O
challenge	O
is	O
that	O
few	O
missense	O
variants	O
have	O
been	O
classified	O
with	O
respect	O
to	O
their	O
clinical	O
significance	O
,	O
with	O
the	O
only	O
23	O
individual	O
missense	O
variants	O
termed	O
clinically	O
important	O
by	O
BIC	O
,	O
17	O
in	O
BRCA1	O
and	O
six	O
in	O
BRCA2	O
.	O

Moreover	O
,	O
these	O
are	O
restricted	O
in	O
terms	O
of	O
the	O
domains	O
/	O
regions	O
in	O
which	O
they	O
occur	O
,	O
residing	O
in	O
the	O
BRCA1	O
start	O
site	O
(	O
n	O
=	O
2	O
)	O
,	O
ring	O
finger	O
(	O
n	O
=	O
4	O
)	O
or	O
transactivation	O
domains	O
(	O
n	O
=	O
11	O
)	O
,	O
and	O
the	O
BRCA2	O
CDK2	O
phosphorylation	O
site	O
(	O
n	O
=	O
3	O
)	O
or	O
at	O
one	O
codon	O
(	O
2336	O
,	O
n	O
=	O
3	O
)	O
in	O
a	O
region	O
of	O
unknown	O
function	O
.	O

It	O
will	O
thus	O
be	O
difficult	O
to	O
accrue	O
a	O
panel	O
of	O
known	O
pathogenic	O
missense	O
variants	O
for	O
use	O
in	O
such	O
predictive	O
assays	O
,	O
and	O
will	O
require	O
a	O
concerted	O
collaborative	O
effort	O
.	O

Assuming	O
sufficient	O
pathogenic	O
variants	O
are	O
identified	O
,	O
the	O
successful	O
execution	O
of	O
such	O
a	O
study	O
may	O
eventually	O
distinguish	O
missense	O
-	O
associated	O
gene	O
expression	O
patterns	O
that	O
are	O
generic	O
to	O
missense	O
mutations	O
,	O
and/or	O
those	O
that	O
are	O
specific	O
to	O
the	O
domain	O
location	O
of	O
missense	O
mutations	O
.	O

In	O
addition	O
,	O
a	O
possibly	O
greater	O
challenge	O
will	O
be	O
identifying	O
assay	O
conditions	O
(	O
cell	O
type	O
,	O
perturbation	O
,	O
time	O
-	O
point	O
etc	O
)	O
that	O
can	O
also	O
identify	O
gene	O
expression	O
differences	O
between	O
patients	O
with	O
rare	O
variants	O
of	O
low	O
clinical	O
significance	O
in	O
BRCA1	O
and/or	O
BRCA2	O
and	O
those	O
with	O
truly	O
high	O
-	O
risk	O
pathogenic	O
mutations	O
(	O
truncating	O
or	O
missense	O
)	O
in	O
these	O
genes	O
.	O

Our	O
study	O
,	O
using	O
conditions	O
that	O
were	O
not	O
optimal	O
for	O
separating	O
BRCA1	O
and	O
BRCA2	O
mutations	O
nevertheless	O
identified	O
gene	O
expression	O
differences	O
between	O
BRCA1	O
/	O
2	O
pathogenic	O
mutations	O
and	O
LCS	O
variants	O
,	O
suggesting	O
that	O
larger	O
sample	O
sizes	O
and	O
further	O
experimentation	O
may	O
identify	O
a	O
more	O
robust	O
gene	O
list	O
to	O
separate	O
pathogenic	O
mutations	O
,	O
variants	O
of	O
low	O
clinical	O
significance	O
,	O
and	O
individuals	O
with	O
no	O
sequence	O
alterations	O
in	O
BRCA1	O
/	O
2	O
.	O

27	O
LCLs	O
from	O
women	O
from	O
breast	B
cancer	I
families	O
that	O
have	O
tested	O
negative	O
for	O
pathogenic	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
(	O
BRCAX	O
)	O
after	O
complete	O
sequencing	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
gene	O
dosage	O
assay	O
(	O
MLPA	O
)	O
large	O
deletion	O
testing	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

Ten	O
samples	O
,	O
carried	O
either	O
BRCA1	O
or	O
BRCA2	O
sequence	O
germline	O
variants	O
considered	O
from	O
multifactorial	O
likelihood	O
classification	O
to	O
be	O
LCS	O
(	O
BRCA1	O
3582	O
G	O
>	O
C	O
D1155H	O
,	O
1605	O
C	O
>	O
T	O
R496C	O
,	O
5236	O
G	O
>	O
C	O
G1706A	O
(	O
2	O
samples	O
)	O
;	O
BRCA2	O
353	O
A	O
>	O
G	O
Y42C	O
,	O
2834	O
C	O
>	O
T	O
S869L	O
,	O
3031	O
G	O
>	O
A	O
D935N	O
(	O
3	O
samples	O
)	O
,	O
8795	O
A	O
>	O
C	O
E2856A	O
)	O
[	O
16	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
remaining	O
17	O
samples	O
carried	O
no	O
BRCA1	O
or	O
BRCA2	O
sequence	O
variants	O
other	O
than	O
common	O
polymorphisms	O
.	O

Gene	O
Expression	O
Profiling	O
LCLs	O
were	O
grown	O
in	O
RPMI	O
1640	O
media	O
with	O
15	O
%	O
fetal	O
bovine	O
serum	O
,	O
1	O
%	O
penicillin	O
-	O
streptomycin	O
and	O
1	O
%	O
L	O
-	O
glutamine	O
.	O

The	O
cell	O
number	O
was	O
normalised	O
and	O
fresh	O
medium	O
was	O
added	O
to	O
cells	O
24hr	O
prior	O
to	O
irradiation	O
with	O
10Gy	O
,	O
using	O
a	O
calibrated	O
Cs137	O
c	O
-	O
source	O
delivering	O
1	O
Gy	O
/	O
1.5	O
min	O
.	O

Total	O
RNA	O
was	O
harvested	O
30min	O
later	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Doncaster	O
,	O
VIC	O
)	O
.	O

The	O
Illumina	O
Totalprep	O
RNA	O
amplification	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
was	O
used	O
to	O
amplify	O
and	O
biotinylate	O
450ng	O
of	O
total	O
RNA	O
.	O

Biotinylated	O
RNA	O
was	O
hybridised	O
overnight	O
at	O
55	O
°	O
C	O
to	O
Illumina	O
Human-6	O
version	O
1	O
BeadChips	O
containing	O
>	O
46,000	O
probes	O
(	O
Illumina	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
microarrays	O
were	O
washed	O
,	O
stained	O
with	O
streptavidin	O
-	O
Cy3	O
,	O
and	O
then	O
scanned	O
with	O
an	O
Illumina	O
BeadArray	O
Scanner	O
.	O

Duplicate	O
arrays	O
were	O
performed	O
for	O
eight	O
cell	O
lines	O
across	O
the	O
different	O
groups	O
for	O
quality	O
control	O
purposes	O
,	O
with	O
duplicates	O
performed	O
on	O
different	O
days	O
.	O

All	O
duplicate	O
arrays	O
showed	O
highest	O
correlation	O
with	O
each	O
other	O
(	O
correlation	O
>	O
0.98	O
)	O
.	O

Duplicate	O
samples	O
were	O
not	O
included	O
in	O
analysis	O
.	O

Comparative	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
ten	O
genes	O
on	O
6–8	O
samples	O
,	O
using	O
GAPDH	O
to	O
normalise	O
all	O
data	O
,	O
and	O
the	O
comparative	O
cycle	O
threshold	O
method	O
for	O
analysis	O
.	O

Paired	O
student	O
t	O
tests	O
were	O
performed	O
to	O
determine	O
the	O
significance	O
of	O
gene	O
expression	O
changes	O
.	O

Expression	O
differences	O
were	O
validated	O
for	O
8	O
/	O
10	O
genes	O
tested	O
.	O

Data	O
Analysis	O
Raw	O
data	O
was	O
imported	O
into	O
Illumina	O
Beadstudio	O
and	O
then	O
exported	O
into	O
Genespring	O
v7.3	O
(	O
Agilent	O
Technologies	O
,	O
Forest	O
Hill	O
,	O
VIC	O
)	O
for	O
further	O
analysis	O
.	O

Data	O
was	O
normalised	O
(	O
per	O
chip	O
normalized	O
to	O
50th	O
percentile	O
and	O
per	O
gene	O
normalized	O
to	O
median	O
)	O
and	O
filtered	O
using	O
an	O
Illumina	O
detection	O
score	O
of	O
>	O
0.99	O
in	O
at	O
least	O
one	O
sample	O
,	O
which	O
yielded	O
20,874	O
probes	O
that	O
were	O
used	O
in	O
all	O
further	O
analyses	O
.	O

The	O
majority	O
of	O
these	O
probes	O
used	O
in	O
the	O
analysis	O
were	O
designed	O
by	O
Illumina	O
to	O
assay	O
the	O
curated	O
portion	O
of	O
the	O
NIH	O
Ref	O
sequence	O
database-16,923	O
were	O
present	O
in	O
the	O
Ref	O
sequence	O
database	O
,	O
comprising	O
65	O
%	O
of	O
all	O
Ref	O
sequence	O
-	O
listed	O
probes	O
on	O
the	O
array	O
.	O

Transcripts	O
which	O
had	O
a	O
>	O
2-fold	O
change	O
versus	O
the	O
mean	O
were	O
visualised	O
using	O
unsupervised	O
Hierarchical	O
Clustering	O
(	O
Figures	O
1	O
and	O
2	O
)	O
.	O

The	O
clustering	O
method	O
used	O
was	O
a	O
Pearson	O
correlation	O
similarity	O
measure	O
with	O
an	O
average	O
linkage	O
clustering	O
algorithm	O
.	O

Two	O
different	O
methods	O
were	O
used	O
to	O
classify	O
LCLs	O
based	O
on	O
mutation	O
status	O
:	O
(	O
1	O
)	O
A	O
multi	O
comparison	O
Gaussian	O
Process	O
Classifier	O
(	O
GPC	O
)	O
[	O
42	O
]	O
with	O
Leave	O
-	O
One	O
-	O
Out	O
cross	O
-	O
validation	O
to	O
determine	O
the	O
prediction	O
errors	O
,	O
as	O
previously	O
used	O
to	O
predict	O
BRCA1	O
/	O
BRCA2	O
mutation	O
status	O
of	O
irradiated	O
fibroblasts	O
[	O
31	O
]	O
;	O
(	O
2	O
)	O
A	O
linear	O
classification	O
method	O
commonly	O
used	O
for	O
classification	O
of	O
microarray	O
data	O
,	O
Support	O
Vector	O
Machines	O
(	O
SVM	O
)	O
[	O
43	O
]	O
with	O
Leave	O
-	O
One	O
-	O
Out	O
cross	O
validation	O
.	O

The	O
GPC	O
analysis	O
used	O
2031	O
genes	O
which	O
were	O
derived	O
from	O
a	O
t	O
-	O
test	O
to	O
select	O
the	O
genes	O
that	O
were	O
significantly	O
over	O
/	O
under	O
-	O
expressed	O
at	O
the	O
5	O
%	O
significance	O
,	O
while	O
the	O
SVM	O
used	O
genes	O
from	O
the	O
20,874	O
detected	O
probes	O
which	O
differed	O
between	O
groups	O
of	O
LCLs	O
using	O
a	O
t	O
-	O
test	O
p	O
of	O
0.05	O
.	O

All	O
resulting	O
gene	O
lists	O
are	O
available	O
as	O
supplementary	O
data	O
and	O
all	O
data	O
is	O
available	O
via	O
GEO	O
:	O
Accession	O
number	O
GSE10905	O
.	O

In	O
the	O
present	O
study	O
patients	O
included	O
in	O
the	O
Swedish	O
Polyposis	B
Registry	O
were	O
subjected	O
to	O
a	O
thorough	O
clinical	O
characterization	O
and	O
mutational	O
screening	O
of	O
the	O
APC	O
gene	O
including	O
screening	O
for	O
large	O
deletions	O
and	O
detection	O
of	O
low	O
-	O
frequency	O
alleles	O
caused	O
by	O
germline	O
mosaicism	O
.	O

Sixty	O
-	O
one	O
mutations	O
,	O
including	O
27	O
not	O
described	O
previously	O
,	O
are	O
reported	O
.	O

Among	O
the	O
characterized	O
mutations	O
are	O
elusive	O
changes	O
such	O
as	O
a	O
case	O
of	O
mosaicism	O
,	O
splicing	O
defects	O
,	O
and	O
a	O
mutation	O
in	O
APC	O
exon	O
1	O
which	O
is	O
the	O
most	O
5	O
'	O
APC	O
mutation	O
hitherto	O
reported	O
.	O

The	O
detection	O
of	O
reduced	O
APC	O
expression	O
in	O
one	O
family	O
is	O
also	O
described	O
.	O

A	O
combination	O
of	O
mutation	O
screening	O
techniques	O
was	O
used	O
to	O
achieve	O
as	O
high	O
a	O
mutation	O
-	O
detection	O
frequency	O
as	O
possible	O
.	O

Seven	O
of	O
the	O
identified	O
APC	O
mutations	O
were	O
large	O
deletions	O
,	O
ranging	O
from	O
a	O
deletion	O
of	O
86	O
bp	O
in	O
exon	O
15	O
to	O
a	O
deletion	O
of	O
the	O
whole	O
APC	O
gene	O
(	O
Figure	O
1C	O
)	O
.	O

Three	O
of	O
these	O
deletions	O
have	O
not	O
,	O
to	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
,	O
been	O
described	O
earlier	O
.	O

The	O
deletion	O
encompassing	O
APC	O
exon	O
4	O
in	O
patient	O
3765	O
,	O
c.423	O
-	O
1662_531	O
+	O
1825del3595	O
,	O
was	O
detected	O
by	O
RNA	O
-	O
based	O
PTT	O
with	O
subsequent	O
cDNA	O
sequencing	O
and	O
verified	O
by	O
long	O
-	O
range	O
PCR	O
on	O
genomic	O
DNA	O
.	O

We	O
could	O
not	O
detect	O
this	O
deletion	O
with	O
MLPA	O
even	O
though	O
a	O
probe	O
for	O
exon	O
4	O
is	O
included	O
in	O
the	O
MLPA	O
kit	O
(	O
see	O
the	O
discussion	O
)	O
.	O

Detection	O
of	O
the	O
large	O
deletion	O
in	O
patient	O
C591	O
,	O
encompassing	O
APC	O
exons	O
13	O
through	O
the	O
5	O
'	O
part	O
of	O
exon	O
15	O
,	O
was	O
carried	O
out	O
with	O
MLPA	O
.	O

The	O
deletion	O
in	O
patient	O
2136	O
was	O
identified	O
by	O
PTT	O
and	O
subsequent	O
DNA	O
sequencing	O
.	O

A	O
case	O
of	O
APC	O
mosaicism	O
Three	O
patients	O
(	O
C107	O
,	O
C257	O
,	O
and	O
C505	O
)	O
,	O
negative	O
for	O
mutations	O
in	O
APC	O
,	O
were	O
reported	O
as	O
de	O
novo	O
cases	O
with	O
no	O
known	O
family	O
history	O
of	O
FAP	B
.	O

These	O
patients	O
where	O
all	O
screened	O
for	O
APC	O
mutations	O
present	O
as	O
low	O
-	O
frequency	O
alleles	O
using	O
SSCP	O
/	O
HD	O
.	O

We	O
did	O
not	O
detect	O
any	O
signs	O
of	O
low	O
-	O
frequency	O
mutations	O
in	O
patients	O
C257	O
and	O
C505	O
.	O

However	O
,	O
in	O
patient	O
C107	O
,	O
aberrant	O
bands	O
,	O
possibly	O
originating	O
from	O
formation	O
of	O
heteroduplexes	O
,	O
was	O
detected	O
by	O
SSCP	O
/	O
HD	O
in	O
a	O
very	O
low	O
fraction	O
of	O
her	O
blood	O
lymphocytes	O
.	O

The	O
c.2700_2701delTC	O
mutation	O
,	O
which	O
results	O
in	O
frame	O
shift	O
at	O
codon	O
900	O
,	O
was	O
found	O
by	O
sequencing	O
of	O
the	O
aberrant	O
bands	O
excised	O
from	O
the	O
SSCP	O
/	O
HD	O
gel	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
mutation	O
was	O
detected	O
in	O
approximately	O
one	O
-	O
third	O
of	O
the	O
analyzed	O
tumor	B
-	O
derived	O
cells	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
by	O
DNA	O
sequencing	O
(	O
Figure	O
2B	O
)	O
.	O

The	O
mutation	O
was	O
not	O
detectable	O
at	O
all	O
in	O
the	O
sequence	O
determination	O
of	O
DNA	O
extracted	O
from	O
blood	O
lymphocytes	O
from	O
the	O
patient	O
(	O
Figure	O
2C	O
)	O
.	O

Detection	O
of	O
the	O
mosaic	O
c.2700_2701delTC	O
mutation	O
in	O
patient	O
C107	O
.	O

Nucleotide	O
2700	O
is	O
indicated	O
with	O
an	O
arrow	O
.	O

(	O
A	O
)	O
The	O
aberrant	O
bands	O
indicated	O
by	O
the	O
bracket	O
were	O
excised	O
from	O
the	O
SSCP	O
/	O
HD	O
gel	O
.	O

The	O
resulting	O
DNA	O
sequence	O
is	O
shown	O
to	O
the	O
right	O
.	O

(	O
B	O
)	O
DNA	O
sequence	O
from	O
DNA	O
extracted	O
from	O
tumor	B
-	O
derived	O
cells	O
from	O
the	O
patient	O
.	O

(	O
C	O
)	O
The	O
DNA	O
sequence	O
from	O
DNA	O
isolated	O
from	O
the	O
patient	O
's	O
blood	O
lymphocytes	O
.	O

Mutation	O
at	O
the	O
far	O
5'end	O
DNA	O
sequencing	O
of	O
APC	O
exon	O
1	O
in	O
patient	O
C157	O
revealed	O
the	O
c.70C	O
>	O
T	O
substitution	O
which	O
introduces	O
a	O
nonsense	O
mutation	O
in	O
codon	O
24	O
(	O
Figure	O
1	O
)	O
.	O

The	O
mutation	O
was	O
also	O
detectable	O
by	O
SSCP	O
/	O
HD	O
analysis	O
but	O
was	O
not	O
detectable	O
by	O
PTT	O
due	O
to	O
its	O
localization	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
PTT	O
fragment	O
.	O

However	O
,	O
indication	O
for	O
a	O
mutation	O
was	O
observed	O
as	O
lowered	O
intensity	O
of	O
the	O
full	O
-	O
length	O
fragment	O
.	O

Pedigree	O
presenting	O
a	O
part	O
of	O
family	O
1	O
of	O
the	O
Swedish	O
Polyposis	B
Registry	O
.	O

Family	O
members	O
where	O
positive	O
linkage	O
to	O
APC	O
has	O
been	O
confirmed	O
are	O
indicated	O
with	O
asterisks	O
.	O

A	O
case	O
of	O
APC	O
mosaicism	O
Screening	O
for	O
mosaic	O
mutations	O
in	O
the	O
three	O
APC-	B
and	I
MUTYH	I
-	I
negative	I
patients	O
with	O
de	O
novo	O
mutations	O
revealed	O
the	O
c.2700_2701delTC	O
mutation	O
in	O
patient	O
C107	O
.	O

This	O
mutation	O
was	O
detected	O
in	O
a	O
very	O
low	O
fraction	O
of	O
the	O
lymphocytes	O
and	O
was	O
only	O
detectable	O
using	O
the	O
SSCP	O
/	O
HD	O
analysis	O
(	O
Figure	O
2A	O
)	O
.	O

Owing	O
to	O
the	O
subtle	O
appearance	O
of	O
this	O
mutation	O
it	O
could	O
easily	O
have	O
been	O
overlooked	O
.	O

The	O
phenotype	O
of	O
patient	O
C107	O
does	O
not	O
fit	O
the	O
generally	O
accepted	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
AFAP	B
,	O
in	O
which	O
the	O
disease	B
-	O
causing	O
mutations	O
are	O
situated	O
either	O
in	O
the	O
5	O
'	O
or	O
3	O
'	O
regions	O
or	O
the	O
alternatively	O
spliced	O
part	O
of	O
exon	O
9	O
(	O
see	O
the	O
introduction	O
)	O
.	O

A	O
speculative	O
reason	O
for	O
the	O
attenuated	O
phenotype	O
could	O
be	O
that	O
the	O
patient	O
is	O
mosaic	O
in	O
the	O
epithelial	O
cells	O
of	O
the	O
colon	O
.	O

The	O
parents	O
of	O
patient	O
C107	O
of	O
age	O
73	O
and	O
80	O
years	O
as	O
well	O
as	O
her	O
three	O
children	O
,	O
age	O
31–40	O
years	O
,	O
were	O
free	O
of	O
polyps	B
.	O

No	O
CRC	B
has	O
been	O
diagnosed	O
on	O
either	O
the	O
maternal	O
or	O
paternal	O
side	O
of	O
the	O
family	O
.	O

The	O
mutation	O
was	O
not	O
detected	O
in	O
blood	O
samples	O
from	O
the	O
patient	O
's	O
parents	O
or	O
from	O
her	O
three	O
children	O
.	O

It	O
is	O
possible	O
that	O
either	O
gonadal	O
or	O
somatic	O
mosaicism	O
exists	O
in	O
patient	O
C107	O
.	O

APC	O
mutational	O
mosaicism	O
could	O
be	O
a	O
reason	O
for	O
the	O
quite	O
large	O
number	O
of	O
de	O
novo	O
or	O
sporadic	O
FAP	B
cases	O
that	O
exist	O
[	O
23	O
-	O
25,40	O
]	O
.	O

In	O
the	O
family	O
of	O
C107	O
the	O
mutation	O
has	O
not	O
been	O
passed	O
on	O
to	O
the	O
offspring	O
of	O
the	O
patient	O
and	O
,	O
thus	O
,	O
this	O
appears	O
to	O
be	O
a	O
sporadic	O
case	O
,	O
but	O
,	O
generally	O
,	O
the	O
existence	O
of	O
mosaicism	O
is	O
a	O
risk	O
of	O
error	O
in	O
predictive	O
diagnosis	O
in	O
FAP	B
/	O
AFAP	B
families	O
[	O
43	O
]	O
.	O

In	O
the	O
initial	O
stages	O
,	O
the	O
molecular	O
screening	O
procedure	O
of	O
FAP	B
/	O
AFAP	B
patients	O
uses	O
mainly	O
PCR	O
-	O
based	O
methods	O
for	O
analysis	O
of	O
the	O
APC	O
gene	O
in	O
DNA	O
from	O
isolated	O
blood	O
samples	O
.	O

Therefore	O
,	O
the	O
chances	O
of	O
detecting	O
pathogenic	O
low	O
-	O
frequency	O
APC	O
mutations	O
that	O
are	O
present	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
peripheral	O
blood	O
cells	O
or	O
only	O
in	O
the	O
colon	O
are	O
poor	O
.	O

Approximately	O
25	O
%	O
of	O
neurofibromatosis	B
type	I
2	I
(	O
NF2	B
)	O
patients	O
have	O
been	O
shown	O
to	O
be	O
cases	O
of	O
mosaicism	O
[	O
44	O
]	O
.	O

When	O
investigating	O
NF2	B
mutational	O
mosaicism	O
,	O
the	O
search	O
for	O
constitutional	O
mutations	O
is	O
preferably	O
carried	O
out	O
initially	O
in	O
tumor	B
cells	O
.	O

Detected	O
mutations	O
could	O
subsequently	O
be	O
verified	O
in	O
blood	O
leukocyte	O
samples	O
.	O

However	O
,	O
this	O
approach	O
would	O
not	O
be	O
applicable	O
for	O
FAP	B
mosaisicm	O
as	O
somatic	O
APC	O
mutations	O
are	O
frequently	O
found	O
in	O
tumors	B
.	O

Splice	O
-	O
site	O
affecting	O
mutations	O
Two	O
novel	O
germline	O
APC	O
mutations	O
that	O
introduce	O
different	O
cryptic	O
splice	O
sites	O
are	O
characterized	O
in	O
this	O
study	O
.	O

Both	O
mutations	O
result	O
in	O
the	O
aberrant	O
splicing	O
of	O
APC	O
exons	O
7	O
and	O
8	O
and	O
prematurely	O
truncated	O
APC	O
protein	O
,	O
and	O
both	O
are	O
defined	O
as	O
pathogenic	O
.	O

The	O
aberrant	O
splicing	O
identified	O
in	O
patient	O
C496	O
(	O
c.835	O
-	O
7	O
T	O
>	O
G	O
)	O
is	O
caused	O
by	O
an	O
introduction	O
of	O
a	O
new	O
active	O
splice	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
wildtype	O
AG	O
splice	O
site	O
of	O
intron	O
7	O
.	O

This	O
acceptor	O
site	O
is	O
apparently	O
preferred	O
by	O
the	O
splicing	O
machinery	O
,	O
as	O
shown	O
by	O
the	O
results	O
of	O
the	O
cDNA	O
sequencing	O
(	O
Figure	O
3	O
)	O
.	O

The	O
c.834	O
G	O
>	O
C	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
7	O
in	O
patient	O
C633	O
,	O
would	O
theoretically	O
introduce	O
a	O
missense	O
mutation	O
at	O
codon	O
278	O
.	O

However	O
,	O
as	O
demonstrated	O
by	O
the	O
cDNA	O
sequencing	O
results	O
(	O
Figure	O
4	O
)	O
the	O
mutation	O
leads	O
to	O
the	O
use	O
of	O
a	O
cryptic	O
splice	O
donor	O
site	O
11	O
bp	O
upstream	O
in	O
exon	O
7	O
.	O

This	O
real	O
outcome	O
of	O
the	O
mutation	O
would	O
easily	O
have	O
been	O
overlooked	O
unless	O
the	O
RNA	O
-	O
based	O
methods	O
had	O
been	O
used	O
.	O

Other	O
examples	O
of	O
aberrant	O
splicing	O
of	O
the	O
APC	O
gene	O
due	O
to	O
missense	O
mutations	O
have	O
recently	O
been	O
described	O
[	O
16	O
]	O
.	O

One	O
case	O
of	O
use	O
of	O
aberrant	O
splice	O
-	O
acceptor	O
site	O
of	O
APC	O
exon	O
8	O
has	O
been	O
reported	O
previously	O
in	O
a	O
patient	O
with	O
classical	O
polyposis	B
[	O
15	O
]	O
.	O

However	O
,	O
an	O
alternative	O
acceptor	O
splice	O
site	O
(	O
c.845	O
-	O
17A	O
>	O
G	O
)	O
in	O
intron	O
7	O
has	O
been	O
reported	O
from	O
a	O
patient	O
with	O
a	O
milder	O
phenotype	O
,	O
multiple	O
synchronous	O
colorectal	O
adenomas	B
[	O
45	O
]	O
.	O

Owing	O
to	O
the	O
fact	O
that	O
RNA	O
-	O
based	O
PTT	O
was	O
used	O
at	O
the	O
initial	O
stage	O
of	O
the	O
mutational	O
screening	O
,	O
detection	O
of	O
the	O
disease	B
-	O
causing	O
splice	O
-	O
site	O
mutations	O
was	O
straightforward	O
.	O

Sequencing	O
of	O
genomic	O
DNA	O
was	O
then	O
used	O
to	O
pinpoint	O
the	O
genetic	O
alteration	O
causing	O
the	O
aberrant	O
mRNA	O
sequence	O
that	O
was	O
visualized	O
in	O
the	O
PTT	O
experiments	O
.	O

The	O
use	O
of	O
both	O
DNA-	O
and	O
mRNA	O
-	O
based	O
methods	O
is	O
a	O
prerequisite	O
for	O
high	O
-	O
quality	O
investigation	O
of	O
splice	O
-	O
site	O
mutations	O
.	O

A	O
case	O
of	O
reduced	O
APC	O
expression	O
The	O
study	O
of	O
mRNA	O
levels	O
was	O
the	O
next	O
step	O
in	O
the	O
line	O
of	O
investigation	O
of	O
the	O
cause	O
of	O
disease	B
in	O
patients	O
with	O
no	O
detected	O
APC	O
mutation	O
.	O

Family	O
1	O
is	O
the	O
largest	O
kindred	O
in	O
the	O
Swedish	O
Polyposis	B
Registry	O
;	O
this	O
family	O
includes	O
150	O
individuals	O
of	O
whom	O
57	O
are	O
affected	B
by	O
the	O
disease	B
(	O
Figure	O
6	O
shows	O
part	O
of	O
the	O
pedigree	O
)	O
.	O

However	O
,	O
no	O
pathogenic	O
mutation	O
had	O
been	O
detected	O
after	O
screening	O
the	O
whole	O
coding	O
region	O
of	O
the	O
APC	O
gene	O
but	O
as	O
the	O
family	O
did	O
show	O
positive	O
linkage	O
to	O
the	O
APC	O
locus	O
we	O
decided	O
to	O
perform	O
expression	O
analyses	O
and	O
evidence	O
of	O
lowered	O
APC	O
expression	O
was	O
obtained	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
result	O
was	O
supported	O
by	O
the	O
indication	O
of	O
a	O
lower	O
expression	O
from	O
the	O
T	O
-	O
allele	O
from	O
analysis	O
of	O
the	O
APC	O
c.5465A	O
>	O
T	O
polymorphism	O
in	O
the	O
cDNA	O
sequencing	O
diagram	O
of	O
two	O
affected	B
family	O
members	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
search	O
for	O
mutations	O
in	O
the	O
DNA	O
sequence	O
of	O
the	O
APC	O
promoters	O
has	O
been	O
initiated	O
,	O
but	O
no	O
pathogenic	O
change	O
has	O
been	O
detected	O
to	O
this	O
date	O
.	O

The	O
possibility	O
of	O
the	O
pathogenic	O
change	O
being	O
epigenetic	O
will	O
have	O
to	O
be	O
investigated	O
further	O
.	O

Hypermethylation	O
of	O
CpG	O
sites	O
in	O
the	O
promoter	O
of	O
APC	O
has	O
been	O
reported	O
as	O
a	O
means	O
of	O
gene	O
silencing	O
in	O
colorectal	O
tumors	B
[	O
46	O
-	O
49	O
]	O
.	O

To	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
no	O
germ	O
-	O
line	O
inactivation	O
of	O
APC	O
caused	O
by	O
promoter	O
hypermethylation	O
has	O
been	O
reported	O
.	O

However	O
,	O
cases	O
of	O
pathogenic	O
germline	O
epimutations	O
have	O
been	O
identified	O
in	O
the	O
MLH1	O
gene	O
,	O
which	O
causes	O
hereditary	B
non	I
-	I
polyposis	I
CRC	B
[	O
50,51	O
]	O
.	O

Mutation	O
-	O
detection	O
frequency	O
The	O
61	O
different	O
APC	O
mutations	O
listed	O
in	O
Additional	O
file	O
2	O
were	O
identified	O
among	O
81	O
of	O
the	O
96	O
families	O
of	O
the	O
Swedish	O
Polyposis	B
Registry	O
that	O
were	O
screened	O
for	O
APC	O
mutations	O
.	O

Fifteen	O
of	O
the	O
cases	O
shown	O
to	O
be	O
APC	B
-	I
mutation	I
negative	I
where	O
all	O
subjected	O
to	O
mutational	O
screening	O
of	O
the	O
MUTYH	O
gene	O
and	O
six	O
of	O
them	O
were	O
shown	O
to	O
carry	O
biallelic	O
MUTYH	O
mutations	O
(	O
reported	O
in	O
Kanter	O
Smoler	O
et	O
al	O
[	O
31	O
]	O
)	O
.	O

The	O
overall	O
mutation	O
-	O
detection	O
rate	O
in	O
APC	O
and	O
MUTYH	O
among	O
the	O
families	O
in	O
our	O
study	O
was	O
thus	O
90	O
%	O
.	O

In	O
total	O
,	O
84	O
%	O
of	O
the	O
families	O
carried	O
APC	O
mutations	O
while	O
6	O
%	O
where	O
positive	O
for	O
biallelic	O
MUTYH	O
mutations	O
.	O

The	O
mutation	O
-	O
detection	O
rate	O
we	O
have	O
reached	O
in	O
this	O
study	O
is	O
notably	O
high	O
.	O

In	O
fact	O
,	O
a	O
disease	B
-	O
causing	O
mutation	O
was	O
detected	O
in	O
all	O
cases	O
who	O
presented	O
with	O
a	O
classical	O
FAP	B
phenotype	O
(	O
except	O
for	O
family	O
1	O
(	O
C152	O
)	O
,	O
where	O
we	O
have	O
clear	O
indications	O
for	O
inactivation	O
of	O
the	O
APC	O
transcription	O
)	O
.	O

The	O
mutation	O
-	O
negative	O
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	B
.	O

However	O
,	O
as	O
we	O
have	O
also	O
found	O
subtle	O
mutations	O
in	O
the	O
APC	O
gene	O
in	O
patients	O
with	O
attenuated	O
FAP	B
,	O
we	O
have	O
to	O
consider	O
inactivation	O
of	O
APC	O
to	O
be	O
responsible	O
for	O
some	O
of	O
these	O
FAP	B
cases	O
.	O

In	O
comparison	O
to	O
MLH1	O
and	O
MSH2	O
,	O
the	O
phenotype	O
of	O
MSH6	O
is	O
characterised	O
by	O
a	O
later	O
age	O
of	O
onset	O
of	O
CRC	B
,	O
incomplete	O
penetrance	O
,	O
and	O
a	O
higher	O
risk	O
and	O
later	O
age	O
of	O
onset	O
of	O
EC	B
in	O
female	O
MSH6	O
carriers15,21	O
.	O

MSH6	O
mutation	O
carriers	O
may	O
be	O
missed	O
amongst	O
analysis	O
of	O
HNPCC	B
families	O
if	O
the	O
Amsterdam	O
criteria	O
are	O
used	O
as	O
selection	O
criteria22	O
It	O
is	O
likely	O
that	O
MSH6	O
mutations	O
may	O
occur	O
at	O
a	O
higher	O
prevalence	O
in	O
a	O
cohort	O
of	O
EC	B
patients	O
in	O
comparison	O
to	O
HNPCC	B
cohorts	O
that	O
have	O
been	O
selected	O
by	O
the	O
Amsterdam	O
criteria	O
which	O
are	O
characteristic	O
of	O
HNPCC	B
families	O
with	O
a	O
mutation	O
in	O
MLH1	O
or	O
MSH2	O
.	O

A	O
few	O
studies	O
have	O
looked	O
at	O
the	O
prevalence	O
of	O
MSH6	O
mutations	O
in	O
EC	B
patients	O
with	O
estimates	O
between	O
1.7	O
%	O
of	O
patients	O
with	O
EC	B
less	O
than	O
50	O
years23	O
,	O
and	O
4.7	O
%	O
identified	O
in	O
EC	B
patients	O
un	O
-	O
selected	O
for	O
age	O
or	O
family	O
history24	O
.	O

In	O
this	O
study	O
we	O
sought	O
to	O
determine	O
the	O
prevalence	O
of	O
MSH6	O
mutations	O
in	O
our	O
Northern	O
Ireland	O
HNPCC	B
cohort	O
with	O
less	O
restrictive	O
inclusion	O
criteria	O
than	O
the	O
Amsterdam	O
II	O
criteria	O
,	O
in	O
an	O
attempt	O
to	O
include	O
as	O
many	O
MSH6	O
phenotype	O
families	O
as	O
possible	O
given	O
the	O
probable	O
later	O
onset	O
of	O
colon	B
cancers	I
;	O
and	O
also	O
determine	O
the	O
prevalence	O
of	O
mutations	O
in	O
an	O
unselected	O
cohort	O
of	O
EC	B
patients	O
.	O

All	O
DNA	O
was	O
or	O
had	O
been	O
extracted	O
by	O
the	O
Nucleic	O
Acid	O
Extraction	O
Centre	O
(	O
NAEC	O
)	O
,	O
Belfast	O
City	O
Hospital	O
,	O
and	O
stored	O
at	O
−80	O
°	O
C	O
.	O

Working	O
dilutions	O
in	O
X1	O
TE	O
were	O
made	O
at	O
5ng	O
/	O
μl	O
.	O

All	O
ten	O
exons	O
and	O
at	O
least	O
20	O
base	O
pair	O
(	O
bp	O
)	O
of	O
flanking	O
intronic	O
sequence	O
was	O
subject	O
to	O
direct	O
sequencing	O
analysis	O
.	O

PCR	O
products	O
for	O
nine	O
of	O
ten	O
exons	O
of	O
MSH6	O
were	O
obtained	O
using	O
Applied	O
Biosystems	O
VariantSEQr	O
™	O
Requencing	O
System	O
(	O
product	O
number	O
:	O
RSS000012234_02	O
)	O
.	O

All	O
reactions	O
were	O
carried	O
out	O
using	O
standard	O
reaction	O
mix	O
and	O
conditions	O
as	O
determined	O
by	O
ABI	O
.	O

Exon	O
1	O
primers	O
were	O
as	O
follows	O
:	O
1F	O
PCR	O
;	O
TCCGTCCGACAGAACGGTTG	O
,	O
1R	O
PCR	O
;	O
ATGCTCCAGACTCGACCCG	O
,	O
using	O
a	O
standard	O
25μl	O
reaction	O
mix	O
with	O
3.4μl	O
of	O
25	O
mm	O
MgCl2	O
and	O
0.4μl	O
of	O
5U	O
/	O
μl	O
Expand	O
DNA	O
polymerase	O
(	O
ABI	O
)	O
at	O
an	O
annealing	O
temperature	O
of	O
60	O
°	O
C	O
.	O

All	O
PCR	O
products	O
were	O
subject	O
to	O
clean	O
up	O
using	O
ExoSAPIT	O
®	O
	O
to	O
remove	O
excess	O
primer	O
dimer	O
,	O
unincorporated	O
dNTPs	O
,	O
and	O
non	O
-	O
specific	O
DNA	O
products	O
.	O

Sequencing	O
reactions	O
were	O
carried	O
out	O
using	O
BigDye	O
®	O
terminator	O
Ready	O
Reaction	O
Mix	O
v1.1	O
from	O
ABI	O
®	O
,	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O

Additional	O
primers	O
were	O
required	O
to	O
sequence	O
exons	O
7	O
and	O
8	O
because	O
of	O
a	O
poly	O
T	O
at	O
the	O
5′	O
end	O
of	O
exon	O
7	O
,	O
which	O
resulted	O
in	O
slippage	O
during	O
the	O
sequencing	O
reaction	O
,	O
and	O
polymorphisms	O
situated	O
at	O
the	O
3′	O
,	O
(	O
c.3646	O
+	O
35_38delATCT	O
)	O
of	O
exon	O
7	O
,	O
and	O
5′	O
,	O
(	O
c.3647	O
−51_−35	O
del	O
17	O
)	O
,	O
and	O
3′	O
(	O
c.3802–42insT	O
)	O
end	O
of	O
exon	O
8	O
,	O
which	O
made	O
sequence	O
of	O
the	O
exons	O
unreadable	O
when	O
the	O
polymorphisms	O
were	O
present	O
in	O
the	O
heterozygous	O
state	O
.	O

Additional	O
sequencing	O
primers	O
for	O
exon	O
7	O
(	O
7F	O
Seq	O
;	O
TTGTGATTTTTTTTTTTTTAAG	O
,	O
7R	O
Seq	O
;	O
TAGTCTTCAAATGAGAAG	O
)	O
and	O
8	O
(	O
8F	O
Seq	O
;	O
GAGTTACTTCCTTATGCA	O
,	O
8R	O
Seq	O
;	O
GAAGTGCCCTCTCAAAAAACC	O
)	O
were	O
designed	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
by	O
the	O
Queen	O
's	O
University	O
Belfast	O
genomic	O
core	O
facility	O
on	O
an	O
ABI	O
3730	O
DNA	O
analyser	O
.	O

MLPA	O
Analysis	O
All	O
samples	O
were	O
subject	O
to	O
MLPA	O
analysis	O
using	O
SALSA	O
MLPA	O
KIT	O
POO8	O
MSH6	O
/	O
PMS2	O
from	O
MRC	O
-	O
Holland	O
.	O

Reaction	O
mix	O
and	O
conditions	O
are	O
as	O
determined	O
by	O
MRC	O
-	O
Holland	O
.	O

Electrophoresis	O
was	O
carried	O
on	O
an	O
ABI	O
3100	O
Avant	O
DNA	O
analyzer	O
using	O
a	O
GeneScan	O
™	O
-	O
500	O
ROX	O
™	O
size	O
standard	O
.	O

From	O
the	O
raw	O
data	O
generated	O
,	O
peak	O
heights	O
of	O
each	O
amplification	O
product	O
were	O
exported	O
to	O
Excel	O
worksheets	O
designed	O
by	O
Dr	O
Andrew	O
Wallace	O
,	O
National	O
Genetics	O
Reference	O
Laboratory	O
,	O
Manchester	O
,	O
so	O
that	O
the	O
result	O
of	O
each	O
sample	O
could	O
be	O
'	O
normalised	O
'	O
.	O

Statistical	O
Methods	O

The	O
cohort	O
sizes	O
necessary	O
to	O
obtain	O
estimates	O
with	O
adequate	O
precision	O
were	O
initially	O
calculated	O
using	O
a	O
Normal	O
approximation	O
to	O
the	O
binomial	O
sampling	O
distribution	O
provided	O
by	O
the	O
StatCalc	O
program	O
in	O
the	O
EpiInfo	O
package	O
(	O
)	O
.	O

The	O
Stata	O
package	O
(	O
)	O
was	O
used	O
to	O
give	O
the	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
(	O
Table	O
I	O
)	O
.	O

CONCLUSION	O
From	O
this	O
study	O
we	O
have	O
identified	O
the	O
minimum	O
prevalence	O
of	O
pathogenic	O
mutations	O
in	O
MSH6	O
to	O
be	O
higher	O
in	O
an	O
unselected	O
cohort	O
of	O
EC	B
patients	O
,	O
than	O
a	O
cohort	O
of	O
HNPCC	B
patients	O
who	O
have	O
been	O
selected	O
by	O
criteria	O
'	O
widened	O
'	O
from	O
the	O
traditional	O
Amsterdam	O
II	O
criteria	O
,	O
in	O
keeping	O
with	O
the	O
described	O
phenotype	O
of	O
MSH6	O
.	O

Unlike	O
the	O
other	O
more	O
common	O
MMR	O
genes	O
,	O
genomic	O
rearrangements	O
do	O
not	O
contribute	O
to	O
a	O
large	O
proportion	O
of	O
mutations	O
in	O
MSH6	O
.	O

HNPCC	B
families	O
may	O
not	O
be	O
identified	O
if	O
patients	O
present	O
with	O
HNPCC	B
associated	B
cancers	I
,	O
such	O
as	O
gynaecological	B
cancer	I
,	O
rather	O
than	O
the	O
more	O
commonly	O
recognised	O
phenotype	O
of	O
CRC	B
.	O

Clinicians	O
should	O
be	O
vigilant	O
to	O
this	O
possibility	O
when	O
presented	O
with	O
a	O
history	O
of	O
endometrial	B
cancer	I
in	O
young	O
women	O
.	O

Further	O
work	O
on	O
immunohistochemistry	O
of	O
possible	O
missense	O
variants	O
may	O
increase	O
the	O
true	O
frequency	O
of	O
mutations	O
in	O
MSH6	O
.	O

To	O
understand	O
more	O
precisely	O
the	O
mechanistic	O
roles	O
that	O
Mlh3	O
and	O
Pms2	O
play	O
in	O
GI	O
tumor	B
suppression	O
,	O
we	O
generated	O
Mlh3−	O
/	O
−;Apc1638N	O
(	O
MA	O
)	O
and	O
Mlh3−	O
/	O
−;Pms2−	O
/	O
−;Apc1638N	O
(	O
MPA	O
)	O
mice	O
.	O

We	O
show	O
that	O
in	O
vivo	O
Mlh3	O
mutations	O
significantly	O
increase	O
frameshift	O
mutation	O
rates	O
in	O
Apc	O
,	O
and	O
increase	O
GI	O
tumorigenesis	B
.	O

Unlike	O
typical	O
MSI	O
-	O
induced	O
mutations	O
,	O
Mlh3	O
deficiency	O
also	O
results	O
in	O
frameshift	O
mutations	O
in	O
non	O
-	O
repetitive	O
sequences	O
,	O
a	O
unique	O
mutational	O
signature	O
among	O
MMR	O
deficient	O
mice	O
found	O
only	O
in	O
Mlh3	B
deficient	I
mice	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
Pms2	O
in	O
SBR	O
,	O
combined	O
Mlh3	O
and	O
Pms2	O
mutations	O
proportionally	O
increase	O
point	O
mutations	O
and	O
show	O
a	O
sequence	O
preference	O
for	O
a	O
CpG	O
mutation	O
hotspot	O
also	O
previously	O
seen	O
in	O
Mlh1−	O
/	O
−	O
mice	O
.	O

Because	O
MPA	O
mutant	O
mice	O
also	O
have	O
significantly	O
increased	O
rates	O
of	O
GI	O
adenocarcinomas	B
vs.	O
Apc1638N	O
or	O
MA	O
mice	O
,	O
we	O
investigated	O
mechanisms	O
of	O
tumor	B
progression	O
.	O

Using	O
array	O
-	O
CGH	O
,	O
we	O
identified	O
a	O
recurrent	O
5-Mb	O
amplification	O
on	O
chromosome	O
12	O
in	O
GI	O
tumors	B
from	O
MPA	O
mice	O
.	O

We	O
defined	O
the	O
amplicon	O
critical	O
interval	O
and	O
demonstrated	O
that	O
it	O
contains	O
a	O
previously	O
uncharacterized	O
member	O
of	O
the	O
Transducin	O
enhancer	O
of	O
Split	O
(	O
TLE	O
)	O
/	O
Groucho	O
family	O
of	O
transcriptional	O
co	O
-	O
regulators	O
,	O
Tle6-like	O
,	O
that	O
contributes	O
to	O
tumor	B
progression	O
.	O

Tle6-like	O
overexpression	O
in	O
colon	B
cancer	I
cell	O
lines	O
increases	O
cell	O
proliferation	O
,	O
colony	O
-	O
formation	O
ability	O
,	O
cell	O
migration	O
and	O
xenograft	B
tumorigenicity	I
.	O

Human	O
TLE6D	O
,	O
an	O
alternatively	O
spliced	O
isoform	O
of	O
TLE6	O
,	O
with	O
a	O
domain	O
structure	O
similar	O
to	O
Tle6-like	O
,	O
has	O
functional	O
activity	O
similar	O
to	O
Tle6-like	O
.	O

Both	O
Tle6-like	O
and	O
TLE6D	O
interact	O
with	O
GI	O
tumor	B
suppressor	O
,	O
RUNX3	O
[	O
34	O
]	O
,	O
and	O
antagonize	O
RUNX3	O
gene	O
target	O
tranactivation	O
.	O

TLE6D	O
is	O
overexpressed	O
in	O
multiple	O
human	O
microsatellite	B
stable	I
(	O
MSS	O
)	O
and	O
microsatellite	B
unstable	I
(	O
MSI	O
-	O
H	O
)	O
CRCs	B
,	O
and	O
TLE6D	O
expression	O
levels	O
correlate	O
with	O
RUNX3	O
expression	O
levels	O
.	O

Collectively	O
,	O
these	O
findings	O
provide	O
important	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
through	O
which	O
MMR	B
-	I
deficiency	I
contributes	O
to	O
GI	O
tumorigenesis	B
and	O
implicate	O
a	O
novel	O
association	O
between	O
TLE6	O
isoforms	O
and	O
antagonism	O
of	O
RUNX	O
target	O
gene	O
expression	O
in	O
CRC	B
tumor	B
progression	O
.	O

RUNX	O
family	O
genes	O
regulate	O
lineage	O
and	O
stage	O
specific	O
gene	O
transcription	O
by	O
direct	O
binding	O
to	O
DNA	O
promoters	O
and	O
enhancer	O
elements	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Loss	O
of	O
Runx3	O
in	O
the	O
mouse	O
results	O
in	O
the	O
development	O
of	O
gastric	O
mucosal	O
hyperplasia	B
,	O
decreased	O
apoptosis	O
and	O
attenuated	O
TGF	O
-	O
β	O
anti	O
-	O
proliferative	O
signaling	O
.	O

Consistent	O
with	O
previous	O
observations	O
of	O
interactions	O
between	O
RUNX3	O
and	O
TLE	O
family	O
members	O
mediated	O
through	O
the	O
Runt	O
and	O
WD	O
repeat	O
domains	O
,	O
respectively	O
[	O
46	O
]	O
,	O
[	O
48	O
]	O
,	O
we	O
detected	O
an	O
interaction	O
between	O
RUNX3	O
and	O
Tle6-like	O
/	O
TLE6D	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
Tle6-like	O
/	O
TLE6D	O
antagonized	O
RUNX3	O
regulated	O
transcriptional	O
targets	O
.	O

However	O
,	O
while	O
these	O
experiments	O
show	O
an	O
association	O
between	O
RUNX3∶TLE6D	O
interactions	O
and	O
tumor	B
progression	O
,	O
they	O
do	O
not	O
demonstrate	O
mechanistically	O
the	O
functional	O
importance	O
of	O
this	O
interaction	O
in	O
accelerating	O
tumor	B
progression	O
.	O

Alternative	O
mRNA	O
splicing	O
allows	O
multiple	O
gene	O
products	O
to	O
be	O
produced	O
from	O
a	O
single	O
coding	O
sequence	O
,	O
and	O
through	O
this	O
mechanism	O
a	O
higher	O
diversity	O
of	O
mammalian	O
genes	O
is	O
generated	O
[	O
68	O
]	O
.	O

Several	O
distinct	O
TLE	O
/	O
Grg	O
gene	O
alternative	O
splice	O
forms	O
,	O
such	O
as	O
Grg-1s	O
,	O
QD	O
of	O
TLE4	O
,	O
and	O
Grg3b	O
[	O
42	O
]	O
,	O
[	O
69	O
]	O
,	O
[	O
70	O
]	O
,	O
have	O
been	O
reported	O
.	O

While	O
the	O
human	O
genome	O
does	O
not	O
encode	O
a	O
TLE6-LIKE	O
ortholog	O
,	O
a	O
structurally	O
equivalent	O
protein	O
,	O
TLE6D	O
,	O
is	O
generated	O
through	O
alternative	O
splicing	O
.	O

The	O
observation	O
that	O
GI	O
adenocarcinomas	B
from	O
both	O
humans	O
and	O
mice	O
use	O
two	O
very	O
distinct	O
mechanisms	O
to	O
amplify	O
Tle6-like	O
/	O
TLE6D	O
activity	O
suggests	O
a	O
strong	O
growth	O
advantage	O
and	O
selective	O
pressure	O
for	O
this	O
TLE	O
isoform	O
in	O
tumor	B
progression	O
.	O

Similarly	O
,	O
the	O
correlation	O
between	O
TLE6D	O
and	O
RUNX3	O
expression	O
in	O
human	O
CRC	B
suggests	O
a	O
model	O
whereby	O
RUNX3	O
inactivation	O
by	O
TLE6D	O
could	O
be	O
an	O
important	O
factor	O
driving	O
this	O
growth	O
advantage	O
in	O
both	O
MSI	B
-	I
H	I
and	O
MSS	B
CRC	B
.	O

Future	O
studies	O
will	O
be	O
required	O
to	O
understand	O
the	O
mechanistic	O
implications	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
in	O
CRC	B
progression	O
in	O
more	O
precise	O
detail	O
.	O

Materials	O
and	O
Methods	O
Mouse	O
Lines	O
and	O
Survival	O
Analyses	O
,	O
Tumor	B
Analysis	O
,	O
and	O
Apc	O
Mutation	O
Analysis	O
Wild	O
-	O
type	O
(	O
Wt	O
)	O
,	O
Pms2+	O
/	O
−	O
and	O
Mlh3+	O
/	O
−	O
mice	O
were	O
maintained	O
on	O
the	O
129	O
Sv	O
/	O
Ev	O
genetic	O
background	O
and	O
intercrossed	O
to	O
generate	O
Mlh3+	O
/	O
−;Pms2+	O
/	O
−	O
mice	O
as	O
described	O
before	O
[	O
13	O
]	O
.	O

Apc1638N	O
mice	O
were	O
backcrossed	O
four	O
times	O
to	O
129	O
Sv	O
/	O
Ev	O
and	O
subsequently	O
intercrossed	O
with	O
Mlh3+	O
/	O
−	O
;	O
Pms2+	O
/	O
−	O
to	O
generate	O
Mlh3−	O
/	O
−;Apc1638N	O
and	O
Mlh3−	O
/	O
−;Pms2−	O
/	O
−;Apc1638N	O
mice	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
were	O
generated	O
and	O
statistical	O
significance	O
between	O
genotypes	O
was	O
determined	O
using	O
the	O
Log	O
Rank	O
test	O
as	O
previously	O
performed	O
[	O
13	O
]	O
.	O

All	O
lines	O
of	O
mice	O
were	O
necropsied	O
when	O
they	O
became	O
morbid	O
or	O
moribund	O
.	O

Sacrificed	O
mice	O
were	O
surveyed	O
for	O
tumors	B
and	O
suspicious	O
masses	O
were	O
histology	O
analyzed	O
as	O
previously	O
performed	O
.	O

Statistical	O
analyses	O
of	O
tumor	B
onset	O
and	O
incidence	O
among	O
the	O
different	O
mouse	O
lines	O
were	O
performed	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
as	O
previously	O
described	O
[	O
23	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
,	O
[	O
35	O
]	O
,	O
[	O
71	O
]	O
,	O
[	O
72	O
]	O
,	O
[	O
73	O
]	O
,	O
[	O
74	O
]	O
,	O
[	O
75	O
]	O
,	O
[	O
76	O
]	O
.	O

Tumors	B
from	O
stomach	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
were	O
cut	O
into	O
two	O
parts	O
.	O

One	O
part	O
of	O
the	O
tumor	B
was	O
processed	O
for	O
histopathological	O
analysis	O
and	O
the	O
other	O
part	O
was	O
used	O
for	O
DNA	O
/	O
RNA	O
extractions	O
.	O

Genomic	O
DNA	O
samples	O
were	O
extracted	O
using	O
Puregene	O
DNA	O
Isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
and	O
subjected	O
to	O
mutational	O
analysis	O
of	O
Apc	O
gene	O
between	O
codons	O
677–1674	O
as	O
previously	O
described	O
[	O
33	O
]	O
.	O

Array	O
Comparative	O
Genomic	O
Hybridization	O
Analysis	O
Genomic	O
DNAs	O
were	O
isolated	O
from	O
tumor	B
tissue	O
and	O
tail	O
tissue	O
from	O
each	O
mouse	O
using	O
PUREGENE	O
DNA	O
Isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
.	O

DNAs	O
were	O
digested	O
with	O
DpnII	O
and	O
subsequently	O
purified	O
using	O
the	O
QIAquick	O
PCR	O
Purification	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
quality	O
of	O
the	O
DNA	O
samples	O
was	O
evaluated	O
using	O
the	O
Agilent	O
2100	O
BioAnalyzer	O
.	O

The	O
purified	O
fragmented	O
DNA	O
samples	O
were	O
random	O
-	O
prime	O
labeled	O
with	O
either	O
Cy5	O
or	O
Cy3	O
and	O
hybridized	O
as	O
previously	O
described	O
[	O
77	O
]	O
Briefly	O
,	O
for	O
each	O
labeling	O
reaction	O
,	O
2	O
µg	O
of	O
purified	O
digested	O
DNA	O
were	O
used	O
.	O

Each	O
sample	O
was	O
dye	O
-	O
swap	O
labeled	O
for	O
hybridization	O
to	O
mouse	O
70-mer	O
oligonucleotide	O
microarrays	O
(	O
Agilent	O
Technologies	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
containing	O
20,281	O
clones	O
.	O

After	O
hybridization	O
,	O
the	O
arrays	O
were	O
scanned	O
using	O
an	O
Agilent	O
Microarray	O
DNA	O
scanner	O
(	O
Agilent	O
Technologies	O
)	O
and	O
the	O
spot	O
intensity	O
was	O
extracted	O
from	O
slide	O
images	O
using	O
Agilent	O
Feature	O
Extraction	O
Software	O
7.0	O
.	O

The	O
data	O
were	O
further	O
analyzed	O
using	O
the	O
procedures	O
of	O
Automatic	O
Data	O
Analysis	O
Pipeline	O
(	O
ADAP	O
)	O
.	O

Only	O
spots	O
with	O
fluorescence	O
intensities	O
statistically	O
different	O
from	O
the	O
surrounding	O
background	O
(	O
P<0.001	O
)	O
were	O
considered	O
reliable	O
,	O
taking	O
up	O
>	O
85	O
%	O
of	O
total	O
spots	O
on	O
the	O
chip	O
.	O

For	O
further	O
analysis	O
the	O
fluorescence	O
intensity	O
values	O
of	O
reliable	O
spots	O
were	O
transformed	O
to	O
log2	O
.	O

To	O
minimize	O
the	O
effect	O
of	O
the	O
variations	O
,	O
the	O
log2	O
intensity	O
ratios	O
of	O
remaining	O
spots	O
were	O
subjected	O
to	O
normalization	O
by	O
Lowess	O
fitting	O
.	O

Gene	O
copy	O
number	O
changes	O
for	O
each	O
sample	O
was	O
calculated	O
by	O
taking	O
the	O
median	O
of	O
the	O
normalized	O
log2	O
intensity	O
ratios	O
of	O
dye	O
-	O
swapped	O
chip	O
experiments	O
for	O
the	O
corresponding	O
sample	O
.	O

The	O
gene	O
copy	O
numbers	O
were	O
ordered	O
along	O
chromosomes	O
by	O
the	O
map	O
positions	O
of	O
corresponding	O
genes	O
.	O

To	O
eliminate	O
systematic	O
noise	O
,	O
gene	O
copy	O
number	O
changes	O
(	O
log2Ratios	O
)	O
along	O
the	O
chromosomes	O
were	O
smoothed	O
by	O
taking	O
a	O
moving	O
median	O
of	O
symmetric	O
5-nearest	O
neighbors	O
,	O
followed	O
by	O
Lowess	O
fitting	O
(	O
f	O
=	O
0.2	O
)	O
.	O

The	O
mean	O
and	O
standard	O
deviation	O
(	O
SD	O
)	O
of	O
smoothed	O
log2Ratios	O
for	O
all	O
genes	O
in	O
all	O
the	O
samples	O
were	O
calculated	O
.	O

The	O
copy	O
number	O
profiles	O
of	O
at	O
least	O
5	O
consecutive	O
genes	O
that	O
deviated	O
significantly	O
above	O
mean+3SD	O
were	O
interpreted	O
as	O
regional	O
gains	O
,	O
below	O
mean-3SD	O
as	O
regional	O
losses	O
.	O

The	O
threshold	O
for	O
whole	O
chromosomal	O
gain	O
/	O
loss	O
was	O
mean±2SD	O
.	O

The	O
ideograms	O
of	O
chromosomal	O
aberrations	O
were	O
drawn	O
using	O
mapping	O
information	O
of	O
cytogenetic	O
bands	O
to	O
the	O
mouse	O
genome	O
(	O
NCBI	O
Mapview	O
Build	O
32	O
)	O
.	O

Given	O
the	O
above	O
unanticipated	O
characteristics	O
of	O
the	O
newly	O
discovered	O
mutations	O
—	O
especially	O
their	O
low	O
frequency	O
and	O
high	O
rate	O
of	O
heterozygosity	O
—	O
we	O
performed	O
an	O
initial	O
survey	O
to	O
characterize	O
the	O
epigenetic	O
status	O
of	O
genes	O
in	O
colon	B
cancer	I
on	O
a	O
genome	O
-	O
wide	O
level	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
an	O
expression	O
microarray	O
technique	O
to	O
characterize	O
the	O
spectrum	O
of	O
hypermethylated	O
genes	O
in	O
cancers	B
[	O
15	O
]	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
have	O
utilized	O
our	O
global	O
approach	O
to	O
comprehensively	O
compare	O
the	O
epigenetic	O
alteration	O
of	O
the	O
CAN	O
genes	O
in	O
both	O
breast	O
and	O
colon	B
cancers	I
,	O
and	O
included	O
analyses	O
in	O
the	O
specific	O
breast	B
cancer	I
lines	O
where	O
individual	O
mutations	O
were	O
identified	O
by	O
Sjoblom	O
et	O
al.	O
[	O
7	O
]	O
.	O

Genes	O
Targeted	O
by	O
Mutation	O
and	O
Hypermethylation	O
Common	O
Gene	O
Targets	O
of	O
Mutation	O
and	O
Hypermethylation	O
in	O
Breast	B
Cancer	I
MSP	O
and	O
RT	O
-	O
PCR	O
expression	O
analysis	O
of	O
selected	O
genes	O
.	O

Each	O
set	O
of	O
MSP	O
and	O
expression	O
analyses	O
are	O
labeled	O
with	O
the	O
corresponding	O
gene	O
name	O
.	O

U	O
denotes	O
the	O
unmethylated	O
band	O
,	O
and	O
M	O
denotes	O
the	O
methylated	O
band	O
.	O

In	O
vitro	O
methylated	O
DNA	O
(	O
IVD	O
)	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
methylation	O
.	O

cDNA	O
from	O
normal	B
breast	O
(	O
NB	O
)	O
and	O
normal	B
colon	O
(	O
NC	O
)	O
(	O
Figure	O
3	O
)	O
was	O
used	O
to	O
determine	O
the	O
expression	O
of	O
the	O
genes	O
in	O
normal	B
tissue	O
.	O

DKO	O
corresponds	O
to	O
DNMT	O
1	O
/	O
3b	O
double	O
knockout	O
HCT116	O
cells	O
.	O

All	O
RT	O
-	O
PCR	O
experiments	O
were	O
performed	O
in	O
parallel	O
without	O
reverse	O
transcriptase	O
as	O
a	O
control	O
,	O
and	O
in	O
all	O
cases	O
,	O
no	O
PCR	O
product	O
was	O
generated	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
control	O
experiment	O
performed	O
without	O
RT	O
for	O
normal	B
breast	O
is	O
shown	O
(	O
NB	O
no	O
RT	O
)	O
for	O
each	O
gene	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
for	O
all	O
cancer	B
lines	O
with	O
beta	O
-	O
actin	O
primers	O
to	O
control	O
for	O
the	O
amount	O
of	O
cDNA	O
(	O
Figure	O
3	O
,	O
bottom	O
)	O
.	O

Common	O
Gene	O
Targets	O
of	O
Mutation	O
and	O
Hypermethylation	O
in	O
Colon	B
Cancer	I
MSP	O
and	O
RT	O
-	O
PCR	O
expression	O
analysis	O
of	O
selected	O
genes	O
.	O

Each	O
set	O
of	O
MSP	O
and	O
expression	O
analyses	O
are	O
labeled	O
with	O
the	O
corresponding	O
gene	O
name	O
.	O

U	O
denotes	O
the	O
unmethylated	O
band	O
,	O
and	O
M	O
denotes	O
the	O
methylated	O
band	O
.	O

In	O
vitro	O
methylated	O
DNA	O
(	O
IVD	O
)	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
methylation	O
.	O

cDNA	O
from	O
normal	B
breast	O
(	O
NB	O
)	O
and	O
normal	B
colon	O
(	O
NC	O
)	O
was	O
used	O
to	O
determine	O
the	O
expression	O
of	O
the	O
genes	O
in	O
normal	B
tissue	O
.	O

DKO	O
corresponds	O
to	O
DNMT	O
1	O
/	O
3b	O
double	O
knockout	O
HCT116	O
cells	O
.	O

All	O
RT	O
-	O
PCR	O
experiments	O
were	O
performed	O
in	O
parallel	O
without	O
reverse	O
transcriptase	O
as	O
a	O
control	O
,	O
and	O
in	O
all	O
cases	O
,	O
no	O
PCR	O
product	O
was	O
generated	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
control	O
experiment	O
performed	O
without	O
RT	O
for	O
normal	B
colon	O
is	O
shown	O
(	O
NC	O
no	O
RT	O
)	O
for	O
each	O
gene	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
for	O
all	O
cancer	B
lines	O
with	O
beta	O
-	O
actin	O
primers	O
to	O
control	O
for	O
the	O
amount	O
of	O
cDNA	O
.	O

From	O
the	O
analysis	O
of	O
methylation	O
and	O
expression	O
status	O
of	O
the	O
36	O
common	O
target	O
genes	O
,	O
it	O
is	O
clear	O
that	O
,	O
although	O
hypermethylation	O
was	O
accompanied	O
by	O
loss	O
of	O
gene	O
expression	O
in	O
nearly	O
all	O
cases	O
,	O
loss	O
of	O
gene	O
expression	O
in	O
the	O
overlap	O
genes	O
can	O
occur	O
by	O
mechanisms	O
other	O
than	O
methylation	O
(	O
Table	O
S1	O
)	O
.	O

Potential	O
mechanisms	O
include	O
repressive	O
chromatin	O
modifications	O
,	O
mutational	O
changes	O
outside	O
the	O
coding	O
regions	O
that	O
destabilize	O
the	O
mRNA	O
,	O
or	O
coordinate	O
downregulation	O
of	O
relevant	O
pathways	O
.	O

For	O
example	O
,	O
p21	O
expression	O
is	O
frequently	O
decreased	O
in	O
tumors	B
with	O
inactivating	O
p53	O
mutations	O
[	O
25	O
]	O
.	O

To	O
confirm	O
our	O
MSP	O
results	O
,	O
we	O
analyzed	O
the	O
methylation	O
status	O
of	O
selected	O
genes	O
using	O
sequencing	O
of	O
bisulfite	O
-	O
treated	O
genomic	O
DNA	O
from	O
samples	O
that	O
were	O
used	O
in	O
the	O
MSP	O
studies	O
.	O

In	O
all	O
cases	O
,	O
bisulfite	O
sequencing	O
confirmed	O
the	O
results	O
obtained	O
with	O
MSP	O
(	O
Figure	O
4	O
)	O
.	O

For	O
another	O
control	O
,	O
we	O
also	O
studied	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
the	O
genes	O
in	O
a	O
derivative	O
of	O
HCT116	O
human	O
colon	B
cancer	I
cells	O
in	O
which	O
the	O
DNMT1	O
and	O
DNMT3b	O
DNA	O
methyltransferases	O
were	O
homozygously	O
deleted	O
(	O
DKO	O
cells	O
)	O
.	O

These	O
simultaneous	O
deletions	O
result	O
in	O
nearly	O
complete	O
lack	O
of	O
DNA	O
methylation	O
and	O
the	O
promoter	O
DNA	O
demethylation	O
and	O
re	O
-	O
expression	O
of	O
all	O
known	O
DNA	O
hypermethylated	O
genes	O
examined	O
in	O
these	O
cells	O
[	O
26	O
]	O
.	O

In	O
all	O
cases	O
,	O
the	O
loss	O
or	O
absence	O
of	O
methylation	O
at	O
the	O
promoter	O
regions	O
of	O
the	O
36	O
DNA	O
hypermethylated	O
loci	O
in	O
DKO	O
cells	O
was	O
associated	O
with	O
expression	O
of	O
these	O
genes	O
(	O
Figures	O
2	O
and	O
3	O
and	O
unpublished	O
data	O
)	O
.	O

Importantly	O
,	O
in	O
all	O
cases	O
,	O
these	O
36	O
overlap	O
genes	O
were	O
also	O
found	O
to	O
be	O
expressed	O
in	O
normal	B
colon	O
and	O
breast	O
tissue	O
(	O
Figures	O
2	O
and	O
3	O
and	O
Table	O
S1	O
)	O
.	O

The	O
above	O
data	O
may	O
be	O
particularly	O
significant	O
because	O
the	O
vast	O
majority	O
of	O
CAN	O
gene	O
mutations	O
identified	O
are	O
heterozygous	O
missense	O
mutations	O
.	O

It	O
is	O
possible	O
that	O
many	O
of	O
these	O
mutations	O
result	O
in	O
haploinsufficiency	O
or	O
cause	O
small	O
decreases	O
in	O
protein	O
or	O
transcript	O
abundance	O
that	O
may	O
be	O
functionally	O
meaningful	O
for	O
driving	O
tumorigenesis	O
.	O

Small	O
changes	O
in	O
expression	O
of	O
a	O
number	O
of	O
tumor	B
suppressor	O
genes	O
(	O
such	O
as	O
APC	O
,	O
SMAD4	O
,	O
MSH2	O
,	O
etc	O
.	O
)	O
have	O
now	O
been	O
well	O
described	O
to	O
have	O
tumorigenic	O
effects	O
[	O
8,29,30	O
]	O
.	O

Consistent	O
with	O
the	O
hemizygous	O
nature	O
of	O
the	O
mutations	O
,	O
it	O
seems	O
likely	O
that	O
DNA	O
methylation	O
deepens	O
the	O
haploinsufficiency	O
status	O
of	O
the	O
genes	O
when	O
both	O
changes	O
are	O
found	O
in	O
the	O
same	O
tumor	B
or	O
,	O
more	O
often	O
just	O
with	O
the	O
epigenetic	O
changes	O
alone	O
.	O

The	O
accompanying	O
loss	O
of	O
function	O
can	O
compound	O
,	O
and	O
thus	O
progressively	O
contribute	O
to	O
,	O
tumorigenesis	O
.	O

Functional	O
Associations	O
of	O
Common	O
Target	O
Genes	O
Next	O
,	O
we	O
analyzed	O
the	O
functional	O
associations	O
of	O
the	O
18	O
common	O
target	O
genes	O
that	O
demonstrate	O
cancer	B
-	O
specific	O
hypermethylation	O
.	O

We	O
utilized	O
Gene	O
Ontology	O
(	O
GO	O
)	O
classification	O
and	O
available	O
data	O
in	O
the	O
literature	O
to	O
describe	O
the	O
functional	O
associations	O
of	O
the	O
genes	O
(	O
Figure	O
8)	O
.	O

A	O
number	O
of	O
genes	O
are	O
involved	O
in	O
cell	O
adhesion	O
and	O
motility	O
and/or	O
signal	O
transduction	O
.	O

Examination	O
of	O
the	O
literature	O
revealed	O
that	O
at	O
least	O
six	O
of	O
these	O
genes	O
possess	O
known	O
tumor	O
suppressive	O
properties	O
,	O
defined	O
as	O
the	O
ability	O
to	O
modulate	O
known	O
tumor	B
suppressor	O
(	O
i.e.	O
,	O
p53	O
,	O
wnt	O
,	O
etc	O
.	O
)	O
function	O
or	O
inhibit	O
cancer	B
cell	O
growth	O
in	O
vitro	O
and/or	O
in	O
vivo	O
(	O
Figure	O
8)	O
.	O

We	O
then	O
determined	O
the	O
chromosomal	O
location	O
of	O
these	O
18	O
genes	O
.	O

We	O
compared	O
these	O
chromosomal	O
locations	O
to	O
those	O
that	O
have	O
been	O
shown	O
to	O
be	O
deleted	O
in	O
primary	O
human	O
tumors	B
in	O
the	O
literature	O
using	O
standard	O
genetic	O
mapping	O
or	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
.	O

Sixteen	O
out	O
of	O
18	O
(	O
89	O
%	O
,	O
next	O
to	O
last	O
panel	O
)	O
of	O
these	O
genes	O
map	O
to	O
loci	O
that	O
have	O
been	O
found	O
to	O
be	O
deleted	O
in	O
cancers	B
(	O
including	O
colon	O
,	O
breast	O
,	O
prostate	O
,	O
Wilm	B
's	I
tumor	I
,	O
hematopoietic	O
tumors	B
,	O
and	O
medulloblastoma	B
)	O
.	O

For	O
example	O
,	O
Yang	O
et	O
al.	O
demonstrated	O
that	O
19p13.3	O
,	O
the	O
location	O
of	O
APC2	O
,	O
is	O
a	O
common	O
site	O
of	O
LOH	O
or	O
deletion	O
in	O
breast	O
carcinoma	B
[	O
31	O
]	O
.	O

Similarly	O
,	O
SYNE1	O
localizes	O
to	O
6p25	O
,	O
a	O
location	O
that	O
is	O
subject	O
to	O
frequent	O
deletion	O
in	O
a	O
number	O
of	O
tumors	B
[	O
32,33	O
]	O
.	O

CHD5	O
is	O
a	O
well	O
-	O
documented	O
tumor	B
suppressor	O
gene	O
located	O
on	O
1p36	O
,	O
a	O
region	O
that	O
is	O
commonly	O
lost	O
in	O
malignancies	B
of	O
epithelial	O
,	O
neural	O
,	O
and	O
hematopoietic	O
origin	O
[	O
34	O
]	O
.	O

Referenced	O
data	O
are	O
summarized	O
in	O
Table	O
S4	O
.	O

Thus	O
,	O
the	O
18	O
genes	O
we	O
have	O
identified	O
are	O
genes	O
that	O
are	O
found	O
to	O
be	O
mutated	O
in	O
breast	O
and	O
colon	B
cancer	I
,	O
silenced	O
by	O
hypermethylation	O
in	O
these	O
tumors	B
,	O
and	O
reside	O
at	O
locations	O
subject	O
to	O
LOH	O
or	O
deletion	O
in	O
a	O
number	O
of	O
human	O
neoplasms	B
.	O

Statistical	O
Analyses	O
Unpaired	O
t	O
test	O
,	O
z	O
test	O
,	O
and	O
χ2	O
test	O
were	O
used	O
.	O

The	O
data	O
were	O
calculated	O
with	O
Statistica	O
6	O
(	O
StatSoft	O
,	O
Tulsa	O
,	O
OK	O
,	O
USA	O
)	O
.	O

Values	O
are	O
presented	O
as	O
arithmetrical	O
mean	O
±	O
SEM	O
.	O

The	O
present	O
study	O
describes	O
a	O
population	O
based	O
analysis	O
of	O
the	O
frequency	O
of	O
variants	O
of	O
unknown	O
significance	O
in	O
hMLH1	O
and	O
hMSH2	O
in	O
Danish	O
patients	O
with	O
sporadic	O
CRC	B
and	O
in	O
a	O
sub	O
-	O
cohort	O
of	O
controls	O
.	O

Some	O
of	O
the	O
variants	O
have	O
been	O
described	O
in	O
other	O
studies	O
,	O
and	O
some	O
are	O
,	O
to	O
our	O
knowledge	O
,	O
new	O
variants	O
unique	O
to	O
the	O
Danish	O
population	O
.	O

We	O
have	O
analyzed	O
the	O
allele	O
frequencies	O
of	O
29	O
variants	O
in	O
hMLH1	O
and	O
hMSH2	O
to	O
reveal	O
whether	O
they	O
cause	O
increased	O
susceptibility	O
to	O
sporadic	O
CRC	B
in	O
the	O
Danish	O
population	O
or	O
whether	O
they	O
are	O
private	O
variants	O
/	O
mutations	O
found	O
only	O
in	O
the	O
families	O
where	O
they	O
were	O
originally	O
identified	O
.	O

In	O
addition	O
to	O
the	O
29	O
variants	O
identified	O
in	O
Danish	O
individuals	O
,	O
six	O
variants	O
identified	O
in	O
other	O
Caucasian	O
populations	O
were	O
also	O
investigated	O
.	O

MLH1	O
and	O
MSH2	O
variants	O
*	O
identified	O
in	O
CRC	B
families	O
from	O
other	O
Caucasian	O
populations	O
than	O
the	O
Danish	O
Genotyping	O
using	O
Single	O
Base	O
Extension	O
(	O
SBE	O
)	O
-tag	O
arrays	O

Primer	O
design	O
The	O
multiplex	O
PCR	O
primers	O
were	O
designed	O
using	O
Oligo	O
6	O
[	O
22	O
]	O
.	O

The	O
PCR	O
products	O
were	O
between	O
100	O
and	O
450	O
bp	O
.	O

The	O
optimal	O
annealing	O
temperature	O
(	O
Ta	O
)	O
was	O
set	O
to	O
~50	O
°	O
C	O
,	O
the	O
GC	O
content	O
to	O
~40	O
%	O
and	O
the	O
primer	O
Tm	O
difference	O
to	O
≤1	O
.	O

The	O
single	O
base	O
extension	O
(	O
SBE	O
)	O
primers	O
contained	O
5	O
'	O
20-bp	O
'	O
tag	O
'	O
sequences	O
that	O
were	O
from	O
the	O
Affymetrix	O
GeneChip	O
®	O
Tag	O
Collection	O
.	O

The	O
gene	O
specific	O
part	O
of	O
the	O
SBE	O
primers	O
had	O
a	O
Tm	O
of	O
~50–60	O
°	O
C	O
(	O
calculated	O
using	O
PrimerExpress	O
2.0	O
)	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

The	O
tagged	O
SBE	O
primers	O
were	O
tested	O
for	O
major	O
hairpin	O
loop	O
formation	O
using	O
Oligo6	O
.	O

All	O
variants	O
were	O
typed	O
using	O
SBE	O
-	O
primers	O
for	O
both	O
DNA	O
strands	O
.	O

The	O
primers	O
were	O
synthesized	O
by	O
DNA	O
Technology	O
(	O
Aarhus	O
,	O
Denmark	O
)	O
.	O

The	O
multiplex	O
PCR	O
primer	O
and	O
the	O
SBE	O
primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Multiplex	O
PCR	O
The	O
multiplex	O
PCR	O
amplification	O
was	O
performed	O
with	O
6–9	O
primer	O
pairs	O
per	O
reaction	O
.	O

Twenty	O
ng	O
of	O
genomic	O
DNA	O
with	O
0.5	O
μl	O
Accuprime	O
™	O
DNA	O
polymerase	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
1	O
×	O
Accuprime	O
™	O
Buffer	O
I	O
,	O
and	O
0.08–1	O
μM	O
primers	O
was	O
amplified	O
in	O
25	O
μl	O
volumes	O
using	O
the	O
following	O
PCR	O
conditions	O
:	O
1	O
cycle	O
of	O
95	O
°	O
C	O
for	O
10	O
min	O
;	O
13	O
cycles	O
of	O
95	O
°	O
C	O
for	O
30	O
sec.	O
,	O
67	O
°	O
C	O
(	O
-1	O
°	O
C	O
/	O
cycle	O
)	O
for	O
45	O
sec.	O
and	O
72	O
°	O
C	O
for	O
45	O
sec.	O
;	O
20	O
cycles	O
of	O
95	O
°	O
C	O
for	O
30	O
sec.	O
,	O
55	O
°	O
C	O
for	O
45	O
sec.	O
and	O
72	O
°	O
C	O
for	O
45	O
sec.	O
;	O
1	O
cycle	O
of	O
72	O
°	O
C	O
for	O
10	O
min	O
.	O

A	O
subset	O
of	O
the	O
multiplex	O
PCR	O
products	O
were	O
analysed	O
on	O
a	O
2100	O
Bioanalyzer	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
to	O
test	O
the	O
performance	O
of	O
the	O
multiplex	O
PCR	O
.	O

The	O
multiplex	O
PCR	O
products	O
from	O
each	O
sample	O
were	O
pooled	O
for	O
further	O
analysis	O
.	O

Single	O
Base	O
Extension	O
(	O
SBE	O
)	O
reaction	O

The	O
pooled	O
PCR	O
products	O
from	O
each	O
sample	O
were	O
treated	O
with	O
Exonuclease	O
I	O
and	O
shrimp	O
alkaline	O
phosphatase	O
and	O
used	O
for	O
template	O
in	O
the	O
SBE	O
reaction	O
(	O
mini	O
-	O
sequencing	O
)	O
as	O
described	O
by	O
Lindross	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescent	O
labelled	O
ddNTP	O
were	O
Cyanine	O
5	O
(	O
Cy5	O
)	O
-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
®	O
-5-ddATP	O
and	O
R110-ddGTP	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

Preparation	O
of	O
microarrays	O
'	O
Anti	O
-	O
tag	O
'	O
oligonucleotides	O
complimentary	O
to	O
the	O
'	O
tag	O
'	O
sequences	O
of	O
the	O
SBE	O
primers	O
modified	O
with	O
NH2	O
groups	O
in	O
their	O
3	O
'	O
ends	O
,	O
and	O
containing	O
a	O
3'-spacer	O
of	O
15	O
T	O
residues	O
were	O
coupled	O
covalently	O
to	O
CodeLink	O
Activated	O
Slides	O
(	O
Amersham	O
Biosciences	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
according	O
to	O
manufacturer	O
instructions	O
.	O

The	O
only	O
exception	O
was	O
that	O
the	O
'	O
anti	O
-	O
tag	O
'	O
oligonucleotides	O
were	O
dissolved	O
in	O
150	O
mM	O
sodium	O
carbonate	O
buffer	O
,	O
pH	O
8.5	O
with	O
1	O
mM	O
betaine	O
at	O
a	O
concentration	O
of	O
20	O
μM.	O
The	O
oligonucleotides	O
were	O
printed	O
onto	O
the	O
slides	O
using	O
a	O
VersArray	O
ChipWriter	O
(	O
BioRad	O
,	O
Hercules	O
,	O
CA	O
)	O
with	O
3	O
Stealth	O
Micro	O
Spotting	O
Pins	O
(	O
TeleChem	O
International	O
Inc.	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Each	O
slide	O
consists	O
of	O
75	O
sub	O
-	O
arrays	O
with	O
13	O
×	O
12	O
spots	O
in	O
each	O
subarray	O
.	O

The	O
spots	O
were	O
130–150	O
μM	O
in	O
diameter	O
and	O
the	O
centre	O
-	O
to	O
-	O
centre	O
distance	O
between	O
two	O
spots	O
was	O
200	O
μM.	O
The	O
'	O
anti	O
-	O
tag	O
'	O
oligonucleotides	O
were	O
printed	O
in	O
duplicates	O
in	O
each	O
sub	O
-	O
array	O
.	O

The	O
spot	O
quality	O
was	O
tested	O
after	O
each	O
series	O
of	O
microarray	O
preparation	O
using	O
a	O
Cy3	O
labelled	O
random	O
oligonucleotide	O
hybridizing	O
to	O
all	O
spots	O
on	O
the	O
slide	O
independent	O
on	O
the	O
'	O
anti	O
-	O
tag	O
'	O
sequence	O
.	O

The	O
printed	O
slides	O
were	O
stored	O
at	O
room	O
temperature	O
until	O
use	O
.	O

Linkage	O
disequilibrium	O
(	O
LD	O
)	O
analysis	O
showed	O
high	O
LD	O
in	O
the	O
genomic	O
regions	O
covering	O
hMLH1	O
and	O
most	O
of	O
the	O
genomic	O
region	O
covering	O
hMSH2	O
in	O
the	O
Danish	O
population	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
variants	O
in	O
the	O
two	O
genes	O
in	O
general	O
are	O
not	O
associated	O
with	O
susceptibility	O
to	O
sporadic	O
CRC	B
in	O
a	O
Danish	O
population	O
.	O

The	O
age	O
of	O
the	O
cohort	O
of	O
cases	O
with	O
sporadic	O
CRC	B
is	O
relatively	O
young	O
(	O
mean	O
~58	O
years	O
)	O
compared	O
to	O
the	O
mean	O
age	O
of	O
onset	O
of	O
colorectal	O
CRC	B
in	O
the	O
general	O
Danish	O
population	O
(	O
mean	O
~70	O
years	O
)	O
[	O
49	O
]	O
.	O

Consequently	O
,	O
the	O
results	O
obtained	O
in	O
the	O
present	O
study	O
do	O
not	O
rule	O
out	O
that	O
variants	O
in	O
hMLH1	O
and	O
hMSH2	O
might	O
be	O
associated	O
with	O
sporadic	O
colorectal	B
cancer	I
at	O
an	O
older	O
age	O
.	O

However	O
,	O
generally	O
cancers	B
reflecting	O
an	O
inherited	O
susceptibility	O
seem	O
to	O
occur	O
in	O
a	O
relatively	O
young	O
age	O
.	O

Using	O
in	O
silico	O
analysis	O
several	O
of	O
the	O
analyzed	O
variants	O
were	O
predicted	O
to	O
either	O
abolish	O
or	O
introduce	O
ESEs	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
has	O
,	O
however	O
,	O
been	O
shown	O
that	O
only	O
a	O
minor	O
fraction	O
of	O
the	O
variants	O
predicted	O
to	O
change	O
ESEs	O
in	O
hMLH1	O
and	O
hMSH2	O
using	O
in	O
silico	O
analysis	O
do	O
indeed	O
change	O
the	O
pre	O
-	O
mRNA	O
splice	O
pattern	O
in	O
vivo	O
[	O
14,15	O
]	O
.	O

In	O
the	O
study	O
by	O
Auclair	O
et	O
al.	O
,	O
only	O
ESEs	O
at	O
or	O
close	O
to	O
5	O
'	O
splice	O
sites	O
were	O
found	O
to	O
cause	O
aberrant	O
splicing	O
.	O

None	O
of	O
the	O
variants	O
analysed	O
in	O
the	O
present	O
study	O
affected	O
5	O
'	O
splice	O
sites	O
.	O

Nevertheless	O
,	O
no	O
final	O
conclusions	O
regarding	O
splicing	O
can	O
be	O
drawn	O
from	O
the	O
in	O
silico	O
analyses	O
.	O

Twenty	O
two	O
variants	O
were	O
not	O
detected	O
in	O
the	O
sporadic	O
CRC	B
cases	O
and	O
in	O
the	O
sub	O
-	O
cohort	O
.	O

Among	O
those	O
were	O
the	O
six	O
variants	O
originally	O
identified	O
more	O
or	O
less	O
frequently	O
in	O
other	O
populations	O
(	O
Table	O
2	O
)	O
.	O

All	O
except	O
one	O
variant	O
(	O
c.380	O
A	O
>	O
G	O
,	O
p.	O

Asn127Ser	O
)	O
performed	O
very	O
well	O
in	O
the	O
SBE	O
-	O
tag	O
array	O
assay	O
.	O

This	O
rules	O
out	O
that	O
failure	O
in	O
detecting	O
the	O
variants	O
caused	O
their	O
absence	O
in	O
the	O
present	O
cohorts	O
.	O

Consequently	O
,	O
these	O
six	O
variants	O
are	O
not	O
polymorphic	O
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
variants	O
were	O
rare	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

They	O
were	O
only	O
detected	O
in	O
individuals	O
with	O
familiar	O
CRC	B
and	O
some	O
of	O
them	O
have	O
been	O
classified	O
as	O
pathogenic	O
mutations	O
or	O
neutral	O
variants	O
in	O
other	O
populations	O
(	O
see	O
Table	O
2	O
for	O
references	O
)	O
.	O

Four	O
rare	O
missense	O
variants	O
i.e.	O
hMLH1	O
c.1379	O
A	O
>	O
C	O
(	O
p.	O

Glu460Ala	O
)	O
and	O
c.1689	O
A	O
>	O
G	O
(	O
p.	O

Ile563Met	O
)	O
and	O
,	O
hMSH2	O
c.2062	O
A	O
>	O
G	O
(	O
p.	O

Met688Val	O
)	O
and	O
c.2542	O
G	O
>	O
T	O
(	O
p.	O

Ala848Ser	O
)	O
were	O
unclassified	O
and	O
have	O
to	O
our	O
knowledge	O
never	O
been	O
described	O
previously	O
neither	O
in	O
the	O
Danish	O
population	O
nor	O
in	O
other	O
populations	O
.	O

Other	O
disease	B
causing	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
families	O
harbouring	O
the	O
two	O
hMLH1	O
variants	O
changing	O
non	O
-	O
conserved	O
amino	O
acids	O
i.e.	O
pGlu460Ala	O
and	O
p.	O

Ile563Met	O
(	O
unpublished	O
results	O
)	O
consequently	O
,	O
these	O
variants	O
are	O
most	O
likely	O
neutral	O
and	O
not	O
involved	O
in	O
HNPCC	B
.	O

However	O
,	O
no	O
other	O
disease	B
causing	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
families	O
harbouring	O
the	O
hMSH2	O
variants	O
changing	O
conserved	O
amino	O
acids	O
i.e.	O
p.	O

Met688Val	O
and	O
p.	O

Ala848Ser	O
variants	O
.	O

Further	O
characterization	O
of	O
these	O
variants	O
such	O
as	O
functional	O
studies	O
and	O
segregations	O
analysis	O
are	O
needed	O
before	O
any	O
final	O
conclusion	O
can	O
be	O
drawn	O
regarding	O
their	O
pathogenicity	O
.	O

In	O
conclusion	O
,	O
high	O
penetrance	O
cancer	B
susceptibility	O
genes	O
involved	O
in	O
hereditary	O
syndromes	B
have	O
rarely	O
emerged	O
as	O
definitive	O
low	O
-	O
penetrance	O
genes	O
as	O
a	O
result	O
of	O
common	O
variants	O
increasing	O
disease	B
susceptibility	O
[	O
19	O
]	O
.	O

The	O
results	O
shown	O
in	O
the	O
present	O
study	O
demonstrate	O
that	O
the	O
high	O
-	O
penetrance	O
HNPCC	B
genes	O
hMLH1	O
and	O
hMSH2	O
also	O
do	O
not	O
appear	O
to	O
be	O
low	O
penetrance	O
genes	O
involved	O
in	O
sporadic	O
CRC	B
in	O
the	O
Danish	O
population	O
.	O

Design	O
considerations	O
in	O
a	O
sib	O
-	O
pair	O
study	O
of	O
linkage	O
for	O
susceptibility	O
loci	O
in	O
cancer	B
Abstract	O
Background	O
Modern	O
approaches	O
to	O
identifying	O
new	O
genes	O
associated	O
with	O
disease	B
allow	O
very	O
fine	O
analysis	O
of	O
associaton	O
and	O
can	O
be	O
performed	O
in	O
population	O
based	O
case	O
-	O
control	O
studies	O
.	O

However	O
,	O
the	O
sibpair	O
design	O
is	O
still	O
valuable	O
because	O
it	O
requires	O
few	O
assumptions	O
other	O
than	O
acceptably	O
high	O
penetrance	O
to	O
identify	O
genetic	O
loci	O
.	O

Methods	O
We	O
conducted	O
simulation	O
studies	O
to	O
assess	O
the	O
impact	O
of	O
design	O
factors	O
on	O
relative	O
efficiency	O
for	O
a	O
linkage	O
study	O
of	O
colorectal	B
cancer	I
.	O

We	O
considered	O
two	O
test	O
statistics	O
,	O
one	O
comparing	O
the	O
mean	O
IBD	O
probability	O
in	O
affected	B
pairs	O
to	O
its	O
null	O
value	O
of	O
0.5	O
,	O
and	O
one	O
comparing	O
the	O
mean	O
IBD	O
probabilities	O
between	O
affected	B
and	O
discordant	O
pairs	O
.	O

We	O
varied	O
numbers	O
of	O
parents	O
available	O
,	O
numbers	O
of	O
affected	B
and	O
unaffected	B
siblings	O
,	O
reconstructing	O
the	O
genotype	O
of	O
an	O
unavailable	O
affected	B
sibling	O
by	O
a	O
spouse	O
and	O
offspring	O
,	O
and	O
elimination	O
of	O
sibships	O
where	O
the	O
proband	O
carries	O
a	O
mutation	O
at	O
another	O
locus	O
.	O

Results	O
Power	O
and	O
efficiency	O
were	O
most	O
affected	O
by	O
the	O
number	O
of	O
affected	B
sibs	O
,	O
the	O
number	O
of	O
sib	O
pairs	O
genotyped	O
,	O
and	O
the	O
risk	O
attributable	O
to	O
linked	O
and	O
unlinked	O
loci	O
.	O

Genotyping	O
unaffected	B
siblings	O
added	O
little	O
power	O
for	O
low	O
penetrance	O
models	O
,	O
but	O
improved	O
validity	O
of	O
tests	O
when	O
there	O
was	O
genetic	O
heterogeneity	O
and	O
for	O
multipoint	O
testing	O
.	O

The	O
efficiency	O
of	O
the	O
concordant	O
-	O
only	O
test	O
was	O
nearly	O
always	O
better	O
than	O
the	O
concordant	O
-	O
discordant	O
test	O
.	O

Replacement	O
of	O
an	O
unavailable	O
affected	B
sibling	O
by	O
a	O
spouse	O
and	O
offspring	O
recovered	O
some	O
linkage	O
information	O
,	O
particularly	O
if	O
several	O
offspring	O
were	O
available	O
.	O

In	O
multipoint	O
analysis	O
,	O
the	O
concordant	O
-	O
only	O
test	O
was	O
showed	O
a	O
small	O
anticonservative	O
bias	O
at	O
5	O
cM	O
,	O
while	O
the	O
multipoint	O
concordant	O
-	O
discordant	O
test	O
was	O
generally	O
the	O
most	O
powerful	O
test	O
,	O
and	O
was	O
not	O
biased	O
away	O
from	O
the	O
null	O
at	O
5	O
cM.	O
Conclusion	O
Genotyping	O
parents	O
and	O
unaffected	B
siblings	O
is	O
useful	O
for	O
detecting	O
genotyping	O
errors	O
and	O
if	O
allele	O
frequencies	O
are	O
uncertain	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
an	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	B
and	O
unaffected	B
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

Methods	O
The	O
choice	O
of	O
sampling	O
schemes	O
for	O
a	O
colon	O
sibpair	O
study	O
requires	O
evaluation	O
,	O
as	O
several	O
different	O
options	O
exist	O
simultaneously	O
for	O
the	O
sampling	O
plan	O
(	O
how	O
many	O
families	O
and	O
which	O
relatives	O
to	O
sample	O
)	O
,	O
disease	B
model	O
(	O
penetrance	O
,	O
allele	O
frequency	O
,	O
etc	O
)	O
,	O
and	O
statistical	O
test	O
of	O
linkage	O
.	O

These	O
aspects	O
,	O
in	O
addition	O
to	O
the	O
method	O
of	O
generating	O
the	O
data	O
sets	O
for	O
the	O
simulations	O
comprise	O
the	O
methods	O
of	O
determining	O
an	O
optimal	O
design	O
strategy	O
for	O
a	O
colon	O
sibpair	O
study	O
.	O

In	O
our	O
analysis	O
of	O
design	O
issues	O
we	O
have	O
pursued	O
a	O
deterministic	O
simulation	O
approach	O
.	O

The	O
first	O
step	O
was	O
to	O
check	O
that	O
the	O
tests	O
we	O
considered	O
had	O
appropriate	O
size	O
,	O
using	O
extensive	O
simulations	O
.	O

For	O
those	O
tests	O
that	O
were	O
valid	O
,	O
we	O
then	O
performed	O
a	O
moderate	O
number	O
of	O
simulations	O
of	O
a	O
large	O
number	O
of	O
families	O
,	O
to	O
obtain	O
the	O
noncentrality	O
parameters	O
describing	O
the	O
behavior	O
of	O
each	O
design	O
configuration	O
and	O
test	O
.	O

We	O
were	O
then	O
able	O
to	O
compare	O
the	O
attributes	O
of	O
these	O
studies	O
across	O
the	O
different	O
design	O
configurations	O
genetic	O
models	O
and	O
tests	O
by	O
fitting	O
regression	O
models	O
,	O
as	O
further	O
described	O
below	O
.	O

Disease	B
Model	O
Parameter	O
Choices	O
Genetic	O
Heterogeneity	O
The	O
genetic	O
basis	O
of	O
many	O
complex	O
human	O
diseases	B
,	O
including	O
some	O
common	O
cancers	B
,	O
is	O
known	O
to	O
include	O
mutations	O
in	O
loci	O
that	O
confer	O
a	O
high	O
penetrance	O
to	O
carriers	O
.	O

In	O
order	O
to	O
minimize	O
the	O
impact	O
that	O
such	O
genetic	O
heterogeneity	O
may	O
have	O
on	O
the	O
statistical	O
efficiency	O
to	O
identify	O
novel	O
loci	O
,	O
gene	O
-	O
hunting	O
studies	O
are	O
often	O
restricted	O
to	O
those	O
cases	O
that	O
have	O
been	O
determined	O
not	O
to	O
be	O
related	O
to	O
any	O
known	O
susceptibility	O
locus	O
.	O

For	O
example	O
,	O
the	O
second	O
susceptibility	O
locus	O
for	O
breast	B
cancer	I
,	O
BRCA2	O
,	O
was	O
mapped	O
by	O
Wooster	O
et	O
al.	O
[	O
37	O
]	O
based	O
on	O
high	O
-	O
risk	O
families	O
for	O
whom	O
BRCA1	O
linkage	O
was	O
excluded	O
.	O

Genetic	O
syndromes	B
such	O
as	O
juvenile	B
polyposis	I
,	O
Peutz	B
-	I
Jeghers	I
syndrome	I
and	O
familial	B
adenomatous	I
polyposis	I
can	O
be	O
readily	O
eliminated	O
prior	O
to	O
sample	O
collection	O
on	O
the	O
basis	O
of	O
phenotypic	O
characteristics	O
.	O

However	O
,	O
mutations	O
in	O
mismatch	O
repair	O
(	O
MMR	O
)	O
loci	O
such	O
as	O
hMSH2	O
or	O
hMLH1	O
can	O
not	O
be	O
excluded	O
without	O
performing	O
molecular	O
studies	O
.	O

(	O
Measures	O
of	O
tumor	B
microsatellite	O
instability	O
or	O
immunohistochemistry	O
can	O
be	O
helpful	O
in	O
identifying	O
likely	O
carriers	O
,	O
but	O
are	O
neither	O
fully	O
sensitive	O
nor	O
specific	O
.	O
)	O

Estimating	O
the	O
proportion	O
of	O
affected	B
families	O
that	O
might	O
be	O
excluded	O
from	O
analysis	O
because	O
they	O
carry	O
MMR	O
mutations	O
is	O
difficult	O
.	O

Population	O
-	O
based	O
estimates	O
of	O
the	O
prevalence	O
of	O
germ	O
-	O
line	O
MMR	O
mutations	O
among	O
subjects	O
diagnosed	O
with	O
colorectal	B
cancer	I
vary	O
widely	O
even	O
within	O
populations	O
of	O
European	O
descent	O
[	O
38	O
-	O
41	O
]	O
,	O
and	O
only	O
a	O
few	O
estimates	O
are	O
available	O
for	O
other	O
ethnic	O
groups	O
[	O
42,43	O
]	O
.	O

Moreover	O
,	O
recruiting	O
from	O
high	O
-	O
risk	O
clinics	O
may	O
lead	O
to	O
disproportionate	O
over	O
-	O
representation	O
of	O
families	O
who	O
have	O
MMR	O
mutations	O
.	O

One	O
large	O
study	O
in	O
Finland	O
[	O
44	O
]	O
found	O
that	O
12	O
%	O
of	O
affected	B
sib	O
pairs	O
(	O
ASP	O
)	O
showed	O
MMR	O
defects	O
.	O

The	O
number	O
of	O
families	O
F	O
required	O
for	O
a	O
desired	O
level	O
of	O
power	O
sample	O
was	O
calculated	O
in	O
the	O
standard	O
way	O
[	O
59	O
]	O
by	O
solving	O
Zα+Z1−βF	O
=	O
ZsimFsim	O
for	O
F	O
,	O
where	O
Zα	O
and	O
Z1-β	O
are	O
the	O
quantiles	O
of	O
the	O
standard	O
normal	O
distribution	O
for	O
selected	O
values	O
of	O
α	O
and	O
β	O
,	O
and	O
Zsim	O
is	O
the	O
sample	O
mean	O
of	O
the	O
Z	O
-	O
scores	O
(	O
Zc	O
or	O
Zp	O
)	O
based	O
on	O
the	O
sample	O
size	O
Fsim	O
of	O
the	O
simulation	O
run	O
.	O

Comparison	O
of	O
Sampling	O
Strategies	O

The	O
relative	O
efficiency	O
and	O
absolute	O
power	O
comparisons	O
were	O
evaluated	O
over	O
a	O
range	O
of	O
assumptions	O
about	O
disease	B
allele	O
frequency	O
,	O
penetrance	O
,	O
and	O
heterogeneity	O
.	O

Summaries	O
are	O
provided	O
for	O
the	O
relative	O
efficiency	O
from	O
the	O
non	O
-	O
null	O
simulations	O
of	O
each	O
combination	O
of	O
parameters	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

Our	O
simulations	O
involved	O
the	O
manipulation	O
of	O
16	O
parameters	O
,	O
with	O
over	O
725,000	O
possible	O
combinations	O
arising	O
just	O
among	O
the	O
limited	O
set	O
of	O
settings	O
we	O
chose	O
for	O
each	O
parameter	O
.	O

In	O
practice	O
,	O
we	O
were	O
able	O
to	O
simulate	O
20	O
replicates	O
for	O
332	O
actual	O
parameter	O
combinations	O
.	O

In	O
order	O
to	O
assess	O
the	O
impact	O
of	O
each	O
variable	O
parameter	O
setting	O
on	O
the	O
power	O
and	O
efficiency	O
of	O
each	O
study	O
design	O
,	O
and	O
to	O
facilitate	O
generalization	O
of	O
our	O
results	O
to	O
other	O
similar	O
situations	O
that	O
we	O
did	O
not	O
specifically	O
simulate	O
,	O
we	O
constructed	O
linear	O
regression	O
models	O
of	O
the	O
square	O
root	O
of	O
the	O
per	O
-	O
family	O
contribution	O
to	O
the	O
noncentrality	O
parameter	O
(	O
Zsim	O
/	O
Fsim	O
)	O
and	O
ARE	O
estimates	O
resulting	O
from	O
each	O
simulation	O
as	O
a	O
function	O
of	O
the	O
simulation	O
parameters	O
.	O

Residuals	O
from	O
the	O
models	O
were	O
approximately	O
normally	O
distributed	O
,	O
and	O
scale	O
-	O
location	O
plots	O
did	O
not	O
suggest	O
the	O
data	O
were	O
heteroscedastic	O
.	O

We	O
evaluated	O
the	O
fit	O
of	O
alternative	O
regression	O
models	O
with	O
quadratic	O
,	O
inverse	O
,	O
or	O
logarithmic	O
transformations	O
of	O
both	O
the	O
predictor	O
and	O
outcome	O
variables	O
;	O
none	O
fit	O
the	O
observed	O
data	O
better	O
than	O
a	O
simple	O
linear	O
multiple	O
regression	O
model	O
.	O

The	O
proportion	O
of	O
variance	O
in	O
ZsimFsim	O
explained	O
by	O
the	O
linear	O
regression	O
(	O
R2	O
)	O
ranged	O
from	O
70–75	O
%	O
.	O

The	O
open	O
source	O
statistical	O
package	O
R	O
[	O
60	O
]	O
was	O
used	O
to	O
perform	O
all	O
regression	O
analyses	O
.	O

In	O
order	O
to	O
facilitate	O
interpretation	O
,	O
the	O
genetic	O
effects	O
(	O
baseline	O
disease	B
prevalence	O
,	O
allele	O
frequencies	O
,	O
and	O
relative	O
risks	O
of	O
the	O
linked	O
and	O
unlinked	O
loci	O
)	O
were	O
collapsed	O
into	O
""""	O
attributable	O
risks	O
""""	O
(	O
AR	O
)	O
for	O
the	O
linked	O
and	O
unlinked	O
loci	O
respectively	O
.	O

The	O
attributable	O
risk	O
is	O
the	O
proportion	O
of	O
the	O
total	O
disease	B
risk	O
attributable	O
to	O
variation	O
at	O
each	O
genetic	O
locus	O
.	O

The	O
fit	O
of	O
linear	O
regression	O
models	O
employing	O
the	O
two	O
AR	O
values	O
is	O
as	O
good	O
as	O
those	O
employing	O
the	O
five	O
original	O
terms	O
to	O
fit	O
the	O
data	O
,	O
using	O
the	O
Akaike	O
Information	O
Criterion	O
(	O
not	O
shown	O
;	O
[	O
61	O
]	O
)	O
.	O

Effect	O
of	O
design	O
and	O
population	O
parameters	O
or	O
non	O
-	O
centrality	O
parameters	O
Multiple	O
linear	O
regression	O
of	O
Z	O
/	O
F	O
on	O
simulation	O
parameters	O
.	O

aStandard	O
error	O
of	O
Estimate	O
;	O
bNumber	O
available	O
for	O
Zc	O
,	O
number	O
genotyped	O
for	O
Zp	O
;	O
cIndicator	O
variable	O
.	O

In	O
general	O
,	O
the	O
effects	O
on	O
power	O
of	O
changes	O
to	O
the	O
genetic	O
and	O
design	O
parameters	O
were	O
very	O
similar	O
for	O
the	O
discordant	O
test	O
.	O

Increasing	O
the	O
number	O
of	O
unaffected	B
sibs	O
typed	O
did	O
yield	O
a	O
small	O
increase	O
in	O
power	O
,	O
but	O
increasing	O
the	O
number	O
of	O
affected	B
sibs	O
,	O
parents	O
or	O
offspring	O
proxies	O
increased	O
power	O
by	O
a	O
larger	O
amount	O
,	O
even	O
with	O
the	O
discordant	O
pair	O
test	O
.	O

The	O
effect	O
of	O
experimental	O
screening	O
for	O
the	O
unlinked	O
syndrome	B
varied	O
substantially	O
depending	O
on	O
the	O
relative	O
magnitude	O
of	O
the	O
effects	O
of	O
the	O
unlinked	O
syndrome	B
:	O
if	O
the	O
unlinked	O
syndrome	B
had	O
an	O
attributable	O
risk	O
greater	O
than	O
or	O
equal	O
to	O
that	O
of	O
the	O
linked	O
syndrome	O
,	O
experimental	O
screening	O
resulted	O
in	O
a	O
large	O
increase	O
in	O
power	O
.	O

Otherwise	O
,	O
the	O
effect	O
of	O
experimental	O
screening	O
was	O
negligible	O
.	O

Power	O
for	O
a	O
given	O
sample	O
size	O
F	O
and	O
test	O
size	O
α	O
with	O
a	O
specified	O
combination	O
of	O
design	O
and	O
genetic	O
parameters	O
can	O
be	O
derived	O
from	O
the	O
regression	O
models	O
in	O
Table	O
5	O
by	O
first	O
obtaining	O
an	O
estimate	O
of	O
the	O
noncentrality	O
parameter	O
Z	O
/	O
F	O
from	O
the	O
appropriate	O
column	O
of	O
Table	O
4	O
,	O
multiplying	O
by	O
F	O
to	O
obtain	O
z^	O
,	O
and	O
then	O
solving	O
for	O
β	O
in	O
the	O
equation	O
below	O
:	O
β	O
=	O
Φ	O
(	O
Zα−z^	O
)	O
,	O
where	O
β	O
is	O
the	O
probability	O
of	O
Type	O
II	O
error	O
(	O
hence	O
power	O
is	O
1-β	O
)	O
and	O
Φ	O
(	O
z	O
)	O
is	O
the	O
cumulative	O
standard	O
normal	O
distribution	O
.	O

A	O
script	O
for	O
computing	O
the	O
predicted	O
power	O
for	O
any	O
particular	O
combination	O
of	O
these	O
parameters	O
,	O
using	O
the	O
statistical	O
languages	O
S	O
-	O
plus	O
or	O
R	O
is	O
also	O
available	O
from	O
the	O
website	O
[	O
65	O
]	O
.	O

Figures	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
show	O
estimated	O
power	O
of	O
the	O
Zc	O
test	O
for	O
varying	O
sample	O
sizes	O
given	O
several	O
values	O
of	O
AR	O
for	O
the	O
linked	O
and	O
unlinked	O
loci	O
,	O
recombination	O
fraction	O
(	O
θ	O
)	O
,	O
number	O
of	O
parents	O
genotyped	O
,	O
and	O
number	O
of	O
offspring	O
proxies	O
.	O

Except	O
as	O
noted	O
,	O
the	O
power	O
estimates	O
are	O
based	O
on	O
the	O
following	O
settings	O
of	O
the	O
genetic	O
and	O
design	O
parameters	O
:	O
two	O
total	O
affected	B
sibs	O
,	O
both	O
sampled	O
,	O
two	O
unaffected	B
sibs	O
(	O
not	O
sampled	O
)	O
,	O
no	O
parents	O
or	O
offspring	O
proxies	O
,	O
AR1	O
(	O
linked	O
locus	O
)	O
=	O
0.1	O
,	O
AR2	O
(	O
unlinked	O
locus	O
)	O
=	O
0.05	O
,	O
θ	O
=	O
0.05	O
,	O
and	O
no	O
screening	O
to	O
exclude	O
unlinked	O
families	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
attributable	O
risk	O
at	O
the	O
linked	O
locus	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
attributable	O
risk	O
at	O
the	O
unlinked	O
locus	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
recombination	O
fraction	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
number	O
of	O
typed	O
parents	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
varying	O
number	O
of	O
offspring	O
proxies	O
on	O
power	O
for	O
families	O
of	O
two	O
affected	B
siblings	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
numbers	O
of	O
offspring	O
proxies	O
(	O
1	O
or	O
2	O
)	O
on	O
estimated	O
power	O
,	O
families	O
with	O
two	O
affected	B
sibs	O
,	O
with	O
only	O
one	O
available	O
for	O
genotyping	O
(	O
1	O
or	O
2	O
)	O
,	O
compared	O
with	O
families	O
with	O
both	O
affected	B
sibs	O
available	O
for	O
genotyping	O
(	O
S	O
=	O
2	O
)	O
.	O

Effect	O
of	O
varying	O
number	O
of	O
offspring	O
proxies	O
on	O
power	O
for	O
families	O
of	O
three	O
affected	B
siblings	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
numbers	O
of	O
offspring	O
proxies	O
(	O
O	O
)	O
on	O
estimated	O
power	O
,	O
families	O
with	O
three	O
affected	B
sibs	O
,	O
with	O
only	O
two	O
available	O
for	O
genotyping	O
(	O
O	O
=	O
0	O
,	O
1	O
,	O
or	O
2	O
)	O
,	O
compared	O
with	O
families	O
with	O
all	O
three	O
affected	B
sibs	O
available	O
for	O
genotyping	O
(	O
S	O
=	O
3	O
)	O
.	O

Relative	O
Efficiency	O
of	O
Alternative	O
Designs	O
Because	O
the	O
power	O
of	O
the	O
discordant	O
test	O
was	O
rarely	O
much	O
greater	O
than	O
that	O
of	O
the	O
concordant	O
test	O
,	O
and	O
the	O
concordant	O
test	O
requires	O
genotyping	O
of	O
only	O
the	O
affected	B
sibs	O
,	O
the	O
ARE	O
of	O
the	O
concordant	O
test	O
was	O
always	O
greater	O
on	O
average	O
than	O
that	O
of	O
the	O
discordant	O
test	O
.	O

Nevertheless	O
,	O
we	O
were	O
interested	O
in	O
specific	O
combinations	O
of	O
design	O
and	O
genetic	O
parameters	O
that	O
might	O
have	O
resulted	O
in	O
better	O
relative	O
efficiency	O
for	O
the	O
discordant	O
test	O
.	O

Overall	O
,	O
the	O
ARE	O
for	O
the	O
discordant	O
test	O
was	O
larger	O
than	O
that	O
for	O
the	O
concordant	O
test	O
in	O
13	O
%	O
of	O
the	O
replications	O
.	O

We	O
used	O
a	O
logistic	O
regression	O
model	O
with	O
the	O
same	O
parameters	O
as	O
those	O
in	O
Tables	O
2	O
,	O
3	O
and	O
4	O
to	O
predict	O
the	O
probability	O
that	O
Zp	O
would	O
outperform	O
Zc	O
in	O
terms	O
of	O
relative	O
efficiency	O
(	O
not	O
shown	O
)	O
.	O

Only	O
under	O
circumstances	O
that	O
would	O
result	O
in	O
very	O
low	O
power	O
,	O
such	O
as	O
attributable	O
risks	O
for	O
the	O
unlinked	O
locus	O
more	O
than	O
twice	O
as	O
large	O
as	O
attributable	O
risks	O
for	O
the	O
linked	O
locus	O
,	O
or	O
recombination	O
fractions	O
>	O
0.1	O
,	O
was	O
Zp	O
predicted	O
to	O
outperform	O
Zc	O
in	O
our	O
simulated	O
sample	O
of	O
500	O
families	O
.	O

In	O
principle	O
,	O
including	O
genotype	O
data	O
from	O
unaffected	B
siblings	O
can	O
improve	O
the	O
ability	O
to	O
estimate	O
haplotypes	O
and	O
thereby	O
improve	O
power	O
when	O
multipoint	O
data	O
are	O
studied	O
.	O

Table	O
6	O
compares	O
estimates	O
of	O
Zc	O
and	O
Zp	O
for	O
a	O
selected	O
set	O
of	O
simulations	O
with	O
multipoint	O
Zm	O
scores	O
for	O
the	O
same	O
families	O
as	O
calculated	O
by	O
the	O
computer	O
program	O
Merlin	O
[	O
58	O
]	O
.	O

In	O
these	O
simulations	O
,	O
when	O
markers	O
were	O
spaced	O
no	O
closer	O
than	O
10	O
cM	O
from	O
one	O
another	O
,	O
as	O
is	O
usually	O
the	O
case	O
in	O
an	O
initial	O
genome	O
scan	O
,	O
we	O
observed	O
no	O
improvement	O
in	O
power	O
with	O
the	O
concordant	O
multipoint	O
statistic	O
,	O
but	O
an	O
improvement	O
in	O
power	O
with	O
the	O
discordant	O
test	O
.	O

When	O
markers	O
were	O
spaced	O
at	O
5	O
cM	O
intervals	O
,	O
however	O
,	O
the	O
power	O
of	O
both	O
multipoint	O
statistics	O
to	O
detect	O
linkage	O
exceeded	O
that	O
of	O
both	O
Zc	O
and	O
Zp	O
.	O

The	O
conservative	O
bias	O
of	O
Zmc	O
noted	O
in	O
Tables	O
2	O
and	O
3	O
appears	O
to	O
decrease	O
as	O
marker	O
intervals	O
become	O
smaller	O
.	O

To	O
test	O
this	O
,	O
we	O
conducted	O
additional	O
simulations	O
under	O
the	O
null	O
hypothesis	O
as	O
described	O
above	O
for	O
Tables	O
2	O
and	O
3	O
,	O
with	O
1000	O
repetitions	O
and	O
markers	O
spaced	O
at	O
5	O
,	O
10	O
,	O
and	O
20	O
cM.	O
The	O
magnitude	O
of	O
the	O
conservative	O
bias	O
in	O
Zmc	O
decreases	O
consistently	O
(	O
mean	O
Zmc	O
=	O
-0.58	O
at	O
20	O
cM	O
,	O
-0.23	O
at	O
10	O
cM	O
,	O
and	O
0.06	O
at	O
5	O
cM	O
)	O
as	O
marker	O
intervals	O
contract	O
,	O
becoming	O
significantly	O
anti	O
-	O
conservative	O
at	O
5	O
cM.	O

Discussion	O
In	O
studying	O
a	O
disease	B
like	O
colon	B
cancer	I
with	O
both	O
incomplete	O
penetrance	O
and	O
a	O
high	O
incidence	O
of	O
sporadics	O
,	O
prior	O
studies	O
have	O
shown	O
that	O
to	O
be	O
efficient	O
,	O
families	O
must	O
include	O
two	O
or	O
more	O
individuals	O
with	O
the	O
same	O
disease	B
from	O
whom	O
samples	O
can	O
be	O
obtained	O
.	O

The	O
practical	O
experience	O
of	O
many	O
investigators	O
suggests	O
that	O
once	O
an	O
initial	O
entree	O
is	O
gained	O
into	O
a	O
family	O
,	O
the	O
chances	O
of	O
enrolling	O
other	O
members	O
are	O
quite	O
high	O
.	O

Close	O
relatives	O
are	O
often	O
very	O
motivated	O
to	O
participate	O
in	O
research	O
into	O
a	O
disease	B
that	O
has	O
afflicted	O
their	O
family	O
,	O
especially	O
when	O
the	O
commitment	O
is	O
minimal	O
,	O
involving	O
only	O
a	O
blood	O
specimen	O
and	O
a	O
signed	O
consent	O
,	O
which	O
are	O
all	O
that	O
are	O
required	O
for	O
a	O
linkage	O
study	O
of	O
diseases	B
that	O
have	O
an	O
easily	O
established	O
phenotype	O
,	O
like	O
cancer	B
.	O

In	O
our	O
simulations	O
,	O
we	O
considered	O
inclusion	O
of	O
unaffected	B
sibs	O
and	O
the	O
use	O
of	O
spouse	O
and	O
offspring	O
to	O
replace	O
missing	O
affected	B
sibs	O
.	O

Including	O
unaffected	B
siblings	O
in	O
the	O
design	O
of	O
a	O
study	O
can	O
improve	O
the	O
power	O
to	O
detect	O
linkage	O
for	O
highly	O
-	O
penetrant	O
diseases	B
[	O
53,66	O
]	O
.	O

However	O
,	O
our	O
simulation	O
studies	O
demonstrate	O
that	O
for	O
the	O
model	O
-	O
free	O
linkage	O
tests	O
we	O
studied	O
,	O
for	O
low	O
penetrance	O
loci	O
,	O
and	O
with	O
no	O
genotyping	O
error	O
,	O
little	O
increase	O
in	O
power	O
can	O
be	O
gained	O
by	O
including	O
unaffected	B
siblings	O
in	O
the	O
design	O
of	O
a	O
sib	O
-	O
pair	O
study	O
of	O
a	O
late	O
onset	O
,	O
complex	O
disease	B
such	O
as	O
colorectal	B
cancer	I
.	O

The	O
inclusion	O
of	O
unaffected	B
siblings	O
can	O
be	O
useful	O
,	O
however	O
,	O
in	O
reducing	O
anti	O
-	O
conservative	O
biases	O
arising	O
from	O
heterogeneity	O
or	O
misspecification	O
of	O
marker	O
allele	O
frequencies	O
or	O
genotyping	O
errors	O
,	O
and	O
conservative	O
biases	O
arising	O
if	O
multipoint	O
statistics	O
are	O
used	O
with	O
an	O
insufficiently	O
dense	O
marker	O
set	O
.	O

Table	O
2	O
shows	O
that	O
,	O
with	O
markers	O
spaced	O
at	O
10	O
cM	O
intervals	O
,	O
Zmc	O
is	O
conservatively	O
biased	O
,	O
while	O
exhibiting	O
an	O
anticonservative	O
bias	O
in	O
Table	O
3	O
under	O
conditions	O
of	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
.	O

In	O
Table	O
6	O
,	O
Zmp	O
outperforms	O
with	O
markers	O
spaced	O
at	O
10	O
and	O
20	O
cM.	O
At	O
5	O
cM	O
,	O
Zmc	O
becomes	O
anticonservatively	O
biased	O
,	O
as	O
noted	O
above	O
.	O

It	O
may	O
be	O
useful	O
to	O
perform	O
simulations	O
to	O
assess	O
the	O
characteristics	O
of	O
the	O
tests	O
when	O
the	O
marker	O
spacing	O
decreases	O
,	O
as	O
would	O
be	O
possible	O
with	O
the	O
newer	O
SNP	O
array	O
-	O
based	O
platforms	O
.	O

Further	O
,	O
since	O
genome	O
-	O
wide	O
-	O
association	O
studies	O
do	O
not	O
utilize	O
the	O
full	O
power	O
of	O
the	O
sibpair	O
design	O
,	O
future	O
research	O
should	O
be	O
aimed	O
at	O
assessing	O
the	O
optimal	O
setting	O
for	O
relying	O
on	O
the	O
sibpair	O
design	O
,	O
as	O
it	O
is	O
premature	O
to	O
move	O
completely	O
away	O
from	O
this	O
study	O
design	O
[	O
15	O
]	O
.	O

If	O
a	O
secondary	O
goal	O
of	O
a	O
study	O
is	O
to	O
estimate	O
the	O
penetrance	O
,	O
then	O
unaffected	B
relatives	O
should	O
be	O
included	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
also	O
unaffected	B
siblings	O
could	O
help	O
in	O
evaluating	O
the	O
impact	O
of	O
environmental	O
factors	O
upon	O
disease	B
risk	O
.	O

Genotyping	O
errors	O
for	O
microsatellites	O
scans	O
are	O
currently	O
very	O
low	O
but	O
are	O
hard	O
to	O
assess	O
without	O
the	O
availability	O
of	O
parents	O
or	O
siblings	O
.	O

Our	O
findings	O
parallel	O
those	O
of	O
Holmans	O
et	O
al.	O
[	O
67	O
]	O
,	O
who	O
suggested	O
that	O
genotyping	O
affected	B
individuals	O
only	O
is	O
efficient	O
.	O

Crude	O
stratification	O
by	O
recruitment	O
center	O
is	O
unlikely	O
to	O
be	O
reliable	O
enough	O
for	O
controlling	O
population	O
heterogeneity	O
without	O
additional	O
adjustment	O
.	O

Stratification	O
by	O
ethnicity	O
is	O
generally	O
more	O
crucial	O
than	O
by	O
geography	O
,	O
although	O
both	O
factors	O
should	O
ideally	O
be	O
incorporated	O
.	O

However	O
,	O
collection	O
of	O
ethnicity	O
is	O
not	O
entirely	O
trivial	O
if	O
it	O
is	O
to	O
be	O
worthwhile	O
.	O

Although	O
various	O
coding	O
systems	O
have	O
been	O
established	O
by	O
different	O
agencies	O
,	O
no	O
consensus	O
has	O
been	O
established	O
regarding	O
the	O
level	O
of	O
detail	O
required	O
on	O
ethnicity	O
data	O
in	O
genetic	O
research	O
,	O
e.g.	O
category	O
distinctions	O
,	O
mixed	O
-	O
race	O
marriages	O
.	O

Mandal	O
et	O
al.	O
[	O
81	O
]	O
have	O
shown	O
that	O
marker	O
allele	O
frequencies	O
are	O
less	O
important	O
if	O
there	O
are	O
four	O
or	O
more	O
persons	O
per	O
family	O
,	O
especially	O
when	O
very	O
polymorphic	O
markers	O
are	O
used	O
.	O

When	O
the	O
parents	O
of	O
the	O
sibpair	O
have	O
been	O
genotyped	O
,	O
then	O
there	O
is	O
no	O
dependence	O
on	O
population	O
marker	O
allele	O
frequencies	O
and	O
no	O
source	O
of	O
bias	O
in	O
linkage	O
analysis	O
.	O

CpG	O
Island	O
Methylation	O
in	O
Familial	O
Colorectal	B
Cancer	I
Patients	O
Not	O
Fulfilling	O
the	O
Amsterdam	O
Criteria	O
Abstract	O
To	O
determine	O
the	O
role	O
of	O
methylation	O
in	O
colorectal	B
cancer	I
patients	O
with	O
a	O
family	B
history	I
,	O
we	O
enrolled	O
25	O
colorectal	B
cancer	I
patients	O
with	O
a	O
family	B
history	I
of	I
colorectal	I
cancer	I
but	O
without	O
a	O
mutation	O
in	O
the	O
hMLH1	O
and	O
hMSH2	O
genes	O
.	O

Thirty	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
were	O
included	O
as	O
control	O
.	O

The	O
methylation	O
status	O
of	O
COX2	O
,	O
MGMT	O
,	O
hMLH1	O
,	O
TIMP3	O
,	O
p16	O
,	O
and	O
MINT2	O
in	O
normal	B
mucosa	O
and	O
tumor	B
were	O
assessed	O
using	O
methylation	O
-	O
specific	O
PCR	O
.	O

In	O
patients	O
with	O
a	O
family	B
history	I
,	O
the	O
methylation	O
frequency	O
ranged	O
from	O
4.0	O
%	O
for	O
TIMP3	O
to	O
44.4	O
%	O
for	O
MGMT	O
,	O
whereas	O
,	O
in	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
,	O
it	O
ranged	O
from	O
6.7	O
%	O
for	O
TIMP3	O
to	O
50.0	O
%	O
for	O
p16	O
.	O

Nine	O
of	O
the	O
25	O
patients	O
with	O
family	B
history	I
(	O
36.0	O
%	O
)	O
were	O
classified	O
as	O
methylation	O
-	O
prone	O
,	O
and	O
nine	O
of	O
the	O
30	O
patients	O
with	O
sporadic	O
cancers	B
(	O
30.0	O
%	O
)	O
were	O
as	O
methylation	O
-	O
prone	O
,	O
making	O
their	O
methylation	O
indices	O
0.19	O
and	O
0.16	O
,	O
respectively	O
(	O
p=0.522	O
)	O
.	O

As	O
for	O
the	O
individual	O
genes	O
,	O
the	O
methylation	O
rate	O
of	O
MGMT	O
was	O
higher	O
in	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
(	O
44.0	O
%	O
vs.	O
13.0	O
%	O
,	O
p=0.016	O
)	O
,	O
whereas	O
the	O
methylation	O
rate	O
of	O
p16	O
was	O
higher	O
in	O
sporadic	O
colorectal	B
cancers	I
(	O
50.0	O
%	O
vs.	O
8.7	O
%	O
,	O
p=0.046	O
)	O
.	O

While	O
CpG	O
island	O
methylation	O
of	O
tumor	B
suppressor	O
genes	O
may	O
play	O
a	O
role	O
in	O
colorectal	O
carcinogenesis	O
,	O
the	O
genes	O
involved	O
may	O
be	O
different	O
between	O
tumors	B
of	O
patients	O
with	O
and	O
without	O
a	O
family	O
history	O
of	O
colorectal	B
cancer	I
.	O

RESULTS	O
Methylation	O
in	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
We	O
determined	O
CpG	O
island	O
methylation	O
at	O
six	O
loci	O
and	O
MSI	O
in	O
paired	O
normal	B
mucosa	O
and	O
tumor	B
tissue	O
from	O
25	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
.	O

Of	O
the	O
25	O
tumors	B
,	O
16	O
(	O
64.0	O
%	O
)	O
showed	O
promoter	O
methylation	O
of	O
at	O
least	O
one	O
gene	O
,	O
ranging	O
to	O
four	O
genes	O
.	O

Seven	O
tumors	B
showed	O
methylation	O
at	O
one	O
gene	O
,	O
seven	O
at	O
two	O
genes	O
,	O
one	O
at	O
three	O
genes	O
,	O
and	O
one	O
at	O
four	O
genes	O
.	O

In	O
contrast	O
,	O
of	O
the	O
25	O
samples	O
of	O
normal	B
colonic	O
mucosa	O
,	O
12	O
(	O
48.0	O
%	O
)	O
showed	O
promoter	O
methylation	O
:	O
eight	O
samples	O
at	O
one	O
gene	O
,	O
and	O
four	O
samples	O
at	O
two	O
genes	O
.	O

When	O
patients	O
with	O
a	O
family	B
history	I
were	O
categorized	O
as	O
having	O
0	O
-	O
1	O
(	O
MR	O
group	O
)	O
or	O
≥2	O
(	O
MP	O
group	O
)	O
methylated	O
loci	O
,	O
we	O
found	O
that	O
36.0	O
%	O
of	O
the	O
tumors	B
and	O
16.0	O
%	O
of	O
the	O
normal	B
mucosa	O
samples	O
could	O
be	O
categorized	O
as	O
MP	O
.	O

The	O
mean	O
methylation	O
index	O
(	O
the	O
number	O
of	O
methylated	O
loci	O
divided	O
by	O
the	O
total	O
number	O
of	O
tested	O
loci	O
)	O
was	O
0.11	O
(	O
0	O
-	O
0.33	O
)	O
in	O
normal	B
mucosa	O
and	O
0.19	O
(	O
0	O
-	O
0.66	O
)	O
in	O
tumors	B
(	O
p=0.078	O
)	O
.	O

A	O
high	O
proportion	O
of	O
tumors	B
(	O
44.0	O
%	O
)	O
were	O
methylated	O
at	O
the	O
MGMT	O
locus	O
,	O
whereas	O
20.0	O
%	O
,	O
20.0	O
%	O
,	O
and	O
16.0	O
%	O
were	O
methylated	O
at	O
the	O
COX2	O
,	O
hMLH1	O
,	O
and	O
MINT2	O
loci	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
only	O
8.0	O
%	O
of	O
p16	O
loci	O
and	O
4.0	O
%	O
of	O
TIMP3	O
loci	O
were	O
methylated	O
(	O
Fig.	O
2	O
)	O
.	O

We	O
found	O
that	O
the	O
COX2	O
,	O
MGMT	O
,	O
and	O
p16	O
loci	O
were	O
methylated	O
at	O
28.0	O
%	O
,	O
20.0	O
%	O
,	O
and	O
16.0	O
%	O
,	O
respectively	O
,	O
of	O
normal	B
mucosa	O
samples	O
of	O
patients	O
with	O
a	O
family	B
history	I
,	O
whereas	O
the	O
hMLH1	O
,	O
TIMP3	O
,	O
and	O
MINT2	O
loci	O
were	O
not	O
methylated	O
in	O
any	O
of	O
the	O
normal	B
mucosa	O
samples	O
.	O

The	O
frequency	O
of	O
methylation	O
of	O
the	O
COX2	O
and	O
p16	O
loci	O
was	O
higher	O
in	O
normal	B
mucosa	O
than	O
in	O
tumor	B
,	O
but	O
the	O
difference	O
did	O
not	O
reach	O
a	O
statistical	O
significance	O
.	O

Methylation	O
in	O
sporadic	O
colorectal	B
cancer	I
patients	O
We	O
also	O
assayed	O
CpG	O
island	O
methylation	O
at	O
these	O
six	O
loci	O
and	O
MSI	O
in	O
paired	O
tumors	B
and	O
normal	B
mucosa	O
from	O
30	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
.	O

We	O
found	O
that	O
16	O
(	O
53.0	O
%	O
)	O
of	O
the	O
tumors	B
showed	O
promoter	O
methylation	O
of	O
at	O
least	O
one	O
gene	O
,	O
ranging	O
to	O
three	O
genes	O
.	O

Seven	O
tumors	B
showed	O
methylation	O
at	O
one	O
locus	O
,	O
six	O
at	O
two	O
loci	O
,	O
and	O
one	O
at	O
three	O
loci	O
.	O

In	O
contrast	O
,	O
only	O
7	O
(	O
23.0	O
%	O
)	O
of	O
the	O
normal	B
colonic	O
mucosa	O
samples	O
showed	O
promoter	O
methylation	O
,	O
each	O
at	O
one	O
gene	O
.	O

We	O
found	O
that	O
30.0	O
%	O
of	O
the	O
tumors	B
,	O
and	O
none	O
of	O
the	O
normal	B
mucosa	O
,	O
could	O
be	O
classified	O
as	O
MP	O
.	O

The	O
mean	O
methylation	O
index	O
was	O
0.04	O
(	O
0	O
-	O
0.17	O
)	O
in	O
normal	B
mucosa	O
and	O
0.16	O
(	O
0	O
-	O
0.5	O
)	O
in	O
tumors	B
(	O
p<0.001	O
)	O
.	O

Methylation	O
of	O
the	O
p16	O
locus	O
was	O
observed	O
in	O
a	O
high	O
proportion	O
(	O
33.3	O
%	O
)	O
of	O
sporadic	O
tumors	B
cases	O
,	O
whereas	O
methylation	O
of	O
the	O
COX2	O
,	O
MGMT	O
,	O
and	O
MINT2	O
loci	O
were	O
observed	O
in	O
20.0	O
%	O
,	O
13.3	O
%	O
,	O
and	O
13.3	O
%	O
,	O
respectively	O
,	O
of	O
these	O
tumors	B
.	O

In	O
contrast	O
,	O
only	O
6.7	O
%	O
of	O
tumors	B
were	O
methylated	O
at	O
the	O
TIMP3	O
promoter	O
(	O
Fig.	O
3	O
)	O
.	O

Methylation	O
of	O
the	O
p16	O
,	O
COX2	O
,	O
and	O
MGMT	O
loci	O
were	O
observed	O
in	O
13.3	O
%	O
,	O
6.7	O
%	O
,	O
and	O
3.4	O
%	O
,	O
respectively	O
,	O
of	O
the	O
normal	B
mucosa	O
samples	O
,	O
whereas	O
we	O
did	O
not	O
observe	O
methylation	O
of	O
the	O
hMLH1	O
,	O
TIMP3	O
,	O
and	O
MINT2	O
loci	O
in	O
any	O
of	O
these	O
tissues	O
.	O

Several	O
reports	O
have	O
described	O
an	O
association	O
between	O
the	O
methylation	O
status	O
of	O
multiple	O
genes	O
and	O
a	O
familial	O
tendency	O
to	O
colorectal	B
cancer	I
(	O
15	O
,	O
28	O
)	O
.	O

A	O
recent	O
large	O
study	O
,	O
however	O
,	O
found	O
no	O
evidence	O
that	O
patients	O
with	O
heavily	O
methylated	O
colorectal	B
cancers	I
were	O
more	O
likely	O
to	O
develop	O
a	O
second	O
malignancy	O
or	O
have	O
a	O
positive	O
family	B
history	I
of	I
cancer	I
(	O
29	O
)	O
.	O

Aberrant	O
methylation	O
may	O
result	O
from	O
an	O
inherited	O
defect	O
in	O
the	O
methylation	O
apparatus	O
.	O

In	O
this	O
study	O
,	O
considerable	O
proportions	O
of	O
cancer	B
in	O
both	O
groups	O
with	O
or	O
without	O
familial	O
history	O
of	O
colorectal	B
cancer	I
presented	O
the	O
methylated	O
genes	O
that	O
may	O
involved	O
in	O
carcinogenetic	O
pathways	O
.	O

It	O
still	O
remains	O
to	O
be	O
elucidated	O
whether	O
promoter	O
methylation	O
in	O
multiple	O
genes	O
is	O
one	O
of	O
main	O
mechanism	O
to	O
evoke	O
cancer	B
or	O
simple	O
bystander	O
.	O

However	O
,	O
our	O
results	O
confirm	O
that	O
CpG	O
island	O
promoter	O
methylation	O
may	O
be	O
a	O
universal	O
event	O
in	O
sporadic	O
or	O
familial	O
colorectal	B
cancer	I
,	O
and	O
is	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
for	O
'	O
second	O
hits	O
'	O
by	O
which	O
tumor	B
suppressor	O
genes	O
are	O
inactivated	O
.	O

Evidence	O
for	O
this	O
mechanism	O
in	O
familial	O
colorectal	B
cancers	I
was	O
previously	O
reported	O
in	O
studies	O
showing	O
aberrant	O
methylation	O
of	O
individual	O
genes	O
,	O
including	O
CDH1	O
,	O
VHL	O
,	O
and	O
hMLH1	O
,	O
in	O
hereditary	O
cancer	B
syndromes	I
(	O
30	O
-	O
32	O
)	O
.	O

Cancer	B
is	O
a	O
genetic	O
disease	B
.	O

Most	O
cancer	B
-	O
causing	O
mutations	O
are	O
somatic	O
,	O
occurring	O
in	O
the	O
affected	B
tissue	O
during	O
the	O
course	O
of	O
carcinogenesis	O
.	O

However	O
,	O
most	O
cancers	B
also	O
have	O
a	O
hereditary	O
component	O
,	O
caused	O
by	O
predisposing	O
mutations	O
that	O
affect	O
the	O
germline	O
,	O
are	O
heritable	O
,	O
contribute	O
to	O
the	O
initiation	O
of	O
carcinogenesis	O
,	O
and	O
influence	O
the	O
carcinogenesis	O
pathway	O
.	O

Although	O
hypermethylation	O
is	O
not	O
a	O
rare	O
event	O
,	O
either	O
in	O
sporadic	O
colorectal	B
cancers	I
or	O
in	O
colorectal	B
cancers	I
with	O
family	B
history	I
,	O
predisposing	O
germline	O
alterations	O
can	O
affect	O
detailed	O
aspects	O
of	O
methylation	O
.	O

Our	O
data	O
showed	O
two	O
of	O
the	O
genes	O
methylated	O
at	O
their	O
promoters	O
,	O
p16	O
and	O
MGMT	O
,	O
differ	O
according	O
to	O
the	O
tumor	B
type	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
methylation	O
of	O
p16	O
,	O
leading	O
to	O
its	O
loss	O
of	O
function	O
,	O
may	O
be	O
a	O
dominant	O
and	O
necessary	O
event	O
for	O
sporadic	O
colorectal	O
carcinogenesis	B
,	O
whereas	O
methylation	O
of	O
MGMT	O
may	O
be	O
dominant	O
and	O
necessary	O
in	O
colorectal	O
carcinogenesis	B
in	O
individuals	O
with	O
a	O
family	B
history	I
.	O

It	O
was	O
reported	O
that	O
the	O
frequency	O
and	O
pattern	O
of	O
gene	O
methylation	O
varied	O
between	O
HNPCC	B
syndrome	B
and	O
sporadic	O
adenomas	B
,	O
implying	O
differences	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
tumors	B
(	O
33	O
)	O
.	O

MGMT	O
has	O
been	O
considered	O
as	O
a	O
critical	O
step	O
of	O
genetic	O
instability	O
and	O
methylation	O
of	O
MGMT	O
are	O
proposed	O
to	O
show	O
a	O
distinctive	O
phenotype	O
of	O
MSI	B
-	I
L	I
or	O
mild	B
family	I
history	I
of	O
colorectal	B
cancer	I
(	O
34	O
,	O
35	O
)	O
.	O

The	O
present	O
study	O
also	O
showed	O
a	O
possibility	O
that	O
different	O
pathways	O
to	O
cancer	B
may	O
exit	O
according	O
to	O
the	O
molecular	O
background	O
and	O
some	O
subgroup	O
of	O
familial	O
colorectal	B
cancer	I
are	O
related	O
to	O
the	O
loss	O
of	O
function	O
of	O
MGMT	O
.	O

Thus	O
,	O
genes	O
selected	O
for	O
methylation	O
-	O
induced	O
functional	O
loss	O
may	O
differ	O
according	O
to	O
the	O
genetic	O
background	O
.	O

While	O
methylation	O
seems	O
to	O
be	O
a	O
universal	O
mechanism	O
by	O
which	O
gene	O
function	O
is	O
inactivated	O
,	O
the	O
germline	O
mutations	O
in	O
familial	O
tumors	B
confer	O
a	O
selective	O
advantage	O
for	O
their	O
tumorigenic	O
growth	O
,	O
but	O
other	O
genetic	O
and	O
epigenetic	O
lesions	O
are	O
also	O
necessary	O
.	O

Genetic	O
predisposition	O
to	O
CpG	O
island	O
methylation	O
may	O
be	O
a	O
modifying	O
factor	O
that	O
contributes	O
to	O
the	O
penetrance	O
of	O
HNPCC	B
.	O

Our	O
findings	O
thus	O
expand	O
these	O
early	O
observations	O
on	O
methylation	O
in	O
familial	O
colorectal	B
cancer	I
and	O
highlight	O
the	O
selective	O
advantage	O
of	O
epigenetic	O
gene	O
silencing	O
.	O

Impact	O
of	O
BRAF	O
,	O
MLH1	O
on	O
the	O
incidence	O
of	O
microsatellite	B
instability	I
high	I
colorectal	B
cancer	I
in	O
populations	O
based	O
study	O
Abstract	O
We	O
have	O
identified	O
an	O
alternative	O
pathway	O
of	O
tumorigenesis	B
in	O
sporadic	O
colon	B
cancer	I
,	O
involving	O
microsatellite	O
instability	O
due	O
to	O
mismatched	O
repair	O
methylation	O
,	O
which	O
may	O
be	O
driven	O
by	O
mutations	O
in	O
the	O
BRAF	O
gene	O
(	O
V600E	O
)	O
.	O

Colorectal	B
cancer	I
(	O
CRC	B
)	O
is	O
the	O
most	O
common	O
cancer	B
in	O
the	O
world	O
,	O
and	O
African	O
Americans	O
show	O
a	O
higher	O
incidence	O
than	O
other	O
populations	O
in	O
the	O
United	O
States	O
.	O

We	O
analyzed	O
sporadic	O
CRCs	B
in	O
Omani	O
(	O
of	O
African	O
origin	O
,	O
N	O
=	O
61	O
)	O
,	O
Iranian	O
(	O
of	O
Caucasian	O
origin	O
,	O
N	O
=	O
53	O
)	O
and	O
African	O
American	O
(	O
N	O
=	O
95	O
)	O
patients	O
for	O
microsatellite	O
instability	O
,	O
expression	O
status	O
of	O
mismatched	O
repair	O
genes	O
(	O
hMLH1	O
,	O
hMSH2	O
)	O
and	O
presence	O
of	O
the	O
BRAF	O
(	O
V600E	O
)	O
mutation	O
.	O

In	O
the	O
Omani	O
group	O
,	O
all	O
tumors	B
with	O
BRAF	O
mutations	O
were	O
located	O
in	O
the	O
left	O
side	O
of	O
the	O
colon	O
,	O
and	O
for	O
African	O
Americans	O
,	O
88	O
%	O
[	O
7	O
]	O
of	O
tumors	B
with	O
BRAF	O
mutations	O
were	O
found	O
in	O
the	O
right	O
side	O
of	O
the	O
colon	O
.	O

In	O
African	O
Americans	O
,	O
31	O
%	O
of	O
tumors	B
displayed	O
microsatellite	O
instability	O
at	O
two	O
or	O
more	O
markers	O
(	O
MSI	B
-	I
H	I
)	O
,	O
while	O
this	O
rate	O
was	O
26	O
%	O
and	O
13	O
%	O
for	O
tumors	B
in	O
the	O
Iranian	O
and	O
Omani	O
groups	O
,	O
respectively	O
.	O

A	O
majority	O
of	O
these	O
MSI	B
-	I
H	I
tumors	B
were	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
right	O
side	O
)	O
in	O
African	O
American	O
and	O
Iranian	O
subjects	O
,	O
whereas	O
most	O
were	O
located	O
in	O
the	O
distal	O
colon	O
(	O
left	O
side	O
)	O
in	O
Omani	O
subjects	O
.	O

Defects	O
in	O
hMLH1	O
gene	O
expression	O
were	O
found	O
in	O
77	O
%	O
of	O
MSI	B
-	I
H	I
tumors	B
in	O
both	O
African	O
Americans	O
and	O
Iranians	O
and	O
in	O
38	O
%	O
of	O
tumors	B
in	O
Omanis	O
.	O

BRAF	O
mutations	O
were	O
observed	O
in	O
all	O
subjects	O
:	O
10	O
%	O
of	O
tumors	B
in	O
African	O
Americans	O
(	O
8	O
/	O
82	O
)	O
,	O
2	O
%	O
of	O
tumors	B
in	O
Iranians	O
(	O
1	O
/	O
53	O
)	O
,	O
and	O
19	O
%	O
of	O
tumors	B
in	O
Omanis	O
(	O
11	O
/	O
59	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
CRC	B
occurs	O
at	O
a	O
younger	O
age	O
in	O
Omani	O
and	O
Iranian	O
patients	O
,	O
and	O
these	O
groups	O
showed	O
a	O
lower	O
occurrence	O
of	O
MSI	O
-	O
H	O
than	O
did	O
African	O
American	O
patients	O
.	O

Our	O
multivariate	O
model	O
suggests	O
an	O
important	O
and	O
significant	O
role	O
of	O
hMLH1	O
expression	O
and	O
BRAF	O
mutation	O
in	O
MSI	B
-	I
H	I
CRC	B
in	O
these	O
populations	O
.	O

The	O
high	O
occurrence	O
of	O
MSI	B
-	I
H	I
tumors	B
in	O
African	O
Americans	O
may	O
have	O
significant	O
implications	O
for	O
treatment	O
,	O
since	O
patients	O
with	O
MSI	B
-	I
H	I
lesions	B
display	O
a	O
different	O
response	O
to	O
chemotherapeutic	O
agents	O
such	O
as	O
5-fluorouracil	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
samples	O
from	O
two	O
different	O
populations	O
of	O
African	O
descent	O
(	O
African	O
American	O
and	O
Omani	O
)	O
and	O
a	O
Caucasian	O
population	O
(	O
Iranian	O
)	O
for	O
microsatellite	O
instability	O
and	O
BRAF	O
mutations	O
.	O

We	O
correlated	O
our	O
findings	O
with	O
the	O
silencing	O
of	O
genes	O
involved	O
in	O
DNA	O
MMR	O
.	O

We	O
evaluated	O
and	O
compared	O
the	O
demographic	O
and	O
clinicopathological	O
data	O
in	O
relation	O
to	O
molecular	O
alterations	O
in	O
specific	O
genes	O
(	O
BRAF	O
,	O
DNA	O
MMR	O
)	O
to	O
improve	O
our	O
understanding	O
of	O
colon	O
tumorgenesis	O
in	O
people	O
living	O
in	O
different	O
environments	O
.	O

Methods	O
Patients	O
A	O
total	O
of	O
95	O
African	O
American	O
CRC	B
patients	O
(	O
from	O
Howard	O
University	O
and	O
Johns	O
Hopkins	O
Hospital	O
between	O
1997	O
and	O
2004	O
;	O
self	O
-	O
identified	O
as	O
African	O
American	O
)	O
,	O
61	O
Omani	O
CRC	B
patients	O
(	O
from	O
the	O
two	O
tertiary	O
referral	O
hospitals	O
in	O
Oman	O
Sultan	O
Qaboos	O
University	O
Hospital	O
and	O
the	O
Royal	O
Hospital	O
between	O
2000	O
and	O
2004	O
who	O
underwent	O
surgical	O
resection	O
)	O
and	O
53	O
Iranian	O
CRC	B
patients	O
(	O
from	O
the	O
two	O
referral	O
hospitals	O
in	O
Shiraz	O
,	O
Iran	O
Namazi	O
Hospital	O
and	O
Saadi	O
Hospital	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
archival	O
tissue	O
was	O
collected	O
(	O
with	O
approval	O
from	O
all	O
above	O
sites	O
'	O
Institutional	O
Review	O
Boards	O
)	O
and	O
clinical	O
data	O
was	O
obtained	O
(	O
including	O
race	O
,	O
age	O
,	O
site	O
of	O
primary	O
tumor	B
,	O
mucin	O
production	O
and	O
tumor	B
differentiation	O
)	O
.	O

In	O
addition	O
,	O
the	O
family	O
history	O
of	O
cancer	B
was	O
analyzed	O
to	O
identify	O
those	O
pedigrees	O
that	O
met	O
either	O
the	O
Amsterdam	O
I	O
or	O
Amsterdam	O
II	O
criteria	O
for	O
HNPCC	B
.	O

The	O
study	O
was	O
performed	O
on	O
unselected	O
and	O
serially	O
collected	O
specimens	O
.	O

All	O
cases	O
underwent	O
surgery	O
within	O
the	O
given	O
collection	O
.	O

DNA	O
isolation	O
and	O
MSI	O
analysis	O
Archived	O
and	O
fresh	O
tumor	B
blocks	O
were	O
cut	O
into	O
5-μm	O
sections	O
on	O
Superfrost	O
slides	O
(	O
Fisher	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

The	O
tumor	B
and	O
normal	B
area	O
were	O
diagnosed	O
by	O
a	O
pathologist	O
using	O
the	O
H&E	O
matched	O
slide	O
and	O
microdissected	O
to	O
pinpoint	O
the	O
tumor	B
areas	O
as	O
well	O
as	O
normal	O
areas	O
from	O
at	O
least	O
two	O
slides	O
.	O

A	O
pinpoint	O
DNA	O
extraction	O
kit	O
was	O
used	O
as	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Zymo	O
Research	O
)	O
.	O

The	O
extracted	O
tumor	B
and	O
normal	B
matched	O
DNA	O
were	O
used	O
as	O
template	O
in	O
PCR	O
reactions	O
where	O
five	O
microsatellite	O
markers	O
(	O
Cancer	B
Research	O
58:5248–5257	O
,	O
1998;	O
[	O
21	O
]	O
;	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
and	O
D2S123	O
)	O
were	O
used	O
to	O
evaluate	O
MSI	O
status	O
.	O

PCR	O
products	O
were	O
analyzed	O
in	O
a	O
3130	O
ABI	O
GeneScan	O
.	O

Those	O
displaying	O
DNA	O
instability	O
at	O
only	O
one	O
of	O
the	O
markers	O
(	O
including	O
the	O
dinucleotides	O
)	O
were	O
labeled	O
MSI	O
-	O
L	O
,	O
those	O
displaying	O
instability	O
with	O
two	O
or	O
more	O
markers	O
were	O
labeled	O
MSI	O
-	O
H	O
,	O
and	O
those	O
displaying	O
no	O
instability	O
with	O
any	O
of	O
the	O
five	O
markers	O
tested	O
were	O
labeled	O
MSS	O
.	O

Due	O
to	O
unclear	O
characteristics	O
of	O
MSI	O
-	O
L	O
,	O
we	O
combined	O
MSS	O
and	O
MSI	O
-	O
L	O
as	O
one	O
group	O
(	O
non	O
-	O
MSI	O
-	O
H	O
)	O
.	O

Methylation	O
-	O
specific	O
PCR	O
The	O
presence	O
or	O
absence	O
of	O
hMLH1	O
and	O
p16	O
methylation	O
in	O
cancers	B
was	O
determined	O
by	O
comparing	O
the	O
signals	O
from	O
tumor	B
-	O
derived	O
tissues	O
with	O
those	O
from	O
normal	B
,	O
non	B
-	I
cancerous	I
tissues	O
,	O
as	O
previously	O
described	O
[	O
3,4	O
]	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
samples	O
using	O
a	O
Gentra	O
DNA	O
extraction	O
kit	O
(	O
Gentra	O
)	O
and	O
was	O
modified	O
using	O
DNA	O
modification	O
kits	O
as	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Zymo	O
Research	O
)	O
.	O

MSP	O
was	O
used	O
to	O
distinguish	O
unmethylated	O
from	O
methylated	O
alleles	O
,	O
based	O
on	O
sequence	O
alterations	O
produced	O
by	O
bisulfite	O
treatment	O
of	O
DNA	O
,	O
to	O
convert	O
unmethylated	O
cytosines	O
to	O
uracil	O
.	O

These	O
changes	O
are	O
identified	O
by	O
subsequent	O
PCR	O
using	O
primers	O
specific	O
to	O
the	O
methylated	O
(	O
unchanged	O
)	O
or	O
unmethylated	O
(	O
changed	O
)	O
DNA	O
.	O

Briefly	O
,	O
1	O
μg	O
of	O
genomic	O
DNA	O
was	O
denatured	O
by	O
treatment	O
with	O
NaOH	O
and	O
was	O
modified	O
by	O
the	O
addition	O
of	O
sodium	O
bisulfite	O
.	O

DNA	O
samples	O
were	O
purified	O
using	O
Wizard	O
DNA	O
purification	O
resin	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Promega	O
)	O
.	O

These	O
DNA	O
samples	O
were	O
again	O
treated	O
with	O
NaOH	O
,	O
then	O
precipitated	O
with	O
ethanol	O
and	O
resuspended	O
in	O
water	O
.	O

PCR	O
reactions	O
were	O
performed	O
using	O
the	O
primer	O
pairs	O
described	O
below	O
in	O
the	O
following	O
reaction	O
mix	O
:	O
10	O
×	O
PCR	O
buffer	O
[	O
16.6	O
mM	O
ammonium	O
sulfate	O
,	O
67	O
mM	O
Tris	O
(	O
pH	O
8.8	O
)	O
,	O
6.7	O
mM	O
MgCl2	O
,	O
and	O
10	O
mM	O
2-mercaptoethanol	O
]	O
,	O
dNTPs	O
(	O
each	O
at	O
1.25	O
mM	O
)	O
,	O
primers	O
(	O
50	O
pmol	O
each	O
per	O
reaction	O
)	O
,	O
and	O
bisulfite	O
-	O
modified	O
DNA	O
(	O
50	O
ng	O
)	O
in	O
a	O
final	O
volume	O
of	O
50	O
μl	O
.	O

Reactions	O
were	O
hot	O
-	O
started	O
at	O
95	O
°	O
C	O
for	O
5	O
min	O
,	O
after	O
which	O
1.25	O
units	O
of	O
Taq	O
polymerase	O
(	O
Life	O
Technologies	O
,	O
Inc.	O
)	O
were	O
added	O
.	O

Amplification	O
was	O
carried	O
out	O
in	O
an	O
Applied	O
Biosystem	O
temperature	O
cycler	O
for	O
40	O
cycles	O
(	O
30	O
sec	O
at	O
95	O
°	O
C	O
,	O
30	O
sec	O
at	O
59	O
°	O
C	O
then	O
30	O
sec	O
at	O
72	O
°	O
C	O
)	O
,	O
followed	O
by	O
a	O
final	O
4-min	O
extension	O
at	O
72	O
°	O
C	O
.	O

Two	O
sets	O
of	O
primers	O
were	O
used	O
simultaneously	O
to	O
check	O
for	O
methylated	O
or	O
unmethylated	O
CpG	O
islands	O
at	O
the	O
level	O
of	O
hMLH1	O
and	O
p16	O
promoters	O
.	O

The	O
primer	O
sequences	O
were	O
as	O
in	O
our	O
previous	O
study	O
[	O
4	O
]	O
.	O

Controls	O
for	O
methylated	O
and	O
unmethylated	O
DNA	O
were	O
DNA	O
from	O
the	O
SW48	O
colon	B
cancer	I
cell	O
line	O
and	O
normal	B
lymphocytes	O
,	O
respectively	O
.	O

Each	O
PCR	O
reaction	O
product	O
(	O
10	O
μl	O
)	O
was	O
directly	O
loaded	O
into	O
a	O
2	O
%	O
agarose	O
gel	O
,	O
which	O
was	O
later	O
stained	O
with	O
ethidium	O
bromide	O
to	O
allow	O
DNA	O
visualization	O
under	O
UV	O
illumination	O
.	O

The	O
presence	O
of	O
a	O
band	O
in	O
unmethylated	O
tumor	B
and	O
matched	O
normal	B
with	O
the	O
absence	O
of	O
a	O
methylation	O
band	O
in	O
the	O
tumor	B
was	O
defined	O
as	O
unmethylated	O
.	O

However	O
,	O
when	O
a	O
methylated	O
band	O
was	O
present	O
for	O
tumor	B
and	O
absent	O
for	O
the	O
normal	B
,	O
we	O
defined	O
the	O
sample	O
as	O
methylated	O
(	O
or	O
semi	O
-	O
methylated	O
if	O
both	O
unmethylated	O
or	O
methylated	O
bands	O
were	O
present	O
in	O
the	O
tumor	B
)	O
.	O

Multivariate	O
analysis	O
for	O
the	O
risk	O
factors	O
associated	O
with	O
MSI	O
-	O
H	O
occurrence	O
(	O
Model	O
including	O
single	O
term	O
and	O
interactions	O
effect	O
)	O
*	O
indicates	O
the	O
interaction	O
term	O
between	O
two	O
variables	O
.	O

Correlation	O
between	O
hMLH1	O
protein	O
expression	O
and	O
MSI	O
status	O
Expression	O
of	O
the	O
hMLH1	O
and	O
hMSH2	O
nuclear	O
proteins	O
was	O
examined	O
immunohistochemically	O
in	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
[	O
4	O
]	O
.	O

In	O
all	O
cases	O
,	O
non	O
-	O
neoplastic	O
cells	O
displayed	O
positive	O
nuclear	O
staining	O
for	O
both	O
hMLH1	O
and	O
hMSH2	O
.	O

The	O
nuclear	O
stained	O
slides	O
were	O
read	O
by	O
two	O
different	O
pathologists	O
,	O
and	O
normal	B
tissue	O
on	O
slides	O
where	O
no	O
primary	O
antibody	O
stained	O
was	O
used	O
as	O
negative	O
control	O
.	O

In	O
total	O
,	O
76	O
African	O
American	O
,	O
61	O
Omani	O
,	O
and	O
25	O
Iranian	O
cases	O
were	O
analyzed	O
.	O

Thirty	O
-	O
five	O
and	O
11	O
%	O
of	O
African	O
American	O
tumors	B
assayed	O
showed	O
loss	O
of	O
staining	O
for	O
hMLH1	O
and	O
hMSH2	O
,	O
respectively	O
.	O

Moreover	O
,	O
loss	O
of	O
hMLH1	O
and	O
hMSH2	O
staining	O
was	O
observed	O
in	O
77	O
%	O
and	O
5	O
%	O
of	O
MSI	B
-	I
H	I
African	O
American	O
tumors	B
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

The	O
loss	O
of	O
hMLH1	O
and	O
hMSH2	O
staining	O
was	O
observed	O
in	O
17	O
%	O
and	O
13	O
%	O
of	O
non	B
-	I
MSI	I
-	I
H	I
African	O
American	O
tumors	B
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

In	O
Omani	O
tumors	B
:	O
38	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
the	O
MSI	B
-	I
H	I
tumors	B
showed	O
absences	O
of	O
hMLH1	O
expression	O
(	O
Table	O
2	O
)	O
;	O
30	O
%	O
(	O
n	O
=	O
16	O
)	O
of	O
the	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
had	O
negative	O
hMLH1	O
.	O

Fifty	O
-	O
six	O
cases	O
of	O
Omani	O
patient	O
tested	O
for	O
the	O
presence	O
of	O
hMSH2	O
protein	O
by	O
immunohistochemical	O
staining	O
,	O
seven	O
Omani	O
cases	O
were	O
MSI	B
-	I
H.	I
In	O
Iranian	O
patients	O
,	O
77	O
%	O
[	O
10	O
]	O
of	O
the	O
MSI	B
-	I
H	I
tumors	B
were	O
negative	O
for	O
hMLH1	O
expression	O
(	O
Table	O
3	O
)	O
;	O
all	O
of	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
were	O
positive	B
for	I
hMLH1	I
expression	I
,	O
while	O
for	O
hMSH2	O
these	O
figures	O
were	O
8	O
%	O
[	O
1	O
]	O
and	O
0	O
,	O
respectively	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	O
expression	O
has	O
a	O
significant	O
preventive	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
0.13	O
(	O
0.04–0.41	O
)	O
;	O
p	O
<	O
0.0001	O
;	O
(	O
Table	O
4	O
)	O
)	O
.	O

Correlation	O
between	O
BRAF	O
mutation	O
and	O
MSI	O
status	O
Samples	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
a	O
point	O
mutation	O
that	O
frequently	O
occurs	O
in	O
the	O
oncogene	O
BRAF	O
leading	O
to	O
the	O
change	O
of	O
valine	O
to	O
glutamic	O
acid	O
at	O
position	O
600	O
of	O
the	O
BRAF	O
protein	O
.	O

In	O
all	O
samples	O
only	O
10	O
%	O
[	O
8	O
]	O
African	O
American	O
,	O
19	O
%	O
[	O
11	O
]	O
Omani	O
and	O
2	O
%	O
[	O
1	O
]	O
Iranian	O
samples	O
displayed	O
the	O
mutation	O
by	O
sequencing	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

In	O
the	O
MSI	B
-	I
H	I
group	O
,	O
the	O
BRAF	O
mutation	O
was	O
32	O
%	O
[	O
7	O
]	O
in	O
African	O
Americans	O
,	O
25	O
%	O
[	O
2	O
]	O
in	O
Omani	O
,	O
and	O
7	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
,	O
respectively	O
.	O

Eighteen	O
percent	O
and	O
2	O
%	O
of	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
carry	O
the	O
BRAF	O
mutation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
,	O
while	O
none	O
of	O
the	O
Iranians	O
carried	O
a	O
BRAF	O
mutation	O
in	O
this	O
group	O
.	O

A	O
BRAF	O
mutation	O
is	O
a	O
significant	O
risk	O
factor	O
for	O
MSI	O
-	O
H	O
occurrence	O
even	O
after	O
controlling	O
for	O
other	O
factors	O
in	O
the	O
multivariate	O
model	O
(	O
OR	O
=	O
12.11	O
(	O
2.82–52.03	O
)	O
;	O
p	O
=	O
0.001	O
;	O
(	O
Table	O
4	O
)	O
)	O
.	O

Discussion	O
DNA	O
MMR	O
gene	O
silencing	O
and/or	O
mutation	O
are	O
the	O
main	O
factors	O
leading	O
to	O
accumulation	O
of	O
mutations	O
within	O
genes	O
and	O
general	O
genome	O
instability	O
[	O
19	O
]	O
.	O

The	O
MSI	O
phenotype	O
resulting	O
from	O
such	O
alterations	O
is	O
one	O
of	O
the	O
early	O
events	O
leading	O
to	O
the	O
development	O
of	O
certain	O
cancers	B
.	O

It	O
occurs	O
in	O
patients	O
with	O
Lynch	B
syndrome	I
and	O
in	O
those	O
that	O
acquire	O
such	O
alterations	O
somatically	O
[	O
24	O
]	O
.	O

Another	O
event	O
occurring	O
in	O
adenoma	B
polyp	B
is	O
mutation	O
in	O
oncogenes	O
,	O
specifically	O
in	O
K	O
-	O
ras	O
and	O
BRAF	O
genes	O
in	O
the	O
case	O
of	O
colon	B
cancer	I
[	O
24	O
-	O
26	O
]	O
.	O

The	O
linkage	O
between	O
BRAF	O
mutations	O
and	O
MSI	O
was	O
previously	O
reported	O
[	O
27	O
-	O
30	O
]	O
.	O

In	O
general	O
,	O
Omani	O
people	O
have	O
a	O
mixed	O
Asian	O
and	O
African	O
ethnic	O
background	O
[	O
10	O
]	O
and	O
Iranians	O
are	O
of	O
Caucasian	O
ethnicity	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
African	O
Americans	O
,	O
Omanis	O
and	O
Iranians	O
,	O
the	O
MSI	B
phenotype	O
occurs	O
in	O
31	O
%	O
,	O
26	O
%	O
and	O
13	O
%	O
of	O
CRC	B
tumors	B
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
locations	O
of	O
the	O
tumors	B
in	O
African	O
Americans	O
and	O
Iranians	O
were	O
primarily	O
proximal	O
compared	O
to	O
distal	O
for	O
Omanis	O
;	O
and	O
BRAF	O
mutations	O
were	O
more	O
prevalent	O
in	O
Omanis	O
than	O
African	O
Americans	O
or	O
Iranians	O
(	O
19	O
%	O
,	O
10	O
%	O
and	O
2	O
%	O
,	O
respectively	O
)	O
.	O

While	O
the	O
MSI	B
phenotype	O
in	O
this	O
sample	O
of	O
African	O
Americans	O
is	O
less	O
than	O
we	O
previously	O
reported	O
(	O
43–45	O
%	O
)	O
,	O
[	O
3,4	O
]	O
it	O
appears	O
to	O
be	O
more	O
prevalent	O
in	O
African	O
Americans	O
than	O
in	O
others	O
and	O
still	O
high	O
in	O
the	O
general	O
US	O
population	O
[	O
31	O
-	O
33	O
]	O
.	O

The	O
current	O
sample	O
contained	O
more	O
African	O
Americans	O
and	O
more	O
right	O
-	O
sided	O
than	O
left	O
-	O
sided	O
tumors	B
.	O

The	O
MSI	B
phenotype	O
was	O
more	O
common	O
in	O
proximal	O
tumors	B
than	O
in	O
distal	O
ones	O
(	O
p	O
=	O
0.47	O
)	O
,	O
strengthening	O
earlier	O
findings	O
of	O
such	O
an	O
association	O
[	O
31	O
-	O
33	O
]	O
.	O

The	O
prevalence	O
of	O
MSI	B
-	I
H	I
tumors	B
indicates	O
the	O
importance	O
of	O
BRAF	O
mutations	O
,	O
particularly	O
in	O
the	O
African	O
Americans	O
,	O
since	O
they	O
represent	O
a	O
higher	O
mutation	O
profile	O
than	O
Iranians	O
and	O
Omanis	O
.	O

This	O
finding	O
suggests	O
that	O
,	O
at	O
least	O
within	O
the	O
MSI	B
-	I
H	I
group	O
of	O
patients	O
,	O
the	O
BRAF	O
V600E	O
mutation	O
in	O
exon	O
15	O
is	O
the	O
major	O
event	O
leading	O
to	O
tumor	B
development	O
.	O

In	O
addition	O
,	O
the	O
distal	O
location	O
of	O
Omani	O
MSI	B
-	I
H	I
tumors	B
may	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
presentation	O
of	O
the	O
disease	B
compared	O
to	O
proximal	O
ones	O
in	O
the	O
African	O
American	O
and	O
Iranian	O
populations	O
.	O

The	O
lower	O
frequency	O
of	O
MSI	B
-	I
H	I
tumors	B
observed	O
in	O
Omani	O
patients	O
could	O
be	O
related	O
to	O
the	O
higher	O
frequency	O
of	O
the	O
distal	O
location	O
.	O

This	O
needs	O
to	O
be	O
verified	O
in	O
a	O
larger	O
sample	O
size	O
.	O

The	O
absence	O
of	O
hMLH1	O
expression	O
was	O
more	O
pronounced	O
in	O
MSI	B
-	I
H	I
tumors	B
from	O
African	O
American	O
and	O
Iranian	O
patients	O
(	O
77	O
%	O
of	O
tumors	B
in	O
these	O
groups	O
showed	O
no	O
hMLH1	O
expression	O
)	O
.	O

However	O
,	O
for	O
Omanis	O
,	O
the	O
moderate	O
hMLH1expression	O
(	O
62	O
%	O
)	O
in	O
MSI	B
-	I
H	I
may	O
indicate	O
some	O
other	O
defects	O
in	O
the	O
component	O
of	O
base	O
excision	O
repair	O
(	O
Oxidative	O
DNA	O
damaged	O
markers	O
such	O
as	O
8-hydroxyguanosine	O
)	O
,	O
or	O
distinct	O
lymphangiogenic	O
phenotype	O
associated	O
with	O
MSI	O
other	O
than	O
in	O
mismatch	O
repair	O
genes	O
.	O

The	O
tumors	B
that	O
we	O
have	O
studied	O
included	O
MSI	B
-	I
H	I
tumors	B
that	O
were	O
negative	O
using	O
immunohistochemistry	O
for	O
hMLH1	O
.	O

This	O
incidence	O
is	O
less	O
than	O
compared	O
to	O
that	O
described	O
in	O
the	O
literature	O
(	O
77	O
%	O
[	O
34	O
]	O
)	O
,	O
although	O
the	O
numbers	O
described	O
are	O
small	O
.	O

Survival	O
of	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
patients	O
compared	O
with	O
sporadic	O
colorectal	B
cancer	I
patients	O
Abstract	O
Background	O
Patients	O
with	O
hereditary	B
non	I
-	I
poliposys	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
have	O
better	O
prognosis	O
than	O
sporadic	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

Aim	O
of	O
our	O
retrospective	O
study	O
was	O
to	O
compare	O
the	O
overall	O
survival	O
between	O
sporadic	O
CRC	B
and	O
HNPCC	B
patients	O
.	O

Methods	O
We	O
analyzed	O
a	O
cohort	O
of	O
40	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
HNPCC	B
cases	O
with	O
a	O
hospital	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	B
observed	O
during	O
the	O
period	O
1970–1993	O
.	O

In	O
15	O
HNPCC	B
patients	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	B
instability	I
.	O

Survival	O
rates	O
were	O
calculated	O
by	O
Kaplan	O
-	O
Meier	O
method	O
and	O
compared	O
with	O
log	O
rank	O
test	O
.	O

Results	O
The	O
median	O
age	O
at	O
diagnosis	O
of	O
the	O
primary	O
CRC	B
was	O
46.8	O
years	O
in	O
the	O
HNPCC	B
series	O
versus	O
61	O
years	O
in	O
sporadic	O
CRC	B
group	O
.	O

In	O
HNPCC	B
group	O
85	O
%	O
had	O
a	O
right	O
cancer	B
location	O
,	O
vs.	O
57	O
%	O
in	O
the	O
sporadic	O
cancer	B
group	O
.	O

In	O
the	O
sporadic	O
cancer	B
group	O
61.6	O
%	O
were	O
early	O
-	O
stages	O
cancer	B
(	O
Dukes	O
'	O
A	O
and	O
B	O
)	O
vs.	O
70	O
%	O
in	O
the	O
HNPCC	B
group	O
(	O
p	O
=	O
ns	O
)	O
.	O

The	O
crude	O
5-years	O
cumulative	O
survival	O
after	O
the	O
primary	O
CRC	B
was	O
94.2	O
%	O
in	O
HNPCC	B
patients	O
vs.	O
75.3	O
%	O
in	O
sporadic	O
cancer	B
patients	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
Our	O
results	O
show	O
that	O
overall	O
survival	O
of	O
colorectal	B
cancer	I
in	O
patients	O
with	O
HNPCC	B
is	O
better	O
than	O
sporadic	O
CRC	B
patients	O
.	O

The	O
different	O
outcome	O
probably	O
relates	O
to	O
the	O
specific	O
tumorigenesis	O
involving	O
DNA	O
mismatch	O
repair	O
dysfunction	O
.	O

Background	O
Colorectal	B
cancer	I
is	O
one	O
of	O
the	O
most	O
common	O
neoplasm	B
in	O
humans	O
[	O
1,2	O
]	O
.	O

It	O
's	O
known	O
that	O
a	O
definite	O
fraction	O
,	O
ranging	O
between	O
1	O
and	O
5	O
%	O
of	O
all	O
cases	O
of	O
colorectal	O
tumors	B
,	O
is	O
transmitted	O
from	O
one	O
generation	O
to	O
another	O
in	O
accordance	O
with	O
an	O
autosomal	O
dominant	O
model	O
;	O
this	O
is	O
the	O
case	O
of	O
Hereditary	B
Non	I
-	I
Polyposis	I
Colorectal	I
Cancer	I
(	O
HNPCC	B
)	O
and	O
of	O
Familial	B
Adenomatous	I
Polyposis	I
(	O
FAP	B
)	O
[	O
2	O
]	O
.	O

HNPCC	B
is	O
an	O
autosomal	O
dominant	O
disease	B
characterized	O
by	O
early	O
appearance	O
of	O
cancer	B
usually	O
of	O
the	O
right	O
colon	O
,	O
frequent	O
occurrence	O
of	O
multiple	O
lesions	B
(	O
both	O
synchronous	O
and	O
metachronous	O
)	O
and	O
a	O
striking	O
association	O
with	O
tumours	B
of	O
other	O
organs	O
,	O
in	O
particular	O
endometrium	O
,	O
urinary	O
tract	O
,	O
ovary	O
,	O
stomach	O
and	O
small	O
bowel	O
.	O

The	O
Amsterdam	O
criteria	O
,	O
currently	O
used	O
for	O
the	O
diagnosis	O
of	O
HNPCC	B
,	O
were	O
introduced	O
in	O
1989	O
to	O
provide	O
a	O
uniform	O
evaluation	O
of	O
familial	O
and	O
personal	O
history	O
.	O

They	O
were	O
revised	O
in	O
1999	O
and	O
included	O
various	O
extra	O
-	O
colonic	O
tumours	B
:	O
1	O
)	O
at	O
least	O
three	O
or	O
more	O
relatives	O
with	O
histological	O
verified	O
tumour	B
in	O
the	O
spectrum	O
of	O
HNPCC	B
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
)	O
at	O
least	O
two	O
generations	O
should	O
be	O
affected	O
;	O
3	O
)	O
one	O
or	O
more	O
tumours	B
diagnosed	O
when	O
under	O
the	O
age	O
of	O
50	O
years	O
;	O
4	O
)	O
FAP	B
should	O
be	O
excluded	O
[	O
3,4	O
]	O
.	O

Colorectal	O
tumours	B
with	O
microsatellite	B
instability	I
(	O
MSI	O
phenotype	O
)	O
have	O
mutations	O
in	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
and	O
in	O
particular	O
in	O
the	O
MSH2	O
and	O
MLH1	O
genes	O
,	O
respectively	O
found	O
on	O
chromosome	O
arms	O
2p	O
and	O
3p	O
[	O
5	O
-	O
9	O
]	O
.	O

These	O
mutations	O
lead	O
to	O
inactivation	O
of	O
the	O
genes	O
and	O
thus	O
to	O
a	O
defect	O
in	O
replication	O
/	O
repair	O
of	O
DNA	O
and	O
an	O
accumulation	O
in	O
the	O
cancer	B
cell	O
genome	O
of	O
ubiquitous	O
somatic	O
clonal	O
mutations	O
[	O
10	O
]	O
.	O

Constitutional	O
mutations	O
of	O
MMR	O
genes	O
are	O
found	O
in	O
50–70	O
%	O
of	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
and	O
in	O
the	O
Muir	B
-	I
Torre	I
syndrome	I
;	O
90	O
%	O
of	O
them	O
MLH1	B
and	I
MSH2	I
positive	I
[	O
11,12	O
]	O
.	O

A	O
certain	O
proportion	O
(	O
around	O
12–15	O
%	O
)	O
of	O
sporadic	O
colon	B
cancers	I
also	O
display	O
MSI	B
phenotype	O
[	O
13	O
-	O
17	O
]	O
.	O

Otherwise	O
,	O
MSI	O
seems	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
various	O
human	O
cancer	B
such	O
as	O
sporadic	O
endometrial	O
cancer	B
[	O
18	O
]	O
and	O
oral	O
squamous	O
cell	O
carcinoma	B
[	O
19	O
]	O
.	O

Colorectal	B
cancer	I
(	O
CRC	B
)	O
in	O
HNPCC	B
more	O
often	O
have	O
a	O
better	O
prognosis	O
than	O
in	O
sporadic	O
colorectal	O
carcinoma	B
[	O
3,4,20	O
-	O
22	O
]	O
,	O
but	O
it	O
has	O
been	O
unclear	O
whether	O
this	O
could	O
be	O
due	O
to	O
difference	O
in	O
stage	O
at	O
diagnosis	O
or	O
to	O
a	O
more	O
favourable	O
prognosis	O
of	O
cancer	B
in	O
HNPCC	B
and	O
FAP	B
.	O

The	O
aim	O
of	O
our	O
retrospective	O
study	O
was	O
to	O
compare	O
stage	O
and	O
overall	O
survival	O
between	O
patients	O
with	O
hereditary	O
and	O
sporadic	O
colorectal	B
cancer	I
patients	O
.	O

Conclusion	O
In	O
conclusion	O
,	O
our	O
findings	O
appear	O
to	O
confirm	O
previous	O
studies	O
[	O
30,31	O
]	O
which	O
detected	O
that	O
an	O
improved	O
survival	O
for	O
colon	B
cancer	I
in	O
HNPCC	B
,	O
compared	O
to	O
sporadic	O
CRC	B
,	O
usually	O
occur	O
.	O

In	O
fact	O
,	O
our	O
series	O
of	O
HNPCC	B
patients	O
reveals	O
a	O
marked	O
overall	O
survival	O
advantage	O
,	O
which	O
persisted	O
also	O
after	O
stratification	O
by	O
Dukes	O
'	O
stage	O
.	O

Therefore	O
,	O
survival	O
of	O
HNPCC	B
patients	O
not	O
always	O
depends	O
on	O
an	O
early	O
diagnosis	O
,	O
but	O
probably	O
also	O
on	O
distinct	O
biologic	O
features	O
.	O

In	O
this	O
context	O
,	O
MSI	O
mutation	O
pattern	O
plays	O
an	O
important	O
prognostic	O
role	O
since	O
colon	B
cancer	I
with	O
MSI	B
has	O
a	O
better	O
prognosis	O
than	O
tumours	B
without	O
MSI	O
.	O

A	O
large	O
series	O
of	O
HNPCC	B
should	O
be	O
examined	O
to	O
confirm	O
this	O
data	O
.	O

Furthermore	O
,	O
we	O
need	O
more	O
information	O
about	O
MSI	O
in	O
all	O
kind	O
of	O
colorectal	O
carcinomas	B
,	O
in	O
order	O
to	O
establish	O
postoperative	O
surveillance	O
thus	O
improving	O
patients	O
'	O
prognosis	O
and	O
allowing	O
clinicians	O
to	O
plan	O
more	O
accurate	O
and	O
targeted	O
therapy	O
.	O

Mutation	O
Rates	O
of	O
and	O
Coding	O
Microsatellites	O
in	O
Human	O
Cells	O
with	O
Defective	O
DNA	O
Mismatch	O
Repair	O
Abstract	O
Microsatellite	O
instability	O
promotes	O
colonic	O
tumorigenesis	O
through	O
generating	O
frameshift	O
mutations	O
at	O
coding	O
microsatellites	O
of	O
tumor	B
suppressor	O
genes	O
,	O
such	O
as	O
TGFBR2	O
and	O
ACVR2	O
.	O

As	O
a	O
consequence	O
,	O
signaling	O
through	O
these	O
TGFβ	O
family	O
receptors	O
is	O
abrogated	O
in	O
DNA	O
Mismatch	B
repair	I
(	I
MMR	I
)	I
-deficient	I
tumors	B
.	O

How	O
these	O
mutations	O
occur	O
in	O
real	O
time	O
and	O
mutational	O
rates	O
of	O
these	O
human	O
coding	O
sequences	O
have	O
not	O
previously	O
been	O
studied	O
.	O

We	O
utilized	O
cell	O
lines	O
with	O
different	O
MMR	O
deficiencies	O
(	O
hMLH1−	O
/	O
−	O
,	O
hMSH6−	O
/	O
−	O
,	O
hMSH3−	O
/	O
−	O
,	O
and	O
MMR	O
-	O
proficient	O
)	O
to	O
determine	O
mutation	O
rates	O
.	O

Plasmids	O
were	O
constructed	O
in	O
which	O
exon	O
3	O
of	O
TGFBR2	O
and	O
exon	O
10	O
of	O
ACVR2	O
were	O
cloned	O
+	O
1	O
bp	O
out	O
of	O
frame	O
,	O
immediately	O
after	O
the	O
translation	O
initiation	O
codon	O
of	O
an	O
enhanced	O
GFP	O
(	O
EGFP	O
)	O
gene	O
,	O
allowing	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
to	O
drive	O
EGFP	O
expression	O
.	O

Mutation	O
-	O
resistant	O
plasmids	O
were	O
constructed	O
by	O
interrupting	O
the	O
coding	O
microsatellite	O
sequences	O
,	O
preventing	O
frameshift	O
mutation	O
.	O

Stable	O
cell	O
lines	O
were	O
established	O
containing	O
portions	O
of	O
TGFBR2	O
and	O
ACVR2	O
,	O
and	O
nonfluorescent	O
cells	O
were	O
sorted	O
,	O
cultured	O
for	O
7–35	O
days	O
,	O
and	O
harvested	O
for	O
flow	O
cytometric	O
mutation	O
detection	O
and	O
DNA	O
sequencing	O
at	O
specific	O
time	O
points	O
.	O

DNA	O
sequencing	O
revealed	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
(	O
A9	O
in	O
TGFBR2	O
and	O
A7	O
in	O
ACVR2	O
)	O
in	O
the	O
fluorescent	O
cells	O
.	O

Two	O
distinct	O
fluorescent	O
populations	O
,	O
M1	O
(	O
dim	O
,	O
representing	O
heteroduplexes	O
)	O
and	O
M2	O
(	O
bright	O
,	O
representing	O
full	O
mutants	O
)	O
were	O
identified	O
,	O
with	O
the	O
M2	O
fraction	O
accumulating	O
over	O
time	O
.	O

hMLH1	O
deficiency	O
revealed	O
11	O
(	O
5.91	O
×	O
10−4	O
)	O
and	O
15	O
(	O
2.18	O
×	O
10−4	O
)	O
times	O
higher	O
mutation	O
rates	O
for	O
the	O
TGFBR2	O
and	O
ACVR2	O
microsatellites	O
compared	O
to	O
hMSH6	O
deficiency	O
,	O
respectively	O
.	O

The	O
mutation	O
rate	O
of	O
the	O
TGFBR2	O
microsatellite	O
was	O
∼3	O
times	O
higher	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
than	O
the	O
ACVR2	O
microsatellite	O
.	O

The	O
−1	O
bp	O
frameshift	O
mutation	O
rates	O
of	O
TGFBR2	O
and	O
ACVR2	O
microsatellite	O
sequences	O
are	O
dependent	O
upon	O
the	O
human	O
MMR	O
background	O
.	O

Colon	B
cancer	I
cell	O
models	O
highlight	O
the	O
relationship	O
between	O
defective	O
DNA	O
MMR	O
and	O
TGFBR2	O
and	O
ACVR2	O
frameshift	O
mutations	O
.	O

Both	O
genes	O
commonly	O
have	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
with	O
defective	O
MMR	O
.	O

Restoration	O
of	O
wild	O
type	O
(	O
WT	O
)	O
TGFBR2	O
and	O
ACVR2	O
by	O
chromosome	O
transfer	O
reveals	O
growth	O
suppression	O
in	O
the	O
cells	O
and	O
slower	O
growth	O
in	O
xenografts	O
in	O
nude	O
mice	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

Interestingly	O
,	O
HCT116+chr3	O
cells	O
,	O
which	O
have	O
two	O
mutant	O
hMLH1	O
and	O
two	O
mutant	O
TGFBR2	O
alleles	O
plus	O
one	O
WT	O
hMLH1	O
and	O
one	O
WT	O
TGFBR2	O
allele	O
,	O
express	O
∼33	O
%	O
WT	O
TGFBR2	O
mRNA	O
and	O
∼67	O
%	O
mutant	O
TGFBR2	O
mRNA	O
(	O
unpublished	O
data	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
HCT116+chr2	O
cells	O
,	O
which	O
have	O
two	O
mutant	O
hMLH1	O
and	O
two	O
mutant	O
ACVR2	O
alleles	O
plus	O
one	O
WT	O
ACVR2	O
allele	O
,	O
express	O
∼20	O
%	O
WT	O
ACVR2	O
mRNA	O
[	O
22	O
]	O
,	O
suggesting	O
a	O
slow	O
but	O
steady	O
mutation	O
of	O
the	O
transferred	O
ACVR2	O
allele	O
in	O
hMLH1	O
deficiency	O
.	O

Determining	O
mutation	O
rates	O
of	O
actual	O
human	O
coding	O
genes	O
in	O
human	O
MMR	O
deficiency	O
has	O
not	O
been	O
previously	O
performed	O
,	O
although	O
model	O
systems	O
using	O
noncoding	O
sequences	O
with	O
human	O
cell	O
and	O
yeast	O
MMR	O
systems	O
have	O
been	O
utilized	O
[	O
24	O
]	O
–	O
[	O
27	O
]	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
TGFBR2	O
and	O
ACVR2	O
frameshift	O
mutations	O
are	O
dependent	O
on	O
the	O
human	O
MMR	O
background	O
,	O
we	O
constructed	O
EGFP	O
plasmids	O
in	O
which	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
at	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
was	O
detected	O
by	O
EGFP	O
expression	O
in	O
human	O
colon	B
cancer	I
cells	O
with	O
MMR	O
deficiency	O
.	O

With	O
this	O
new	O
cell	O
model	O
,	O
we	O
were	O
able	O
to	O
calculate	O
a	O
human	O
gene	O
mutation	O
rate	O
in	O
each	O
human	O
MMR	O
-	O
deficient	O
background	O
,	O
and	O
could	O
directly	O
compare	O
the	O
mutation	O
rate	O
between	O
TGFBR2	O
and	O
ACVR2	O
.	O

EGFP	O
expression	O
of	O
stably	O
transfected	O
HCT116	O
cell	O
lines	O
(	O
hMLH1−	O
/	O
−	O
)	O
containing	O
exon	O
3	O
of	O
TGFBR2	O
sequences	O
.	O

(	O
A	O
)	O
MR	O
TGFBR2	O
IF	O
cells	O
,	O
a	O
postive	O
control	O
,	O
showed	O
99	O
%	O
EGFP	O
expression	O
.	O

(	O
B	O
)	O
MR	O
TGFBR2	O
OF	O
cells	O
,	O
a	O
negative	O
control	O
,	O
showed	O
no	O
visible	O
fluorescence	O
.	O

(	O
C	O
)	O
TGFBR2	O
OF	O
cells	O
showed	O
1.22	O
%	O
net	O
fluorescence	O
.	O

Photomicrographs	O
of	O
stable	O
HCT116	O
cell	O
lines	O
are	O
representative	O
of	O
the	O
other	O
stable	O
cell	O
lines	O
containing	O
TGFBR2	O
exon	O
3	O
or	O
ACVR2	O
exon	O
10	O
sequences	O
.	O

Photomicrographs	O
in	O
top	O
panels	O
were	O
taken	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Zeiss	O
,	O
Germany	O
)	O
and	O
photomicrographs	O
in	O
bottom	O
panels	O
were	O
taken	O
with	O
a	O
light	O
microscope	O
of	O
the	O
identical	O
area	O
under	O
40	O
×	O
magnification	O
.	O

TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
coding	O
microsatellite	O
mutations	O
are	O
dependent	O
on	O
the	O
MMR	O
background	O
To	O
determine	O
mutation	O
frequencies	O
of	O
the	O
TGFBR2	O
and	O
ACVR2	O
coding	O
microsatellites	O
in	O
cells	O
with	O
different	O
MMR	O
backgrounds	O
(	O
Table	O
S1	O
)	O
,	O
nonfluorescent	O
cells	O
containing	O
either	O
MR	O
TGFBR2	O
OF	O
,	O
TGFBR2	O
OF	O
,	O
MR	O
ACVR2	O
OF	O
or	O
ACVR2	O
OF	O
were	O
sorted	O
and	O
exponentially	O
grown	O
for	O
7	O
to	O
35	O
days	O
.	O

At	O
specific	O
time	O
points	O
(	O
day	O
7	O
,	O
14	O
,	O
21	O
,	O
28	O
,	O
and/or	O
35	O
)	O
three	O
cultures	O
of	O
each	O
cell	O
line	O
were	O
analyzed	O
in	O
parallel	O
for	O
EGFP	O
expression	O
by	O
using	O
flow	O
cytometry	O
to	O
detect	O
−1	O
bp	O
frameshift	O
mutations	O
.	O

Three	O
different	O
populations	O
were	O
identified	O
according	O
to	O
their	O
EGFP	O
fluorescence	O
intensity	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
population	O
with	O
no	O
fluorescence	O
was	O
named	O
M0	O
,	O
the	O
population	O
with	O
low	O
fluorescence	O
M1	O
,	O
and	O
the	O
population	O
with	O
high	O
fluorescence	O
M2	O
.	O

EGFP	O
histograms	O
of	O
MR	O
TGFBR2	O
OF	O
and	O
TGFBR2	O
OF	O
cells	O
in	O
different	O
MMR	O
backgrounds	O
at	O
day	O
21	O
are	O
shown	O
in	O
Fig.	O
3E	O
,	O
in	O
which	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
showed	O
2	O
distinct	O
EGFP	O
cell	O
populations	O
,	O
M1	O
and	O
M2	O
.	O

M2	O
cells	O
from	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
showed	O
brighter	O
EGFP	O
expression	O
compared	O
to	O
M1	O
cells	O
(	O
Fig.	O
S1	O
)	O
.	O

Mutation	O
analysis	O
by	O
flow	O
cytometry	O
.	O

Nonfluorescent	O
cells	O
were	O
sorted	O
and	O
cells	O
were	O
exponentially	O
grown	O
for	O
7	O
to	O
35	O
days	O
.	O

At	O
specific	O
time	O
points	O
,	O
cells	O
were	O
harvested	O
,	O
and	O
200,000	O
cells	O
were	O
analyzed	O
for	O
EGFP	O
expression	O
(	O
identifying	O
a	O
−1	O
bp	O
mutation	O
)	O
by	O
flow	O
cytometry	O
.	O

For	O
example	O
,	O
with	O
hMLH1−	O
/	O
−	O
ACVR2	O
OF	O
cells	O
,	O
region	O
R1	O
,	O
R3	O
,	O
and	O
R2	O
were	O
set	O
according	O
to	O
(	O
A	O
)	O
cell	O
size	O
,	O
(	O
B	O
)	O
live	O
cells	O
,	O
and	O
(	O
C	O
)	O
fluorescence	O
.	O

Gated	O
R1	O
and	O
R3	O
(	O
live	O
cells	O
)	O
,	O
and	O
R2	O
were	O
analyzed	O
on	O
an	O
EGFP	O
histogram	O
(	O
D	O
)	O
and	O
two	O
distinct	O
EGFP	O
populations	O
were	O
plotted	O
.	O

The	O
population	O
displaying	O
no	O
fluorescence	O
was	O
designated	O
M0	O
,	O
the	O
population	O
with	O
dim	O
EGFP	O
expression	O
was	O
designated	O
M1	O
,	O
and	O
the	O
population	O
with	O
bright	O
EGFP	O
expression	O
was	O
designated	O
M2	O
.	O

(	O
E	O
)	O
EGFP	O
histograms	O
of	O
MR	O
TGFBR2	O
OF	O
and	O
TGFBR2	O
OF	O
cells	O
in	O
different	O
MMR	O
deficient	O
backgrounds	O
at	O
day	O
21	O
were	O
shown	O
as	O
representatives	O
of	O
mutation	O
analysis	O
.	O

Scaling	O
of	O
cell	O
counts	O
in	O
each	O
EGFP	O
histogram	O
is	O
different	O
for	O
each	O
MMR	O
background	O
.	O

Frameshift	O
mutation	O
at	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
in	O
different	O
human	O
MMR	O
deficient	O
backgrounds	O
.	O

Cells	O
from	O
the	O
M1	O
and/or	O
M2	O
populations	O
of	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
or	O
ACVR2	O
OF	O
cells	O
,	O
hMSH6−	O
/	O
−	O
TGFBR2	O
OF	O
or	O
ACVR2	O
OF	O
cells	O
,	O
and	O
hMSH3−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
were	O
sorted	O
and	O
cultured	O
.	O

DNA	O
from	O
each	O
cell	O
line	O
was	O
amplified	O
by	O
PCR	O
,	O
sub	O
-	O
cloned	O
and	O
all	O
single	O
cell	O
clones	O
were	O
individually	O
sequenced	O
to	O
assess	O
for	O
frameshift	O
mutation	O
of	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
.	O

Sequence	O
analysis	O
of	O
DNA	O
clones	O
from	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
revealed	O
mostly	O
1	O
bp	O
deletion	O
at	O
microsatellites	O
(	O
A9	O
for	O
TGFBR2	O
or	O
A7	O
for	O
ACVR2	O
)	O
,	O
shifting	O
the	O
EGFP	O
gene	O
into	O
the	O
reading	O
frame	O
and	O
leading	O
to	O
its	O
expression	O
(	O
A	O
)	O
.	O

Note	O
that	O
M2	O
clones	O
from	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
revealed	O
100	O
%	O
A9	O
/	O
T9	O
microsatellite	O
sequences	O
,	O
termed	O
a	O
""""	O
full	O
mutant	O
�	O
?	O
whereas	O
M1	O
clones	O
revealed	O
a	O
mixture	O
of	O
A10	O
/	O
T10	O
and	O
A9	O
/	O
T9	O
microsatellite	O
sequences	O
,	O
which	O
suggests	O
the	O
presence	O
of	O
an	O
A10	O
/	O
T9	O
heteroduplex	O
,	O
termed	O
an	O
""""	O
intermediate	O
mutant	O
�	O
?	O
(	O
B	O
)	O
.	O

To	O
determine	O
the	O
nature	O
of	O
the	O
mutations	O
observed	O
in	O
the	O
M1	O
population	O
,	O
we	O
analyzed	O
pooled	O
cells	O
as	O
well	O
as	O
single	O
cell	O
clones	O
.	O

In	O
pooled	O
samples	O
,	O
unlike	O
fully	O
mutant	O
sequences	O
observed	O
in	O
the	O
M2	O
populations	O
,	O
M1	O
population	O
sequences	O
often	O
revealed	O
two	O
overlapping	O
sequences	O
,	O
suggestive	O
of	O
heteroduplexes	O
(	O
A9	O
/	O
T10	O
in	O
TGFBR2	O
and	O
A7	O
/	O
T8	O
in	O
ACVR2	O
)	O
(	O
Fig.	O
5B	O
)	O
.	O

Single	O
cell	O
clones	O
revealed	O
the	O
presence	O
of	O
both	O
WT	O
and	O
−1	O
bp	O
frameshift	O
mutants	O
(	O
Fig.	O
5B	O
)	O
,	O
consistent	O
with	O
heteroduplexes	O
that	O
weakly	O
drive	O
EGFP	O
expression	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
hMLH1	O
deficiency	O
has	O
the	O
highest	O
susceptibility	O
for	O
frameshift	O
mutation	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
of	O
the	O
three	O
different	O
MMR	O
deficiencies	O
(	O
hMLH1−	O
/	O
−	O
,	O
hMSH6−	O
/	O
−	O
and	O
hMSH3−	O
/	O
−	O
)	O
.	O

In	O
addition	O
,	O
the	O
coding	O
microsatellite	O
of	O
TGFBR2	O
exon	O
3	O
has	O
a	O
higher	O
susceptibility	O
to	O
a	O
1	O
bp	O
frameshift	O
mutation	O
than	O
that	O
of	O
ACVR2	O
exon	O
10	O
in	O
hMLH1	O
,	O
hMSH6	O
,	O
(	O
and	O
hMSH3	O
)	O
deficiencies	O
.	O

The	O
frameshift	O
mutation	O
rates	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
are	O
dependent	O
on	O
the	O
MMR	O
background	O
The	O
M2	O
population	O
(	O
full	O
mutants	O
)	O
was	O
used	O
to	O
calculate	O
the	O
mutation	O
rates	O
at	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
by	O
the	O
""""	O
method	O
of	O
the	O
mean	O
�	O
?	O

[	O
28	O
]	O
(	O
Table	O
1	O
)	O
.	O

A	O
single	O
mutation	O
rate	O
was	O
calculated	O
by	O
taking	O
a	O
weighted	O
average	O
of	O
the	O
mutation	O
rates	O
at	O
the	O
different	O
time	O
points	O
,	O
the	O
weights	O
of	O
which	O
were	O
chosen	O
to	O
minimize	O
the	O
variance	O
of	O
the	O
estimate	O
as	O
previously	O
described	O
[	O
25	O
]	O
.	O

As	O
predicted	O
,	O
the	O
mutation	O
rate	O
at	O
the	O
microsatellite	O
of	O
TGFBR2	O
in	O
the	O
hMLH1−	O
/	O
−	O
background	O
was	O
highest	O
:	O
5.91	O
×	O
10−4±1.26	O
×	O
10−4	O
.	O

Mutation	O
at	O
the	O
A10	O
microsatellite	O
of	O
TGFBR2	O
is	O
∼3	O
times	O
more	O
frequent	O
than	O
mutation	O
at	O
the	O
A8	O
microsatellite	O
of	O
ACVR2	O
in	O
hMLH1	O
deficiency	O
(	O
P<0.01	O
)	O
.	O

In	O
addition	O
,	O
mutation	O
at	O
the	O
microsatellite	O
of	O
TGFBR2	O
is	O
∼4	O
times	O
higher	O
than	O
mutation	O
at	O
the	O
microsatellite	O
of	O
ACVR2	O
in	O
hMSH6	O
deficiency	O
.	O

Furthermore	O
,	O
mutations	O
at	O
the	O
microsatellites	O
of	O
TGFBR2	O
and	O
ACVR2	O
are	O
∼11–15	O
times	O
higher	O
in	O
hMLH1	O
deficiency	O
than	O
in	O
hMSH6	O
deficiency	O
(	O
P<0.01	O
)	O
.	O

Mutation	O
rates	O
from	O
hMSH3−	O
/	O
−	O
and	O
MMR	O
-	O
proficient	O
cell	O
lines	O
were	O
not	O
calculated	O
due	O
to	O
a	O
lack	O
of	O
net	O
fluorescent	O
M2	O
populations	O
.	O

These	O
data	O
confirm	O
that	O
hMLH1	O
deficiency	O
allows	O
a	O
higher	O
susceptibility	O
for	O
mutation	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
than	O
hMSH6	O
and	O
hMSH3	O
deficiencies	O
,	O
and	O
that	O
TGFBR2	O
exon	O
3	O
has	O
a	O
higher	O
susceptibility	O
to	O
mutation	O
at	O
its	O
coding	O
microsatellite	O
over	O
ACVR2	O
exon	O
10	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
.	O

As	O
we	O
hypothesized	O
,	O
the	O
mutational	O
frequencies	O
and	O
rates	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
microsatellites	O
are	O
dependent	O
on	O
the	O
MMR	O
deficient	O
background	O
with	O
hMLH1−	O
/	O
−>hMSH6−	O
/	O
−>hMSH3−	O
/	O
−.	O
As	O
TGFBR2	O
and	O
ACVR2	O
mutations	O
may	O
drive	O
the	O
pathogenesis	O
of	O
colorectal	B
cancers	I
,	O
our	O
human	O
data	O
is	O
consistent	O
with	O
the	O
virulence	O
of	O
tumor	B
formation	O
in	O
Lynch	B
syndrome	I
.	O

Patients	O
with	O
germline	O
mutation	O
in	O
hMLH1	O
may	O
present	O
with	O
cancer	B
at	O
younger	O
ages	O
compared	O
to	O
those	O
with	O
a	O
hMSH6	O
germline	O
mutation	O
[	O
29	O
]	O
.	O

Data	O
on	O
mutation	O
rates	O
for	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
(	O
Table	O
1	O
)	O
showed	O
similar	O
results	O
.	O

hMLH1−	O
/	O
−	O
TGFBR2	O
showed	O
the	O
highest	O
mutation	O
rate	O
at	O
its	O
coding	O
microsatellite	O
sequence	O
(	O
5.91	O
×	O
10−4	O
)	O
.	O

This	O
mutation	O
rate	O
is	O
similar	O
to	O
that	O
calculated	O
for	O
noncoding	O
(	O
CA	O
)	O
13	O
microsatellites	O
in	O
hMLH1−	O
/	O
−	O
cells	O
[	O
25	O
]	O
,	O
suggesting	O
that	O
this	O
coding	O
A10	O
and	O
the	O
noncoding	O
(	O
CA	O
)	O
13	O
microsatellites	O
are	O
equally	O
vulnerable	O
to	O
hMLH1	O
deficiency	O
.	O

The	O
mutation	O
rate	O
for	O
TGFBR2	O
was	O
3	O
fold	O
higher	O
than	O
that	O
for	O
ACVR2	O
in	O
both	O
hMLH1	O
(	O
5.91	O
×	O
10−4	O
)	O
and	O
hMSH6	O
(	O
0.54	O
×	O
10−4	O
)	O
deficiencies	O
.	O

The	O
rapid	O
rate	O
for	O
TGFBR2	O
mutation	O
with	O
MMR	O
deficiency	O
might	O
be	O
due	O
partly	O
to	O
TGFBR2	O
's	O
longer	O
polyadenine	O
tract	O
compared	O
to	O
ACVR2	O
,	O
as	O
longer	O
microsatellite	O
tracts	O
mutate	O
more	O
frequently	O
in	O
MMR	O
deficiency	O
[	O
7	O
]	O
.	O

In	O
the	O
case	O
of	O
ACVR2	O
exon	O
10	O
,	O
even	O
though	O
the	O
mutation	O
rate	O
is	O
slower	O
than	O
TGFBR2	O
exon	O
3	O
,	O
ultimately	O
fully	O
mutant	O
clones	O
accumulate	O
.	O

The	O
rapid	O
rate	O
for	O
TGFBR2	O
exon	O
3	O
mutation	O
is	O
probably	O
most	O
reflective	O
in	O
the	O
M1	O
population	O
,	O
as	O
there	O
is	O
a	O
rapid	O
heteroduplex	O
formation	O
particularly	O
in	O
hMLH1	O
deficiency	O
,	O
followed	O
by	O
full	O
mutation	O
.	O

In	O
ACVR2	O
exon	O
10	O
,	O
heteroduplex	O
formation	O
is	O
relatively	O
slower	O
.	O

With	O
both	O
TGFBR2	O
and	O
ACVR2	O
constructs	O
,	O
heteroduplex	O
formation	O
and	O
subsequent	O
full	O
mutation	O
are	O
slower	O
in	O
the	O
hMSH6−	O
/	O
−	O
background	O
compared	O
to	O
hMLH1−	O
/	O
−	O
background	O
.	O

It	O
has	O
been	O
shown	O
that	O
MSH6	O
and	O
MSH3	O
are	O
redundant	O
in	O
regard	O
to	O
frameshift	O
mutagenesis	O
in	O
a	O
yeast	O
model	O
[	O
30	O
]	O
,	O
which	O
supports	O
our	O
finding	O
that	O
hMSH6	O
and	O
hMSH3	O
defects	O
have	O
much	O
lower	O
frameshift	O
mutation	O
rates	O
than	O
the	O
hMLH1	O
defect	O
that	O
completely	O
eliminates	O
MMR	O
.	O

Lower	O
frameshift	O
mutation	O
rate	O
in	O
hMSH6	O
deficiency	O
would	O
logically	O
predict	O
a	O
lower	O
penetrance	O
in	O
Lynch	B
syndrome	I
for	O
which	O
no	O
germline	O
hMSH3	O
mutation	O
has	O
been	O
reported	O
.	O

In	O
summary	O
,	O
we	O
established	O
and	O
utilized	O
a	O
cell	O
model	O
in	O
which	O
actual	O
human	O
coding	O
microsatellite	O
sequences	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
were	O
evaluated	O
in	O
real	O
time	O
for	O
frameshift	O
mutation	O
in	O
different	O
human	O
MMR	O
backgrounds	O
.	O

hMLH1	O
deficiency	O
confers	O
a	O
significantly	O
higher	O
mutation	O
rate	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
and	O
ACVR2	O
compared	O
to	O
hMSH6	O
and	O
hMSH3	O
deficiencies	O
.	O

In	O
addition	O
,	O
TGFBR2	O
mutates	O
at	O
a	O
higher	O
rate	O
than	O
ACVR2	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
.	O

These	O
bona	O
-	O
fide	O
human	O
genes	O
targeted	O
for	O
mutation	O
in	O
MMR	O
deficiency	O
mutate	O
at	O
differing	O
rates	O
,	O
and	O
lose	O
expression	O
of	O
their	O
encoded	O
proteins	O
in	O
colonic	O
neoplastic	O
cells	O
.	O

Understanding	O
these	O
targeted	O
genes	O
in	O
MMR	O
deficiency	O
has	O
implications	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
MSI	B
colorectal	O
tumors	B
.	O

Pedigree	O
for	O
Family	O
#	O
3	O
(	O
CRC	B
:	O
Colorectal	B
cancer	I
;	O
ESC	B
:	O
Oesophageal	B
cancer	I
;	O
LC	B
:	O
Lung	B
cancer	I
)	O
.	O

Of	O
the	O
17	O
CRC	B
patients	O
with	O
the	O
Lys618Ala	O
variant	O
,	O
two	O
had	O
MSI	B
(	O
11.8	O
%	O
)	O
,	O
one	O
in	O
the	O
familial	O
CRC	B
group	O
(	O
1	O
/	O
8	O
)	O
and	O
one	O
in	O
the	O
sporadic	O
CRC	B
group	O
(	O
1	O
/	O
9	O
)	O
.	O

The	O
MSI	B
-	I
positive	I
patient	O
from	O
the	O
familial	O
CRC	B
group	O
showed	O
loss	O
of	O
immunohistochemical	O
expression	O
of	O
MLH1	O
.	O

This	O
is	O
the	O
index	O
subject	O
(	O
II-3	O
)	O
for	O
the	O
third	O
family	O
(	O
Figure	O
4	O
)	O
and	O
no	O
hypermethylation	O
of	O
MLH1	O
gene	O
promoter	O
;	O
no	O
BRAF	O
p.	O

Val600Glu	O
mutation	O
were	O
detected	O
in	O
this	O
case	O
.	O

As	O
most	O
disease	O
pedigrees	O
are	O
small	O
,	O
it	O
is	O
difficult	O
to	O
obtain	O
a	O
sufficient	O
number	O
of	O
samples	O
from	O
affected	B
and	O
informative	O
unaffected	B
individuals	O
.	O

Moreover	O
,	O
LS	B
deleterious	O
variants	O
are	O
not	O
completely	O
penetrant	O
.	O

For	O
these	O
reasons	O
,	O
it	O
is	O
rarely	O
possible	O
to	O
categorize	O
variants	O
as	O
deleterious	O
based	O
on	O
segregation	O
alone	O
.	O

The	O
co	O
-	O
occurrence	O
of	O
another	O
known	O
deleterious	O
variant	O
reduces	O
the	O
likelihood	O
that	O
an	O
UV	O
is	O
truly	O
deleterious	O
,	O
especially	O
when	O
both	O
variants	O
are	O
located	O
in	O
trans	O
[	O
3	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
co	O
-	O
occurrence	O
of	O
a	O
deleterious	O
variant	O
in	O
one	O
of	O
the	O
LS	B
genes	O
with	O
the	O
p.	O

Lys618Ala	O
variant	O
has	O
been	O
observed	O
in	O
only	O
two	O
families	O
.	O

Liu	O
et	O
al	O
[	O
14	O
]	O
described	O
an	O
index	O
subject	O
from	O
a	O
LS	B
family	O
with	O
two	O
heterozygous	O
variants	O
(	O
c.546	O
-	O
2A	O
>	O
G	O
and	O
c.1852_1853AA	O
>	O
GC	O
)	O
;	O
only	O
the	O
former	O
segregated	O
with	O
LS	B
in	O
the	O
family	O
.	O

Similarly	O
,	O
Steinke	O
et	O
al	O
[	O
15	O
]	O
,	O
described	O
the	O
co	O
-	O
occurrence	O
of	O
the	O
p.	O

Lys618Ala	O
(	O
c.1852_1853AA	O
>	O
GC	O
)	O
variant	O
with	O
the	O
MSH6	O
p.	O

Arg1068X	O
(	O
c.3202C	O
>	O
T	O
)	O
deleterious	O
variant	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
coexistence	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
with	O
deleterious	O
variants	O
in	O
another	O
two	O
unrelated	O
LS	B
families	O
.	O

In	O
one	O
family	O
,	O
the	O
allele	O
distribution	O
of	O
the	O
pathogenic	O
and	O
unclassified	O
variant	O
was	O
in	O
trans	O
,	O
in	O
the	O
other	O
family	O
the	O
pathogenic	O
variant	O
was	O
detected	O
in	O
the	O
MSH6	O
gene	O
and	O
only	O
the	O
deleterious	O
variant	O
co	O
-	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
.	O

This	O
evidence	O
indicates	O
that	O
the	O
p.	O

Lys618Ala	O
variant	O
is	O
not	O
deleterious	O
.	O

The	O
molecular	O
hallmark	O
of	O
LS	B
tumours	B
is	O
an	O
MSI	B
phenotype	O
,	O
a	O
functional	O
consequence	O
of	O
MMR	O
deficiency	O
.	O

It	O
is	O
expected	O
that	O
the	O
putative	O
germ	O
-	O
line	O
mutation	O
responsible	O
for	O
LS	B
would	O
confer	O
the	O
MSI	B
phenotype	O
.	O

We	O
tested	O
the	O
MSI	O
status	O
of	O
17	O
tumours	B
from	O
p.	O

Lys618Ala	O
carriers	O
and	O
detected	O
only	O
two	O
cases	O
of	O
MSI	O
(	O
11.8	O
%	O
)	O
.	O

Taking	O
into	O
consideration	O
the	O
bias	O
caused	O
by	O
the	O
over	O
-	O
representation	O
of	O
Bethesda	O
Criteria	O
-	O
positive	O
tumours	B
in	O
this	O
subset	O
of	O
cases	O
(	O
8	O
/	O
17	O
)	O
,	O
the	O
MSI	O
frequency	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
unselected	O
CRC	B
group	O
[	O
7	O
]	O
.	O

This	O
is	O
further	O
proof	O
that	O
the	O
presence	O
of	O
this	O
variant	O
is	O
irrelevant	O
to	O
the	O
functional	O
inactivation	O
of	O
MLH1	O
in	O
CRC	B
patients	O
.	O

Nonetheless	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
this	O
variant	O
may	O
result	O
in	O
a	O
small	O
increase	O
in	O
susceptibility	O
to	O
CRC	B
or	O
adenomas	B
,	O
as	O
was	O
suggested	O
by	O
Fearnhead	O
et	O
al	O
[	O
16	O
]	O
.	O

Further	O
studies	O
with	O
appropriate	O
sample	O
sizes	O
are	O
required	O
to	O
address	O
the	O
low	O
penetrance	O
effect	O
of	O
this	O
variant	O
in	O
CRC	B
.	O

Finally	O
,	O
we	O
hypothesize	O
that	O
the	O
clinical	O
significance	O
of	O
a	O
genetic	O
variant	O
may	O
differ	O
according	O
to	O
genetic	O
background	O
.	O

Gene	O
functionality	O
may	O
be	O
the	O
net	O
result	O
of	O
the	O
effects	O
of	O
allelic	O
structures	O
and	O
their	O
interactions	O
with	O
environmental	O
factors	O
.	O

It	O
is	O
possible	O
that	O
low	O
-	O
penetrance	O
variants	O
behave	O
differently	O
in	O
different	O
populations	O
,	O
making	O
it	O
difficult	O
to	O
make	O
predictions	O
in	O
terms	O
of	O
conferred	O
risk	O
.	O

Conclusions	O
Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
and	O
others	O
indicate	O
that	O
the	O
c.1852_1853AA	O
>	O
GC	O
variant	O
should	O
be	O
considered	O
a	O
neutral	O
variant	O
for	O
LS	B
.	O

These	O
findings	O
have	O
considerable	O
relevance	O
for	O
the	O
clinical	O
management	O
of	O
CRC	B
probands	O
and	O
their	O
relatives	O
.	O

